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Summary 
Human hypertension is the biggest contributor to the global burden of 
cardiovascular disease and it is the most prevalent modifiable risk factor for 
cardiovascular morbidity and mortality. The causation of hypertension is 
multifactorial and is related to perturbation in the pathways that regulate blood 
pressure. The known blood pressure regulating pathways include those that 
regulate intravascular volume, vascular tone and peripheral vascular resistance 
through renal, the renin-angiotensin-aldosterone and autonomic systems, which 
are targets of the commonly used antihypertensive drugs. In the largest 
investigation of blood pressure using a metabolomics approach, a novel pathway 
for blood pressure regulation was identified, involving a dicarboxylic acid, 
hexadecanedioate. Hexadecanedioate is a long chain dicarboxylic acid, which is 
generated during fatty acid omega-oxidation pathway (ω-oxidation). Higher 
circulating levels of hexadecanedioate were significantly associated with both 
high blood pressure and mortality. 
This research project aimed to examine the functional role of hexadecanedioate 
and investigate its underpinning mechanisms in blood pressure regulation using in-
vivo, ex-vivo and metabolomics studies in two animal models; the Wistar Kyoto 
(WKY) and the Spontaneously Hypertensive Stroke Prone rats (SHRSP). 
In the first results chapter (chapter 3), we conducted three independent 
interventional studies to examine the effects of hexadecanedioate on blood 
pressure regulation. Circulating levels of hexadecanedioate were significantly 
increased in WKY rats after treatment with oral hexadecanedioic acid leading to 
blood pressure elevation and impairment of vascular function in WKY rats. 
However, hexadecanedioic acid treatment was unable to further increase 
circulating hexadecanedioate levels or blood pressure in SHRSP rats, indicating 
that hexadecanedioate levels may already be maximally elevated in the 
hypertensive model. The data also show an increase in adiposity index despite 
reduced body weight in SHRSP rats after treatment with hexadecanedioic acid. 
These results may indicate muscle wasting and altered cellular energy homeostasis 
such as an impairment of the beta-oxidation pathway (β-oxidation).  
25 
In the second results chapter (chapter 4), a global metabolomics study was carried 
out in WKY rats to demonstrate the metabolic effect of hexadecanedioic acid 
treatment in cardiovascular tissues (i.e. heart, kidney, liver, aorta, adipose and 
brain) in order to identify the metabolic pathways leading to hexadecanedioate-
induced blood pressure elevation. Several alterations in metabolic readouts, 
including changes in metabolites related to lipid and glucose metabolisms, bile 
acid metabolism, redox homeostasis, and uric acid cycle were observed after 
hexadecanedioic acid treatment. Hexadecanedioate increased in all tested tissues 
of hexadecanedioic acid-treated WKY rats except brain, where this metabolite 
was below the threshold of detection. Our data indicated significant increases in 
peroxisomal ω-oxidation metabolites (i.e. dicarboxylic fatty acids) along with 
marked changes in mitochondrial fatty acid β-oxidation metabolites such as 
phospholipids, lysolipid, sphingolipid, monoacylglycerol and acyl carnitine in all 
tested tissues. These changes in fatty acid availability indicate that 
hexadecanedioic acid treatment induced changes in mitochondrial β-oxidation 
and a shift toward increased use of peroxisomal ω-oxidation. 
In the third results chapter (chapter 5), the ω- oxidation pathway was investigated 
by measuring the expression levels of the different enzymes involved in the 
pathway (i.e. CYP4A, alcohol dehydrogenase (ADH), and aldehyde dehydrogenase 
(ALDH)) in two different rat strains; the normotensive WKY and hypertensive 
SHRSP rat models. The gene expression results show significant reduction in 
expression of the ALDH isoform, ALDH1L2, in the liver tissues of SHRSP rats 
compared to WKY. In addition, the levels of ALDH enzyme were measured in the 
liver tissues using ELISA assay, which showed a trend towards an increase in SHRSP 
rats compared to WKY rats.  
Blood pressure was assessed after modulation of endogenous hexadecanedioate 
levels by perturbing the ω-oxidation pathway in both WKY and SHRSP by either 
inhibition or stimulation of enzymes critical to ω-oxidation. Inhibition of the final 
ω-oxidation pathway enzyme, ALDH by disulfiram resulted in a significant lowering 
of blood pressure in the hypertensive SHRSP rat. A pilot study was also conducted 
to examine the effect of HET0016 (CYP4A antagonist) on blood pressure of SHRSP 
rats, which showed no significant changes. However, stimulation of the ω-
oxidation pathway enzyme, CYP4A by fenofibrate caused a significant reduction 
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of blood pressure in WKY rats, along with significant increase in the CYP4A 
expression in kidney and liver tissues.  
In the final results chapter (chapter 6), an alternative mechanism was examined 
that may lead to elevated circulating levels of hexadecanedioate via altered 
activity of the solute carrier organic anion transporter (SLCO), which encodes the 
protein organic anion transporting polypeptide (OATP). It has been found that the 
human SLCO1B1 gene is associated with elevated levels of circulating 
hexadecanedioate. SLCO1B1 may have a role in hexadecanedioate elimination 
from the body, and any alteration in this liver transporter may cause increases in 
circulating hexadecanedioate levels leading to blood pressure elevation. A 
preliminary investigation was performed to identify the sequence variants in the 
rat homolog, the Slco1b2 gene. Genotype analysis of the SHRSPGla and WKYGla 
genome sequence identified an insertion of 9 nucleotides (GTCTATCTA) within an 
intronic region (intron 3/14) on chromosome 4 at position 240,062,637 bp, band 
4q44 forward strand in the WKYGla strain rather than a G nucleotide in the SHRSPGla 
strain. The deletion of 4 nucleotides (TATC) within the 3’untranslated region 
(UTR) was also detected on chromosome 4 at position 240,102,755 bp of the 
WKYGla genome sequence. Total Slco1b2 mRNA expression was measured in liver 
tissues of WKY and SHRSP, which showed significantly decreased levels in SHRSP 
compared to WKY. These genetic variants within the Slco1b2 gene may contribute 
to altered function of the Oatp1b2 transporter, which may in turn contribute to 
elevated levels of circulating hexadecanedioate in the SHRSP rat model of 
hypertension.  
In summary, we have investigated the functional role of hexadecandioate in blood 
pressure regulation. The findings presented in this thesis demonstrate novel 
targets associated with hexadecandioate; including the ω-oxidation pathway and 
the solute carrier organic anion mechanism in regulation of blood pressure. 
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1.1 Cardiovascular disease 
Cardiovascular disease (CVD) is a complex set of disorders, involving pathological 
changes in heart, blood vessels, kidneys and brain; including hypertension, angina, 
stroke, coronary heart disease, myocardial infractions, renal diseases and 
metabolic syndromes (Nichols et al., 2014). According to the World Health 
Organization (WHO), cardiovascular disease is the number one cause of worldwide 
deaths, accounting for 30% (17.7 million people) of total global deaths in 2015 
(World Health Organization, 2018). Cardiovascular disease is the main cause of 
mortality burden in European countries (51% of deaths among women and 42% 
among men), which is considered a greater risk for mortality than cancer (19% of 
deaths among women and 23% among men) (Nichols et al., 2014). The main CVD 
disorders representing the common cause of death are coronary heart disease (7.4 
million) and stroke (6.7 million) (World Health Organization, 2018). The most 
important risk factors identified for developing of CVD are divided into 
controllable risk factors, including smoking, poor diet, high alcohol consumption, 
high blood cholesterol, high blood pressure, lack of exercise, obesity, and diabetes 
(Saeidi et al., 2015; Mozaffarian et al., 2015). Additionally, there are major non 
controllable risk factors that include ethnicity (George et al., 2017), age, sex, 
family history and genetics (Mozaffarian et al., 2015). Two types of interventions 
are used to reduce the burden of CVD. The cost effective primary intervention, 
includes control of smoking and alcohol, reducing the intake of foods that are high 
in fat, sugar and salt and increased physical activity (Piepoli et al., 2016, 2014). 
Secondary prevention of cardiovascular disease includes use of medications such 
as antiplatelet therapy (aspirin), blood pressure-lowering agents (i.e. beta-
blockers and angiotensin-converting enzyme inhibitors), where a systolic BP ≥140 
mm Hg and lipid-lowering agents (statins) where low-density lipoprotein (LDL) 
cholesterol ≥2.5 mmol/L (Bansilal et al., 2015). In addition, there are more 
expensive surgical interventions that include coronary artery bypass (Kulik et al., 
2015), balloon angioplasty (Matsuzawa et al., 2015) and valve repair and 
replacement (Acker et al., 2014).   
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1.2 Blood pressure: definition 
Blood circulates in the arteries and veins, and carries essential substances such as 
oxygen, nutrients and hormones to cells, tissues and organs, also transports the 
waste products such as carbon dioxide away from those cells, tissues and organs. 
The pressure of the blood against the inner walls of the blood vessels is called 
blood pressure. Blood pressure is measured in millimetres of mercury (mmHg) and 
recorded as a fraction with the maximum pressure (systolic) representing the peak 
pressure during heart contraction over the minimum pressure (diastolic) that 
represents the pressure during heart relaxation. Blood pressure is categorised into 
pulsatile (pulse arterial pressure) and steady components (mean arterial 
pressure), which are considered to be important predictor of cardiovascular 
disease.(Haider et al., 2003; Sesso et al., 2000). Pulse pressure is the difference 
between systolic and diastolic blood pressure, which is associated with vessel 
stiffness, left ventricular ejection fraction, development of large-vessel 
atherosclerosis and small-vessel disease (Haider et al., 2003; Sesso et al., 2000). 
Mean arterial pressure (MAP) is a function of left ventricular contractility, heart 
rate, and vascular resistance (Haider et al., 2003; Sesso et al., 2000). The main 
factors of diastolic blood pressure (DBP) are the mean circulatory filling pressure, 
total peripheral vascular resistance and the interval between heart beats 
(Ackermann, 2004). Mean arterial blood pressure is the average pressure, which is 
calculated from diastolic and pulse pressure values using the following formula 
(Ackermann, 2004): 
Mean arterial blood pressure = diastolic pressure +1/3 pulse pressure 
The normal value of mean arterial blood pressure is about 100 mmHg. Small 
variations from this value occur regularly during daily life, but compensatory 
mechanisms control the pressure within a normal range (Ackermann, 2004). 
Normal blood pressure readings are <120 mmHg systolic and <80 mmHg diastolic, 
although there is some variability between normal healthy people (O’Shea et al., 
2017). 
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1.3 Physiological blood pressure regulation 
Blood pressure refers to the pressure imposed by circulating blood on the walls of 
blood vessels. It is a quantitative feature, which is variable between individuals, 
and it is mainly determined by cardiac output and total peripheral resistance. 
Cardiac output and total peripheral resistance are controlled by homeostatic 
regulatory mechanisms, which are a complex system of cooperating physiological 
pathways, including neural, hormonal, vascular and renal mechanisms to regulate 
blood pressure (Taylor and Abdel-Rahman, 2009). Three cardiovascular factors are 
involved in blood pressure regulation, including total peripheral vascular 
resistance, stroke volume and heart rate (Ackermann, 2004). The first of these, 
peripheral vascular resistance regulation, is specified by the luminal diameter of 
arterioles, which is determined by the degree of constriction of vascular smooth 
muscles cells around the arterioles (Ackermann, 2004; Martinez-Lemus, 2012). The 
vascular smooth muscles cells are regulated by vasodilation factors (e.g. nitric 
oxide) and by vasoconstrictor factors (e.g. sympathetic nervous system activity), 
as well as vasoconstrictor substances, for example angiotensin II, adrenaline and 
vasopressin (Brozovich et al., 2016; Ackermann, 2004). Overall regulation of total 
peripheral vascular resistance is accomplished via sympathatic vasoconstriction, 
as well as stroke volume regulation, which is determined by cardiac performance 
via heart contractility, preload (initial stretching of the cardiac myocytes prior to 
contraction), afterload (the pressure against which the heart must work to eject 
blood) and heart rate (Ackermann, 2004; Poole and Erickson, 2014). Heart rate is 
regulated by generation of action potentials in dominant pacemaker cells in the 
heart, enhanced by cardiac sympathatic nervous activity (positive chronotropic) 
and is reduced by cardiac parasympathetic nervous activities (negative 
chronotropic) (Ackermann, 2004; Gordan et al., 2015) (Figure 1-1). 
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Figure 1-1: Schematic diagram showing physiological factors that regulate blood pressure. 
Abbreviation: Na+, Sodium; β1- receptor, Beta 1- receptor; α1- adrenargic receptor, Alpha 1-adrenargic receptor; O2, Oxygen; CO2, Carbon dioxide; H2, Hydrogen; 
GPCRs, G-protein-coupled receptors. 
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 Role of the central nervous system in blood pressure 
regulation  
Two types of autonomic nervous system have an essential role in controlling 
cardiovascular functions; there are the sympathatic nervous system (SNS) and the 
parasympathatic nervous system (PNS). Both nervous systems mainly regulate 
heart rate, physical activity, the sleep/awake phase and the emotional state of 
the individual. In addition, PNS has a minor role in vascular resistance regulation 
(Taylor and Abdel-Rahman, 2009). The central nervous system (CNS) plays an 
important role in short-term and long-term regulation of blood pressure (Taylor 
and Abdel-Rahman, 2009). In the short-term (seconds to hours), the autonomic 
nervous system regulates the circulation compatible with behaviour (i.e. 
exercise), the environment (i.e. thermoregulation) and emotions (i.e. fright and 
shock) (Guyenet, 2006).  
Baroreceptors are the only identified neural sensor that regulate blood pressure, 
and have a dominant role in short-term blood pressure regulation. However, their 
impact on the long-term regulation of blood pressure is less well understood 
(Guyenet, 2006). An elevation in arterial blood pressure occurs as a consequence 
of baroreceptor stimulation, which send nerve impulses to the medullary 
vasomotor centres and causes central inhibition of sympathetic tone and a rise in 
parasympathetic tone. In contrast, a reduction in arterial pressure causes 
baroreceptor reflex-mediated withdrawal of vagal tone and sympathetic 
activation, leading to cardiac acceleration, improved myocardial performance, 
and decreased arterial resistance (Marr and Reimer, 2009). 
The autonomic nervous system also regulates both vascular resistance and cardiac 
output, which consequently regulates blood pressure. Cardiac output is dependent 
on end-diastolic volume, myocardial contractility and heart rate. End-diastolic 
volume is the volume of blood achieved by the ventricular chamber before 
contraction and the beginning of filling, which is related to venous smooth muscle 
tone and blood volume, both are under sympathetic control. Furthermore, 
myocardial contractility and heart rate are controlled by both the sympathetic 
and parasympathetic autonomic nervous system (Guyenet, 2006). The definitive 
consequences of increased activity of the sympathatic nervous system are an 
increase in heart rate and heart contractility due to activation of beta 1 receptor 
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(β1 receptor), and a rise in vascular resistance due to activation of alpha 1 
receptor (α1 receptors) (Ackermann, 2004) (Figure 1-1). 
The vascular system is mainly innervated by sympathetic adrenergic nerves that 
release noradrenaline as a neurotransmitter. However, some blood vessels are 
innervated by either parasympathetic cholinergic or sympathetic cholinergic 
nerves. Both of them release acetylcholine as their neurotransmitter. These 
neurotransmitters bind to the adrenergic and cholinergic receptors, which 
activate signal transduction pathways causing changes in vascular function (Taylor 
and Abdel-Rahman, 2009). Vascular smooth muscle are usually innervated by 
sympathetic vasodilating innervation, while there is no parasympathetic 
innervation to the vascular smooth muscle. Sympathetic vasodilating innervation 
to the skeletal muscle vasculature in certain vascular beds is mediated by the 
release of acetylcholine from these sympathetic nerve terminals. Circulating 
acetylcholine can contribute to vascular resistance by two mechanisms. Firstly, 
acetylcholine stimulation of presynaptic cholinergic nicotinic receptors on 
noradrenergic nerve terminals lead to increase noradrenaline release. Inversely, 
acetylcholine stimulation of presynaptic muscarinic receptors cause inhibition of 
noradrenaline release from noradrenergic nerve terminals. Secondly, stimulation 
of muscarinic cholinergic receptors on endothelial cells increases nitric oxide (NO) 
release. These different effects of cholinergic modulation of noradrenaline and 
NO release contribute differentially to vascular tone control (Taylor and Abdel-
Rahman, 2009). 
A non-noradrenergic, non-cholinergic transmitter (NANC) is also known as a 
neurotransmitter of the autonomic nervous system besides two main transmitters 
(i.e. noradrenaline and acetylcholine). The transmitters for NANC include purine 
bodies (ATP), neuropeptide (e.g. neuropeptide Y (NPY), vasoactive intestinal 
peptide (VIP), gonadotropin-releasing hormone (GnRH), substance P), and nitric 
oxide. These transmitters are co-released with noradrenaline and acetylcholine 
as the neurotransmitters to control the vascular tone and contraction or relaxation 
of smooth muscle cells (Uno and Hisa, 2016). 
The sympathetic nervous system also has a role in stimulation of the chromaffin 
cells in the adrenal medulla to release epinephrine, as well as simulating renal 
juxtaglomerular cells to release renin, and peripheral synapses to release 
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noradrenaline, located in cardiac muscle cells and the vascular smooth muscles 
that surround the blood vessels.(Ackermann, 2004; Bakris and Mensah, 2003; Singh 
et al., 2010).  
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 Role of kidney in blood pressure regulation  
The kidney has an important role in regulation of blood pressure through adjusting 
electrolyte balance, salt and water homeostasis and the total fluid volume as well 
as through its role in the renin angiotensin aldosterone system (RAAS) (Ko and 
Bakris, 2008). RAAS is considered to be a major hormonal system, which controls 
functions of the cardiovascular and renal systems, as well as the adrenal glands 
by regulating blood pressure, fluid volume, fluid homeostasis and electrolytes (i.e. 
sodium and potassium) balance, and also is known to be involved in hypertension 
pathophysiology (Pacurari et al., 2014; Te Riet et al., 2015). Renin is released 
from juxtaglomerular cells in the media layer of the afferent glomerular arterioles 
of the kidney into the circulation (Friis et al., 2013). Renin expression and 
secretion are regulated at the juxtaglomerular cell by three different 
mechanisms: intrarenal baroreceptors of the afferent arteriole, the influence of 
sympathetic nerves on the arterioles of the juxtaglomerular apparatus and 
alterations in the delivery of sodium chloride to the macula densa cells (Sparks et 
al., 2014; Friis et al., 2013; Harrison-bernard, 2009). 
The first mechanism, via renal baroreceptors, is an independent mechanism for 
renin regulation. Intrarenal baroreceptors act as high-pressure baroreceptors, 
which are able to detect any change in blood pressure. An elevation of renal 
arterial pressure inhibits renin release, whereas reductions in renal arterial 
pressure and calcium concentration lead to enhanced release of renin from the 
juxtaglomerular apparatus (Chapleau, 2012; Harrison-bernard, 2009; Sparks et al., 
2014; Friis et al., 2013). Secondly, renin release is increased by activation of 
sympathetic nerves and β-adrenergic receptors (Harrison-bernard, 2009).Thirdly, 
increased distal delivery of sodium chloride to the macula densa of the thick 
ascending limb of the loop of Henle leads to reduction in renin secretion and vice 
versa (Harrison-bernard, 2009). Increase in release of cyclooxygenase 2 in the 
macula densa cells leads to increased prostaglandin E2 (PGE2) production and PGE2 
receptor activation causing stimulation of adenylyl cyclase, and subsequently 
increases in the second messenger for renin secretion cyclic adenosine 
monophosphate (cAMP). 
Increased renin secretion results in an increase in the level of the potent 
vasoconstrictor Angotensin II, which results in increased blood pressure (Harrison-
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bernard, 2009). Angiotensin II (Ang II) is produced from angiotensin I (Ang I), by 
angiotensin converting enzyme (ACE) that is mainly expressed by the lungs. 
Angiotensin (AngIII) is then generated from Ang II (precursor) via aminopeptidase 
A (APA), which has been shown to be involved in central control of blood pressure 
(Taylor and Abdel-Rahman, 2009) (Figure 1-2). This mechanism is essential for 
systemic arterial pressure regulation as well as tissue perfusion through reduced 
vascular volume (Harrison-bernard, 2009). 
Ang II has a range of actions on different vascular and organ systems. It increases 
peripheral resistance and blood pressure by vasoconstriction of renal and systemic 
arterioles. In addition, Ang II causes an increase of arginine and vasopressin 
release from the posterior pituitary gland leading to increases in fluid retention 
in the renal collecting duct of the kidneys in order to maintain blood volume 
(Harrison-bernard, 2009). Ang II is released in response to blood pressure changes 
through circulatory depression, blood volume depletion or sodium depletion. It 
enhances sodium reabsorption through activation of aldosterone secretions, this 
results in hemodynamic effects and epithelial transport. Constriction of efferent 
arterioles is mediated by angiotensin II, causing reduction of renal blood flow, 
hydrostatic pressure of peritubular capillary and elevating osmotic pressure of 
peritubular colloid. Ang II activates exchange of Na+/H+ and enhances Na+/ K+ 
adenosine triphosphatase (ATPase) activity in proximal renal tubules (Harrison-
bernard, 2009). Ang II also activates angotensin II type 1 receptors (AT1R), leading 
to aldosterone release from the adrenal cortex and increase reabsorption of 
sodium chloride and fluid in the distal nephron to increase extracellular fluid 
volume (Harrison-bernard, 2009). Aldosterone is a sodium retaining hormone, 
which affects blood pressure regulation by increasing renal reabsorption of sodium 
in the collecting ducts, distal tubules and cortical collecting tubules. Aldosterone 
works by binding to intracellular mineralocorticoid receptors (MRs), leading to 
activation of Na+/K+ ATPase pump at the basolateral epithelial membrane and 
stimulation of amiloride-sensitive sodium channels at the luminal epithelial 
membrane (Hall et al., 2013). 
In the brain, sympathoexcitatory effects are produced by Ang II, while 
intracerebroventricular action of Ang II and Ang III cause identical increases in 
blood pressure and identical agonist activation of central AT1R receptors (Figure 
1-2). Thus, the RAAS acts to produce a balancing effect on vascular resistance 
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resulting in blood pressure homeostasis. However, impaired AT1R signalling due 
to imbalanced effects causes hypertension known as high-renin hypertension 
(Taylor and Abdel-Rahman, 2009). 
An alternative pathway for blood pressure regulation by Ang II is via angotensin II 
type 2 receptor (AT2R) (Mas receptors) and other angiotensin fragments (i.e. 
Ang1–7). The roles of Ang1–7 and AT2R receptors in blood pressure regulation and 
in the pathophysiology of hypertension have recently been identified. Activation 
of AT2R receptors by Ang II and Ang1-7 results in vasodilation and reduction of 
vascular resistance. Stimulation of Mas receptors via Ang1-7 results in increased 
of bradykinin–nitric oxide release, anti-proliferation, natriuresis and vasodilation. 
Ang1-7 reduces blood pressure by central and peripheral mechanisms that involve 
nitric oxide and bradykinin, generating antifibrotic and antihypertrophic effects 
(Taylor and Abdel-Rahman, 2009; Carey et al., 2001; Singh and Karnik, 2016). 
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Figure 1-2: Renin-angotensin-aldestrone system. 
Abbreviation: ACE, Angiotensin Converting Enzyme; APA, aminopeptidase A; Na+, Sodium; Cl-, Chloride; K+, Potassium; H2O, Water; ADH, antidiuretic hormone.  
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 Role of Endothelium in blood pressure regulation 
The endothelium plays an important role in the regulation of vascular tone via 
release of vasoactive factors, such as nitric oxide (NO), prostacyclin (PGI2) and 
endothelium derived hyperpolarizing factor (EDHF) or vasoconstrictive factors 
such as thromboxane (TXA2) and endothelin-1 (ET-1) (Taylor and Abdel-Rahman, 
2009). NO is an endothelium-dependent vasodilator of the smooth muscle, which 
is produced from L- arginine by nitric oxide synthase (NOS) enzymes. Three 
isoforms of NOS, includes neuronal isoform (nNOS), which yields NO to act as a 
neuronal messenger that controls synaptic neurotransmitter release. Inducible 
isoform (iNOS), which is only expressed in cells that have been exposed to 
inflammatory mediators or damage activated macrophages, and endothelial NOS 
(eNOS), which produces nitric oxide in the vasculature (Hall et al., 2013). 
NO is released from renal tubular cells and vascular endothelial cells, which 
maintain blood pressure regulation through vasodilatation via an increase in the 
production of intracellular cyclic GMP in vascular smooth muscle cells (Taylor and 
Abdel-Rahman, 2009). Long-term blockade of nitric oxide synthase reduces renal 
pressure natriuresis and hypertension. Also, a decrease of nitric oxide synthesis 
leads to an increase in Na+ reabsorption and alteration of renal interstitial 
hydrostatic pressure (Hall et al., 2013). eNOS couples with tetrahydrobiopterin 
(BH4) and caveolin to maintain the enzyme activities within the physiological 
limit, while uncoupling leads to formation of superoxide and reactive oxygen 
species that impair the function and structure of cardiac and vascular smooth 
muscles and elevation in peripheral resistance leading to hypertension (Köhler et 
al., 2001; Taylor and Abdel-Rahman, 2009). Reactive oxygen species (ROS) may 
play a role in the development of cardiovascular diseases related to high blood 
pressure. ROS are formed from nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases, which generate superoxide and cause uncoupling of endothelial 
nitric oxide synthases. There are four types of NADPH oxidase (Nox enzymes), 
which are considered main sources of reactive oxygen species; these are Nox1, 
Nox2, Nox4, and Nox5. Elevation of renal oxidative stress causes renal vascular 
resistance, reduction of glomerular filtration rate, decreasing the excretion of 
sodium via an increase of renal tubular reabsorption leading to impaired renal 
pressure natriuresis (Hall et al., 2013). 
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The synergistic actions of prostacyclin (PGI2) and thromboxane (TXA2) also 
regulate vascular function. Their production is catalyzed by cyclooxygenase (COX) 
enzymes, which are classified into two isoforms COX-1 and COX-2. COX-1 is 
expressed in endothelial cells, whereas COX-2 is only expressed when the 
endothelium is damaged and exposed to inflammatory cytokines (Hall et al., 
2013). COX-2 converts arachidonic acid to prostaglandin H2, which is then 
synthesized into PGI2 by prostacyclin synthase. PGI2 binds to the prostacyclin 
receptors (IP), which are located on vascular smooth muscle cells, which activates 
adenylate cyclase that induces cyclic adenosine monophosphate (cAMP) synthesis. 
cAMP then activates protein kinase A, which allows relaxation of the smooth 
muscle (Sandoo et al., 2010). 
Endothelium-derived hyperpolarizing factor (EDHF) is a substance or electrical 
signal, which hyperpolarizes the smooth muscle to generate the membrane 
potential of the vascular smooth muscle cell, causing vasodilation. The identity of 
EDHF is still unknown. Indeed, NO and PGI2 can also dilate the vessel by 
hyperpolarizing the smooth muscle cells but for a short period (Sandoo et al., 
2010; Hall et al., 2013). 
Endothelin (ET) is a vasoconstrictor, which is expressed in the body in three 
isoforms, ET-1, ET-2, and ET-3. ET-1 causes potent vasoconstriction, which 
stimulates ETA receptors, leading to hypertension, systemic and renal 
vasoconstriction and impaired renal pressure natriuresis (Hall et al., 2013). ET-1 
receptors have been identified on smooth muscle cells; are ETA and ET-B2, also ET-
B1 on endothelial cells. Regulation of ET-1 production is stimulated by 
inflammatory cells; such as interleukins and TNF-α and decreased by NO and PGI2 
(Sandoo et al., 2010). ET-1 binds to ETA or ET-B2 receptors, which cause smooth 
muscle Ca2+ channels to open allowing extracellular Ca2+ into the cell. This causes 
vasoconstriction of smooth muscle cells. ET-B1 receptors on the endothelial cells 
are downregulated, though ET-B2 receptors on smooth muscle cells are 
upregulated, therefore enhancing vasoconstriction (Hall et al., 2013; Sandoo et 
al., 2010). 
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1.4 Human essential hypertension 
Hypertension is considered a main risk factor for CVD and mortality and is 
characterised by chronically increased arterial blood pressure (Carretero and 
Oparil, 2000). The Sixth Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) previously 
classified hypertension in adults (Chobanian et al., 2003) and has been recently 
updated to be comprehensive and incorporates new information from studies 
regarding blood pressure related risk of CVD, and blood pressure thresholds to 
initiate antihypertensive drug treatment (Whelton and Carey, 2018), as shown in 
Figure 1-3. Human hypertension is diagnosed when a systolic blood pressure (SBP) 
is ≥140 mm Hg and a diastolic blood pressure (DBP) is ≥90 mm Hg (Muntner et al., 
2014).  
Essential hypertension accounts for approximately 90-95% of all hypertension 
cases, however around 5-10% of hypertension cases are caused by identifiable 
secondary pathological conditions; such as renal vascular hypertension, primary 
hyperaldosteronism, cushing's syndrome, pheochromocytoma and gestational 
hypertension (Carretero and Oparil, 2000). Essential or primary hypertension is a 
multi-factorial disease involving major contribution from both genes and 
environmental factors (Carretero and Oparil, 2000). Several risk factors underlying 
essential hypertension have also been identified including age, sex, genetics and 
demographic factors (Ruppert and Maisch, 2003). Thirty to fifty percent of genetic 
elements found to contribute to hypertension. Genetic variations can affect 
hypertension genesis, which demonstrates risk factor for development of stroke, 
ischemic heart disease, peripheral vascular disease and renal damage (Larsson et 
al., 2013). Genome wide association studies (GWAS) have identified more than 
100 loci associated with blood pressure (Russo et al., 2018). A number of candidate 
genes have been identified, including those coding for components of renin 
angiotensin system, sodium epithelial channels, catecholaminergic/adrenergic 
function, lipoprotein metabolism, hormone receptors and growth factors 
(Pintérová et al., 2011). 
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Figure 1-3: Hypertension classifications, adapted from (Whelton and Carey, 2018). 
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 Hypertension prevalence 
Hypertension is predominant within the population; affecting 40% of adults aged 
25 years and older in 2008. The prevalence of uncontrolled hypertension increased 
in the population from 600 million in 1980 to nearly 1 billion in 2008. In addition, 
it caused 7.5 million deaths around the world and 57 million disability adjusted 
life years (DALYS) (World Health Organization, 2018). 
The prevalence of Hypertension is highest in Africa with 46% for both sexes. 
However, the Americas had the lowest prevalence of hypertension with 35%, 
where men have higher prevalence than women (39% for men and 32% for women). 
These differences in blood pressure between sex were also statistically significant 
in Europe (World Health Organization, 2018).  
The 2018 WHO statistical report revealed that low and middle income countries 
had highest prevalence of hypertension at around 40%. However, the prevalence 
in high-income countries was lower, at 35% (World Health Organization, 2018). 
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 Hypertension risk factors 
Hypertension risk factors are classified into modifiable risk factors such as weight, 
smoking, high alcohol intake, diabetes, insulin resistance, low physical activity, 
stress/depression, caffeine intake, low potassium intake, low calcium intake, 
vitamin D deficiency and high salt intake and unmodifiable risk factors such age, 
sex, ethnicity and family history (Cohen, 2009; Gong et al., 2014).  
1.4.2.1  Environmental risk factors  
It is been identified that environmental risk factors account for approximately 80% 
of hypertension prevalence (Beilin, 2004). Epidemiologic studies show that 10–20 
mmHg of the average systolic blood pressure levels among Western population in 
adolescence ages can be attributed to many life style factors; obesity, low 
physical activity, high alcohol intake, unbalanced diet containing high salt, 
saturated fat and sugar, and low in fruit and vegetables (Beilin, 2004). It has been 
found obesity is associated with increased prevalence of cardiovascular risks 
including hypertension worldwide (Rahmouni, 2014). A strong association has been 
observed between increased body mass index (BMI) and systolic/diastolic blood 
pressures (Timpson et al., 2009). This might be due to the underlying mechanisms 
of increased tubular sodium reabsorption in obese patients with hypertension; 
including increased renal interstitial pressure of the kidneys by retroperitoneal 
visceral and renal sinus fat, thus reducing tubular and medullary blood flow and 
increasing sodium reabsorption in the loop of Henle. Also, stimulation of the RAAS 
system promotes sodium/fluid retention through increased renal tubular sodium 
reabsorption. Increased angiotensin II and aldosterone levels activate vascular 
production of reactive oxygen species by NADPH oxidase resulting in oxidative 
stress in obese individuals. In addition, increased activity of mineralocorticoid 
receptors (MRs) by leptin, which is a 167 amino acid hormone released by adipose 
tissue, plays an important role in energy expenditure and storage. Leptin 
contributes to the progression of hypertension in obese individuals through 
activation of sympathetic nervous system by modulation of the brain melanocortin 
system and increases peripheral vascular resistance by activation of arterial MRs 
(Samson et al., 2017). Furthermore, obesity leads to insulin resistance, a condition 
where cells fail to response to normal insulin, which is also associated with 
elevated blood pressure through reduction of tyrosine kinase activity in 
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adipocytes. It is also associated with increased insulin secretion and the 
production of inflammatory biomarkers such as leptin, Interleukin-1 (IL-1), 
Interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), which lead to dysregulation 
of carbohydrate and lipid metabolism (D’Elia and Strazzullo, 2018) (Figure 1-4). 
Previous clinical and animal studies have determined that weight gain can increase 
arterial pressure, however weight loss has a beneficial effect on controlling of 
blood pressure (Weisbrod et al., 2013; Haufe et al., 2012; De Ciuceis et al., 2011). 
Lifestyle modifications are mostly recommended as the first line of hypertension 
treatment (non-pharmacologic therapy) to help weight loss (Rahmouni, 2014) 
(Figure 1-3). 
 Salt sensitivity  
Sodium is an important nutrient in the body, which is essential for nerves and 
muscles to function correctly and is involved in the regulation of the water 
homeostasis (Ha, 2014). However, high dietary salt intake is a challenge to the 
kidneys requiring eliminating of large amounts of salt administered, and excessive 
sodium intake predisposes to hypertension and cardiovascular diseases (Ha, 2014; 
Choi et al., 2015; Stanhewicz and Kenney, 2015). A large international 
epidemiologic study of salt and blood pressure (INTERSALT) examined the 
association between urinary sodium excretion level and blood pressure. Results of 
the study showed a significant association between excessive salt intake and 
hypertension (Ha, 2014). The World Health Organization (WHO) strongly 
recommend restricting dietary salt intake to less than 5 g/day as one of the top 
priority actions to lower rate of hypertension and cardiovascular diseases 
prevalence and reduce approximately 2.5 million deaths per year (World Health 
Organization, 2018). Currently, salt intake remains high because of highly salted 
processed foods (Frisoli et al., 2012).  
However, blood pressure responses to dietary salt intake can differ either between 
hypertensive patients or between normotensive individuals. Some individuals can 
efficiently eliminate high dietary salt intake without an increase in blood pressure, 
who are considered salt insensitive. However, salt sensitive individuals are unable 
to excrete high salt intake leading to an increase in blood pressure (Choi et al., 
2015). The mechanisms underlying hypertension associated with salt-sensitivity 
have not been clearly identified (Stanhewicz and Kenney, 2015). The possible 
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mechanisms relating to salt induced hypertension involve an impairment in the 
ability of the kidneys to excrete sodium by inhibition of the sodium pump, which 
causes increased intracellular sodium, low potassium levels and drives calcium 
into cells leading to vascular smooth muscle contraction, increased blood volume 
and increased peripheral vascular resistance (Frisoli et al., 2012). The effects of 
a high-salt diet are related to the function of the RAAS, whereby high-salt diet 
suppresses angiotensin II level through physiological blood pressure level control 
mechanisms (Drenjacnevic-Peric et al., 2011). Also, there is an association 
between the level of angiotensin II and an increase in the production of reactive 
oxygen species, which leads to decreased nitric oxide bioavailability, and 
impairment of endothelium-dependent relaxation to acetylcoline in salt-sensitive 
hypertensive rats (Zhou et al., 2006, 2003). Early studies by Bragulat et al. 
identified impairment of endothelium-derived nitric oxide system and 
acetylcholine-induced vasodilation in salt-resistant hypertensive individuals due 
to impairment of the L-arginine– nitric oxide pathway (Bragulat et al., 2001). 
 Genetic risk factors 
Twin studies and nuclear family studies have identified significant variances in 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) due to genetic 
effects that contribute 30–50% of heritability of blood pressure (Tarnoki et al., 
2014). A previous study evaluated familial aggregation of blood pressure and found 
that the relative risks of hypertension are 4.1 times in men and 5 times in women 
aged 20–39 who had two first-degree relatives affected by hypertension (Hunt et 
al., 1986). The early adoption study identified significant correlations in blood 
pressure between biological parent and siblings than parent and adopted siblings 
(Mongeau et al., 1986). Furthermore, the Victorian family Heart study showed 
correlations are more likely between hypertension and identical twins 
(monozygotic) than non-identical twin (dizygous) twins and non-twin siblings 
(Harrap et al., 2000). The identification of genetic mechanisms involved in 
hypertension is challenging due to many genes each with mild effects responding 
to different environmental stimuli contributing to blood pressure (Tarnoki et al., 
2014). 
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1.4.4.1 Mendelian forms of inheritance 
A number of monogenic or Mendelian forms of hypertension have been identified 
by positional cloning using large family pedigrees, showing an inheritance pattern 
(Padmanabhan et al., 2018). Rare mutations affect a range of genes involved in 
common pathways of hypertension including increased distal tubular re-absorption 
of sodium and chloride and volume expansion that suppresses plasma renin activity 
(Padmanabhan et al., 2018; Luft, 2003).  
1.4.4.2 Glucocorticoid- Remediable Aldosteronism or Familial 
Hyperaldosteronism Type 1 
Glucocorticoid-remediable aldosteronism is an autosomal dominant disorder 
characterised by an early onset of hypertension with normal or elevated 
aldosterone levels despite lower or suppressed renin activity and hypokalemia 
(McMahon and Dluhy, 2004). This is caused by a chimeric gene fusing nucleotide 
sequence between two closely related aldosterone steroid biosynthesis genes; the 
5′ regulatory sequences of 11β-hydroxylase (CYP11B1) that is fused with the distal 
coding sequences of aldosterone synthase (CYP11B2). This leads to aldosterone 
synthase being expressed in the adrenal gland under the regulation of 
adrenocorticotropic hormone (ACTH) rather than angiotensin II as the main 
regulator of aldosterone secretions. Aldosterone secretions become linked to 
cortisol secretions leading to increased volume expansion, metabolic alkalosis 
with hypokalemia, low renin, high aldosterone, and hypertension (Toka, 2018; 
McMahon and Dluhy, 2004).  
1.4.4.3 Apparent Mineralocorticoid excess  
Apparent mineralocorticoid excess (AME) is an autosomal recessive disorder 
characterised by early onset hypertension with hypokalaemia, metabolic alkalosis, 
low plasma renin activity, aldosterone concentration and responsiveness to 
spironolactone. This is due to the impaired activity of the enzyme 11β- 
hydroxysteroid dehydrogenase Type 2 (HSD11β2). The normal function of HSD11β2 
is converting cortisol into its inactive metabolites to prevent cortisol from binding 
to the mineralocorticoid receptor. Activation of the mineralocorticoid receptor 
results in aldosterone like effect, sodium and water retention, volume expansion, 
low renin, low aldosterone, and hypertension (Toka, 2018; Funder, 2017).  
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1.4.4.4 Liddle Syndrome 
Liddle syndrome is an autosomal dominant disorder with early onset of 
hypertension. This condition occurs due to mutations in the genes coding the β or 
γ subunits of epithelial sodium channel (ENaC) by deletions of proline-rich regions, 
which are essential for binding of Nedd4-2 (neural precursor cell-expressed 
developmentally down-regulated 4-2) as a regulatory repressor that promotes 
ENaC degradation. Disruption of the β and γ subunits ability to bind Nedd4 leads 
to increase epithelial sodium channels, increased ENaC activity at the renal distal 
tubule apical cell surface, resulting in increased sodium reabsorption, 
hypokalemia alkalosis, suppressed plasma renin activity, and low plasma 
aldosterone levels and hypertension (Toka, 2018). 
1.4.4.5 Hypertension brachydactyly syndrome 
Hypertension with brachydactyly is an autosomal dominant disorder, which is an 
inherited condition affecting individuals at the juvenile stage. This condition is 
characterised by shortened finger bones with severe development of 
hypertension. In this syndrome, blood pressure is not salt-sensitive, there is 
normal function of the renin-angiotensin-aldosterone and catecholamine axis and 
no evidence of left ventricular cardiac hypertrophy. However, baroreceptor reflex 
response is impaired due to a structural variation within chromosome 12, resulting 
in an excessive increase of blood pressure (Toka, 2018). 
1.4.4.6 Gitelman Syndrome 
Gitelman syndrome is an autosomal recessive condition diagnosed with 
hypotension and symptoms similar to individuals who are on thiazide diuretics; 
include hypokalemia, hypomagnesemia, metabolic alkalosis, and renal sodium 
wasting. This condition is associated with a loss function of the thiazide-sensitive 
sodium chloride cotransporter (NCC) gene (i.e. SLC12A3 (Solute Carrier Family 12 
Member 3)) (Toka, 2018). 
1.4.4.7 Bartter Syndrome 
Bartter syndrome is an autosomal transmitted condition characterised by 
hypotension, renal salt wasting, hypokalemic, metabolic alkalosis, and 
hypercalciuria. This condition results from mutations in genes responsible for the 
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reabsorption of sodium chloride in the thick ascending limb (TAL). Neonatal 
bartter syndrome is the most common and life threatening, which is characterised 
by hypotension, polyuria, polydipsia and hypercalciuria. This is caused by 
mutations in three genes that are important in sodium reabsorption in the TAL 
(i.e. NKCC2, ROMK and CLCNKA). Bartter type 1 is caused by loss-of-function 
mutation in the sodium-potassium-2 chloride cotransporter (NKCC2) gene. Bartter 
type 2 is caused by mutation in the renal outer medullary potassium channel 
(ROMK) gene, whilst type 3 bartter is caused by loss-of-function in the voltage-
gated chloride channel Kb (CLCNKB) gene and is usually identified at school age. 
Bartter type 4 is caused by mutations in barttin (BSND), a β-subunit for CLCNKB in 
the TAL. Barttin is also expressed in stria vascularis cells of the inner ear. Mutation 
in barttin leads to renal salt wasting, hypercalciuria and sensorineural hearing loss 
(Toka, 2018). 
1.4.4.8 Pseudohypoaldosteronism Type I 
Pseudohypoaldosteronism (PHA) type features severe neonatal hypotension with 
salt wasting and elevation of aldosterone levels. There are two genetic subtypes, 
autosomal dominant and autosomal recessive. The dominant form arises from 
mutation in the mineralocorticoid receptor gene. In early stages, affected 
children exhibit hyponatremia, hyperkalemia, and urinary salt wasting, frequent 
vomiting, failure to thrive, and short stature. The dominant form can improve 
with age. The autosomal recessive type form arises from loss of function mutation 
in any of the ENaC subunits causing decreased channel activity, renal salt wasting 
and hypotension in neonates. Unlike the dominant form these individual do not 
improve with age (Toka, 2018).  
1.4.4.9 Pseudohypoaldosteronism type II  
Pseudohypoaldosteronism type II (PHA II), also known as Gordon’s syndrome, is an 
autosomal dominant disorder characterised by hypertension, hyperkalaemia, 
hyperchloraemia, and metabolic acidosis. Hypercalciuria has also been reported 
in some cases of Gitelman syndrome. This is the result of mutation in serine-
threonine kinase genes, WNK1 and/or WNK4, causing an increase in sodium re-
absorption by stimulation of the sodium chloride cotransporter (NCC) in the distal 
convoluted tubule despite volume status. Decreases in renal tubular potassium 
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excretion in PHA II occur via inhibition of ROMK, the apical renal outer medullary 
potassium channel resulting in hypertension (Toka, 2018). 
 Treatment of hypertension 
As first line therapy, several non-pharmacological strategies have been 
recommended to control blood pressure in order to improve life style choices such 
as good diet, exercise, weight loss, smoking cessation and reasonable consumption 
of alcohol, tobacco and caffeine. These strategies help to reduce blood pressure 
and consequently reduced the risk of cardiovascular diseases (Liu et al., 2018). 
Nevertheless, pharmacologic therapy is the required treatment for the 
management of blood pressure in hypertensive patients. 
Pharmacological treatments of hypertension are classified to five main classes 
according to the mechanism of actions. These include β-blockers, diuretics, 
angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, and 
calcium channel blockers. Also, four additional pharmacological classes are renin 
inhibitors, alpha-adrenergic receptor blockers, centrally acting agents, and direct 
acting vasodilators (Laurent, 2017) (Figure 1-5).  
1.4.5.1 Angiotensin converting enzyme inhibitors 
Angiotensin converting enzyme inhibitors (ACEI) are considered to be a first-line 
therapy in treatment of stage 1 hypertension as recommended by NICE guidelines 
for antihypertensive treatment (Figure 1-5). ACEI blocks the formation of 
angiotensin II and consequently downstream effects through angiotensin II type 1 
(AT1) receptor and angiotensin II type 2 (AT2) receptor, which leads to reduced 
vascular tone and extracellular fluid volume and thus reduce blood pressure. In 
addition, ACE inhibitors down regulate sympathetic adrenergic activity via 
blocking the effects of angiotensin II on sympathetic nerve release and reuptake 
of noradrenaline (Wang et al., 2014). ACE inhibitors may also be used in 
hypertension caused by renal artery stenosis, which causes renin-dependent 
hypertension due to increased release of renin by the kidneys. ACE inhibitors 
inhibit the breakdown of kinins leading to increased concentration of bradykinin 
that is probably responsible for the unwanted side effects of cough and allergic 
reactions (Sear, 2013; Laurent, 2017) (Table 1-1).  
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1.4.5.2 Angiotensin II receptor blockers 
Angiotensin II receptor blockers (ARBs) have effects that are similar to angiotensin 
converting enzyme (ACE) inhibitors. ARBs block the binding of angiotensin II to the 
AT1 receptor and facilitate stimulation of the AT2 receptor. Thus, ARBs may 
additionally cause vasodilation and natriuresis, which contribute to blood pressure 
reduction (Sear, 2013; Laurent, 2017) (Table 1-2).  
ARBs and ACE inhibitors are less effective in lowering blood pressure in African 
Americans population. Therefore, the recommendations for first-line drug therapy 
differ between Caucasian and African American population (Lund, 2016). 
However, current recommendations are that ACE inhibitors and ARBs are 
appropriate for use in African Americans, but not as monotherapy. A diuretic or 
calcium-channel blocker should be used with an ACE inhibitor or ARB to achieve 
the target reduction in blood pressure, as recommended by NICE guidelines for 
antihypertensive treatment (Figure 1-5). 
1.4.5.3 Diuretics 
Diuretics are one of major therapeutic class of antihypertensive drugs, which help 
to reduce blood pressure by increasing sodium excretion and diuresis. Diuretics 
are classified into three different classes according to different mechanism of 
actions (Table 1-2). Thiazide diuretics inhibit sodium-chloride cotransporters 
(Na+/Cl− co-transporters) in the proximal diluting segment of the distal collecting 
tubule. Loop diuretics act on the medullary and cortical thick ascending limb 
segments of the nephron to prevent sodium, chloride and water reabsorption. 
Loop diuretics are not used as first-line therapy for treatment of hypertension due 
to a short duration of action. The third class is the potassium-sparing diuretics 
such as amiloride, triamterene and spironolactone. Both amiloride and 
triamterene have weak antihypertensive effects. However, spironolactone, which 
also acts as an aldosterone antagonist, is useful as an antihypertensive treatment 
in primary or secondary hyperaldosteronism (Sear, 2013; Laurent, 2017). 
1.4.5.4 Calcium-channel blockers 
Calcium channel blockers act as vasodilators of small resistance arteries by 
blocking Ca2+ influx through L type voltage-gated Ca2+ channels in the smooth 
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muscle cells of the resistance vessels. Also, CCBs reduce the increase in 
intracellular Ca2+ in response to membrane depolarization, thus reduce total 
peripheral resistance and mean blood pressure. Some calcium channel blockers 
also reduce heart rate and myocardial contractility, which leads to decreased 
cardiac output and mean blood pressure (Sear, 2013; Laurent, 2017) (Table 1-2). 
All calcium channel blockers (CCB) are effective in reducing blood pressure, 
although there is some argument over the side effect of short-acting drugs (Sear, 
2013; Laurent, 2017). 
1.4.5.5 Beta-blockers 
β adrenoceptor blocking drugs act on receptors by competitive antagonism, and 
reduce blood pressure elevation by reducing cardiac output (Laurent, 2017) and 
by inhibiting the release of renin from the kidneys (Marr and Reimer, 2009). Β-
blockers are used as effective treatment for angina, cardiac arrhythmia, 
hypertension, glaucoma and migraine (Ladage et al., 2013). Reduced cardiac 
output by β-blockade can be an effective treatment for hypertension in 
conjugation with other antihypertensive agents i.e. diuretics (Laurent, 2017). 
However, acute treatment with a β-blocker is not very effective in decreasing 
arterial pressure due to a compensatory increase in systemic vascular resistance.  
There are several ways of classifying the pharmacologic effects of the β-blockers, 
depending on their receptor specificity, lipophilicity or hydrophilicity and the 
presence of either intrinsic sympathomimetic or vasodilator activity. The β1 
selective drugs such as atenolol, bisoprolol, and metoprolol are cardioselective. 
These drugs reduce the myocardial remodelling effects, while the β adrenoceptor 
blocking drugs do not cause vasodilation effects. Nonselective (β1 and β2) drugs 
such as propranolol, oxprenolol, timolol, alprenolol and nadolol, which have 
similar effects to the selective agents on blood pressure (Sear, 2013; Laurent, 
2017) (Table 1-2). 
 Rationale for combination anti-hypertensive therapy 
A combination of antihypertensive drugs is used when hypertensive patients do 
not achieve the target level of control of their blood pressure. Antihypertensive 
effect of a combination of drugs is greater than that obtained by monotherapy as 
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a result of combined action on several different hypertensive mechanisms 
(Guerrero-García and Rubio-Guerra, 2018). Both the eighth report of the Joint 
National Committee for the Prevention, Detection, Evaluation and Treatment of 
Hypertension (JNC8) published in 2014 (James et al., 2014) and the guidelines of 
the European Society of Cardiology and the European Society of Hypertension 
(ESC/ ESH) for the management of hypertension published in 2018 (Brown, 2018) 
recommend the use of combinations of antihypertensive agents from the 
beginning for individual in which the probability of achieving the recommended 
treatment targets in hypertension with monotherapy is low, i.e. in patients with 
systolic pressure SBP>150 mmHg or DBP> 90 mmHg.  
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Figure 1-4: Pharmacological classes and related mechanisms of action of the 
antihypertensive effect (adapted from Laurent, 2017).  
Bold names mean that this is the main mechanism of action. Molecular targets are given for each 
mechanism of action. Abbreviations: ACEIs, angiotensin converting enzyme inhibitors; ARBs, 
angiotensin receptor blockers; CCBs, calcium channel blockers; DHP, dihydropyridine; SARCKATP, 
sarcolemnal adenosine triphosphate-dependent potassium channels; NKCC, Na-K-Cl cotransporter; 
ENaC, the epithelial sodium channels; RI, renin inhibitor.  
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Table 1-1: Pharmacological classes and sub-classes of antihypertensive drugs (adapted from Laurent, 2017). 
Pharmacological classes Sub-classes  Molecules 
Major classes   Non-vasodilating with β1 Acebutolol, Atenolol, Betaxolol, Bisoprolol 
    
Beta-blockers 
  
  
  
  Non-vasodilating without β 1-selectivity 
  
Carteolol, Esmolol, Metoprolol, Nadolol, Oxprenolol, 
Penbutolol, Propranolol, Timolol   
  
Vasodilating Celiprolol, Carvedilol, Labetalol, Nebivolol, Pindolol   
Diuretics   Loop diuretics Furosemide, Bumetanide, Torsemide 
    
    Thiazides diuretics Bendroflumethiazide, Chlorothiazide, Chlortalidone, 
Hydrochlorothiazide    
      
    Potassium sparing diuretics Amiloride, Eplerenone, Spironolactone, Triamterene 
        
Angiotensin-converting enzyme 
inhibitors 
  Benazepril, Captopril, Cilazapril, Enalapril, Fosinopril, 
Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, 
Ramipril, Trandolapril, Zofenopril 
  
     
Angiotensin II receptor blockers 
  Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, 
Telmisartan, Valsartan  
Calcium-channel blockers Non-dihydropyridines Diltiazem, Verapamil 
   
    Dihydropyridines Amlodipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, 
Manidipine, Nicardipine, Nifedipine, Nitrendipine       
Other classes     
 
Renin inhibitors      Aliskiren 
 
Alpha-adrenergic receptor 
antagonists  
  
 
Doxazosin, Prazosin, Terazosin 
   
 
Centrally acting agents    Clonidine, Methyl-dopa, Rilmenidine 
 
Direct acting vasodilators 
  
 
 
Hydralazine, Minoxidine 
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Figure 1-5: NICE guidelines for antihypertensive treatment (Adapted from the National 
Institute for Health and Care Excellence, 2018). 
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1.5 Resistant hypertension 
Resistant hypertension is uncontrolled blood pressure (>140/90 mm Hg) after 
treatment with more than three antihypertensive medications (Sheppard et al., 
2017). Resistant hypertensive patients have four times higher risk of 
cardiovascular diseases than patients diagnosed with primary hypertension (Tobe 
and Lewanczuck, 2009). Prevalent resistant hypertension increased between 1996 
to 2004, then plateaued and decreased in recent years. Nevertheless, resistant 
hypertension remains common in the UK hypertensive population (Sinnott et al., 
2017).  
Several factors can contribute to resistant hypertension include pseudo-
hypertension that is caused by poor clinic blood pressure measurement technique, 
patient non-adherence to antihypertensive therapy, white-coat effect (i.e. blood 
pressure is high in the clinic but is controlled at home) and life style factors 
(obesity, alcohol, smoking, high salt dietary) (Sarwar et al., 2013; Sheppard et al, 
2017). In addition, many drugs may encourage development of hypertension; such 
as non-steroidal anti-inflammatory drugs, oral contraceptives, adrenal steroids 
and antineoplastic drugs (Sarwar et al., 2013). There are common secondary 
causes of resistant hypertension such as sleep apnea, renal artery stenosis, renal 
parenchymal disease, and primary aldosteronism. However, there are also some 
uncommon causes such as pheochromocytoma, cushing’s disease, thyroid and 
parathyroid dysfunction (Sarwar et al., 2013)  
National Institute for Health and Care Excellence (NICE) guidelines suggest 
pharmacological and non-pharmacological therapy to control resistant 
hypertension. Three classes of hypertension with optimal doses should be used to 
control resistant hypertension; including an ACE inhibitor, a calcium channel 
blocker and a diuretic (NICE, 2018). 
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1.6 New treatments for hypertension 
Despite combining multiple antihypertensive medications together with lifestyle 
modification, there is still not sufficient control of blood pressure in some 
hypertensive patients who suffer from multiple comorbidities. For that reason, 
the need for new treatment for the hypertension is still an area demanding further 
research. There are several studies which aimed to identify novel drugs or 
strategies to enhance antihypertensive effects (Makani et al., 2013; Kunz et al., 
2008). 
 Vasopeptidase inhibitor 
Angiotensin-converting enzyme, neutral endopeptidase (neprilysin) and 
endothelin converting enzyme are pharmacological targets for treatment of 
hypertension. Therefore, inhibition of all these enzymes in a single drug has been 
investigated in order to help improve the control of blood pressure as well as 
reduce organ damage. Vasopeptidase inhibitors, which provide dual inhibition of 
neprilysin and angiotensin-converting enzyme have been developed and reached 
the clinical stage. Both neprilysin and angiotensin-converting enzyme share similar 
structure and catalytic mechanisms, which allowed for the design of dual 
vasopeptidase inhibitors that have the same inhibitory activities against both 
enzymes (Laurent et al., 2012). 
Omapatrilat is a dual vasopeptidase inhibitor, which is highly specific, non-
peptidergic, orally active and more effective for lowering blood pressure than 
angiotensin-converting enzyme inhibitors (ACEIs) alone. Conversely, angioedema 
incident was higher with omapatrilat than with ACEIs. This is due to increased 
bradykinin and reduced levels of substance P and neurokinin, resulting from the 
synergistic inhibition of their degradation by the dual vasopeptidase inhibition. 
Therefore, this drug failed in clinical trials as a potential treatment for congestive 
heart failure and was never marketed.(Laurent et al., 2012). 
LCZ696 (Entresto™) is a first class inhibitor of dual-acting angiotensin-2 type-1 
receptor and neprilysin inhibitors, which was innovated by Novartis 
Pharmaceuticals Canada Inc. Entresto™ was developed by combining the diprotic 
ARB valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio. A 
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number of ongoing phase 2 randomised clinical trials are assessing the role of 
valsartan/sacubitril combination in the treatment of heart failure and 
hypertension (Hubers and Brown, 2016; Laurent et al., 2012; Shaddy et al., 2017). 
 Aldosterone synthase inhibitors 
Novartis Pharmaceuticals developed LCI699, the first-in-class oral inhibitor of 
aldosterone synthase, which has been shown to reduce blood pressure in primary 
hypertensive patients. This drug was designed to overcome side effects that are 
associated with mineralocorticoid receptor-antagonist or aldosterone antagonist 
(i.e. spironolactone and eplerenone). These side effects include hyperkalaemia, 
and increased plasma level of aldosterone and gynaecomastia due to the poor 
selectivity of spironolactone. However, LCI699 also partially inhibited 11-β-
hydroxylase, which catalyses conversion of 11-deoxycortisol to cortisol. 
Therefore, LCI699 development was stopped in 2010, and research focused more 
on selective aldosterone synthase (Laurent et al., 2012; Namsolleck and Unger, 
2014). 
 Endothelin antagonists 
TRACLEER® (bosentan) is an endothelin-A and endothelin-B receptor antagonist. 
Bosentan was developed by Actelion Pharmaceuticals US, Inc and is suitable for 
long-term treatment of pulmonary artery hypertension, however, its use has been 
investigated in patients with resistant hypertension. In resistant hypertension it 
reduced blood pressure, but it was associated with side-effects such as increased 
levels of liver transaminase, oedema, and water retention.  
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1.7 Animal Models  
Animal models have been widely used for investigation of cardiovascular disorders 
for many years, in order to study a range of cardiovascular diseases mechanisms, 
including hypertension. This allows in depth understanding of the functional, 
biochemical, and genetic level effects on development of the disease. Animal 
models are also useful in pre-clinical studies in the development of strategies for 
the prophylaxis, diagnosis and treatment of diseases.(Bähr and Wolf, 2012; 
Hewitson et al., 2015). 
The use of animals is not only based on the biology of most mammals, but also 
based on the fact that human diseases affect other animal species. It is mainly 
the case for most infectious diseases, but also for other common disorders; such 
as cancer, hypertension, diabetes and epilepsy. These diseases share the same 
mechanisms, also the veterinary drugs used to treat animals are similar to those 
used to treat humans. Many human surgical techniques have been designed and 
improved by using a range of animal species before being applied to humans. 
Therefore, many advances in basic science and medical research have been 
possible due to investigation of animal models (Barré-Sinoussi and Montagutelli, 
2015). The most widely used experimental models are rodents models (Olson and 
Graham, 2014).  
 Mouse models 
Mice have been the species of choice for geneticists for many years due to the 
ease of manipulating their genes. Use of the mouse has become an important part 
of many research fields such as embryology, pharmacological, cancer, and 
infectious disease, however, they have been less well studied in CVD. The 
development of genome research and genetic manipulation (i.e. transgenic and 
knockout mouse models) was made the mouse a favoured model for investigating 
the relationship of molecular makeup to disease conditions (Olson and Graham, 
2014).  
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 Rat model 
Rats are the favoured species for hypertension research. There are a variety of 
genetically hypertensive strains and non-genetic models, which demonstrate 
excellent pathophysiological similarities to human diseases. A wide range of 
hypertensive rat strains have been produced over the last 30 years, which are good 
models for both essential and secondary hypertension. Genetic models range from 
inbred strains, such as the spontaneously hypertensive rat (SHR) and stroke-prone 
spontaneously hypertensive rat (SHRSP) to genetically modified rats generated by 
CRISPR/Cas9 protein genetic engineering (Graham et al., 2005; Leong et al., 2015; 
Remy et al., 2017). In addition, non-genetic hypertensive rat models include 
surgically induced hypertension, such as ligation of renal artery (Segarra et al., 
2016), and diet-induced hypertension through increased salt intake, for example 
the Dahl salt-sensitive and Sabra rats (Leong et al., 2015). More details regarding 
some of the animal models used for hypertension and their different aetiologies 
are given in Table 1-2. 
1.7.2.1 The Stroke-Prone Spontaneously Hypertensive Rat 
The Stroke-Prone Spontaneously Hypertensive Rat (SHRSP) is a sub-strain of SHR, 
which were obtained by selective inbreeding of normotensive Wistar-Kyoto (WKY) 
rats in the laboratory of Okamoto and colleagues at the Kyoto University Faculty 
of Medicine, Japan (Yamori et al., 1974; Okamoto et al., 1975). The SHR was 
developed by selective inbreeding of WKY with high systolic blood pressure. The 
blood pressure of SHR spontaneously increase from 4 weeks of age reaching an SBP 
in males of 180-200 mmHg relative to 130 mmHg in the WKY strain. Consequently, 
the SHR was divided into three sub-strains (A-C); where sub-strain A consistently 
exhibited higher SBP and an increased susceptibility for cerebrovascular disease. 
Inbreeding of offspring from sub-strain A produced the SHRSP (Okamoto et al., 
1975; Yamori et al., 1974), as shown in Figure 1-6. 
SHRSP rats are characterised by severe hypertension (220-240 mmHg) and high 
incidence of cerebral stroke (approximately 80%) when compared with the SHR. 
(Yamori et al., 1974; Okamoto et al., 1975). The SHRSP model exhibits end-organ 
damage phenotypes similar to human essential hypertension, such as left 
ventricular hypertrophy, stroke, and renal failure (Graham et al., 2005). However, 
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spontaneous heart failure and atherosclerosis have not been observed in the SHRSP 
(Nabika et al., 2012).  
The Glasgow colony of SHRSP rats (SHRSPGla) was established in 1991 and 
originated from rats provided by Dr DF Bohr at the University of Michigan (more 
details are provided in Chapter 2, Section 2.2.1). Both male and female SHRSPGla 
are hypertensive and display cardiac hypertrophy and endothelial dysfunction, 
however males are more severely affected than females and are more likely to 
display evidence of stroke, typically after 5 months of age (Graham et al., 2004). 
SHRSPGla are salt sensitive and display severe renal disease after 3 weeks of salt-
loading with 1% NaCl in drinking water (Caline Koh-Tan et al., 2017).  
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Table 1-2: Common rodent models for hypertension with different aetiology (adapted from Leong et al., 2015). 
Experimental model Description 
Genetic hypertension 
(i) SHR 
(ii) Dahl salt-sensitive 
(iii) Transgenic 
(i) SHR is developed by inbreeding Wistar rats (brother-to-sister) with the highest BP. The BP increases from week 6 and 
reach systolic BP of 180–200 mmHg. SHR may develop cardiac hypertrophy, cardiac failure, renal dysfunction, and 
impaired endothelium-dependent relaxation.  
  
(ii) Dahl salt-sensitive rats derived from Sprague-Dawley rats on the basis of administering high NaCl diet. Salt-sensitive 
rats become hypertensive when given normal salt diets; however these rats develop severe and fatal hypertension with 
high salt diet (8% NaCl).These rats may develop cardiac hypertrophy severe cardiac failure, hypertensive nephropathy, 
impaired endothelium-dependent relaxations. 
 
(iii) Transgenic model can be generated by overexpression of a specific gene, for example, the mouse Ren-2 gene, and 
TGR (mREN2)27. Manifestations include marked cardiac hypertrophy, moderate proteinuria, and impaired endothelium-
dependent relaxations.  
Endocrine hypertension (i) Administration of DOCA in a combination with high salt diet and unilateral nephrectomy.   
   (ii) DOCA-induced hypertension induces a low renin model of hypertension.  
   (iii) Increased cardiac weight, proteinuria, glomerulosclerosis, and impaired endothelium-dependent relaxations. 
Pharmacological hypertension (i) Nitric oxide-deficient model by administering NOS inhibitors such as L-NAME. 
(ii) Increase in BP was reported during long-term oral treatment with NOS inhibitors.   
   (iii) Development of endothelial dysfunction is gradually with increased of BP.     
Renal hypertension (i) This includes two-kidney one-clip hypertension (2K1C; constriction of one renal artery while the contralateral kidney 
is left intact), one-kidney one-clip hypertension (1K1C; one renal artery is constricted and the contralateral kidney is 
removed), and two-kidney two-clip hypertension (2K2C; constriction of aorta or both renal arteries). 
  
 
(ii) In the two-kidney model, circulating renin and aldosterone levels are increased, which are most notably in the early 
phase of hypertension. 
Abbreviations: SHR, spontaneously hypertensive rat; BP, blood pressure; NaCl, sodium chloride; TGR, transgenic rat; RAAS, renin-angiotensin-aldosterone 
system; DOCA, deoxycorticosterone acetate; NOS, nitric oxide synthase; L-NAME, Nω-nitro-L-arginine methyl ester. 
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Figure 1-6: Genealogical background of the Stroke Prone Spontaneously Hypertensive Rat (SHRSP). 
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1.8 The role of fatty acids in cardiovascular disease 
Fatty acids are long chains of lipid-carboxylic acid found in fats and cell 
membranes as a component of phospholipids and glycolipids. Carboxylic acid is an 
organic acid containing the functional group –COOH. Fatty acids are classified into 
saturated fatty acids, unsaturated fatty acids, monounsaturated fatty acids, the 
omega-6 and omega-3 polyunsaturated, and very long chains fatty acids (Lecerf, 
2009). Fatty acids are metabolised by two different process; catabolic processes 
to produce energy, and anabolic processes to generate biologically important 
molecules such as triglycerides, phospholipids, hormones and ketone bodies. The 
main role of fatty acids metabolism is energy production. Fatty acids are oxidized 
to CO2 and water by beta oxidation (β- oxidation) and the citric acid cycle to 
produce ATP (Lopaschuk et al., 2010). Alterations in fatty acid metabolism have 
been found to be associated with pulmonary arterial hypertension, resulting from 
elevations in the levels of circulating free fatty acids and long chain acylcarnitines 
(Brittain et al., 2016). In pulmonary arterial hypertension patients, it has been 
found that increased fatty acid levels promote left ventricular dysfunction, which 
are characterized by decreased rate of fatty acids oxidation and increased 
accumulation of lipotoxic compounds (Talati and Hemnes, 2015). In addition to 
pulmonary arterial hypertension, alterations in fatty acid oxidation are common 
in many heart diseases such as heart failure, ischaemic heart disease and diabetic 
cardiomyopathies. These impairments include mitochondrial dysfunction and 
defects in energy production, which are characterised by elevations in the relative 
amount of fatty acids oxidised by the mitochondria in relation to oxidized 
carbohydrates, which contributes to decreased heart function (Fillmore et al., 
2014). Studies suggest that cardiac function can be improved by enhancing glucose 
oxidation through inhibition of fatty acid oxidation (Fruchart, 2009; Keech et al., 
2005; Yue et al., 2003; Rubins et al., 2002; Tsunoda et al., 2016).  
1.9 Fatty acid beta oxidation pathway 
The major pathway for fatty acid degradation is mitochondrial fatty acid beta-
oxidation. This pathway plays an essential role in energy homeostasis in heart, 
liver and skeletal muscles. In such conditions as fasting, glucose levels become 
low, thus these tissues switch to using fatty acids to generate energy (Houten and 
Wanders, 2010). β-oxidation takes place within mitochondria to generate acetyl-
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CoA units. Four different enzymes are involved in β-oxidation pathway, which 
degrade acyl-CoAs into acetyl-CoA units. Firstly, an acyl-CoA-ester is 
dehydrogenated to produce a trans-2-enoyl-CoA, followed by hydration of the 
double bond to yield L-3-hydroxy-acyl-CoA. Subsequently, L-3-hydroxy-acyl-CoA is 
dehydrogenated to 3-keto-acyl-CoA, which is then cleaved to generate an acyl-
CoA shortened by two carbon atoms; an acetyl-CoA, one nicotinamide adenine 
dinucleotide (NADH) and one flavin adenine dinucleotide (FADH2). The resulting 
acyl-CoA can then enter another fatty acid oxidation cycle or enter the citric acid 
cycle (Houten and Wanders, 2010) (Figure 1-7). 
 Impairment of fatty acids β oxidation pathway 
High energy demand tissues such as heart, liver and skeletal muscle depends on 
fatty-acid oxidation to produce energy. Therefore, in conditions of fatty acid 
oxidation stress such as impairment of hepatic ketogenesis, glycogen and glucose 
stores, free fatty acids cannot be metabolised and stored in the cytosol as 
triglycerides. This causes weakness and lipid storage myopathy along with fatty 
acid oxidation disorders such as fatty liver, hypertrophic and dilated 
cardiomyopathy (Tein, 2014). In addition, deficiency in gluconeogenesis, β-
oxidation, and the citric acid cycle are caused due to increased levels of short or 
medium-chain fatty acids as well as dicarboxylic fatty acids metabolites from the 
ω-oxidation pathway (Tein, 2014). 
Mitochondrial fatty acid β-oxidation disorders are heterogeneous defects in 
transportation of fatty acid and mitochondrial β-oxidation. These disorders, which 
are inherited as autosomal recessive disorders include; defects in the uptake of 
long-chain fatty acids into mitochondria, and also, intramitochondrial β-oxidation 
deficiencies of long-chain fatty acids and very long chain fatty acids affecting 
membrane bound enzymes (Sim et al., 2002; Vishwanath, 2016). It has been found 
that elevations in levels of long-chain fatty acids may lead to acute muscle 
breakdown or myoglobinuria (Tein, 2014). 
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Figure 1-7: Steps of β-oxidation pathway of fatty acids.  
Fatty acyl-CoA is dehydrogenased by an enzyme acyl-CoA dehydrogenase, which is FAD dependent 
to form trans-2-enoyl-CoA. Hydration occurs at the double bond resulting in the formation of β-
hydroxyacyl-CoA, which then dehydrogenased to form β-ketoacyl-CoA by β-hydroxyacyl-CoA 
dehydrogenase. β-ketoacyl-CoA is celvaged by β-ketoacyl-CoA thiolase to form acetyl CoA, which 
can then enter another fatty acid oxidation cycle or enter the citric acid cycle. 
 
Chapter 1  68 
1.10 Fatty acid omega oxidation pathway 
Very-long-chain fatty acids (VLCFAs) are known to be degraded in peroxisomes via 
the β-oxidation pathway. An alteration in this pathway leads to increases in 
VLCFAs levels which then undergo an alternative fatty acid omega-oxidation 
pathway for breakdown (Sanders et al., 2006, 2008a). ω-oxidation of fatty acids 
consists of the conversion of the ω-methyl group of the fatty acid into an ω-
hydroxyl group by cytochrome P450 enzymes. This step requires NADPH and 
oxygen. Consequently, the ω-hydroxy fatty acid is oxidised into a ω-carboxylic 
acid by an NAD+-dependent alcohol and aldehyde dehydrogenase system to 
produce dicarboxylic acids. Finally, dicarboxylic acids can be β-oxidised in 
peroxisomes and/ or mitochondria to shorter-chain dicarboxylic acids, which are 
then excreted into the urine (Sanders et al., 2006, 2008a) (Figure 1-8).  
 Enzymes involved in fatty acids ω- oxidation pathway 
There are three enzymatic steps within the ω-oxidation pathway (Figure 1-8). 
First, the CYP4A family of enzymes, which introduced the hydroxyl group onto the 
omega carbon to generate fatty-ω-hydroxyl acid. Secondly, alcohol 
dehydrogenase, which oxidised the hydroxyl group to an aldehyde to generate 
fatty-ω-aldo acid. Finally, aldehyde dehydrogenase, which oxidised the aldehyde 
group to a carboxylic acid to produce a dicarboxylic fatty acid (Sanders et al., 
2006, 2008a). 
1.10.1.1 CYP4A enzymes 
Hepatic cytochome P450 enzymes contain a superfamily of heme-containing 
proteins that are involved in oxidative metabolism of a large range of endogenous 
and exogenous compounds; including drugs, steroids and fatty acids (Miura, 2013). 
It has been demonstrated that enzyme systems involving the microsomal or 
mitochondrial cytochrome P-450 catalyse the ω-oxidation of many fatty acids, and 
it has been recognised that cytochrome P-450 enzymes family have an essential 
role in the ω-oxidation of fatty acids (Dhar et al., 2008; Fer et al., 2008; Johnston 
et al., 2011).  
The mammalian CYP4 family of P450 enzymes catalyses the ω-hydroxylation of 
fatty acids and eicosanoids. This family include CYP4A1, CYP4A2, CYP4A3, and 
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CYP4A8, which have been well investigated in terms of their fatty acid ω-
hydroxylase activities in mice, rabbits and other mammals. In humans the 
properties and functions of CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, 
CYP4F12 are well defined, whereas the other five members of the family, 
CYP4A22, CYP4F22, CYP4V2, CYP4X1, and CYP4Z1 are less well examined 
(Johnston et al., 2011).  
1.10.1.2 Alcohol dehydrogenases (ADHs) 
Human alcohol dehydrogenases (ADHs) are a family of enzymes that catalyse 
oxidative conversion of several alcohols to aldehydes. Five kinds of subunits 
(alpha, beta, gamma, pi and chi) governed by 5 non allelic genes have been 
identified; which are ADH1, ADH2, ADH3, ADH4, and ADH5 (Yasunami et al., 1991). 
ADH isoenzymes encoded by these genes, are classified into three different classes 
(Yasunami et al., 1991), which show different physiological functions due to their 
specificity and distribution in tissues. Class I and III are identified in liver and class 
IV in stomach, where all are involved in the oxidation of ω-hydroxyl fatty acids. 
In addition, class I and IV are responsible in retinol oxidation and retinal reduction, 
whereas class IV has an important role in retinoic acid generation (Boleda et al., 
1993).  
1.10.1.3 Aldehyde dehydrogenases (ALDHs) 
Aldehyde dehydrogenases (ALDHs) are a group of enzymes catalysing the 
conversion of aldehydes to the corresponding acids. ALDH activity was first 
detected in mammalian liver over 50 years ago and two ALDH genes were 
identified in 1985 (Yoshida et al., 1998; Hsu et al., 1985). Since then, 12 genes 
have been elucidated in the human ALDH family, of which the coding enzyme 
subunits consists of 500 amino acids residues (Yoshida et al., 1998). In humans, 
there are many forms of ALDH divided into two groups. Firstly, cytoplasmic forms 
include ALDH 1, ALDH 3, ALDH 7, ALDH 8 and ALDH 9. Mitochondrial forms include 
ALDH 2, ALDH 4, ALDH 5, and ALDH 6. The ALDH classes are distributed widely in 
the human body, while ALDH 3 is only expressed in stomach, lungs, liver, skin and 
the cornea. These isoenzymes play a role in elimination of toxic aldehydes, which 
are produced during lipid peroxidation. They are also involved in metabolism of 
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bile acids, prostaglandin and steroids dehydrogenation (Orywal and Szmitkowski, 
2017).  
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Figure 1-8: Conversion of fatty acids to fatty dicarboxylic acids via Omega-oxidation pathway.  
Fatty acids is converted to fatty-ω-hydroxyl acid by a cytochrome P450 and oxidised the hydroxyl 
group to an aldehyde by alcohol dehydrogenase to generate fatty-ω-aldo acid. Aldehyde 
dehydrogenase then oxidised the aldehyde group to a carboxylic acid to produce a dicarboxylic fatty 
acid.  
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1.11 Dicarboxylic acid 
Dicarboxylic acids are generated from omega-oxidation of monocarboxylic acids. 
The process involves fatty acid conversion into ω-hydroxymonocarboxylic acids by 
a microsomal cytochrome P450 and oxidised to ω-ketomonocarboxylic acids and 
then by the sequential action of cytosolic long-chain alcohol and aldehyde 
dehydrogenases to produce dicarboxylic acid (Ferdinandusse et al., 2004). 
Dicarboxylic acids are numbered according to chain length, including adipic (C6), 
suberic (C8), sebacic (C10) and dodecanedioic (C12) acids. Medium chain fatty 
acids are derived from β-oxidation of long chain dicarboxylic acids (Mingrone et 
al., 2013). Short-chain dicarboxylic acids (i.e. 4-carbon) and medium-chain 
dicarboxylic acids (i.e. 8-carbon) are capable of crossing the outer and inner 
mitochondrial membranes as free fatty acids to enter the mitochondrial matrix, 
while long chain fatty acids (i.e.16-carbon) are not able to enter the 
mitochondria. Long-chain dicarboxylic acids are shortened in the peroxisome and 
the products are either excreted in the urine or move to the mitochondrion for 
the β–oxidation (Ferdinandusse et al., 2004).  
Dicarboxylic fatty acids can be transported through the mitochondrial membrane 
by four different pathways, including electrophoretic transport by an inner 
membrane anion channel, by passive diffusion, via tributyltin-mediated transport 
or via transport by the dicarboxylate carrier (Mingrone et al., 2013). The 
dicarboxylate carrier works for short-chain dicarboxylic acids since this 
transportation does not need the carnitine shuttle (i.e. carnitine 
palmitoyltransferase1, carnitine palmitoyltransferase 2 and carnitine 
acetyltransferase). 
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1.12 Hexadecanedioate 
Hexadecanedioic acid (HEXA) is a long chain dicarboxylic acid (HOOC(CH2)14COOH) 
generated during fatty acid ω-oxidation, which is then metabolised by β-oxidation 
in peroxisomes or mitochondria (Reddy and Rao, 2006). The transport of HEXA 
through the inner mitochondrial membrane is facilitated via the carnitine 
acyltransferase enzyme, which catalyses the reversible transfer of acyl groups 
from acyl-CoA to L-carnitine (Pettersen, 1973). However, HEXA can also be β-
oxidized at both peroxisomes and inner mitochondrial membrane components via 
a carnitine-independent pathway (Aarsland et al., 1989; Grego and Mingrone, 
1995). Activation of HEXA transportation is localised in liver, in particular the 
mitochondrial and microsomal fractions in presence of CoA, ATP, and Mg2+ 
(Pettersen, 1973; Pettersen and Aas, 1974). 
HEXA has been reported to have hypotriglyceridemia and hypocholesterolemia 
functions by affecting lipid metabolism through modifying lipid and lipoprotein 
synthesis and degradation. These effects are caused by stimulation of peroxisomal 
β-oxidation and peroxisome proliferation. (Aarsland et al., 1989). The modulating 
capacity of long-chain fatty acids, as opposed to their role as substrates, has 
initiated the design of nonmetabolic long-chain fatty acyl analogues (i.e. MEDICA 
16) (Tzur et al., 1988). MEDICA 16 is a non-metabolic long-chain fatty acyl 
analogue of hexadecanedioic acid, which contains a chain length of C14 to C18 
(i.e. HOOC-CH2- C(CH3)2- (CH2)n-C(CH3)2-CH2-COOH). MEDICA 16 is designed to 
work as a hypolipidemic, hypoglycemic-hypoinsulinemic and antiobesity agent 
(Tzur et al., 1988). It inhibits liver lipogenesis and cholesterogenesis by inhibition 
of liver ATP-citrate lyase, thus decreasing the levels of plasma very-low-density 
lipoprotein (VLDL)-triacylglycerol, VLDL-cholesterol, chylomicrons, triacylglycerol 
and apolipoprotein C III (Tzur et al., 1988; Bar-Tana et al., 1988; Frenkel et al., 
1988, 1994). The decrease in plasma apolipoprotein C-III is due to activation of 
peroxisome proliferator receptors alpha subunit/ the retinoid X receptor 
(PPARα/RXR) (Mayorek et al., 1997). Peroxisome proliferators are known to 
activate dicarboxylation of fatty acids. Interestingly, HEXA is the most potent 
activator of PPARs (Desvergne and Wahli, 1995). 
Previous studies showed that treatment of obese-insulin-resistant rats by MEDICA 
16 caused decreased content of neutral lipids of the epididymal, perirenal, and 
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omental fats leading to decrease in body weight (Tzur et al., 1988; Atkinson et 
al., 2002). Moreover, treatment with MEDICA 16 caused an insulin-induced 
decrease in production of hepatic glucose as well as increase in total-body glucose 
disposal. It activated intracellular reesterification of lipolysed free fatty acids in 
adipose tissue causing reduction in free fatty acid release and plasma free fatty 
acids (Tzur et al., 1988; Mayorek et al., 1997; Atkinson et al., 2002). In addition, 
increased glucose disposal for free fatty acids reesterification was estimated by 
the role of glycerol-3-phosphate (Mayorek et al., 1997). The glycerol-3-phosphate 
shuttle maintains intracellular redox balance and allows the synthesis of NADH in 
the cytosol by glycolysis to contribute to the oxidative phosphorylation pathway 
in the mitochondria to generate ATP (Larsson et al., 1998). In addition, long term 
treatment of MEDICA 16 inhibits the secretion of arginine and potassium (K+) that 
helps to stimulate insulin secretion, inhibition of glucose-induced proinsulin 
biosynthesis and depletion of insulin in the islets of Langerhans (Frenkel et al., 
1988).  
Atkinson et al study exhibited that chronic treatment of MEDICA 16 reduced the 
activity of hepatic acetyl-CoA carboxylase (ACC), followed by reduction in plasma 
triacylglycerol in obese-insulin-resistant JCR:LA-cp rats (Atkinson et al., 2002). 
ACC is the rate-limiting enzyme in fatty acids synthesis and it has an essential role 
in the energy metabolism by regulation of fatty acid biosynthesis and oxidation in 
liver and adipose tissue. ACC catalyses the synthesis of malonyl-CoA, the substrate 
for synthesis of fatty acid and the regulation of fatty acid oxidation. In addition, 
ACC enzyme is considered as a target to regulate cardiovascular diseases such as 
obesity and diabetes (Wakil and Abu-Elheiga, 2009).  
Chapter 1  75 
1.13 Hexadecanedioate and hypertension 
A putative novel pathway for blood pressure regulation involving the dicarboxylic 
acid, hexadecanedioate has been identified in a metabolomics study associating 
blood pressure and mortality outcomes with fasting blood metabolites (Menni et 
al., 2015). A total of 3980 adult females not on blood pressure medications and 
free of renal diseases from the TwinsUK cohort study (Moayyeri et al., 2013) were 
included in the metabolomics study (Menni et al., 2015). The metabolomics 
analysis showed that three metabolites (i.e. hexadecanedioate, dihomo-linoleate 
and caffeine) significantly associated with all-cause mortality. However, 
hexadecanedioate was the only metabolite that showed a direct association with 
blood pressure and mortality, indicating consistent impact of higher levels of 
hexadecanedioate on blood pressure elevation (Menni et al., 2015).  
This result was verified in two additional clinical cohorts (i.e. KORA and 
Hertfordshire). Both studies included male and female participants on 
antihypertensive medications (Menni et al., 2015). The KORA cohort included 1494 
subjects (males=776 and females=718) (Holle et al., 2005), while the 
Hertfordshire cohort included 1515 subjects (males=765 and females=750) (Syddall 
et al., 2010). In these additional cohorts hexadecanediote was again found to be 
significantly associated with systolic blood pressure and diastolic blood pressure 
(Menni et al., 2015). 
In vivo animal experiments were subsequently conducted to provide functional 
evidence of a role for hexadecanedioate in blood pressure regulation. In these 
studies circulating levels of hexadecanedioate and systolic blood pressure (SBP) 
significantly increased in hexadecanedioic acid treated WKY rats compared to 
untreated controls. Baseline circulating hexadecanedioate levels were 
significantly higher in SHRSP rats compared to untreated aged-matched WKY rats 
Three weeks of 1% NaCl administration in drinking water significantly elevated SBP 
in SHRSP rats, though plasma hexadecanedioate levels were not modified by this 
salt-challenge (Menni et al., 2015) (Figure 1-9).  
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These studies provide strong evidence for a link between hexadecanedioate levels 
and blood pressure control. Therefore, investigating of the functional role and the 
pathway underlying hexadecanedioate induced blood pressure elevation are 
necessary.  
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Figure 1-9: In vivo experiments using WKY and SHRSP rat model to examine the effect of 
hexadecanedioate on blood pressure regulation (Menni et al., 2015).  
(A) Plasma hexadecanedioate levels (ng/ml) and (B) systolic blood pressure (mmHg) in WKY rats 
treated with 250 mg/kg/day hexadecanedioate or vehicle for 4 weeks (n=6). (C) Plasma 
hexadecanedioate levels (ng/ml) and (D) SBP (mmHg) in SHRSP rats (n=6) pre- and post-
administration of 1% NaCl in drinking water for 3 weeks. *P<0.05 versus respective untreated group. 
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1.14 Proteomic and mRNA expression of ALDH and ADH 
in SHRSP and WKY 
Previous unpublished studies by Dr Sofia Tsiropoulou, 2015 at the University of 
Glasgow have generated ‘omics’ datasets from cardiovascular tissues (e.g. kidneys 
and vascular tissue) derived from SHRSP and WKY rats. The results of these studies 
showed expression of key enzymes involved in the ω-oxidation pathway are 
perturbed in the hypertensive model in both vascular and renal tissues (Figure 1-
9). For example, microarray expression profiling demonstrated significantly 
increased mRNA expression of the alcohol dehydrogenase family of enzymes, in 
particular ADH1C*, in whole kidney homogenates from SHRSP rats compared to 
WKY. In addition, significantly increased protein expression of aldehyde 
dehydrogenase isoenzymes was identified using SILAC proteomics in cultured 
vascular smooth muscle cells from mesenteric resistance arteries from SHRSP rats 
when compared to WKY. These results indicate that the SHRSP rat may be a useful 
model for examining the ω-oxidation pathway and its potential link with 
development of hypertension. 
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Figure 1-10: Ingenuity Pathway Analysis of ‘omics’ datasets identifies significant expression 
differences in omega oxidation pathway enzymes between SHRSP and WKY for (A) renal 
mRNA expression and (B) VSMC proteomic analysis in SHRSP and WKY rats. (Tsiropoulou, 
2015). 
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1.15 Hypothesis 
We hypothesised that the dicarboxylic acid, hexadecanedioate plays a causal role 
in blood pressure regulation. Elucidating the underpinning mechanism will expand 
our understanding of blood pressure regulation and inform new drug discovery. 
1.16 Aims 
The aims which would allow us to address this hypothesis were as follows: 
1. To investigate the relationship between blood pressure and 
hexadecanediote by assessing the impact of exogenous hexadecanedioic 
acid on blood pressure and end organ damage in a normotensive WKY and 
hypertensive SHRSP rats models. 
2. To examine the metabolic effects of hexadecanedioic acid administration 
in WKY rats.  
3. To assess hemodynamic changes after modulation of endogenous 
hexadecanedioate levels by perturbing the ω-oxidation pathway in both a 
WKY and SHRSP rat models.  
4. To investigate the role of anion transporter Slco1b2 as a regulator of 
circulating hexadecanedioate levels. 
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 Materials and Methods  
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This chapter contains details on general laboratory practice and methods routinely 
used during this PhD project. Methods specific to particular aspects of the project 
are described in the relevant chapters. 
2.1 General laboratory practice  
A laboratory coat and non-latex powder-free gloves were worn during all 
procedures. Hazardous reagents were kept in labelled cabinet and handled as 
described in the Control of Substances Hazardous to Health regulations. Booking 
systems were available for laboratory equipment were communally and routinely 
used. Laboratory glassware was cleaned in Decon 75 detergent (Decon 
Laboratories Ltd, East Sussex, UK), rinsed with distilled water and dried at 37°C. 
Sterile disposable plastic ware were also commonly used, including 0.5 ml, 1.5 ml 
and 2 ml microcentrifuge tubes (Greiner Bio-one, Stonehouse, UK), 15 ml and 50 
ml centrifuge tubes (Corning, Birmingham, UK). Certified nuclease-free reagents 
and plastic ware, including RNase-free microcentrifuge tubes, RAININ nuclease-
free filtered pipette tips and Ambion nuclease-free water were used in 
experiments involving ribonucleic acid (RNA). Pipettes and benches were wiped 
with Ambion RNaseZap reagent before all RNA experiments. Laboratory-ware and 
liquids requiring sterilisation were autoclaved in a Priorclave Tactrol 2. Reagents 
were weighed using an Ohaus Portable Advanced balance (sensitive to 0.01 g), or 
a Mettler HK160 balance (sensitive to 0.0001 g). PH of solutions were measured 
using a Mettler Toledo digital pH meter calibrated with pH 4.0, 7.0 and 10.0. 
Volumes from 0.1 μl to 1,000 μl were dispensed with Thermo fisher pipettes 
(Thermo fisher Scientific, Loughborough, UK). All producers carried out according 
to risk assessment and relevant COSHH forms were read and signed before 
commencement of procedures. 
2.2 In vivo experimental procedures 
2.2.1 Experimental animals 
The animal strains used in this thesis were the Spontaneously Hypertensive Stroke 
Prone rats (SHRSPGla) and Wistar Kyoto rats (WKYGla) where Gla is used as short for 
Glasgow). The animals were housed individually in cages on a 12 hours light/dark 
cycle at room temperature (21± 3°C). A standard rat chow (rat and mouse No. 1 
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maintenance diet, Special Diet Services) and water ad libidum were provided daily 
to the rats. All work with experimental animals were approved by the Animals’ 
Scientific Procedures Act 1986 under the project license of Dr Delyth Graham 
(70/9021). Offspring were weaned, sexed, ear-tagged (National Band and Tag. 
Co.) at 3 to 4 weeks of age and then caged, with a maximum of 3 animals per 
cage, according to sibling group and sex. 
Colonies of WKY and SHRSP rats have been maintained at the University of Glasgow 
since 1991 by brother-sister mating. These colonies originated from 13 SHRSP and 
13 WKY rats (6 males and 7 females of each strain), provided by Dr D.F. Bohr, at 
the Department of Physiology, University of Michigan (USA) who originally 
obtained this breeding stock from the National Institutes of Health, Bethesda, 
Maryland, USA. Rats were phenotyped for blood pressure level before breeding to 
ensure the normotensive and hypertensive phenotypes were maintained within 
the following ranges of blood pressure: 170-190 mmHg (males) and 140-170 mmHg 
(females) for SHRSP adult breeders, and 120-140 mmHg (males) and 100-130 
mmHg (females) for WKY adult breeders. Routine microsatellite screening was 
also used to confirm the maintenance of homozygosity of all loci within strains. 
2.2.2 Hemodynamic profile 
2.2.2.1 Blood pressure measurements by tail cuff plethsymography 
Systolic blood pressure (SBP) measurement was carried out using the well-
established method of tail cuff plethysmography in conscious rats as described 
previously (Evans et al., 1994). Rats were placed in an insulated box and a direct 
heat source (overhead lamp) was applied at 30°C for 15-20 minutes for 
vasodilation of the tail artery. Rats were then wrapped in a soft cloth to restrain 
them and an inflatable cuff placed on their tail along with a piezoceramic 
transducer (Hartmann & Braun type 2) for pulse detection. The pressure in the 
cuff was controlled in 1 mmHg steps over a 300-mmHg range. Numerous cuff 
inflation and deflation steps were carried out over tail cuff session and the 
resulting pulsation detected by the transducer. The detected pulsatile signal was 
then visualised as pressure function and displayed on a computer using Microsoft 
Windows compatible software. A minimum of six readings was taken for each rat 
per session and the average values were taken for systolic blood pressure. 
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2.2.2.2 Blood pressure measurements telemetry 
The animals were anesthetized by isoflurane anesthetic in an induction chamber 
(2.5% isofluorane in 1.5 L/min O2) and their abdomens were shaved and the area 
cleaned with betadine solution (Purdue Pharma L.P., Stamford). The surgical 
procedure was carried out under sterile conditions. The incision was prepared on 
the mid line of the abdomen and opened using retractors. The intestines were 
gently externalised, wrapped in sterile gauze swabs and kept moist with sterile 
PBS (Sigma Aldrich Co Ltd, Irvine, UK). The internal organs were protected by use 
of gauze pads and the descending aorta was exposed by blunt dissection using long 
handled sterile cotton buds. Blood flow along the abdominal aorta was transiently 
prevented by placing silk ties (sloops) on the abdominal aorta (below the renal 
arteries) and on each iliac artery, after which an incision was made immediately 
above the aortic bifurcation with 23 gauge needle. The gel-filled catheter of the 
telemetric probe (TA11PA/C40) was implanted into the distal descending 
abdominal aorta pointing towards the proximal end of the animal (i.e. towards 
the heart), against the flow of blood, and secured with VetBond™ biological glue 
(Data Sciences International, Sheffield, UK). After the silk ties were removed this 
probe was sutured to the wall of the peritoneum cavity with non-absorbable 
sutures to prevent the movement of the probe. After that, the animals were 
injected with carprofen (5 mg/kg) a non-steroidal anti-inflammatory analgesic for 
pain control and allowed to recover for one week for recovery before 
haemodynamic parameters were monitored (i.e. systolic blood pressure (SBP), 
diastolic blood pressure (DPB), mean arterial blood pressure (MAP), pulse pressure 
(PP), heart rate (HR) and locomotors activity). In this process, telemetric probes 
send signals to receiver panels situated under each cage, then measured signals 
were sent to the matrix linked with a computer. Dataquest A.R.T. (system version 
4.2) acquisition software acquired and recorded the raw data. Briefly, heart rate, 
blood pressure, pulse pressure, and activity were recorded for 10 seconds every 5 
min throughout the day and night. Cycles of scheduled sampling occurred every 5 
minutes over a 24-hour period. Blood pressure were recorded and data points 
displayed as daytime/night time averages (averages of daytime (7:00 am - 7:00 
pm) and night time (7:00 pm - 7:00 am)) (Anderson et al., 1999). Data was 
analysed using Microsoft Excel spread sheet macro and the daytime and night time 
averages were used to calculate daily averages which were plotted in the graphs 
for clarity. 
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2.2.3 Echocardiography 
Transthoracic echocardiography was carried out using an ACUSON Sequoia C512 
ultrasound system with a 15-MHz linear array transducer to assess cardiac 
geometry, function and contractility. Echocardiography was performed at baseline 
and weekly during drug administration. Animals were sedated by isoflurane 
anesthetic in an induction chamber (2.5% isoflurane in 1.5 L/min O2) and their 
chest was shaved. After shaving the chest of animals, aquasonic 100-ultrasound 
transmission gel (Parker Laboratories, INC., USA) was applied and rats were placed 
in supine position and a 15-MHz linear array transducer was placed directly on the 
shaved chest wall. 2-dimensional guided M-mode images at a 2-mm depth were 
recorded at the tip of papillary muscles. Averaged data from three consecutive 
cardiac cycles from each M-mode were used to measured anterior wall thickness 
(AWT), posterior wall thicknesses (PWT), end diastolic dimension (EDD) and end 
systolic dimension (ESD) of the left ventricular (LV) chamber during systolic and 
diastolic cycles. Subsequently, the following equations were used to calculate left 
ventricular mass (LVM) (ASE-cube formula with Devereux correction factor) (LVM 
=0.8 [1.04 [(EDD + PWT + AWT) 3 – EDD3]] +0.6). The value of LVM was then 
normalised for both body weight and tibia length. End-systolic volume (ESV) and 
LV end-diastolic volume (EDV) was calculated from two-dimensional images 
according to a modified Simpson’s rule. Ejection fraction (EF), stroke volume (SV) 
and fractional shortening (FS) were then determined from EDV and ESV. Ejection 
fraction [(EDV-ESV)/ ESDx100]. Fractional shortening [(EDD-ESD)/ EDDx100] and 
stroke volume= [(EDV-ESV)] Cardiac output was derived as follows: cardiac output 
[(ESV-EDV) *HR], where HR is heart rate.  
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2.2.4 Metabolic cages 
Metabolic cages were used for housing individual rats for 24 hours for the 
collection of urine and the monitoring of water in-take, at baseline and before 
sacrifice of the animals. The metabolic cages (Techniplast, model number 
3700M022, Buguggiate, Italy) consist of an upper chamber with a support grid that 
allows the rat to stand while allowing urine and feces to pass through the grid and 
into a funnel, which separates and collects the feces and urine. A small feeder 
and marked water bottle on the outside of the cage allows access to standard rat 
chow and water. Urine output and fluid intake were saved and recorded at the 
end of the 24 hours. Urine was collected, allocated into 1 ml samples and stored 
at -80°C for biochemical analysis. 
2.3 Ex vivo experimental procedure 
2.3.1 Tissue preparation 
At sacrifice animals were anesthetized by isoflurane (5% isoflurane in 1.5 L/min 
O2) and the thoracic cavity was opened to expose the heart. Blood samples were 
collected by cardiac puncture with a 23-gauge needle. Tissues (heart, aorta, 
kidneys, lungs, liver, brain and fat) were harvested, either snap frozen in liquid 
nitrogen and stored at -80°C for RNA extraction and protein assays or fixed for 
histological assessment in a 10% formalin solution overnight at room temperature 
and subsequently transferred into 70% ethanol. The fixed samples were later 
embedded in paraffin blocks, which then were cut and baked onto silanised slides 
at 60°C for 3 hours followed by 40°C overnight. Both the paraffin blocks and 
sections were kept at room temperature and stored in appropriate boxes. 
Mesenteric resistance arteries were collected to assess vascular function and 
morphology by wire myography (more specific details in section 2.3.3). Also, blood 
samples collected in VACUETTE® heparin lined tubes (Greiner Bio-One, 
Stonehouse, UK) during sacrifice were kept on ice until centrifugation using VWR® 
Mega Star 3.0 / 3.0R centrifuge (VWR International, Leicestershire, UK) at 2400 
RPM for 20 minutes at 4°C. Plasma was then extracted and stored at -80°C for 
further experiments. 
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2.3.2 Organ mass index 
Organ weight for whole heart, left ventricle plus septum, kidneys, liver, 
epidydimal fat and retroperitoneal fat were measured at the time of tissue 
harvest. This was correlated for both body weight and tibia length. After sacrifice, 
a scalpel blade (Swann-Morton, Sheffield, UK) was used to expose the knee and 
ankle joint on an extended hind limb, the tibia length was determined using a 
double-pointed drawing compass and was subsequently measured with a ruler. 
Both body weight and tibia length were used to measure organ mass index. The 
absolute values are different but the pattern of change is comparable.  
2.3.3 Wire myography 
Wire myography is used to examine the functional response and vascular reactivity 
of isolated small mesenteric resistance arteries. Third order mesenteric resistance 
arteries were dissected from fat and connective tissue under a dissecting 
microscope (Carl Zeiss Ltd, Cambridge, UK) and stored in Krebs buffer overnight 
at 4°C before use. An approximately 2-mm length of artery was mounted onto two 
stainless steel 40 micron wires on a four channel small vessel myograph (Danish 
Myotechnology, Denmark). Changes in force were measured by connecting the 
force transducer to a myo-interface and changes in tension were then recorded 
using a data acquisition package (ADI Instruments Powelab systems). The vessels 
were maintained in Krebs buffer (0.25 M NaCl; 0.001 M KCl; 2 mM MgSO4; 50 mM 
NaHCO3; 2 mM KH2PO4; 2 nM CaCl2) warmed to 37°C and bubbled with 95% O2 and 
5% CO2 (pH 7.4). Following a 30 minutes equilibrium period, vessels were set to a 
normalized internal diameter (L1) in order to achieve optimal contraction. 
Internal diameter was calculated using the following equation, L1 = 0.9*L100; 
whereas L100 was determined using the LaPlace equation (P=T/r; where P is 
effective pressure, T is wall tension and r is the internal rediau. After 1 hour, 
contractile response of the vessel was tested by a pretreatment of KCl (10 µmol/L) 
(wake up technique) to determine the maximum active tension development, 
which allowed for standardization of initial experimental conditions. Vessels were 
then washed 4 times with Krebs buffer and were allowed to rest for 30 minutes. 
A cumulative concentration curve to noradrenalin, 10 nmol/L to 30 µmol/L, was 
performed followed by a carbachol dose response curve, 10 nmol/L to 10 μmol/L. 
The dose response to carbachol was performed to determine the percentage of 
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relaxation in response to the stimulated contraction. The dose response curves 
were followed by a Krebs buffer wash out to baseline. The concentration required 
to achieve 50% of the maximum response (EC50) and area under the curve (AUC) 
were calculated from the response curves. 
2.4 General molecular biology 
2.4.1 mRNA expression 
2.4.1.1 Total RNA extraction from heart, aorta, liver and kidney tissues 
Total RNA was extracted from animal tissue using Qiagen column based miRNeasy 
Mini kits (QIAGEN, Manchester, UK). Whole tissues (≤50 mg) were homogenised in 
700 μl buffer RLT lysis solution, containing 0.01% (v/v) β-mercaptoethanol 
(Qiazol). Tissues were homogenised either with a Polytron 2100 rotor homogeniser 
at full speed, then centrifuged at 5000 g to collect lysates or by using 5 mm (mean 
diameter) stainless steel beads and homogenised on the TissueLyser (QIAGEN, 
Manchester, UK) for 2 minutes at 20 Hz. 140 μl of Chloroform is added to each 
tube and centrifuge for 15 minutes at 12,000 x g at 4°C. The upper aqueous layer 
was collected and transferred to a new collection tube containing 525 μl of 70% 
ethanol. 700 μl of the sample was then transferred into an RNeasy Mini spin column 
in a 2ml collection tube and centrifuge at 8,000 x g for 15 seconds at room 
temperature. The flow through was discarded and 700 μl of buffer RW1 was added 
to the spin columns, samples were spun as before and the flow though discarded. 
An optional on column DNA digest was carried out (refer to section 2.4.1.3). Spin 
columns were then transferred to new collection tubes and 500 μl of buffer RPE 
added, and centrifugations repeated as before. The flow through was discarded 
prior to another 500 μl of buffer RPE. The spin column was then centrifuged for 2 
minutes, at 8000 x g, at room temperature. RNase-free water (50 μl) was then 
added to the column and centrifuge for 1 minute at 8,000 x g. The first eluate was 
pipetted back onto the membrane in the columns and spun for 1 minute. The 
resulting eluate was quantified as described in section 2.4.1.4.  
2.4.1.2 Total RNA extraction from adipose tissue 
Total RNA was isolated from adipose tissue using Qiagen RNeasy lipid tissue Mini 
kit (QIAGEN, Manchester, UK). Fatty tissues (≤100 mg) were homogenised in 1 ml 
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Qiazol lysis reagent using 5 mm stainless steel beads and a TissueLyser for 2 
minutes at 20 Hz. The lysates were transferred into fresh microcentrifuge tubes 
and then 200 μl of chloroform is added to each tube and centrifuged for 15 minutes 
at 12,000 x g at 4°C. The upper aqueous layer was collected and transferred to a 
new collection tube containing 600 μl of 70% ethanol. 700 μl of the sample was 
then transferred into an RNeasy Mini spin column in a 2 ml collection tube and 
centrifuged at 8,000 x g for 15 seconds at room temperature. The flow through 
was discarded and 700 μl of buffer RW1 was added to the spin columns, samples 
were spun as before and the flow though discarded. An optional on column DNA 
digest was carried out (refer to section 2.4.1.3). Spin columns were then 
transferred to new collection tubes and 500 μl of buffer RPE added, and 
centrifugations repeated as before. The flow through was discarded prior to 
another 500 μl of buffer RPE. The Spin column was then centrifuged for 2 minutes, 
at 8000 x g, at room temperature. RNase-free water (50 μl) was then added to the 
column and centrifuged for 1 minute at 8,000 x g. The first eluate was pipetted 
back onto the membrane in the columns and spun for 1 minute. The resulting 
eluate was quantified as described in section 2.4.1.4. 
2.4.1.3 DNase treatment of extracted total RNA 
Extracted total RNA was treated with DNase using the reagents provided in the 
QIAGEN miRNeasy mini kit (QIAGEN, UK) following the manufacturer’s 
recommendations. The on-column digestion of DNA during the RNA purification is 
as follows; 350 μl of buffer RWT was added to the spin column and centrifuged for 
15 seconds at 8000 x g. 10 μl of DNase I stock was added to 70 μl of buffer RDD 
which then added to the spin column and left to incubate for 15 minutes at room 
temperature. Afterwards, 350 μl of buffer RWT was added to the column and 
centrifuged for 15 seconds. All flow through were discarded and spin columns were 
used for completion of RNA purification. 
2.4.1.4 Measuring nucleic acid concentration 
RNA concentrations were quantified using a Nanodrop® ND-1000 
spectrophotometer (Thermo fisher Scientific, Loughborough, UK). Absorbance 
ratios (260 nm/280 nm) of approximately 2.0 for RNA indicated that the nucleic 
acid preparations were sufficiently free from protein contamination for 
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downstream experiments. Also, the ratio of absorption at 260 nm and 230 nm was 
utilised as an indicator of RNA purity; pure RNA has a ratio of (2.0-2.2). A common 
contaminant, phenol, absorbs at 230 nm. The equation of Beer-Lambert Law of 
absorption is used to calculate the concentration of the RNA (μg/ml). 
Concentration of RNA (μg/ml) = (A260 reading – A320 reading) x 40. 
2.4.1.5 Reverse transcription (RT)-PCR 
The preparation of cDNA from RNA templates by reverse transcription for 
quantitative real-time PCR (qRT-PCR) was performed using Applied Biosystems 
High Capacity cDNA Archive Kit (Applied Biosystems). All steps were performed 
according to manufacturer’s instructions. 1 μg of RNA samples were reverse 
transcribed into cDNA in a 20 μl reaction containing a final concentration of 10X 
reaction buffer, 25 mM MgCl2, 2.5 mM dNTP mixture, 20 u/μl RNase inhibitor, 50 
μM of random hexamers, 50 U/μl of reverse transcriptase (Multiscribe) in a 96-
well plate (Thermo Fischer Scientific, Loughborough, UK). The reaction was then 
placed on a thermocycler and underwent the following two-step reaction 
conditions: 25°C for 10 minutes, 48°C for 30 minutes, 95°C for 5 minutes, 4°C for 
10 minutes then 12°C forever. The plate was then stored at -20°C until use. 
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Applied Biosystems TaqMan Reverse Transcription Reagents: 
Reagent Volume (μl) 
10X Reaction Buffer 2 μl 
25 mM MgCl2  4.4 μl 
2.5mM dNTPs  4 μl 
50 μM Random hexamers 1 μl 
20 U/μl RNase Inhibitor 0.4 μl 
50 U/μl MultiScribe RT 0.5 μl 
1 μg RNA  1 μl 
RNAse free water   7.7μl 
Total Volume   20 μl 
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2.4.1.6 Real-Time Polymerase Chain Reaction 
Relative real-time RT-PCR quantitation of the samples was carried out using the 
QuantStudio™ 12K Flex Real-Time PCR System from Applied Biosystems in a 
multiplex reaction. Expression of the gene of interest was always measured 
relative to the housekeeping control gene. The gene of interest and β-actin, B2M 
or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe (housekeeper) 
were amplified in duplex PCR reactions, probes for the gene of interest were 
tagged to 'FAM' labelled fluorescent dyes, while housekeeper probes were labelled 
with 'VIC' dye, they fluoresce at different wavelengths, allowing them to be 
measured in the same reaction. All reactions were performed in 5 μl volumes in 
384-well plates. 
Reaction mix Volume (μl) 
2X Taqman Master Mix 2.5 
Probe FAM labelled 0.25 
Housekeeper VIC labelled  0.25 
cDNA  2.0 
Total Volume 5 μl 
All samples were amplified in triplicate. Fluorescence of FAM and VIC dyes were 
measured for all reactions during temperature cycling. Data was analysed using a 
combination of Applied Biosystems SDS (Sequence Detection Software) and 
Microsoft Excel (2016) software. 
Temperature cycling: 
Heat Cycle  Time 
50 oC  2 min  Stage 1 
95 oC  7.14 min 
95 oC  15 sec Stage 2  
60 oC 1 min X40
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2.4.1.7 Analysis of qRT-PCR 
The exponential phase of the PCR reaction releases the fluorescence from the 
respective qRT-PCR probe (FAM and VIC), which is measured by QuantStudio™ 12K 
Flex Real-Time PCR System. Sequence Detection Software (SDS) plotted the 
amplification curves as cycle number versus fluorescence for both dyes in every 
well. A threshold of fluorescence is set during the exponential phase of 
amplification. The cycle number at which the fluorescence signal crosses this set 
threshold is termed the cycle threshold (Ct) (Figure 2-1). qRT-PCR results were 
analysed using the relative quantification (RQ) method of comparative Ct. The 
'cycle threshold value' (Ct value) for each amplification. The housekeeper acts as 
a normalising control for RNA concentrations and its stability and consistency were 
tested in triplicate for each experimental condition. Housekeeping gene 
expression was used to calculate the ∆Ct for gene of interested and the equation 
to calculate ∆Ct is as follows:  
 ∆Ct = Ct (Sample) – Ct (Housekeeper) 
All experiments were compared to a reference control (calibrator) to calculate 
the ∆∆Ct as follows:  ∆∆Ct = ∆Ct (Sample) – ∆Ct (Reference) 
Relative quantification (Fold of change) was calculated as follows: 
 Relative Quantification (RQ) = 2-∆∆Ct 
The calibrator is untreated or control group which all samples are compared to. 
The calibrator has a RQ value of 1. 
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Range of possible RQ values was calculated by the standard error of the ∆Ct using 
RQ min and RQ max as follows:  
 Pre RQ min= 2-∆∆Ct + standard error 
 Pre RQ max= 2-∆∆Ct - standard error 
From these equations, RQ min and RQ max were calculated as follows: 
 RQ min= RQ - Pre RQ min  
 RQ max= RQ + Pre RQ max 
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Figure 2-1: Example of qPCR amplification curve.  
Amplification plots are created when the fluorescent signal from each sample is plotted against cycle 
number over the duration of the real-time PCR experiment. Threshold cycle (Ct) is the cycle number 
of which the fluorescent signal of the reaction crosses the threshold.  
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2.5 Quantification of hexadecanedioate level in plasma 
samples 
Quantitative analysis of hexadecanedioate level in serum samples of WKY and 
SHRSP rats were carried out by Dr Christian Reichel and Dr Anja Huber (Seibersdorf 
laboratories, Austria) using Liquid chromatography–mass spectrometry (LC-
MS/MS). The method was provided by Dr Christian Reichel.  
2.5.1 Sample preparation 
100 μl of rat serum were mixed with 50 ng of hexadecanedioate-d28 internal 
standard (CDN Isotopes, UK). For protein precipitation, 850 μl of methanol (Merck, 
USA) were added, the mixture was vortexed two times for 5 seconds and 
centrifuged for 3 minutes at 10°C and 14.000 rcf. The supernatant was transferred 
into a new V-vial (Phenomenex, USA) and dried under vacuum pressure for 45 
minutes at 45°C. The dried material was redissolved in 100 μl of 20% methanol 
and hexadecanedioate was measured using LC-MS/MS. 
2.5.2 Calibration 
To generate a calibration curve for hexadecanedioate, six different 
concentrations (5, 10, 20, 30, 40 and 50 ng/ml; in the result table referred to as 
standards 1, 2, 3, 4, 5 and 6) of the substance were each mixed with 50 ng of 
hexadecanedioate-d28 internal standard in new V-vials. The mixture was dried 
under vacuum for 45 minutes at 45°C. The dried material was redissolved in 100 
μl of 20% methanol and hexadecanedioate was measured using LC-MS/MS. 
Standard mixtures 1, 2, 3 and 4 were measured two times on two different days 
to guarantee reproducibility. When fragmented in MS/MS mode, 
hexadecanedioate dissociates into several product ions. The fragment ion showing 
the most intense mass signal was used for quantification (m/z 223) (Figure 2-2). 
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2.5.3 LC-MS/MS 
For all analyses, an LC-MS/MS instrument of the TSQ Vantage series (Thermo 
Scientific), a reversed-phase C-18 column (Dionex Acclaim PolarAdvantage II, 4.6 
x 50 mm, 3 μm) and following chromatographic conditions were used: 100% 
water/0.2% formic acid (1 min, isocratic), linear gradient to 100% methanol/0.1% 
formic acid (3 min), 100% methanol/0.1% formic acid (2.5 min, isocratic) and 
linear gradient back to 100% water/0.2% formic acid (1.5 min). Hexadecanedioate 
was analysed in negative ion mode (ESI-, transition 285→223), meaning that 
negatively charged iones were detected in the mass analyser.  
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Figure 2-2: Calibration curve of hexadecanedioate. 
The product ion showing the most intensive mass peak was used for quantification (m/z 223). On 
the x-axis hexadecanedioate concentration [ng/ml] and on the y-axis the area ratio (ratio between 
signal of standard and internal standard) are shown. 
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2.6 Statistical Analysis 
Statistical analysis was performed using Minitab 17. Data are presented by mean 
± standard error of mean using Graphpad Prism 5 (San Diego, California, USA). 
Statistical significance was assumed at P-value less than 0.05. For comparisons of 
a continuous variable between two experimental groups, paired and two Student's 
t-tests were applied as appropriate. For statistical comparisons in data sets with 
more than two groups, analysis of variance (ANOVA) was applied, followed by post-
hoc Tukey’s test. Repeated measures ANOVA (a general linear model ANOVA) was 
used to compare radiotelemetry and echocardiography data between groups. 
Detailed statistical analyses for certain experiments are specified in the relevant 
results chapters. 
2.6.1  Power calculations: 
Sample size estimates were based on power calculations from previous 
radiotelemetry blood pressure studies in rats. It was estimated that 9-10 rats per 
group would allow 90% power at α=0.05 to detect differences of 10 mmHg. The 
pressor response to noradrenaline measured by wire myography was also 
determined in a previous pilot study, which revealed physiological effects in the 
order of 2 SDs or greater with 90% power at α=0.05 with 9 rats per group. 
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 Effect of exogenous 
hexadecanedioate on blood pressure regulation 
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3.1 Introduction 
Hexadecanedioate is a long chain dicarboxylic fatty acid, which has been found to 
be associated with blood pressure elevation and mortality (Menni et al., 2015). 
The mechanisms through which hexadecanedioate regulates blood pressure are 
currently unknown, and require elucidation. This chapter aimed to verify the 
causal role of hexadecanedioate in blood pressure regulation, by carrying out 
intervention studies using normotensive Wistar Kyoto (WKY) rats and Stroke Prone 
Spontaneously Hypertensive Rats (SHRSP). 
Previous studies in humans and rat models have already demonstrated links 
between fatty acids (FAs) and hypertension. For example levels of several fatty 
acids were found to be highly correlated with development of high blood pressure 
in the spontaneously hypertensive rat (SHR) when compared with Wistar Kyoto 
(WKY) rats (Lu et al., 2008). Also, a cross sectional study performed by Wang et 
al in 232 randomly selected subjects aged between 35 and 60 years, showed that 
essential hypertensive patients had marked alteration in FA metabolism compared 
to normotensive subjects (Wang et al., 2008). Moreover, a study by Guo et al. 
showed that increased free FA level is an independent risk factor for prevalence 
of hypertension (Guo et al., 2015). Therefore, it is suggested that abnormal FA 
metabolism may play an essential role in the pathogenesis of hypertension. 
Although there is evidence that long-chain fatty acids can impact blood pressure 
regulation and influence vasodilatation via large-conductance Ca2+- and voltage-
activated K+ channels (Hoshi et al., 2013), currently there is no evidence regarding 
the mechanism of how hexadecanedioate affects blood pressure elevation. 
Therefore, this study was designed to investigate the relationship between the 
dicarboxylic acid and blood pressure regulation and to identify any underlying 
pathological changes. 
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3.2 Hypothesis 
Increased circulating hexadecanedioate levels mediate blood pressure elevation, 
which leads to target organ damage. 
3.3 Aims 
1. To determine the effect of elevated hexadecanedioate on blood pressure, 
vascular function and end organ damage in normotensive WKY rats using 
exogenous hexadecanedioic acid administration. 
2. To examine the dose response of hexadecanedioic acid on blood pressure 
in adult male WKY rats by oral administration of a range of doses (e.g. 250, 
300, 350, 400, 450 and 500 mg/kg/day) over six-week treatment period. 
3. To examine the impact of longer-term hexadecanedioic acid treatment on 
blood pressure, vascular function and end organ damage in normotensive 
WKY rats and in a hypertensive rat model (SHRSP).  
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3.4 Methods 
3.4.1 Animals 
Three intervention studies were carried out to examine the effects of 
hexadecanedioate on blood pressure regulation and end-organ damage. 
In the first intervention study, male Wistar Kyoto (WKY) rats were purchased from 
Harlan (Hillcrest, UK). In the second and third intervention studies male Wistar 
Kyoto (WKYGla) rats and male Stroke Prone Spontaneously Hypertensive rats 
(SHRSPGla) were obtained from breeding colonies maintained at the University of 
Glasgow. The Gla suffix identifies that strains originate from the Glasgow colonies. 
The rats were housed individually in cages on a 12 hours light/dark cycle at room 
temperature (21± 3°C). Rats were given ad libidum access to food and water. The 
study protocols were approved by the Animals’ Scientific Procedures Act 1986 
under the project license of Dr Delyth Graham (70/9021).  
3.4.2 Experimental protocol for examination the impact of 
hexadecanedioic acid treatment on blood pressure 
regulation 
The first intervention study was carried out in adult male WKY rats aged 10 weeks. 
The oral hexadecanedioic acid treatment (250 mg/kg/day) (Sigma Aldrich Co Ltd, 
Irvine, UK) doses were prepared in baby food (egg custard with rice, Heinz Co. 
Ltd., Hayes, Middx.) on a weekly basis (n=10) and frozen until required, and the 
control group (n=9) was given the same amount of the baby food without the drug. 
The treatment was administered for four weeks with monitoring of the 
haemodynamic parameters carried out using the Dataquest V telemetry system 
(Data Sciences International) and cardiac functions measured by 
echocardiography. Kidney function was assessed using 24 hours urine collections 
by metabolic cages. At sacrifice, blood samples were collected by cardiac 
puncture (Chapter 2, Section 2.3.1), main organs (i.e. heart, liver, kidney and 
vascular tissue) samples were harvested, and mesenteric arteries were dissected 
to assess vascular function and morphology by wire myography (Figure 3-1).  
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3.4.3 Experimental protocol for dose response curve of 
hexadecanedioic acid on blood pressure 
To determine the concentration range at which hexadecanedioic acid levels have 
an impact on blood pressure regulation, WKYGla rats (n=3) implanted with 
radiotelemetry probes, were administered increasing dosages of oral 
hexadecanedioic acid at aged 12 weeks. The dose increased weekly by 50 mg (i.e. 
250 mg/kg, 300 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg and 500 mg/kg). The 
starting dose of hexadecanedioic acid (250 mg/kg/day) was selected based on 
previous studies (Russell et al., 1991; Frenkel et al., 1994). The drug was 
discontinued at dose 500 mg/kg/day to ensure the dose remained palatable for 
the rats and to avoid potential toxicity. Blood pressure parameters were 
monitored via the telemetry system for 7 weeks including at baseline and during 
treatment (Figure 3-2). 
3.4.4 Experimental protocol for longer-term hexadecanedioic acid 
treatment 
Six-week-old male WKYGla and SHRSPGla were treated orally with hexadecanedioic 
acid (250 mg/kg per day; n=3) or vehicle (n=3) for 9 weeks. Blood pressure was 
measured weekly by tail cuff plethysmography and cardiac function was assessed 
at two week intervals by echocardiography. At sacrifice the main organs (i.e. 
heart, liver, kidney and vascular tissue) were harvested, snap frozen and formalin 
fixed for histological analysis (Figure 3-3).  
3.4.5 In vivo analysis 
3.4.5.1 Radiotelemetry surgery 
Systolic (SBP) and diastolic blood pressure (DBP), heart rate and activity were 
directly monitored using the Dataquest V telemetry system (Data Sciences 
International). The animals were anesthetised by isoflurane in an anesthetic 
induction chamber (anaesthesia was induced at 5% Isoflurane in 1.5 L/min O2, and 
subsequently maintained at 2.5% Isoflurane in 1.5 L/min O2) and the operation was 
conducted under sterile conditions. The incision was prepared on the mid line of 
the abdomen and opened by retractors. The intestines were externalised and kept 
moist using sterile gauze soaked in sterile PBS. The internal organs were protected 
with sterile cotton gauze pads to expose the descending aorta. The telemetric 
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probe (TA11PA/C40) was introduced into the peritoneal cavity, and the catheter 
inserted into the distal descending aorta and then secured with biological glue. 
The probe was sutured to the peritoneum muscle wall with non-absorbable sutures 
(Ethilon) (Ethicon, USA), and the outer skin layer secured with absorbable sutures 
(Vicryl) (Ethicon, USA). After that, the animals were left for one week for 
recovery. A more detailed description of the procedure is provided in Chapter 2, 
Section 2.2.2.2.  
3.4.5.2  Tail Cuff Plethsymography 
Measurement of systolic blood pressure was carried out as described in the main 
methods section (Chapter 2, Section 2.2.2.1) and was used for blood pressure 
measurement in the longer-term intervention study. Male WKYGla and SHRSPGla 
rats, starting from the age of 6 weeks old, were measured every week in order to 
measure SBP. Multiple cuff inflation/deflation values were obtained through the 
duration of each tail-cuff session and an average was taken for each animal. 
3.4.5.3 Echocardiography 
Echocardiography was performed on anesthetised rats (1.25%-1.5 % isoflurane in 
1.5l/min O2). Left ventricular motion mode (M-mode) measurements at the level 
of the papillary muscles were used to delineate wall thickness and internal 
diameter at systole (s) and diastole (d). Images were captured using an Acuson 
Sequoia C512 ultrasound system and then used to assess cardiac function and 
contractility. The cardiac index was estimated as cardiac output adjusted for tibia 
length or body weight, as previously described in Chapter 2, Section 2.2.3.  
3.4.5.4 Metabolic cages 
WKY rats were housed in metabolic cages for 24 hours for the collection of urine 
and the monitoring of water in-take at baseline and prior to sacrifice. Urine was 
kept on ice and stored at -80°C, until required for biochemical analysis. More 
information on this process is available in Chapter 2, Section 2.2.4. 
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3.4.6 Ex vivo analysis 
3.4.6.1 Tissue collection 
At sacrifice, animals were anesthetised by isoflurane (5% Isoflurane in 1.5 L/min 
O2) and the thoracic cavity was opened to expose the heart. Blood samples were 
collected by cardiac puncture with a 23-gauge needle. Tissues were excised and 
any excess blood removed by blotting before weighing the kidneys, whole heart, 
left ventricle plus septum, liver and fat after dissection. Tissue/organ weights 
were corrected to tibia length and body weight. Further details are provided in 
Chapter 2, Sections 2.3.1 and 2.3.2. 
3.4.6.2 Wire myography 
Mesenteric resistance arteries were carefully dissected and cleaned from fat and 
connective tissue under a microscope. The arteries were then mounted onto 40 
micron wires in the myograph (Multimyograph Model 610, DMT Denmark) and the 
lengths of arteries were measured by calibrated eyepiece in a microscope. All 
baths of the multimyograph (model 610M) were set at a temperature of 37°C and 
then gassed with 95% O2 and 5% CO2 to place the vessels in standard conditions. 
The evaluation of the physiological responses of the vessels was recorded using 
computer software (Lab chart 7). A normalization technique was used to 
determine the internal circumference the vessel would have under a transmural 
pressure of 100 mmHg (13.3 KPa) by carrying out a number of stepwise stretches 
of the vessel, measuring micrometer (x) and force (y) readings, until a force of 
13.3 KPa is reached. This gives the micrometer reading required to set the vessels 
at the required tension. Forty minutes after normalisation, a wake-up procedure 
was performed. The aims of this technique were to reactivate the signalling 
mechanism of the vessels and validate the function and response of the vessels 
that have not been damaged through the dissection process. This technique was 
implemented following warming, equilibration and stretching with specific passive 
tension (X1). Vessels were then subject to a wake up technique as previously 
described in Chapter 2, Section 2.3.3. To establish the vessel’s contractile 
response curve, noradrenaline was added at the following cumulative 
concentrations: 1x10-9, 3x10-9, 1x10-8, 3x10-8, 1x10-7, 3x10-7, 1x10-6, 3x10-6, 1x10-5 
and 3x10-5 M. To determine the vessel’s endothelium-dependent relaxation 
response, carbachol was added at the following increasing concentrations: 1x10-
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8, 3x10-8, 1x10-7, 3x10-7, 1x10-6, 3x10-6, 1x10-5 M. The maximum response (EC50) 
and area under the curve (AUC) were then calculated from the response curves. 
More details are available in Chapter 2, Section 2.3.3. 
3.4.7 Histology 
3.4.7.1 Tissues preparation for histology 
Tissues (heart, liver and kidney) were fixed for 24 hours in 10% formalin at room 
temperature. After 24 hours, the formalin was replaced with 70% ethanol and kept 
overnight. The next day, tissues were then placed in histology cassettes (Thermo 
Fisher, Paisley, UK) and placed in a Citadel 1000 processor (Fisher Scientific, 
Loughborough, UK) at the following settings: 70 % ethanol 30 minutes, 95 % ethanol 
30 minutes, 100% ethanol 30 minutes, 100% ethanol 30 minutes, 100% ethanol 45 
minutes, 100% ethanol 45 minutes, 100% ethanol 60 minutes, 100% ethanol/xylene 
30 minutes, xylene 30 minutes, xylene 30 minutes, wax 30 minutes, wax 30 
minutes, wax 45 minutes, wax 45 minutes. The total running time was 8 hours and 
30 minutes. Tissues were embedded using Shandon Histocentre 3 embedding 
centre (Thermo Fisher Scientific, Loughborough, UK) and Histoplast paraffin 
(Thermo Fisher Scientific, Loughborough, UK). Paraffin sections of 5 µm were cut 
using a Leica Finese 325 Microtome (Thermo Fisher Scientific, Loughborough, UK) 
and placed in an oven at 60°C overnight. Eight to ten slides were taken per sample 
per animal and then stored at room temperature until used. Paraffin blocks were 
stored at 4°C.  
3.4.7.2 Haematoxylin and Eosin staining 
Immediately prior to staining, slides were deparaffinised twice in histoclear for 7 
minutes then rehydrated through an ethanol gradient (100%, 95% and 75%; 7 
minutes each) into distilled H2O for 7 minutes. Slides were stained with Harris 
haematoxylin (CellPath Ltd, Newtown, UK) for 2 minutes and then washed under 
a running tap water for 5 minutes. The sections were transferred to 70% ethanol 
for 30 seconds and then to eosin (CellPath Ltd, Newtown, UK) for 3 minute. 
Sections were then dehydrated through a reverse ethanol gradient of 95% twice 
for 30 seconds at each stage. The sections were then transferred to 100% ethanol 
for 1 minute followed by 100% ethanol for 5 minutes. Subsequently, sections were 
washed twice with Histoclear for 7 minutes and mounted using DPX (Phthalate 
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free) mounting medium (CellPath Ltd, Newtown, UK). Examination was performed 
under a microscope Olympus BX41 (Olympus America Inc, Center Valley), where 
the nuclei appeared purple and the cytoplasm pink. Eight to ten images were 
taken using a QImaging Go3 camera (QImaging, Canada) attached to the 
microscope and analysed by QCapture pro6 software (Qimaging, Canada). Double-
blind histological analysis was performed using Image J 1.52a (National Institutes 
of health, USA). Percentage of renal artery wall thickness (%WT) was calculated 
by measuring the external diameter and the inner lumen.  
3.4.8 Biochemistry analysis 
3.4.8.1 Biochemistry analysis on plasma and urine samples 
Biochemistry analysis on plasma and urine samples obtained from hexadecanedioic 
acid treated and control WKY rats were carried out by Mrs. Elaine Butler at the 
clinical biochemistry lab (British Heart Foundation Glasgow Cardiovascular 
Research Centre, Glasgow, UK). The quantitative determination of alanine 
aminotransferase (ALT) (U/L), aspartate aminotransferase (AST) (U/L), urea 
(mmol), creatinine (mmol), bilirubin (mmol), albumin (g/L), sodium (Na) (mmol), 
potassium (K) (mmol) and chloride (Cl) (mmol) levels were measured using 
Roche/Hitachi cobas c 311 systems. 
3.4.8.2 Quantification of hexadecanedioate level in plasma samples 
Quantitative analysis of hexadecanedioate levels in plasma samples of WKY rats 
was carried out by Dr Christian Reichel and Dr Anja Huber (Seibersdorf 
laboratories, Austria) using liquid chromatography–mass spectrometry (LC-
MS/MS). More details are provided in Chapter 2, Section 2.5. 
3.4.9 Statistics and Data analysis 
Data are presented by mean ± standard error of mean by Graphpad Prism 5 (San 
Diego, California, USA). Statistical analyses for haemodynamic parameters and 
echocardiography were carried out by repeated measures ANOVA (general linear 
model). For metabolic cage results, paired t-tests were used. One way ANOVA was 
applied to analyse the results of more than two groups, followed by a post-hoc 
Tukey’s test. Two sample t-tests were used in analysis of other data using Minitab 
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16 statistical software. Statistical significance was assumed at P-value less than 
0.05. 
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Figure 3-1: Timeline of the first intervention study to examine the impact of hexadecanedioic acid treatment (250 mg/kg/day) on blood pressure regulation.  
Harlan WKY rats (n=10) treated orally with hexadecanedioic acid for four weeks with monitoring of the haemodynamic parameters carried out using the Dataquest V 
telemetry system and cardiac functions measured by echocardiography. Kidney function was assessed using 24 hours urine collections by metabolic cages. At sacrifice, 
blood samples were collected by cardiac puncture and organs samples were harvested, and mesenteric arteries were dissected to assess vascular function by wire 
myography. 
Chapter 3  111 
 
Figure 3-2: Timeline of dose response curve of hexadecanedioic acid on blood pressure. 
Twelve-week-old male WKYGla (n=3/group) treated with hexadecanedioic acid or vehicle. The dose increased weekly by 50 mg (i.e. 250 mg/kg, 300 mg/kg, 350 mg/kg, 
400 mg/kg, 450 mg/kg and 500 mg/kg). Blood pressure parameters were monitored via the telemetry system for 7 weeks including at baseline and during treatment. 
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Figure 3-3: Timeline of longer-term hexadecanedioic acid treatment.  
Six-week-old male WKYGla and SHRSPGla were treated orally with hexadecanedioic acid (250 mg/kg per day; n=3) or vehicle (n=3) for 9 weeks. Blood pressure was 
measured weekly by tail cuff plethysmography and cardiac function was assessed at two week intervals by echocardiography. At sacrifice, the main organs were collected, 
snap frozen and formalin fixed for histological analysis. 
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3.5 Results 
3.5.1 The impact of hexadecanedioic acid (250 mg/kg/day) on 
blood pressure and end organ damage  
3.5.1.1 The effect of hexadecanedioic acid on haemodynamic parameters 
After the recovery period from the radiotelemetry surgery, a delayed separation 
of systolic blood pressure (SBP) and mean arterial pressure (MAP) were observed 
between hexadecanedioic acid-treated WKY rats and vehicle-treated WKY rats 
occurring one week after the start of hexadecanedioate treatment. However, this 
hexadecanedioic acid-induced rise in blood pressure did not reach statistical 
significance (SBP, P=0.084), (MAP, P=0.057); respectively (Figure 3-4 A, B). There 
was no change in diastolic blood pressure (DBP) between the hexadecanedioic 
acid-treated rats and control rats (P=0.773) (Figure 3-4 C). Also no change was 
observed in heart rate over the course of the study between the hexadecanedioic 
acid-treated rats compared to the control rats (P=0.813) (Figure 3-4 D) (Menni, et 
al., 2015). The activities of hexadecanedioate-treated rats showed no significant 
difference compared to control WKY rats (P=0.10) (Figure 3-5). 
3.5.1.2 Echocardiography 
M-mode echocardiographic findings are summarised in Table 3-1. The levels of left 
ventricular mass normalised either to body weight or tibia length showed no 
significant difference during the study period between hexadecanedioic acid-
treated rats compared with vehicle-treated rats (LVM/ Body weight, P=0.13), 
(LVM/tibia length, P=0.39); respectively. However, final echocardiography 
measurement showed a significant reduction in left ventricular mass normalised 
to body weight in hexadecanedioic acid-treated rats compared to their respective 
controls (P=0.017). Also, no significant changes in left ventricular mass normalised 
to tibia length in hexadecanedioic acid-treated rats compared to their respective 
controls (P=0.092). 
Relative wall thickness (RWT), fractional shortening (FS) and ejection fraction (EF) 
showed no significant changes between hexadecanedioic acid-treated rats 
compared with vehicle-treated rats (Table 3-1). Stroke volume and cardiac output 
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for hexadecanedioic acid-treated rats also showed no difference compared with 
the vehicle-treated rats (SV, P=0.95), (CO, P=0.200); respectively (Table 3-1). 
3.5.1.3 Vascular responses to exogenous noradrenaline and carbachol 
Vascular reactivity to noradrenaline was significantly increased in the mesenteric 
resistance arteries of hexadecanedioic acid-treated rats compared with controls. 
The mesenteric resistance arteries of rats treated with hexadecanedoic acid 
started contraction at lower noradrenaline concentration compared with the 
mesenteric resistance arteries of control rats, indicating a significantly increased 
sensitivity to noradrenaline. This is illustrated as a shift to the left of the 
concentration response curve in the mesenteric resistance arteries of 
hexadecanedoic acid-treated rats (hexadecanedioate area under the curve 
100.8±9.3 versus control area under the curve 81.7±8.8 AUC; P=0.013; EC50, 
P=0.044) (Figure 3-6 A). Relaxation in response to carbachol did not differ between 
the mesenteric resistance arteries from control or hexadecanedioic acid-treated 
WKY rats (Figure 3-6 B).(Menni, et al., 2015). 
3.5.1.4 Plasma hexadecanedioate levels 
Plasma levels of hexadecanedioate were significantly increased in WKY rats after 
treatment with oral hexadecanedioic acid for four weeks compared with controls 
WKY (2.86 ± 0.36 ng/ml vs 1.56 ± 0.18 ng/ml, P=0.014), as shown in figure 3-7 
(Menni et al., 2015). 
3.5.1.5 Renal functions  
No changes were observed in water intake between hexadecanedioic acid-treated 
rats compared to control rats (hexadecanedioic acid-treated water intake 38.7 ± 
4.8 ml versus control water intake 35.9 ± 3.5 ml, P=0.352), as shown in Figure 3-
8 A. Also, no significant difference in water intake levels were observed in 
hexadecanedioic acid-treated rats after treatment with hexadecanedioic acid (∆ 
water intake=3.4 ml, P=0.57). Moreover, no significant difference was observed 
in urine output of hexadecanedioic acid-treated rats compared to control rats 
(hexadecanedioic acid-treated urine output 17.9 ± 2.2 ml versus control urine 
output 12.96 ± 1.22 ml, P=0.09). In addition, no change was observed in urine 
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output level after hexadecanedioic acid administration when compared with pre-
hexadecanedioic acid treatment urine output (16 ± 2.5 ml, P=0.26) (Figure 3-8 B). 
3.5.1.6 Biochemical findings 
The levels of AST, ALT, bilirubin and albumin were measured in plasma samples 
as liver function biomarkers. The hexadecanedioic acid treatment did not affect 
the liver specific enzymes. No changes were observed in the ALT, AST, bilirubin 
or albumin levels of hexadecanedioic acid-treated rats compared to control rats 
(Table 3-2). In addition, the levels of serum kidney biomarkers (i.e. urea, 
creatinine) showed no changes in hexadecanedioic acid-treated rats compared to 
control rats. Also, no changes were observed in the levels of sodium, potassium 
and chloride between hexadecanedioic acid-treated rats or control rats, as 
presented in Table 3-2. However, creatine kinase enzyme levels were significantly 
decreased in hexadecanedioic acid-treated rats compared to control rats 
(P=0.015).  
The levels of bilirubin and creatinine were also measured in urine samples. The 
creatinine levels showed no significant difference between hexadecanedioic acid-
treated rats and control rats (P=0.804). However, bilirubin levels were 
significantly increased in hexadecanedioic acid-treated rats compared to control 
rats (P=0.041), as shown in Table 3-3. 
3.5.1.7 Organ mass index 
Organ mass indexes for whole heart, left ventricle plus septum, liver, kidneys, and 
adipose tissues were measured at time of tissue collection. No significant 
differences were observed in the heart weight when normalised to body weight of 
hexadecanedioic acid-treated rats compared to control rats (P=0.513). To 
compare the accuracy of the left ventricular mass estimated by echocardiography, 
the left ventricular plus septal wall weight of the sacrificed rats was also 
measured. The left ventricular plus septal wall weight normalised to body weight 
showed no significant difference in hexadecanedioic acid-treated rats compared 
to control rats (P=0.18) (Table 3-4). Similarly, there was no significant difference 
in the weight of either right or left kidneys, when normalised to body weight in 
hexadecanedioic acid-treated rats compared to control rats (left kidney, P=0.93; 
right kidney P=0.59) (Table 3-4). Additionally, statistical analysis showed no 
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significant differences in liver weight normalised to body weight of 
hexadecanedioic acid-treated rats compared to controls (P=0.88) (Table 3-4). 
Furthermore, the weight of epididymal fat and retroperitoneal fat pads 
normalised to body weight did not show any differences between hexadecanedioic 
acid-treated rats compared to control rats (epididymal fat, P=0.64; 
retroperitoneal fat, P=0.89). The same pattern was shown when normalised to 
tibia length, as shown in (Table 3-4).  
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Figure 3-4: Radiotelemetry measurement (24-h averages) of haemodynamic parameters for hexadecanedioic acid-treated WKY rats and control WKY rats. 
The levels of (A) systolic blood pressure and (B) mean arterial pressure increased in hexadecanedioic acid (250 mg/kg per day, n=5)-treated WKY compared to vehicle-
treated WKY (n=5). There was no significant difference in (C) diastolic blood pressure, and (H) heart rate observed in WKY rats treated with hexadecanedioic acid or 
vehicle. Each point represented as mean ± standard error of mean.  
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Figure 3-5: Radiotelemetry measurement (24-h averages) of activity in hexadecanedioic acid-
treated WKY rats and control WKY rats. 
There was no significant difference in activity of WKY rats treated with hexadecanedioic acid (n=5) 
compared to vehicle-treated WKY rats (n=5). Each point represented as mean ± standard error of 
mean. 
Chapter 3 119 
Table 3-1: Echocardiographic measurements for WKY treated with hexadecanedioic acid (250 mg/kg per day) or vehicle for 4 weeks. 
Parameters  Pre-treatment 1st week of treatment 2nd week of treatment 3rd week of treatment 4th week of treatment 
ANOVA 
(general linear 
model) 
  control Hexa Control Hexa control Hexa control Hexa control Hexa P value 
LVM (mg)  
0.69 ± 
0.05 
0.65 ± 
0.02 
0.65 ± 
0.04 
0.70 ± 
0.04 
0.69 ± 
0.05 
0.72 ± 
0.09 
0.64 ± 
0.07 
0.64 ± 
0.02 
0.80 ± 
0.08 
0.69 ± 
0.02 
0.640 
LVM/BWt (mg/g) 
2.94 ± 
0.13 
2.60 ± 
0.09 
2.44 ± 
0.13 
2.55 ± 
0.19 
2.52 ± 
0.19 
2.49 ± 
0.29 
2.19 ± 
0.12 
2.13 ± 
0.05 
2.67 ± 
0.14 
2.24 ± 
0.08 * 
0.130 
LVM/tib (mg/mm) 
18.30 ± 
0.09 
17.30 ± 
0.06 
16.60 ± 
0.10 
17.70 ± 
0.09 
17.30 ± 
0.13 
17.40 ± 
0.19 
15.50 ± 
0.14 
15.30 ± 
0.03 
19.40 ± 
0.18 
16.60 ± 
0.04 
0.390 
FS % 
45.57 ± 
1.33 
43.11 ± 
1.83 
48.27 ± 
1.76 
49.16 ± 
2.37 
42.39 ± 
3.93 
46.99 ± 
1.98 
44.14 ± 
1.08 
44.73 ± 
1.82 
40.71 ± 
0.39 
43.47 ± 
2.46 
0.490 
RWT (mm) 
0.49 ± 
0.03 
0.47 ± 
0.02 
0.48 ± 
0.02 
0.55 ± 
0.04 
0.46 ± 
0.05 
0.44 ± 
0.03 
0.43 ± 
0.03 
0.42 ± 
0.02 
0.48 ± 
0.04 
0.46 ± 
0.02 
0.940 
SV (mls) 
0.32 ± 
0.02 
0.31 ± 
0.02 
0.32 ± 
0.04 
0.28 ± 
0.02 
0.34 ± 
0.02 
0.38 ± 
0.02 
0.36 ± 
0.06 
0.36 ± 
0.01 
0.35± 
0.01 
0.34 ± 
0.01 
0.950 
CO (mls/min) 
112.59 ± 
11.83 
114.01 ± 
6.74 
110.41 ± 
15.67 
105.96 ± 
6.15 
114.09 ± 
7.74 
140.82 ± 
4.61 
125.44 ± 
20.64 
128.26 ± 
5.916 
112.85 ± 
5.06 
122.42 ± 
5.67 
0.200 
EF % 
85.80 ± 
2.16 
81.29 ± 
1.86 
86.01 ± 
1.51 
86.42 ± 
1.93 
80.09 ± 
3.87 
84.79 ± 
1.69 
82.51 ± 
1.05 
82.84 ± 
1.62 
77.76 ± 
1.43 
81.40 ± 
2.62 
0.460 
Bwt g 
236.25 ± 
15.95 
250 ± 
2.96 
265 ± 
15.44 
276 ± 
4.59 
275.25 ± 
15.69 
288.5 ± 
4.61 
288 ± 
17.18 
299.33 ± 
5.29 
298.75 ± 
18.56 
310.33 ± 
4.51 
0.0001 
Abbreviations: LVM, Left Ventricular Mass; LVM/BWt, Left Ventricular Mass normalised to body weight; LVM/tib, Left Ventricular Mass normalised to tibia length; FS, 
Fractional Shortening; RWT, Relative Wall Thickness; SV, Strock Volume; CO, Cardiac Output; EF%, % Ejection Fraction; BWt g, Body Weight in gram. Unites: mg, 
milligram; mg/g, milligram per gram; mm, millimetre; mg/mm, milligram per millimetre; mls, millilitres; mls/min, milliliters/ minute. All data are mean ± SEM. (P*<0.05; 
Student Ttest used to compare hexa-treated WKY rats to their respective controls). 
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Figure 3-6: Mesenteric resistance artery function in response to noradrenaline and carbachol.  
(A) Contractile responses to noradrenaline in the mesenteric resistance arteries showed significant 
increase in the mesenteric resistance arteries of 4 weeks hexadecanedioate-treated rats (250 
mg/kg/day, n=10) compared with controls (n=9) (B) relaxation responses to carbachol, which showed 
no significant difference between hexadecanedioate-treated rats and controls (each point represents 
Mean ± Standard error of mean).  
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Figure 3-7: Plasma hexadecanedioate levels (ng/ml) in WKY rats treated with (250 mg/kg/day, 
n=6/group) hexadecanedioic acid or vehicle for 4 weeks. 
Hexadecanedioate levels significantly increased in hexadecanedioic acid-treated WKY rats 
compared to control WKY rats (Each point represents Mean ± Standard error of mean) (P*< 0.05). 
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Figure 3-8: Renal function was assessed by metabolic cages over 24 hours for 
hexadecanedioic acid (n=6) or vehicle-treated WKY rats (n=4). 
(A) Water intake and (B) urine output were measured pre and post treatment with hexadecanedioic 
acid or vehicle. The results showed no significant difference between hexadecanedioic acid-treated 
WKY rats and vehicle-treated WKY rats. Values are presented as Mean ± SEM. 
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Table 3-2: Biochemical analysis for plasma sample obtained from hexadecanedioic acid-treated rats and control rats. 
 
 
Parameters Control Hexadecanedioate P value 
CK (U/L) 269.15 ± 13.78 218.39 ± 13.55 0.015* 
ALT (U/L) 33.62 ± 3.82 37.97 ± 3.78 0.430 
AST (U/L) 76.97 ± 2.91 69.66 ± 2.35 0.063 
Urea (umol/L) 3.54 ± 0.14 3.83 ± 0.21 0.260 
Creatinine (umol/L) 1.30 ± 0.02 1.30 ± 0.01 0.863 
Bilirubin (g/L) 1.20 ± 0.09 1.23 ± 0.07 0.790 
Albumin (mmol/L) 19.42 ± 0.39 19.20 ± 0.38 0.690 
Na (mmol/L) 124.69 ± 2.59 122.08 ± 1.73 0.410 
K (mmol/L) 3.79 ± 0.19 3.89 ± 0.17 0.720 
Cl (mmol/L) 86.42 ± 1.83 83.86 ± 1.33 0.270 
Abbreviations: CK, Creatine Kinase; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; Na, sodium; K, potassium; Cl, 
chloride. Units: mmol/L, millimole/liter; umol/L, micromole/liter; g/L, gram/liter; U/L, units per litre. All data are mean± SEM. 
(P*<0.05; Student Ttest used to compare hexadecanedioic acid-treated WKY rats to their respective controls). 
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Table 3-3: Biochemical analysis for urine sample obtained from hexadecanedioic acid-treated rats and control rats. 
 
Parameters Control  Hexadecanedioate  P value 
Creatinine (umol/L) 3.47 ± 0.16 3.43 ± 0.07 0.548 
Bilirubin (g/L) 0.46 ± 0.68 0.77 ± 0.46 0.041* 
Abbreviations: umol/L, micromole/liter; g/L, gram/liter. All data are mean± SEM. (P*<0.05; Student Ttest used to compare 
hexadecanedioic acid-treated WKY rats to their respective controls). 
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Table 3-4: Organ weights normalised to body weight and tibia length of WKY rats treated with 
hexadecanedioic acid (250 mg/kg per day) or vehicle for 4 weeks at sacrifice. 
 
Parameters Control Hexa 
Ttest 
Control vs Hexa 
H/Bwt (mg/g) 3.42 ± 0.03 3.47 ± 0.01 0.513 
H/tib (mg/mm) 24.77 ± 0.22 24.45 ± 0.34 0.731 
LV+S/Bwt (mg/g) 2.31 ± 0.02 2.41 ± 0.02 0.181 
LV+S/tib (mg/mm) 16.72 ± 0.25 16.99 ± 0.28 0.750 
RK/Bwt (mg/g) 2.92 ± 0.02 2.93 ± 0.05 0.931 
RK/tib (mg/mm) 21.09 ± 0.22 20.64 ± 0.53 0.730 
LK/Bwt (mg/g) 2.81 ± 0.03 2.89 ± 0.06 0.595 
LK/tib (mg/mm) 20.36 ± 0.33 20.39 ± 0.53 0.984 
Epi/Bwt (mg/g) 13.92 ± 0.40 13.27 ± 0.45 0.640 
Epi/tib (mg/mm) 100.50 ± 2.44 93.49 ± 3.62 0.493 
Retro/Bwt (mg/g) 14.41 ± 0.84 13.99 ± 0.96 0.886 
Retro/tib (mg/mm) 103.99 ± 5.89 99.09 ± 7.30 0.821 
Liver/Bwt (mg/g) 32.44 ± 0.57 32.76 ± 0.73 0.883 
Liver/tib (mg/mm) 234.29 ± 2.57 229.26 ± 2.35 0.537 
Bwt (g) 289.56 ± 2.83 283.10 ± 4.59 0.606 
Tib (mm) 40.20 ± 0.26 40.20 ± 0.26 0.792 
Abbreviations: H/Bwt, Heart normalised to body weight; H/tib, Heart normalised 
to tibia length; LV+S/Bwt, Left Ventricular plus Septal wall normalised to body 
weight; LV+S/tib, Left Ventricular plus Septal wall normalised to tibia length; 
RK/Bwt, Right Kidney normalised to body weight; RK/tib, Right Kidney normalised 
to tibia length; LK/Bwt, Left Kidney normalised to body weight; LK/tib, Left Kidney 
normalised to tibia length; Epi/Bwt, Epididymal fat normalised to body weight; 
Epi/tib, Epididymal fat normalised to tibia length; Retro/Bwt, Retroperitoneal fat 
normalised to body weight; Retro/tib, Retroperitoneal fat normalised to tibia 
length; Liver/Bwt, Liver normalised to body weight; Liver/tib, Liver normalised to 
tibia length. Units: mg/g, milligram per gram; mg/mm, milligram/ millimetre; g, 
gram; mm, millimetre. All data are mean± SEM. 
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3.5.2 Dose response of hexadecanedioic acid on blood pressure 
regulation 
The dose response curve was applied to examine the concentration range at which 
hexadecanedioic acid levels have an impact on blood pressure in adult male WKYGla 
rats by oral administration of a range of doses (e.g. 250, 300, 350, 400, 450 and 
500 mg/kg/day) over a six-week treatment period. The step-wise increment in 
hexadecanedioic acid levels induced a gradual increase in the blood pressure of 
WKYGla rats with increasing doses. SBP levels shows a separation between 
hexadecanedioic acid-treated WKYGla rats and vehicle-treated WKYGla rats at 250 
mg/kg/day (P=0.085) and at 300 mg/kg/day (P=0.16), while it did not reach 
statistical significance. SBP significantly increased after treatment with 
hexadecanedioate at 350 mg/kg/day (P=2.3 x10-6), 400 mg/kg/day (P=2.8 x10-10), 
450 mg/kg/day (P=3.1 x10-10) and 500 mg/kg/day (P=4.04 x10-12) (Figure 3-9). 
Gradual elevations in mean arterial pressure (MAP) and diastolic blood pressure 
(DBP) were shown in hexadecanedioic acid-treated rats compared to control rats. 
There were no significant differences in MAP after treatment with 
hexadecanedioate at 250 mg/kg/day (P=0.079) and after a dose of 300 mg/kg/day 
(P=0.31). However, after increasing the dose by 50 mg, the MAP significantly 
increased i.e. 350 mg/kg/day (P=1.8 x10-6), 400 mg/kg/day (P=9.14 x10-9), 450 
mg/kg/day (P=2.34 x10-8) and 500 mg/kg/day (P=2.34 x10-8). Similarly, significant 
differences in DBP were observed between hexadecanedioate-treated rats and 
control rats after dose increment. The levels of DBP showed no significant 
difference after treatment with hexadecanedioic acid at 250 mg/kg/day (P=0.383) 
and 300 mg/kg/day (P=0.50). However, DBP was significantly elevated after 
treatment with hexadecanedioic acid at 350 mg/kg/day (P=4.34 x10-7), 400 
mg/kg/day (P=2.65 x10-7), 450 mg/kg/day (P=1.13 x10-8) and 500 mg/kg/day 
(P=1.92 x10-11) as shown in Figure 3-9. It should be noted that an unexpected fall 
in blood pressure was observed at day 11 of hexadecanedioic acid treatment, 
occurring at a dose of 300 mg/kg/day.  
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Figure 3-9: Dose response curves measured by radiotelemetry of (24-h averages) of WKYGla 
rats-treated with hexadecanedioic acid or vehicle for 6 weeks. 
(A) Systolic blood pressure (mmHg), (B) mean arterial pressure (mmHg) and (C) diastolic blood 
pressure (mmHg) of WKYGla rats treated with hexadecanedioic acid (250 mg/kg per day, 300 mg/kg 
per day, 350 mg/kg per day, 400 mg/kg per day, 450 mg/kg per day and 500 mg/kg per day, n=3) or 
control (n=3) for a total treatment period of 6 weeks. The step-wise increase in hexadecanedioic acid 
dose induced a gradual increase in the blood pressure of WKYGla rats. Each point represents (mean 
± standard error of mean).  
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3.5.3 Longer term hexadecanedioic acid treatment 
3.5.3.1 Effect of longer term hexadecanedioic acid treatment on blood 
pressure of WKYGla and SHRSPGla 
Blood pressure for both strains (i.e. WKYGla and SHRSPGla) increased with time, 
over the ten weeks study period. The blood pressure measurements began in young 
animals (i.e. 6 weeks of age) and followed to adulthood. Longer-term treatment 
with hexadecanedioic acid caused a significant elevation in the systolic blood 
pressure of hexadecanedioic acid-treated WKYGla rats compared to controls 
(P=0.0154). The difference in blood pressure between hexadecanedioic acid-
treated WKYGla rats and control WKYGla rats was observed at 13 weeks of age (i.e. 
at week 8 of treatment) and the elevation was sustained until the last 
measurement. However, there was no changes in the systolic blood pressure of 
hexadecanedioic acid-treated SHRSPGla rats compared with the control untreated 
SHRSPGla rats (P=0.96), as shown in Figure 3-10. 
3.5.3.2 Effect of longer term hexadecanedioic acid treatment on cardiac 
function of WKYGla and SHRSPGla 
Cardiac function of WKYGla 
The main echocardiographic parameters were measured at baseline and after 
treatment at two-week intervals (Table 3.5 and Table 3.6). Significant reduction 
in the levels of left ventricular mass was observed in hexadecanedioic acid-treated 
WKYGla rats compared to vehicle-treated WKYGla rats (Table 3-5). However, no 
significant difference was observed when the levels of LVM were normalised either 
to body weight (P=0.234) or tibia length (P=0.097) (Table 3-5). 
A significant reduction was observed in relative wall thickness (RWT) in 
hexadecanedioic acid-treated rats compared to control WKYGla rats during the 
study period (P=0.049). This significant reduction was observed during the second 
echocardiography measurement, when compared to the respective controls (0.38 
mm± 0.01 vs 0.49 mm± 0.01, P=0.001), and it remained lower at the final 
echocardiography measurement, but did not reach significance (0.46 mm± 0.03 vs 
0.55 mm± 0.04, P=0.131).  
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Other parameters, such as fractional shortening, stroke volume, ejection fraction 
and cardiac output levels showed no difference between WKYGla rats treated with 
either hexadecanedioic acid or vehicle, as shown in Table 3-5.  
The body weights of hexadecanedioic acid-treated WKYGla rats decreased 
significantly during the study timeline when compared to controls (P=0.0002), as 
shown in Table 3-5.  
Cardiac function of SHRSPGla 
Echocardiography measurement showed no difference in LVM either normalised to 
body weight or tibia length of SHRSPGla treated either with hexadecanedioic acid 
or vehicle. In addition, no difference was observed in RWT of SHRSPGla treated 
with hexadecanedioic acid compared to control (P=0.183) (Table 3-6). 
Fractional shortening, stroke volume, ejection fraction and cardiac output levels 
also showed no difference between SHRSPGla rats either treated with 
hexadecanedioic acid or vehicle, as shown in Table 3-6. 
The body weights of hexadecanedioic acid-treated SHRSPGla rats was also 
significantly decreased compared to control rats (P=0.002). This significant 
reduction was observed in the final echocardiography measurement (P=0.035) 
(Table 3-6). 
3.5.3.3 Organ mass index 
Organ weights were measured during collection of the tissues at sacrifice and then 
normalised to animal weight or tibia length to identify morphological changes 
after treatment with hexadecanedioic acid. Analysis of the data showed no 
significant change in heart weight normalised to rats’ body weights between 
hexadecanedioic acid-treated WKYGla rats compared to controls (P=0.067). In 
addition, no significant difference was observed in the heart weight normalised to 
body weight of hexadecanedioic acid-treated SHRSPGla rats compared to controls 
(P=0.937).  
The left ventricular plus septal wall weight of the sacrificed rats was also 
measured to verify the accuracy of the left ventricular mass measurements 
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estimated by echocardiography. Left ventricular plus septal wall weight 
normalised to body weight did not show any significant difference in either WKYGla 
or SHRSPGla, treated with hexadecanedioic acid or vehicle, as shown in Table 3-7.  
Renal indexes were also measured which showed no significant differences in the 
weight of left or right kidneys normalised to body weight between either 
hexadecanedioic acid or vehicle-treated SHRSPGla and WKYGla (Table 3-7). In 
addition, no changes were observed in liver weight normalised to body weight of 
hexadecanedioic acid-treated SHRSPGla or WKYGla rats compared to controls, as 
shown in Table 3-7. 
Adiposity indexes were measured for both epididymal and retroperitoneal fat 
pads. Analysis demonstrated no significant differences in epididymal fat pad 
weight normalised to body weight of hexadecanedioic acid-treated WKYGla or 
SHRSPGla rats compared to controls, as shown in Table 3-7. Furthermore, no 
significant difference in retroperitoneal fat weight normalised to body weight was 
observed in hexadecanedioic acid-treated WKYGla rats compared to control rats 
(P=0.070). However, there was a significant elevation in retroperitoneal fat 
weight normalised to body weight of hexadecanedioic acid-treated SHRSPGla rats 
compared to controls (P=0.048). The same pattern was shown when normalised to 
tibia length (Table 3-7). 
Significant reduction was observed in body weight of hexadecanedioic acid-
treated WKYGla (P=0.004) and SHRSPGla (P=0.03) rats compared to control rats 
(Table 3-7)  
3.5.3.4 Histology 
Histological evaluation using haematoxylin staining was carried out to identify 
evidence of cardiac, hepatic and renal morphology changes during chronic 
treatment with hexadecanedioic acid. No changes were shown in the heart tissues 
of hexadecanedioic acid-treated WKYGla or SHRSPGla rats compared to their 
respective control rats (Figure 3-11). Moreover, no histopathologic alterations 
were observed in liver tissues of hexadecanedioic acid-treated WKYGla or SHRSPGla 
rats compared to their respective controls (Figure 3-12).  
Chapter 3 131 
No gross histopathological changes were observed in kidney sections of WKYGla and 
SHRSPGla rats treated with hexadecanedioic acid when compared with vehicle 
(Figure 3-13). Renal artery wall thickness was measured which showed no 
significant differences in WKYGla rats treated with hexadecanedioic acid compared 
to control WKYGla rats (P=0.36), or in SHRSPGla rats compared to control SHRSPGla 
rats (P=0.48) (Figure 3-14). 
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Figure 3-10: Systolic blood pressure of WKYGla and SHRSPGla rats treated with 
hexadecanedioic acid (250 mg/kg per day, n=3) or vehicle (n=3) for 9 weeks. 
A significant elevation in the SBP of WKYGla rats was observed after longer-term treatment with 
hexadecanedioic acid compared to control WKYGla rats (blue lines). However, there was no 
significant difference in SBP of SHRSPGla after longer-term treatment with hexadecanedioic acid 
compared to control SHRSPGla rats (red lines). Each point represents (mean ± standard error of 
mean) (P*< 0.05). 
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Table 3-5: Echocardiographic measurements for WKYGla treated with hexadecanedioic acid (250 mg/kg per day, n=3) or vehicle (n=3) for 9 weeks. 
 
Parameters Baseline 1st measurement  2nd measurement  3rd measurement  
ANOVA 
(general 
linear 
model) 
  WKYGla WKYGla WKYGla WKYGla 
P value 
  Control Hexa Control Hexa Control Hexa Control Hexa 
LVM (mg) 0.33 ± 0.02 0.32 ± 0.001 0.57 ± 0.02 0.48 ± 0.04 0.79 ± 0.03 0.69 ± 0.03 0.99 ± 0.019 0.88 ± 0.043 0.001 
LVM:weight (mg/g) 2.65 ± 0.12 2.91 ± 0.11 2.59 ± 0.09 2.55 ± 0.20 2.56 ± 0.01 2.61 ± 0.07 2.82 ± 0.07 2.95 ± 0.12 0.234 
LVM:tl (mg/mm) 11.20 ± 0.06 12.60 ± 0.01 17.50 ± 0.07 15.10 ± 0.12 21.0 ± 0.03 19.60 ± 0.11 24.90 ± 0.04 22.90 ± 0.09 0.097 
FS % 34.23 ± 3.57 36.95 ± 4.50 46.44 ± 1.56 44.55 ± 0.92 44.34 ± 1.48 39.09 ± 3.84 37.03 ± 3.77 43.74 ± 4.95 0.626 
RWT (mm) 0.51 ± 0.013 0.53 ± 0.02 0.47 ± 0.01 0.47 ± 0.035 0.49 ± 0.01 0.38 ± 0.01
* 0.55 ± 0.04 0.46 ± 0.03 0.049 
SV (mls) 0.12 ± 0.017 0.12 ± 0.01 0.28 ± 0.002 0.23 ± 0.01 0.35 ± 0.002 0.40 ± 0.03 0.34 ± 0.03 0.43 ± 0.03 0.275 
CO (mls/min) 48.52 ± 6.15 46.43 ± 2.55 112.78 ± 3.17 89.03 ± 7.09 134.48 ± 3.73 129.41 ± 16.23 113.49 ± 16.61 147.25 ± 15.63 0.935 
EF % 71.05 ± 4.76 76.49 ± 5.23 84.56 ± 1.31 82.92 ± 0.85 82.68 ± 1.32 76.88 ± 4.11 74.49 ± 4.74 81.35 ± 4.97 0.629 
weight g 119 ± 2.91 117 ± 4.37 222 ± 4.26 188 ± 2.33
** 310 ± 11.02 264 ± 6.36
* 352 ± 6.94 298 ± 5.17
** 
0.0002 
Abbreviations: LVM, Left Ventricular Mass; LVM/BWt, Left Ventricular Mass normalised to body weight; LVM/tib, Left Ventricular Mass normalised to tibia length; FS, Fractional 
Shortening; RWT, Relative Wall Thickness; SV, Strock Volume; CO, Cardiac Output; EF%, % Ejection Fraction; BWt g, Body Weight in gram. Unites: mg, milligram; mg/g, milligram 
per gram; mm, millimetre; mg/mm, milligram per millimetre; mls, millilitres; mls/min, milliliters/ minute. All data are mean± SEM. (P*<0.05, P**<0.01; Student Ttest used to 
compare hexa-treated WKYGla rats to their respective controls). 
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Table 3-6: Echocardiographic measurements for SHRSPGla treated with hexadecanedioic acid (250 mg/kg per day, n=3) or vehicle (n=3) for 9 weeks. 
 
Parameters Baseline 1st measurement  2nd measurement  3rd measurement  
ANOVA 
(general 
linear 
model) 
  SHRSPGla SHRSPGla SHRSPGla SHRSPGla 
P value 
  Control Hexa Control Hexa Control Hexa Control Hexa 
LVM (mg) 0.35 ± 0.01 0.31 ± 0.02 0.54 ± 0.017 0.61 ±0.04 0.78 ± 0.07 0.87 ± 0.02 1.10 ± 0.06 0.95 ± 0.06 0.953 
LVM:weight (mg/g) 3.41 ± 0.10 3.51 ± 0.33 2.78 ± 0.04 3.10 ± 0.30 3.01 ± 0.23 3.46 ± 0.12 3.79 ± 0.19 3.54 ± 0.27 0.653 
LVM:tl (mg/mm) 13.30 ± 0.02 12.00 ± 0.08 17.50± 0.06 19.40 ± 0.12 20.80 ± 0.16 24.60 ± 0.08 28.90 ± 0.16 25.40 ± 0.13 0.741 
FS % 55.97 ± 7.11 54.36 ± 6.02 54.78 ± 2.69 52.79 ± 1.11 61.40 ± 3.16 56.05 ± 3.48 36.97 ± 3.34 48.36 ± 5.57 0.818 
RWT (mm) 0.56 ± 0.01 0.57 ± 0.06 0.53 ± 0.02 0.54 ± 0.06 0.61 ± 0.02 0.74 ± 0.09 0.66 ± 0.02 0.68 ± 0.05 0.183 
SV (mls) 0.15 ± 0.01 0.12 ± 0.011 0.24 ± 0.02 0.26 ± 0.03 0.29 ± 0.01 0.25 ± 0.04 0.29 ± 0.01 0.28 ± 0.03 0.38 
CO (mls/min) 65.12 ± 4.39 60.95 ± 2.16 100.24 ± 7.16 105.27± 12.64 112.75 ± 4.00 101.07 ± 16.03 93.89 ± 4.49 86.48 ± 4.37 0.287 
EF % 90.17 ± 3.86 89.48 ± 4.13 90.56 ± 1.64 89.44 ± 0.73 94.02 ± 1.37 91.18 ± 2.16 74.55 ± 3.80 85.75 ± 4.47 0.773 
weight g 104 ± 2.52 90 ± 4.48 196 ± 4.91 199 ± 6.65 259 ± 2.89 251 ± 4.33 290 ± 3.61 270 ± 3.00* 0.002 
Abbreviations: LVM, Left Ventricular Mass; LVM/BWt, Left Ventricular Mass normalised to body weight; LVM/tib, Left Ventricular Mass normalised to tibia length; FS, Fractional 
Shortening; RWT, Relative Wall Thickness; SV, Strock Volume; CO, Cardiac Output; EF%, % Ejection Fraction; BWt g, Body Weight in gram. Unites: mg, milligram; mg/g, 
milligram per gram; mm, millimetre; mg/mm, milligram per millimetre; mls, millilitres; mls/min, milliliters/ minute. All data are mean± SEM. (P*<0.05; Student Ttest used to 
compare hexa-treated SHRSPGla rats to their respective controls). 
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Table 3-7: Organ weights normalised to body weight and tibia length of WKYGla and SHRSPGla rats treated with hexadecanedioic acid (250 mg/kg per day, 
n=3) or vehicle (n=3) for 9 weeks at sacrifice. 
 
Parameters 
WKYGla Ttest  SHRSPGla Ttest  One Way ANOVA 
Control Hexa Control vs Hexa Control Hexa Control vs Hexa WKYGla vs SHRSPGla  
H/Bwt (mg/g) 3.38 ± 0.10 3.31 ± 0.088 0.067 4.43 ± 0.03 4.41 ± 0.23 0.937 0.000 
H/tib (mg/mm) 29.94 ± 0.83 28.88 ± 0.37 0.303 33.62 ± 0.34 31.72 ± 0.91 0.100 0.003 
LV+S/Bwt (mg/g) 2.48 ± 0.04 2.70 ± 0.11 0.107 3.13 ± 0.16 3.17 ± 0.02 0.768 0.004 
LV+S/tib (mg/mm) 22.03 ± 0.28 21.05 ± 0.95 0.381 24.55 ± 1.02 22.81 ± 0.44 0.290 0.071 
RK/Bwt (mg/g) 2.73 ± 0.16 2.75 ± 0.06 0.894 3.86 ± 0.12 3.69 ± 0.06 0.349 0.000 
RK/tib (mg/mm) 24.16 ± 1.45 21.39 ± 0.64 0.155 29.34 ± 0.85 26.54 ± 0.22 0.086 0.004 
LK/Bwt (mg/g) 2.70 ± 0.05 2.84 ± 0.04 0.112 3.67 ± 0.06 3.72 ± 0.09 0.641 0.000 
LK/tib (mg/mm) 23.96 ± 0.59 22.09 ± 0.53 0.079 27.86 ± 0.52 26.79 ± 0.04 0.215 0.000 
Epi/Bwt (mg/g) 8.94 ± 0.36 9.21 ± 0.21 0.539 12.87 ± 0.97 14.80 ± 0.78 0.255 0.001 
Epi/tib (mg/mm) 79.17 ± 2.72 71.74 ± 2.67 0.123 97.84 ± 7.81 106.49 ± 2.98 0.464 0.007 
Retro/Bwt (mg/g) 10.46 ± 0.40 11.93 ± 0.44 0.070 13.58 ± 0.44 18.80 ± 2.02 0.048* 0.001 
Retro/tib (mg/mm) 92.66 ± 2.77 92.91 ± 4.49 0.964 103.13 ± 3.18 135.05 ± 11.27 0.042* 0.001 
Liver/Bwt (mg/g) 33.98 ± 0.25 36.65 ± 1.36 0.125 37.59 ± 1.09 38.65 ± 0.34 0.515 0.003 
Liver/tib (mg/mm) 301.19 ± 0.69 285.30 ± 12.34 0.268 285.69 ± 9.57 278.33 ± 4.38 0.605 0.006 
Bwt (g) 351.67 ± 6.94 298.33 ± 5.17 0.004* 290 ± 3.61 270 ± 3.00 0.030* 0.000 
Tib (mm) 37.50 ± 0.50 38.33 ± 0.33 0.148 38.17 ± 0.17 37.50 ± 0.50 0.219 0.000 
Abbreviations: H/Bwt, Heart normalised to body weight; H/tib, Heart normalised to tibia length; LV+S/Bwt, Left Ventricular plus Septal wall 
normalised to body weight; LV+S/tib, Left Ventricular plus Septal wall normalised to tibia length; RK/Bwt, Right Kidney normalised to body 
weight; RK/tib, Right Kidney normalised to tibia length; LK/Bwt, Left Kidney normalised to body weight; LK/tib, Left Kidney normalised to tibia 
length; Epi/Bwt, Epididymal fat normalised to body weight; Epi/tib, Epididymal fat normalised to tibia length; Retro/Bwt, Retroperitoneal fat 
normalised to body weight; Retro/tib, Retroperitoneal fat normalised to tibia length; Liver/Bwt, Liver normalised to body weight; Liver/tib, 
Liver normalised to tibia length. Units: mg/g, milligram per gram; mg/mm, milligram/ millimetre; g, gram; mm, millimetre. All data are mean± 
SEM. (P*<0.05; Student Ttest used to compare hexa-treated rats to their respective controls). 
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Figure 3-11: Haematoxylin and Eosin staining in heart sections from WKYGla and SHRSPGla rats treated with hexadecanedioic acid or vehicle for 9 weeks. 
There was no changes were shown in the heart tissues of hexadecanedioic acid-treated WKYGla/ SHRSPGla rats (B, D) compared to control WKYGla/ SHRSPGla rats (A, 
C). Abbreviation: Artery, A. Magnification=X100; scale bar=100 μm, n= 8-10 slides per animal. 
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Figure 3-12: Haematoxylin and Eosin staining in liver sections from WKYGla and SHRSPGla rats treated with hexadecanedioic acid or vehicle for 9 weeks.  
No changes were detected in liver tissues obtained from WKYGla and SHRSPGla rats after treatment with hexadecanedioic acid (B, D) compared to control (A, C). 
Abbreviation: Central Vein, CV; Portal Vein, PV; Bile Duct, BD; Sinusoid, S. Magnification=X100; scale bar=100 μm, n= 8-10 slides per animal. 
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Figure 3-13: Haematoxylin and Eosin staining in kidney sections from WKYGla and SHRSPGla rats treated with hexadecanedioic acid or vehicle for 9 weeks.  
No changes were detected in kidney tissues obtained from WKYGla and SHRSPGla rats after treatment with hexadecanedioic acid (B, D) compared to control (A, C). 
Abbreviation: Glomeruli (G), proximal convoluted tubules (PCT), distal convoluted tubules (DCT), collecting tubules (CT), and arteries (A). Magnification=X100; scale 
bar=100 μm, n= 8-10 slides per animal. 
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Figure 3-14: Percentage of renal vascular thickness of WKYGla and SHRSPGla rats treated with 
hexadecanedioic acid or vehicle for 9 weeks. 
No changes were observed in the renal artery wall thickness of WKYGla or SHRSPGla rats treated 
with hexadecanedioic acid (n=3) compared to control rats (n=3) (mean ± standard error of mean). 
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3.6 Discussion 
The data presented in this chapter validate the findings from the metabolomics 
studies conducted in the TwinsUK, KORA and Hertfordshire Cohorts (Menni et al., 
2015) demonstrating that hexadecanedioate levels are associated with blood 
pressure regulation (more details in Chapter 1, Section 1.13). Blood pressure was 
increased in adult WKY rats after treatment with hexadecanedioic acid (250 
mg/kg/day) for 4 weeks in parallel with significant elevations in plasma 
hexadecanedioate levels. Furthermore, significant elevation in blood pressure of 
WKYGla rats was observed after chronic treatment with hexadecanedioic acid (250 
mg/kg/day) over a 9 week study period. This elevation in blood pressure was 
observed once the rats reached maturity (i.e. at 13 weeks of age). However, 
chronic treatment with hexadecanedioic acid was unable to further increase blood 
pressure levels in SHRSPGla rats. In a previous publication, we showed that systolic 
blood pressure in SHRSPGla was significantly increased after 1% NaCl administration 
in drinking water for three weeks in order to enhance the level of hypertension 
and end organ damage. Plasma hexadecanedioate levels were already elevated in 
untreated SHRSPGla compared to WKYGla and showed no further elevation after salt 
challenge (Menni et al., 2015) (Figure 1-9). This suggests that elevating blood 
pressure per se does not stimulate hexadecanedioate production. 
The original dose of hexadecanedioic acid (i.e. 250 mg/kg/day) was chosen based 
on previous studies to investigate it’s in vivo effects on circulating lipid levels 
(Russell et al., 1991; Frenkel et al., 1994). The blood pressure response to higher 
doses was examined using a careful step-wise protocol in rats implanted with 
radiotelemetry probes. This dose-response study showed significantly increased 
blood pressure levels in WKYGla rats with progressively higher doses of 
hexadecanedioic acid. Potential toxicity effects prevented higher doses of 
hexadecanedioic acid being administered over longer study periods, since body 
weight was significantly reduced during longer-term treatment in SHRSPGla and 
WKYGla rats even at the 250mg/kg/day dose (Table 3-5), (Table 3-6) and (Table 3-
7).  
The increased vascular reactivity to noradrenaline shown in the mesenteric 
arteries of hexadecanedioic acid-treated rats indicates a vascular mechanism 
underlying the association between hexadecanedioate and blood pressure (Figure 
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3-6 A). It is well established that hypertension is associated with changes in 
vascular structure, mechanics, and function, which reduce the lumen size of 
arteries and hence increase vascular resistance in hypertension (Intengan and 
Schiffrin, 2000). Previous experimental studies in hypertension have demonstrated 
amplified sensitivity to noradrenaline, increased myogenic tone, impaired 
endothelium-dependent relaxation and decreased acetylcholine-induced and 
flow-mediated vasodilatation responses in a range of hypertensive animal models 
investigated (de Wit et al., 1998; Kang, 2014; Lüscher and Vanhoutte, 1986; 
Intengan and Schiffrin, 2000; Izzard and Heagerty, 1999). The stimulation of 
vascular smooth muscle cells with noradrenaline causes Ca2+ influx from 
intracellular Ca2+ stores via the inositol trisphosphate pathway (IP3). IP3 acts to 
release Ca2+ from the endoplasmic reticulum by binding to receptors that are 
ligand-gated Ca2+ channels to regulate vascular smooth muscle cell contraction 
(Liskova et al., 2014). K+ channels also play an important role in modulating 
contraction of vascular smooth muscle, which is mediated by Ca2+ release through 
L-type voltage dependent Ca2+ channels (L-VDCC) (Liskova et al., 2014). Increased 
sensitivity of mesenteric arteries to noradrenaline during hexadecanedioic acid 
treatment may therefore suggest a role for hexadecanedioate on intracellular Ca2+ 
signalling. In systematic metabolomics study performed by Hiltunen et al, which 
verified the role of hexadecanedioate on intracellular Ca2+ signalling. This is 
further indicated by a recent metabolomics study conducted by Hiltunen et al, 
which aimed to identify the metabolic biomarkers related to four classes of anti-
hypertensive drugs. They found that amlodipine (i.e. calcium channel blocker) 
was the only class of drug associated with decreased circulating levels of 
hexadecanedioate in hypertensive patients (Hiltunen et al., 2017). These findings 
suggest that further investigation is needed to examine the role of 
hexadecanedioate on intracellular Ca2+ signalling. 
In this study, no significant alterations were found in the relaxation response to 
carbachol in rats treated with hexadecanedioic acid compared with control rats 
(Figure 3-6 B). Carbachol is a synthetic analogue of acetylcholine and like other 
vasodilatation agents such as substance P, bradykinin, histamine, thrombin, and 
serotonin, it produces endothelium-dependent relaxation of blood vessels via 
nitric oxide (NO) signalling (Sumbria and Fisher, 2017). During hypertension, the 
formation of reactive oxygen species (ROS) increases, leading to increased 
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vascular smooth muscle proliferation and hypertrophy (Loperena and Harrison, 
2017). Particularly, the superoxide radical (O2-) interacts with endothelium-
derived nitric oxide (NO), to form the strong oxidant peroxynitrite (ONOO-), which 
causes a reduction in NO bioavailability, leading to reduced dilation of the arteries 
and enhancement of systemic vascular resistance (Harrison et al., 2007; Loperena 
and Harrison, 2017). The lack of impact of hexadecanedioic acid on carbachol-
induced vasodilation therefore suggests that hexadecanedioate is unlikely to exert 
it’s effect via endothelial–derived relaxation response and NO signalling. It would 
have been beneficial to measure the effect of hexadecanedioate on basal tone 
and NO bioavailability by incorporating an additional dose-response curve into the 
myography protocol to examine the relaxation-reponse to carbachol in the 
presence of L-NAME. However, due to the already extensive tissue harvest and 
analysis protocol on the day of sacrifice it was not posible to carry out this more 
in-depth investigation. 
In hypertension, the function of resistance-artery reactivity may be altered due 
to hypertrophic remodelling which decreases lumen diameter leading to increased 
peripheral resistance (Intengan and Schiffrin, 2001). Hypertrophic vascular 
remodelling characterised by decreased outer and inner wall diameters, unaltered 
cross-sectional area and increased media/lumen ratio without stiffening has been 
shown in spontaneously hypertensive rats and essential hypertensive patients 
(Renna et al., 2013). Unfortunately, time constraints in our study prevented 
assessment of vessel morphology using pressure myography alongside the wire 
myography for functional analysis in mesenteric arteries. This would have allowed 
investigation of any hexadecanedioic acid-induced changes in vessel size, wall 
thickness and elastic properties. However, as a surrogate we examined the % wall 
thickness of the renal arteries by histological analysis. In this analysis, no 
differences in renal wall thickness were observed in hexadecanedioic acid-treated 
WKYGla or SHRSPGla rats compared to control rats. Previous histological studies have 
shown that vascular changes including hyperplasia and smooth muscle cell 
vaccuolation were observed in kidneys from salt-loaded SHRSPGla rats indicating 
accelerated hypertension (Koh-Tan et al., 2013). Renal damage during 
hypertension has been related to growth or migration of vascular smooth muscle 
cells through alterations in inflammatory responses, dysfunction of endothelial 
cells, and degradation or synthesis of extracellular matrix components (Renna et 
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al, 2013). The lack of obvious changes in renal histology suggests that 
hexadecanedioic acid treatment does not impact on these mechanisms, or that 
the effects are too mild to elicit renal damage. 
In accordance with the lack of renal pathology, there were also no changes 
observed in renal mass index or renal function in terms of urine output or levels 
of biomarkers (i.e. urea, creatinine) in urine or plasma in WKY rats after 4-weeks 
of hexadecanedioic acid treatment. However, bilirubin levels in urine samples 
were significantly increased in hexadecanedioic acid-treated rats compared to 
control rats (Table 3-3). Increasing evidence suggests that mildly elevated serum 
bilirubin levels inhibit inflammation and the proliferation of vascular smooth 
muscle cells, which suggests a relationship between serum bilirubin levels and 
cardiovascular disease (Chen et al., 2017; Demir et al., 2014; Yang et al., 2009). 
Studies by Chin et al., 2009 identified that serum bilirubin was inversely 
associated with systolic blood pressure and with the prevalence of hypertension. 
In addition, bilirubin is considered to be a potent anti-oxidant and plays a role in 
oxidative stress by inhibiting the synthesis of reactive oxygen species in vascular 
smooth muscle cells (Wang and Bautista, 2015). However, in this study 
hexadecanedioic acid treatment induced an increase in bilirubin levels only in the 
urine but not in plasma. Increased bilirubin levels in urine may indicate an 
impairment of liver function or obstruction of biliary drainage leading to leakage 
of bilirubin out of liver cells, which is eliminated in the urine.  
In our study, no changes were observed in liver mass index in hexadecanedioic 
acid-treated rats compared to control rats. In addition, biochemical analysis of 
plasma samples from hexadecanedioate–treated rats exhibited no significant 
differences in the liver enzymes alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST). Histological examination of liver sections from WKYGla and 
SHRSPGla rats also showed no major pathological changes after chronic treatment 
with hexadecanedioic acid for 9 weeks (Figure 3-12). Therefore, liver function and 
morphology appear to remain normal in hexadecanedioic acid-treated rats despite 
elevated urine bilirubin levels. However, the lack of pathological changes in these 
studies may be due to the treatment period not being long enough for end-organ 
damage to become apparent.  
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In the longer-term treatment study, significant increases were observed in 
retroperitoneal fat pad weight of SHRSPGla rats treated with hexadecanedioic acid 
compared to control rats. This is in contrast to findings from a previous study 
carried out by Tzur et al. (1988), which demonstrated that treatment with β, β’-
tetramethyl-substituted hexadecanedioic acid (MEDICA 16) caused an acute 
reduction in adiposity. However, the Sands rats used in the Tzur et al study are a 
model of obesity rather than spontaneous hypertension, which may in part explain 
the contrasting results. Flachs et al. (2005) identified that reduced lipid 
accumulation in abdominal fat results in stimulation of fatty acid beta-oxidation 
(β oxidation); where hexadecanedioate is principally metabolised. Elevations in 
fatty acid β-oxidation are found to be negatively correlated with body mass index. 
Therefore, increased fatty acid β-oxidation leads to increased weight loss 
(Rupasinghe et al., 2016). In our study, SHRSPGla and WKYGla rats treated with 
hexadecanedioic acid significantly lost weight during the study period as shown in 
Table 3-5, Table 3-6 and Table 3-7. These results may indicate that treatment 
with hexadecanedioic acid causes an alteration in fatty acid β-oxidation, 
potentially leading to increase in an alternative fatty acid oxidation pathway (i.e. 
the omega oxidation pathway).  
In the current study, cardiac function was also assessed during treatment with 
hexadecanedioic acid for 4 weeks and during chronic treatment for 9 weeks by 
echocardiography. Relative wall thickness was significantly reduced in the 
hexadecanedioic acid-treated WKYGla rats compared to control rats during the 9 
week-treatment period (Table 3-5). However, there were no significant 
differences in heart function parameters such as fractional shortening, stroke 
volume and cardiac output after hexadecanedoic acid treatment in SHRSPGla or 
WKYGla. Cardiac morphology was also evaluated by applying haematoxylin staining 
to heart histology sections, which showed no changes in either WKYGla or SHRSPGla 
rats after chronic treatment with hexadecanedioic acid (Figure 3-11).  
The significant reductions in body weight despite significantly increased 
epididymal fat pad weight and no change in volume drank/urine output in SHRSPGla 
rats may indicate that muscle wasting is induced in treated rats. Accordingly, we 
observed a significant reduction in plasma levels of creatine kinase (CK) in WKY 
rats after 4 weeks of hexadecanedioic acid treatment (Table 3-2). CK is a sensitive 
marker of muscle injury and low levels in plasma may indicate reduced muscle 
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mass. Creatine has an essential role in cellular energy homeostasis in tissues such 
as brain, gut, heart and skeletal muscles which have high dynamic energy demands 
(Kitzenberg et al., 2016). Creatine and its enzyme, CK, enable the transfer of 
high-energy phosphates in the form of phosphocreatine between sites of ATP 
generation such as mitochondrial oxidative phosphorylation and glycolysis 
(Kitzenberg et al., 2016). Reductions in CK levels may occur due to substantial 
changes in cardiac metabolism and myocardial energetics, and plasma CK is used 
as a biomarker to indicate damage to the myocardium and cardiovascular 
functional ability (Stambuk and Konjevoda, 2002). Previous studies have 
demonstrated that CK activity is reduced in humans with left ventricular 
hypertrophy and impaired myocardial contractile function (Intengan and Schiffrin, 
2001; Ingwall et al., 1985). In addition to these observations, decreased 
expression of CK was observed in heart tissues obtained from rats with pulmonary 
artery hypertension and right ventricular failure (Fowler et al., 2015). 
Furthermore, impaired contractile function and independent contributors to heart 
failure development have been found to be associated with reduced CK ATP 
delivery in animal models (Ye et al., 2001b, 2001a; Fowler et al., 2015). 
Hypertension may cause alterations in cardiac metabolism through increased 
myocardial energy demand to compensate for changes in glycolytic intermediates 
and high energy-phosphates (Dodd et al., 2012). Unfortunately, CK levels were 
not examined in plasma from the longer term treatment rats. These 
measurements would need to be completed in order to determine whether CK 
levels were similarly reduced in hexadecanedioic acid-treated SHRSPGla rats. 
However, the absence of cardiac dysfunction together with significant loss of body 
weight would suggest that skeletal muscles rather than cardiac muscles are being 
impacted by hexadecanedioic acid treatment in the longer term intervention 
studies. 
Study limitations 
There were a number of limitations to these studies, including the small number 
of animals used in both longer-term and dose-response hexadecanedioic acid 
studies. These studies were designed to comply with animal welfare regulations 
under the guidance of our vet (NVS)/Home Office Inspector, since we did not know 
how higher doses of hexadecanedioic acid would be tolerated, or potential toxicity 
issues over a longer treatment period. Therefore, the studies were conducted on 
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small batches of animals only. In addition, not all of the studies were carried out 
using WKY rats obtained from the Glasgow colony due to issues with animal supply 
at times, requiring the use of WKY rats from Harlan (Hillcrest, UK). This may 
create variability in the results since WKY rats from different colonies can have 
varying phenotypes (Zhang-James et al., 2013). 
Although blinding was conducted for ex vivo analysis, it was difficult to remain 
blinded during in vivo procedures since the hexadecanedioic acid-treated WKYs 
displayed behavioural issues during handling and restraint for the tail cuff method 
of blood pressure measurement. WKY rats’ activity, measured by radiotelemetry 
in the 4 weeks study, showed no significant difference between control and 
treated groups (i.e. when the rats were unrestrained in their home cage) (Figure 
3-5). However, the treated group resented being handled during tail cuff 
measurements during the longer-term intervention study.  
In conclusion, our data suggests that increased circulating levels of 
hexadecanedioate leads to blood pressure elevation and impairment of vascular 
function in WKY rats. The data also indicate increased adiposity index despite 
reduced body weight in SHRSP rats. These results may indicate muscle wasting 
and altered cellular energy homeostasis such as an impairment of the β-oxidation 
pathway. Further studies to validate and clarify the mechanisms by which 
hexadecanedioate affects blood pressure, are described in the following chapters. 
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 Global metabolomics profiles of 
pathways underling hexadecanediate-induced 
blood pressure elevation 
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4.1 Introduction 
The metabolomics field is currently one of the most influential bioanalytical 
approaches that creates quantitative or semi-quantitative information about 
biochemical metabolites (final products) of the metabolism. It is used to obtain a 
clear picture of the metabolites in biological mechanisms and determining specific 
metabolites related to phenotype, diseases or drug treatments (Sussulini, 2017; 
Van der Hooft et al., 2016). Metabolomics analysis has been widely used in recent 
studies to discover metabolites, drug-metabolites or biomarkers that are related 
to specific disease. (Maltesen et al., 2016; de Oliveira et al., 2016; Cowan et al., 
2016; Van der Hooft et al., 2016). 
Metabolome can be a very sensitive measure of organisms’ phenotypes due to 
metabolites being the final products of several genome-wide or proteome-wide 
interactions. In fact, metabolites are related to the phenotype and any changes 
in metabolites such as amino acids, lipids, and carbohydrates can reflect 
consequences of disease or disease-related conditions (Monteiro et al., 2013; Peng 
et al., 2015). Cardiovascular, neurological, cancer and metabolic diseases have 
been studied by using metabolomics methods (i.e. mass spectrometry and nuclear 
magnetic resonance). This has provided a significant improvement in the discovery 
of biomarkers that are related to these diseases (Gowda and Raftery, 2013). For 
instance, increases in branched-chain amino acids (BCAA) such as leucine, 
isoleucine, and valine contribute to development of obesity-associated insulin 
resistance (Newgard et al., 2013). Moreover, increases in methylated arginine 
species are related to the inhibition of nitric oxide production, leading to 
increased risk of coronary artery disease, myocardial infarction, and stroke (Wang 
et al., 2009). 
The method selected for metabolomics study varies depending on the research 
type, such as targeted analysis of metabolites (i.e. measurement of selected 
compounds, which belong to metabolic pathway). Metabolic fingerprinting 
(untargeted analysis), which is used to detect all metabolites present in a 
biological sample (urine, plasma or tissues) to identify specific metabolites 
related to a particular condition. The fingerprinting approach is also beneficial in 
the discovery of novel pathways and biomarkers to assess new therapeutic targets 
(Monteiro et al., 2013; Sussulini, 2017; Spratlin et al., 2009). In a standard 
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metabolomics analysis, several chemical detection platforms have been used; 
including mass spectrometry (MS) and nuclear magnetic resonance (NMR) 
However, a single analytical technique is not ideal to use for covering a whole 
metabolome due to chemical diversity of the metabolites. Therefore, a 
combination of platforms has been utilised over recent years (Sussulini, 2017). 
Detection of metabolites by using mass spectrometry is a powerful tool for 
investigations of metabolism because of its flexibility for the detection of multiple 
chemical molecular classes and its sensitivity to low-abundant molecules. A 
combination of a separation technique and MS is called a metabolomics platform 
and the most commonly used metabolomics platforms are: capillary 
electrophoresis–mass spectrometry (CEMS), gas chromatography-mass 
spectrometry (GC-MS) and liquid chromatography–mass spectrometry (LC-MS) 
(Wang et al., 2009). 
Ultra-high-resolution and high mass accuracy MS application differentiates the 
molecular classes accurately and identifies the molecular formula. Also, it 
provides a high lateral resolution imaging and highly dense data. However, data 
complexity exists, including challenges in analysing the results by using advanced 
computational analysis programmes and development of technical methodology 
to examine specific classes of metabolites that differentiate between groups (Van 
der Hooft et al., 2016; Madsen et al., 2010). Advanced spectral analysis includes 
multivariate analyses such as principal component analysis (PCA), which are often 
used for sample overview and classification. Also, univariate analysis based on the 
Student’s t-test and Mann-Whitney U test are used for verification (Griffiths et 
al., 2010; Madsen et al , 2010; Zhao et al., 2014). 
Biological interpretation is a crucial step in any metabolomics study. When 
putative metabolites are identified, metabolic pathways are the next step to be 
investigated. The metabolomics process for biological interpretation is divided 
into three main types based on their strategies in metabolite identification. 
Firstly, the chemometrics approach, which mainly emphasises classifying and 
understanding the subset of spectral features as the only significant features 
(Madsen et al , 2010; Sussulini, 2017). The second method is the metabolic 
profiling approach which generally focuses on classification of all detectable 
metabolites from the spectral data before subsequent functional analysis 
(Sussulini, 2017). Consequently, the third approach, the chemo-enrichment 
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analysis approach is mainly focused on an estimation of biological activities 
directly from the spectral features by mapping all detected metabolites, then 
linking them with pathways. (Booth et al., 2013; Barupal and Fiehn, 2017). 
The general aims of metabolomics studies are to measure the up-regulation and 
down-regulation of metabolites in abundance. They are also used for determining 
the impact of metabolites variations on metabolic pathways and identifying 
biomarkers to understand physiological variations in response to environmental 
changes (Peng et al , 2015). Our study is design to understand the metabolic 
impact of hexadecanedioate on the Wistar Kyoto (WKY) rats in order to identify 
metabolic pathways underlying hexadecanedioate-induced hypertension. 
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4.2 Hypothesis 
Distinct metabolite signatures are associated with elevated circulating 
hexadecanedioate levels, which will allow identification of dysregulated pathways 
underlying hypertension.  
4.3 Aims 
The aim of this chapter is to investigate the metabolic effect of hexadecanedioic 
acid administration on cardiovascular tissues (i.e. heart, kidney, liver, aorta and 
brain) obtained from Wistar Kyoto (WKY) rats which were treated with 
hexadecanedioic acid (hexa) or vehicle. This will allow identification of the 
metabolic pathways leading to hexadecanedioate-induced hypertension. 
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4.4 Methods 
4.4.1 Experimental animals  
Eleven-week-old male WKY rats (Harlan, UK) were treated orally with 
hexadecanedioic acid mixed with baby food (250 mg/kg per day; n=5) or vehicle 
(n=5) for 4 weeks. The rats were housed individually in cages on a 12 hours 
light/dark circle at room temperature (21± 3°C). Food and water were provided 
daily to the rats. The study protocols were approved by the Animals’ Scientific 
Procedures Act 1986 under the project license of Dr Delyth Graham (70/9021). 
4.4.2 Sample preparation  
At sacrifice, liver, kidney, heart, aorta, brain and retroperitoneal fat tissues were 
collected from hexadecanedioic acid-treated and control WKY rats. The tissues 
were harvested, frozen in liquid nitrogen and maintained at -80 oC. Tissues were 
then sent to Metabolon©, Inc. (Research Triangle Park, Durham, NC) for 
metabolomics analysis. Once the samples arrived at Metabolon©, the samples 
were inventoried and immediately stored at -80 oC. Each sample received was 
recorded into the Metabolon LIMS system (Laboratory Information Management 
System) and assigned with a unique identifier code. Samples were prepared using 
the automated MicroLab STAR® system from Hamilton Company. Several recovery 
standards were added prior to the first step in the extraction process for quality 
control (QC) purposes. Following data acquisition and processing, proteins were 
precipitated with methanol under vigorous shaking for two minutes (Glen Mills 
GenoGrinder 2000) followed by centrifugation to remove protein, dissociate small 
molecules bound to protein or trapped in the precipitated protein matrix, and to 
recover chemically diverse metabolites. The resulting extract was divided into 
five fractions (platforms): (i) early and (ii) late eluting compounds for analysis by 
ultra-high performance LC-MS/MS (UPLC-MS/MS) using positive ionization, (iii) for 
analysis by UPLC-MS/MS using negative ionization, (iv) for analysis using a UPLC-
MS/MS polar platform with negative ionization, and (v) a sample reserved for 
backup if needed. Samples were placed on a TurboVap® (Zymark) to remove the 
organic solvent. The sample extracts were stored overnight under nitrogen before 
preparation for analysis. 
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4.4.3 Metabolomic analyses using Ultra-High Performance Liquid 
Chromatography-Tandem Mass Spectroscopy (UPLC-
MS/MS)  
All methods utilised a Waters ACQUITY ultra-performance liquid chromatography 
(UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass 
spectrometer interfaced with a heated electrospray ionization (HESI-II) source and 
Orbitrap mass analyser operated at 35,000 mass resolution. The sample extract 
was dried, then reconstituted in solvents compatible to each of the four methods. 
Each reconstitution solvent contained a series of standards at fixed concentrations 
to ensure injection and chromatographic consistency. One aliquot was analysed 
using acidic positive ion conditions and chromatographically optimised for more 
hydrophilic compounds. In this method, the extract was gradient eluted from a 
C18 column (Waters UPLC BEH C18-2.1x100 mm, 1.7 µm) using water and 
methanol, containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid 
(FA). The second aliquot was also analysed using acidic positive ion conditions. In 
this method, the extract was gradient eluted from C18 column using methanol, 
acetonitrile, water, 0.05% PFPA and 0.01% FA and was operated at a higher organic 
content. The third aliquot was analysed using basic negative ion optimized 
conditions using a separate dedicated C18 column. The basic extracts were 
gradient eluted from the column using methanol, water and with 6.5 mM 
Ammonium Bicarbonate at pH 8. The fourth aliquot was analysed via negative 
ionization following elution from a HILIC column (Waters UPLC BEH Amide 2.1x150 
mm, 1.7 µm) using a gradient consisting of water and acetonitrile with 10 mM 
Ammonium Formate, pH 10.8. 
4.4.4 Metabolomics bioinformatics analysis 
For bioinformatic analysis, Metabolon© used informatics systems consisting of the 
Laboratory Information Management System (LIMS), the data extraction and peak-
identification software, data processing tools for quality control and compound 
identification, and a collection of information interpretation and visualization 
tools to analyse the data. The hardware and software foundations for these 
informatics components were the LAN backbone, and a database server running 
Oracle 10.2.0.1 Enterprise Edition. 
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4.4.5 Statistical analysis 
4.4.5.1 Methods for identifying treatment-associated metabolites 
R statistical software (a free software environment for statistical computing and 
graphics) was used under the guidance of Dr Desmond Campbell to analyse the 
raw data, which was provided by Metabolon©. Following the log transformation 
and imputation of missing values, comparisons between the groups’ metabolomic 
profiles were performed using Welch’s two-sample t-test, Student’s T Test, 
Shrinkage T Test, and Random Forest to identify biochemical metabolites that 
significantly differed between hexadecanedioic acid-treated rats and controls. 
The level of significance was set at p<0.05. Also, the false discovery rate was 
assessed using the q-value to correct for multiple testing. The q-value (q<0.10) is 
an indication of high confidence in the results. A q-value of 0.1 means that we 
should expect 10% of tests with q-values of less than 0.1 to be false positives. 
4.4.5.2 Wilcoxon Rank Sum (Man Whitney test) 
The samples were ranked according to metabolite level. The Wilcoxon Rank Sum 
test is applied to see whether the ranks of one treatment group are significantly 
higher or lower than control group. The Wilcoxon Rank Sum test’s power is low 
because it is rank (not value) based and the sample size is small (i.e. 5 rats/group). 
Under the null hypothesis, each arrangement of treatments and controls is equally 
likely. Number of all possible cases when five observations were selected from the 
set with 10 observations: 
10!
5! 5!
= 252 
The most extreme Wilcoxon Rank Sum statistics are given by arrangements 
completely separating the groups, i.e. AAAAABBBBB and BBBBBAAAAA. In fact, the 
most significant (one sided test) p-value that the test could generate for a dataset 
is (p value for one-sided test = 5/252 = 0.0198. p value for two-sided test = 2 * 
(5/252) = 0.0396). 
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4.4.5.3 Student’s T Test 
A Student’s T-test is most commonly applied when the test statistic would follow 
a normal distribution. This test is based on the ratio of between groups or within 
group distribution. Assumption of student t-test is that the variable under test is 
assumed to be normally (Gaussian) distributed and with equal variances. In the 
dataset, the majority of metabolite distributions looked Gaussian, but a minority 
were skewed and/or had outliers. Such departures from normality might cause 
very significant t-test p-values. We found the T test to be conservative when the 
data contained outliers or distributions that were skewed, as shown in Figure (4-
1), Figure (4-2) and Figure (4-3). The distribution in figure (4-1) is heavier tailed, 
meaning that outliners are more common. We simulated datasets of 10 samples in 
which 5000 variables had been observed. Samples were divided into two groups of 
five. Data followed the null hypothesis (i.e. no significant difference between the 
means of the two groups). 
4.4.5.4 Welch’s T test (unequal variances t-test)  
Welch’s T test is used in cases where the Student’s T test is not applicable. 
Distribution within group is not the same across groups. Welch’s T test allows for 
distribution to differ across groups. Welch's t-test is used for unequal variances, 
but the assumption of normality is maintained. 
4.4.5.5 Shrinkage T Test 
When sample sizes are small, the Student’s T test lacks power because the ratio 
between and within group variance is poorly estimated. The shrinkage t-statistic 
is used to overcome this by incorporating a James Stein estimator, which 
estimates the metabolite’s variance. When applied to a set of (three or more) 
metabolites, the vector of shrinkage t-statistics generated is guaranteed to be 
closer (on average) to the true t-statistic vector than the corresponding vector 
composed of Student t-statistics. In brief, metabolite ranking based on shrinkage 
t-statistics should be more accurate than ranking based on Student t alone. 
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Skewed and heavy Tailed 
 
Figure 4-1: Skewed distribution is heavy tailed. Based on 5000 variables of 10 samples. 
(Values taken from a mixture distribution of 0.9× Normal (0,1) +0.1×Uniform (0,10)). 
 
Heavy Tailed 
 
Figure 4-2: Heavy tailed distribution based on 5000 variables of 10 samples. 
(Values taken from a mixture distribution of 0.9×Normal (0,1 +0.1×Uniform (10,10)). 
 
Light tailed 
 
Figure 4-3: Light tailed distribution based on 5000 variables of 10 samples. 
(Values from taken a mixture distribution of 0.9×Normal (0,1) +0.1×Uniform (1,1)). 
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4.4.5.6 Empirical Cumulative Distribution Functions 
An empirical cumulative distribution function is a non-parametric estimator of the 
underlying cumulative distribution function of a random variable. Empirical 
cumulative distribution function is usually represented by; 
?̂?𝑛(𝑥) = ?̂?𝑛(𝑋 ≤ 𝑥) = 𝑛
−1 ∑ 𝐼(𝑥𝑖 ≤ 𝑥)
𝑛
𝑖=1
 
Where, ?̂?𝑛(𝑥) = ?̂?𝑛(𝑋 ≤ 𝑥) is empirical cumulative distribution function and 
𝐼(𝑥𝑖 ≤ 𝑥) is the indicator function which has two possible values; ( 𝑥𝑖 =
1, 2 , 3, 4, … . . , 𝑛) is an independent, random variable. 
 𝐼(𝑥𝑖 ≤ 𝑥) = {
1 𝑥𝑖 ≤ 𝑥
 0 𝑥𝑖 > 𝑥 
 
4.4.5.7 Random Forest (RF) 
Random forest analysis (RFA) is a statistical tool utilizing a supervised 
classification technique based on an ensemble of decision trees and can aid in the 
identification of biomarkers differentiating classification groups. For a given 
decision tree, a random subset of the data with identifying true class information 
is selected to build the tree and then the remaining data are passed down the tree 
to obtain a class prediction for each sample. This process is repeated thousands 
of times to produce the forest. The final classification of each sample is 
determined by computing the class prediction frequency (votes). For example, 
suppose the random forest consists of 50,000 trees and that 25,000 trees had a 
prediction for sample 1. Of these 25,000, suppose 15,000 trees classified the 
sample as belonging to Group A and the remaining were 10,000 classifieds 
belonging to Group B. Then the votes are 0.6 for Group A and 0.4 for Group B, and 
hence the final classification is Group A. This method is unbiased, since the 
prediction for each sample is based on trees built from a subset of samples that 
do not include that sample. When the full forest is grown, the class predictions 
are compared to the true classes, generating a measure of prediction accuracy. 
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4.4.5.8 Correlation 
Inter specimen correlation in metabolite deviations is applied by a heatmap 
representation of the specimen metabolite deviations correlation matrix (10 by 
10). Correlations were calculated as Kendal’s Tau which is a non-parametric 
measure of correlation between two ranked variables. Correlations are in range (-
0.2, 1). 1 is highly correlated and < 0 is intended low correlated. 
4.4.5.9 Pathway enrichment 
Two tests were used to measure pathway enrichment. Firstly, the hypergeometric 
test, which is used to measure the statistical significance of having samples 
containing of a defined number of successes from a population. Also, the fisher 
method test is used to combine the results from several independent tests with 
the same overall hypothesis. Enrichment values are based on the significant 
compounds relative to all detected compounds in the pathway. Enrichment = 
(number of significant metabolites in pathway/ total number of detected 
metabolites in pathway)/ (total number of significant metabolites/ total number 
of detected metabolites). 
4.4.5.10 Principle component analysis (PCA) 
Principal components analysis is an unsupervised, uncorrelated analysis that 
reduces the dimension of the data (i.e. reduces a large correlated number of 
variables to a small uncorrelated number of variables that still contains most of 
the information in the large set). Each principal component is a linear combination 
of every metabolite and the number of principal components is equal to the 
number of observations. The first principal component accounts by determining 
the coefficients of the metabolites that maximise the variance of the linear 
combination. The first principal component has the largest possible variance, that 
is it accounts for as much of the variability in the data as possible. The second 
component finds the coefficients that maximise the variance with the condition 
that the second component is orthogonal to the first. The second principal 
component captures the highest variance from what is left after the first principal 
component. The third component is orthogonal to the first two components and 
so on. The total variance is defined as the sum of the variances of the predicted 
values of each component (the variance is the square of the standard deviation), 
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and for each component, the proportion of the total variance is accounted. For 
example, if the standard deviation of the predicted values of the first principal 
component is 0.4 and the total variance = 1, then 100*0.4*0.4/1 = 16% of the total 
variance is explained by the first component. 
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4.5 Results 
4.5.1 Quality control 
4.5.1.1 Kidney 
The missingness distribution helps to develop the quality control strategy and to 
improve analysis of the datasets. Approximately 10% of metabolites (missing) were 
dropped from the kidney dataset during quality control process and 469 of 
metabolites remained. 
The dataset consisted of 10 samples (5 controls, 5 treated) containing 469 
metabolites. The distribution of values within each metabolite cannot easily be 
characterised, as the sample size is 10. However, investigating the relationship 
between summary statistics across metabolites and across the samples can be 
performed. Scatterplots (Figure 4-4) show the relation between the mean and 
standard deviation per metabolite (A and B) and per sample (C and D). There is a 
linear relationship between mean and standard deviation per metabolite on the 
log scale, as shown in B. Also, there is an outlier (sample number K1_A_6469), as 
shown in C and D. 
The empirical cumulative mass of metabolite deviation was also performed per 
sample stratified by platform to evaluate the distribution of our data. All samples 
performed well except for sample (K1_A_6469) (marked in blue colour) since this 
sample has unusual values for metabolites as measured by the LC/MS (Figure 4-5). 
4.5.1.2 Heart 
Twenty percent of metabolites (missing) were dropped from the heart dataset 
during the quality control process and 435 of metabolites remained. Scatterplots 
(Figure 4-6) show the relation between the mean and standard deviation per 
metabolite (A and B) and per sample (C and D). There is a linear relationship 
between mean and standard deviation per metabolite on the log scale, as shown 
in (Figure 4-6 B). Also, the empirical cumulative mass of metabolite deviations per 
subject stratified by platform illustrated that all samples were well distributed 
for metabolites measured by LC/MS, as shown in Figure 4-7. 
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4.5.1.3 Liver 
Following initial quality control, the remaining dataset consisted of 10 samples (5 
controls, 5 treated) containing 558 metabolites. No outliers were observed in liver 
samples. Scatterplots (Figure 4-8) show the relationship between the mean and 
standard deviation per metabolite (A and B) and per sample (C and D). There is a 
linear relationship between mean and standard deviation per metabolite on the 
log scale, as shown in (Figure 4-8 B). Also, the empirical cumulative mass of 
metabolite deviations per subject stratified by platform illustrate that all samples 
were well distributed for metabolites measured by LC/MS, as shown in Figure 4-
9. 
4.5.1.4 Aorta  
380 metabolites were detected in aorta samples. There were no obvious outliers. 
Scatterplots (Figure 4-10) show the relationship between the mean and standard 
deviation per metabolite (A and B) and per sample (C and D). There is a linear 
relationship between mean and standard deviation per metabolite on the log 
scale, as shown in (Figure 4-10 B). The empirical cumulative mass of metabolite 
deviations per subject stratified by platform illustrate that all samples were well 
distributed for metabolites measured by LC/MS, as shown in Figure 4-11. 
4.5.1.5 Brain 
The remaining dataset consisted of 10 samples (5 controls, 5 treated) containing 
454 metabolites. There were no obvious outliers. Scatterplots (Figure 4-12) show 
the relationship between the mean and standard deviation per metabolite (A and 
B) and per sample (C and D). There is a linear relationship between mean and 
standard deviation per metabolite on the log scale, as shown in (Figure 4-12 B). 
Also, the empirical cumulative mass of metabolite deviations per subject 
stratified by platform illustrate that all samples were well distributed for 
metabolites measured by LC/MS, as shown in Figure 4-13. 
4.5.1.6 Adipose tissue 
The remaining dataset consisted of 10 samples (5 controls, 5 treated) containing 
380 metabolites. There were no obvious outliers. Scatterplots (Figure 4-14) show 
the relationship between the mean and standard deviation per metabolite (A and 
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B) and per sample (C and D). There is a linear relationship between mean and 
standard deviation per metabolite on the log scale, as shown in (Figure 4-14 B). 
Also, the empirical cumulative mass of metabolite deviations per subject 
stratified by platform illustrate that all samples were well distributed for 
metabolites measured by LC/MS, as shown in Figure 4-15. 
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Figure 4-4: Scatterplots show the relationship between the mean and standard deviation per 
metabolite and per kidney sample. 
The relationship between the mean and standard deviation per metabolite (A, B) and per kidney 
sample (C, D). Figures (A, C) represent the original scale and figures (B, D) represent the log scale. 
There is a linear relationship between mean and standard deviation per metabolite on the log scale 
(B). The red circle indicates the outlier (sample number K1_A_6469). 
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Figure 4-5: The empirical cumulative mass of metabolite deviation per kidney sample. 
The empirical cumulative mass of metabolite deviation per kidney sample showed (A) 81 metabolites 
detected in LC/MS polar platform, (B) 166 metabolites detected in LC/MS positive early platform, (C) 
64 metabolites detected in LC/MS positive late platform and (D) 158 metabolites detected in LC/MS 
negative platform. Y axis presents empirical cumulative mass function and X axis presents sample 
stratified by platform. Each colour represents an individual animal (sample). All samples performed 
well in all platforms except one sample (K1_A_6469) in the LC/MS negative platform, which 
appeared not well distributed (marked in blue colour). 
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Figure 4-6: Scatterplots show the relationship between the mean and standard deviation per 
metabolite and per heart sample. 
Linear relationship was observed between mean and standard deviation per metabolite on the log 
scale (B). Scatterplots show that no outliers were observed in the relationship between the mean 
and standard deviation per metabolite (A, B) and per heart sample (C, D). Figures (A, C) represent 
the original scale and Figures (B, D) represent the log scale. 
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Figure 4-7: The empirical cumulative mass of metabolite deviation per heart sample. 
The empirical cumulative mass of metabolite deviation per heart sample. (A) 70 metabolites detected 
in LC/MS positive late platform, (B) 116 metabolites detected in LC/MS negative platform, (C) 176 
metabolites detected in LC/MS positive early platform and (D) 73 metabolites detected in LC/MS 
polar platform. Y axis presents empirical cumulative mass function and X axis presents samples 
stratified by platform. Each colour represents an individual animal (sample). All samples performed 
well in all platforms. 
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Figure 4-8: Scatterplots show the relationship between the mean and standard deviation per 
metabolite and per liver sample. 
There is a linear relationship between mean and standard deviation per metabolite on the log scale 
(B).Scatterplots show that no outliers were observed in the relationship between the mean and 
standard deviation per metabolite (A, B) and per liver sample (C, D). Figures (A, C) represent the 
original scale and Figures (B, D) represent the log scale. 
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Figure 4-9: The empirical cumulative mass of metabolite deviation per liver sample.  
The empirical cumulative mass of metabolite deviation per liver sample. (A) 78 metabolites detected 
in LC/MS positive late platform, (B) 181 metabolites detected in LC/MS negative early platform, (C) 
203 metabolites detected in LC/MS positive early platform and (D) 87 metabolites detected in LC/MS 
polar platform. Y axis presents empirical cumulative mass function and X axis presents samples 
stratified by platform. Each colour represents an individual animal (sample). All samples performed 
well in all platforms. 
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Figure 4-10: Scatterplots show the relationship between the mean and standard deviation per 
metabolite and per aorta sample. 
Linear relationship between mean and standard deviation per metabolite on the log scale (B). 
Scatterplots show that no outliers were observed in the relationship between the mean and standard 
deviation per metabolite (A, B) and per aorta sample (C, D). Figures (A, C) represent the original 
scale and Figures (B, D) represent the log scale. 
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Figure 4-11: The empirical cumulative mass of metabolite deviation per aorta sample. 
The empirical cumulative mass of metabolite deviation per aorta sample. (A) 88 metabolites detected 
in LC/MS positive late platform, (B) 142 metabolites detected in LC/MS negative platform, (C) 187 
metabolites detected in LC/MS positive early platform and (D) 74 metabolites detected in LC/MS 
polar platform. Y axis presents empirical cumulative mass function and X axis presents samples 
stratified by platform. Each colour represents an individual animal number (sample). All samples 
performed well in all platforms. 
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Figure 4-12: Scatterplots show the relationship between the mean and standard deviation per 
metabolite and per brain sample. 
There is a linear relationship between mean and standard deviation per metabolite on the log scale 
(B). Scatterplots show that no outliers were observed in the relationship between the mean and 
standard deviation per metabolite (A, B) and per brain sample (C, D). Figures (A, C) represent the 
original scale and Figures (B, D) represent the log scale. 
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Figure 4-13: The empirical cumulative mass of metabolite deviation per brain sample. 
The empirical cumulative mass of metabolite deviation per brain sample. (A) 79 metabolites detected 
in LC/MS positive late platform, (B) 114 metabolites detected in LC/MS negative platform, (C) 147 
metabolites detected in LC/MS positive early platform and (D) 69 metabolites detected in LC/MS 
polar platform. Y axis presents empirical cumulative mass function and X axis presents samples 
stratified by platform. Each colour represents an individual animal number (sample). All samples 
performed well in all platforms.  
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Figure 4-14: Scatterplots show the relationship between the mean and standard deviation per 
metabolite and per adipose sample. 
There is a linear relationship between mean and standard deviation per metabolite on the log scale 
(B). Scatterplots show that no outliers were observed in the relationship between the mean and 
standard deviation per metabolite (A, B) and per adipose sample (C, D). Figures (A, C) represent the 
original scale and Figures (B, D) represent the log scale. 
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Figure 4-15: The empirical cumulative mass of metabolite deviation per adipose sample. 
The empirical cumulative mass of metabolite deviation per adipose sample. (A) 92 metabolites 
detected in LC/MS negative platform, (B) 75 metabolites detected in LC/MS positive late platform, 
(C) 151 metabolites detected in LC/MS positive early platform and (D) 62 metabolites detected in 
LC/MS polar platform. Y axis presents empirical cumulative mass function and X axis presents 
samples stratified by platform. Each colour represents an individual animal number (sample). All 
samples performed well in all platforms. 
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4.5.2 Heat map  
Inter specimen correlation in metabolite deviations is applied by a heatmap 
representation of the specimen metabolite deviations correlation matrix (10 by 
10). Correlations were calculated as Kendal’s Tau. The hypothesis is that there 
would be no correlation between the hexadecanedioic acid-treated group and the 
control group. The pattern in the kidney is not very strong; low correlation was 
observed between the hexadecanedioic acid-treated group and control group 
(Figure 4-16 A). A low correlation also occurred between the hexadecanedioic 
acid-treated group and the control group in heart and liver patterns (Figure 4-16 
B) (Figure 4-16 C). The Aorta heatmap shows also low correlations between the 
hexadecanedioic acid-treated group and control group, as shown in Figure 4-16 D. 
In the brain and adipose, low correlation also shown between the hexadecanedioic 
acid-treated group and the control group (Figure 4-17 A) (Figure 4-17 B). 
4.5.3 Principle components analysis (PCA)  
Principle component analysis (PCA) was used to identify any separation between 
the hexadecanedioic acid-treated group and the control group. PCA for aorta, 
adipose, brain and liver matrices demonstrated overlapping populations when 
analysed by group. However, heart and kidney PCA showed a tendency to 
segregate by groups, which could suggest greater effects of hexadecanedioate on 
these matrices as shown in Figure 4-18. 
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Figure 4-16: Heatmap representation of the samples’ metabolite deviations correlation in (A) kidney, (B) heart, (C) liver and (D) aorta matrix. 
Correlations are in range (-0.2, 1). 1 (purple colour) is highly correlated and < 0 (yellow colour) is low correlated. 
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Figure 4-17: Heatmap representation of the samples’ metabolite deviations correlation in (A) brain and (B) adipose matrix. 
Correlation are in range (-0.2, 1). 1 (purple colour) is highly correlated and < 0 (yellow colour) is low correlated. 
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Figure 4-18: Principal Component Analysais (PCA). 
PCA for (A) kidney and (B) heart showed a tendency to segregate by groups. However, (C) liver, (D) 
aorta, (E) brain and (F) adipose matrices demonstrated overlapping populations when analysed by 
group. Red symbols indicate samples from hexadecanedioic acid-treated animals. Blue symbols 
indicate samples from control animals. 
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4.5.4 Random forest analysis (RFA) 
In the heart and kidney, the RFA was effective at separating samples into the 
appropriate group, with a predictive accuracy of 80% and 100% respectively 
(random chance would be expected to generate a predictive accuracy of 50%). 
RFAs for adipose, liver, aorta, and brain were not effective at classifying samples 
(with predictive accuracy approaching random chance). RFAs highlighted the top 
30 metabolites important for segregating samples in the heart and kidney in 
related pathways, including carbohydrate metabolism (e.g. myo-inositol, maltose, 
maltotriose, and maltotetraose), lipid metabolism (e.g. acylcarnitines, 
malonylcarnitine, and hexadecanedioate) and in the kidneys, amino acid 
metabolism (e.g. alpha-hydroxyisovalerate). Several of these observations are 
discussed in more detail in Section 4.5.6.  
4.5.5 Hexadecanedioate levels in tissues 
The level of hexadecanedioate was significantly increased in heart (P=0.009), 
kidney (P= 0.003), liver (P= 0.042), adipose (P= 0.01) and with an increase in aorta 
(P=0.895) samples from hexadecanedioic acid-treated rats compared with control 
rats (Figure 4-19). However, hexadecanedioate levels were below the threshold 
of detection in the brain, which may reflect poor diffusion through the blood-brain 
barrier.  
Ranking tests were used to identify association between hexadecanedioate and 
metabolites. The null hypothesis assumes that there is no association of 
metabolites with hexadecanedioate. Scatter plots (Upper diagonal) compare 
metabolite ranking for pairs of methods, where high rank (i.e. 400) indicates a 
strong association between metabolite levels and hexadecanedioate. Analyses are 
illustrated in the following order; Wilcoxon Rank Sum Test, Shrinkage T test (with 
and without equal within group variance assumption), Student T test (with and 
without equal within group variance assumption) and Random Forest. 
The number of hexadecanedioate-associating metabolites is high in kidney, liver 
and adipose tissues, but low in heart tissue (Figure 4-20). In the aorta, T Test 
results were incompatible with Wilcoxon Rank Sum and Random Forest tests over 
hexadecanedioate drug ranking. This was probably caused by an outlier (Figure 4-
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21 A). Nevertheless, there is little expectation of finding treatment-associating 
metabolites in the brain due to hexadecanedioate not being measurable in this 
tissue and because the principle component analysis did not show any separation 
between groups (Figure 4-21 B). 
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Figure 4-19: Hexadecanedioate metabolites levels. 
Hexadecanedioate-treated rats (compared to control) showed significant increases in 
hexadecanedioate levels in the heart (P=0.009), kidney (P=0.003), liver (P=0.042), adipose tissue 
(P=0.01) and an increase in aorta (p=0.895), with no change in hexadecanedioate levels in the brain. 
(P*<0.05), (P**< 0.01). 
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Figure 4-20: The rankings of association between hexadecanedioate and metabolites in (A) kidney, (B) liver, (C) kidney and (D) heart. 
Upper diagonal - scatter plots compare metabolite ranking for pairs of methods, where >400 indicates strong association. Diagonal analyses are in order; Wilcoxon Rank 
Sum Test, Shrinkage T test (with and without equal within group variance assumption), Student T test (with and without equal within group variance assumption) and 
Random Forest. Lower diagonal – correlation. Red circle shows the hexadecanedioate drug. 
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Figure 4-21: The rankings of association between hexadecanedioate and metabolites in (A) aorta, (B) brain. 
Upper diagonal - scatter plots compare metabolite ranking for pairs of methods, where >400 indicates strong association. Diagonal analyses are in order; Wilcoxon Rank 
Sum Test, Shrinkage T test (with and without equal within group variance assumption), Student T test (with and without equal within group variance assumption) and 
Random Forest lower diagonal – correlation. Red circle shows the hexadecanedioate drug. 
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4.5.6 Enrichment of Metabolomic Pathways 
A pathway enrichment overview of altered metabolites highlights lipids, 
carbohydrates and amino acid metabolism as being significantly enriched in the 
quantitative metabolomics of the heart, liver, kidney, aorta, adipose and brain 
tissues of hexadecanedioic acid-treated rats compared with control rats. Figure 
4-22 illustrates enriched pathways, including only those that contain more than 
one detected metabolite. The size of the line indicates the number of metabolites 
enriched in the defined pathway. The greatest impact after three weeks of 
hexadecanedioic acid treatment include the dicarboxylate fatty acid pathway and 
bile acid metabolism (Figure 4-22). 
4.5.6.1 Adipose  
In adipose tissue, 10 metabolites achieved statistical significance (p≤0.05) and 11 
approaching significance (0.05<p<0.10), as shown in the volcano plot (Figure 4-23 
A). These altered metabolites are correlated to two super pathways, including 
lipid and carbohydrate metabolism. A pathway enrichment overview of altered 
metabolites highlights dicarboxylate fatty acids, primary and secondary bile acid, 
and pentose phosphate metabolisms as being significantly enriched in the 
quantitative metabolomics of adipose tissue from hexadecanedioic acid-treated 
rats compared with control rats (Figure 4-23 B). 
Lipid metabolism 
Our metabolomics results showed significantly increased levels of 
hexadecanedioate (P=8x10-4), as well as the dicarboxylate fatty acids (DFAs) 
tetradecanedioate and octadecanedioate in the adipose tissues of 
hexadecanedioic acid-treated rats compared with control rats (P=0.045), 
(P=0.042); respectively, as listed in the appendix Table A1, (Figure 4-24). DFAs 
are the end products of ω-oxidation pathway generated by oxidation of the 
aldehyde group to a carboxylic acid. 
The free fatty acids phospholipids (1,2-dipalmitoleoyl-GPC(16:1/16:1)*) were 
significantly increased in hexadecanedioic acid-treated rats compared with 
control rats (P=0.039), as shown in Figure 4-25 A. Lysolipid (1-oleoyl-GPI (18:1) *) 
(Figure 4-25 D), as well as acyl carnitine (myristoylcarnitine and oleoylcarnitine) 
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levels (Figure 4-25 E), decreased in hexadecanedioic acid-treated rats compared 
with control rats. Hexadecanedioic acid-treated WKY rats also demonstrated an 
increase in the levels of monohydroxy (i.e. 16-hydroxypalmitate) (Appendix, Table 
A1), sphingolipid (i.e. sphingomyelin (d18:1/20:1,d18:2/20:0)*) and 
monoacylglycerol (i.e. 1-palmitoleoylglycerol (16:1) *) compared with untreated 
control WKY rats (Figure 4-25 C, B). 
Bile acid metabolism 
Several taurine-conjugated primary bile acids (i.e. tauro-chenodeoxycholate, 
taurocholate) were significantly elevated in the adipose tissues of 
hexadecanedioic acid-treated rats compared with control rats (P=0.0151), 
(P=3.5x10-3); respectively. Also, a marked increase in muricholic acids bile acids, 
tauro-alpha-muricholate (P=0.071) and tauro-beta-muricholate were observed 
(P=1.3x10-3) (Figure 4-26 A). In addition, secondary (i.e taurodeoxycholate) bile 
acid was significantly elevated in the adipose tissues of hexadecanedioic acid-
treated rats compared with control rats (P=6.1 x10-3) (Figure 4-26 B) (Appendix, 
Table A1). 
Carbohydrate metabolism 
Sedoheptulose-7-phosphate is an intermediate compound in the pentose 
phosphate pathway, which was significantly reduced in the adipose tissues of 
hexadecanedioic acid-treated rats compared with control rats (P=0.04) (Appendix, 
Table A1). 
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Figure 4-22: Circular visualisation of the metabolomics dataset. 
Circular visualisation of the metabolomics dataset illustrating enrichment of metabolomic pathways 
and metabolites for the heart, liver, kidney, aorta, adipose and brain tissues analysed. The pathways 
demonstrating greatest impact after three weeks of hexadecanedioic acid treatment include the 
dicarboxylate fatty acid pathway and bile acid metabolism. 
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Figure 4-23: Enrichment pathway of significantly associated metabolites in adipose tissues. 
(A) Volcano plot shows up to 21 metabolites are identified in adipose tissues, which are the top 10 
by p-value with fold change. Colours indicate metabolite membership in the most significant 
pathways according to hypergeometric enrichment test p-value. (B) Fold enrichment pathway of 
significantly associated metabolites in adipose tissues. Enrichment values are based on the 
significant compounds relative to all detected compounds in the pathway. Enrichment = (number of 
significant metabolites in pathway/ total number of detected metabolites in pathway)/ (total number 
of significant metabolites/ total number of detected metabolites). Fold change is red labelled. Welch 
T- test p-value marked as blue and Fisher p-value is marked as green.  
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Figure 4-24: The levels of dicarboxylic fatty acids in adipose tissue of hexadecanedioic acid-treated rats compared with control rats. 
(A) Fatty acid ω-oxidation pathway. (B) the level of hexadecanedioate (P=8x10-4), tetradecanedioate (P=0.045) and octadecanedioate (P=0.042) significantly increased 
in adipose tissue of hexadecanedioic acid-treated rats compared with control rats. (P*<0.05) (P***<0.001). 
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Figure 4-25: Fatty acid oxidation and carnitine metabolites in adipose tissues of 
hexadecanedioic acid- treated rats compared with control rats. 
Fatty acid oxidation and carnitine metabolism pathways were significantly altered by 
hexadecanedioate. In adipose tissue, the level of (A) phospholipid, (B) monoacyl glycerol and (C) 
sphingolipid increased in hexadecanedioic acid-treated rats compared with control rats. Whereas, 
the level of (D) lysolipid and (E) acyl carnitine decreased in adipose tissue of in hexadecanedioic 
acid-treated rats compared with control rats. 
.
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Figure 4-26: Bile acids metabolism in adipose tissues of hexadecanedioic acid-treated rats 
compared with control rats. 
In adipose tissue, the level of (A) primary bile acids, tauro-chenodeoxycholate, taurocholate and 
tauro-beta-muricholate significantly increased in hexadecanedioic acid-treated rats compared with 
control rats. (B) The level of secondary bile acid, taurodeoxycholate also significantly increased in 
hexadecanedioic acid-treated rats compared with control rats. 
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4.5.6.2 Kidney 
In kidney tissues, 49 metabolites achieved statistical significance (p≤0.05) and 39 
approaching significance (0.05<p<0.10), as shown in the volcano plot (Figure 4-27 
A). These perturbed metabolites are correlated to super pathways, including lipid, 
carbohydrate, and amino acid metabolisms (Appendix, Table A2). A pathway 
enrichment outline of altered metabolites that related to increase energy 
demands such as glycolysis, gluconeogenesis, glycogen, fatty acids (i.e. long chain 
fatty acid, dicarboxylate and phospholipid), ketone bodies, bile acid and co 
factors (i.e. FAD and FMN) were found in the kidney tissues of hexadecanedioic 
acid-treated rats compared with control rats (Figure 4-27 B). 
Lipid metabolism 
An increase in long-chain fatty acids (i.e. myristate, myristoleate, palmitoleate, 
10-heptadecenoate and 10-nonadecenoate) as well as increase in branched fatty 
acid and acylcarnitine was observed in the kidney tissues of hexadecanedioic acid-
treated rats compared with control rats (Figure 4-28 A, B). Also, the levels of 
dicarboxylic fatty acid; decanedioate (P=0.02) and inositol; myo-inositol (P=0.01) 
significantly decreased, with a significant increase in ketone bodies (BHBA) 
(P=0.015) in the kidney tissues of hexadecanedioic acid-treated rats compared 
with control rats (Figure 4-28 C, E and F). 
There were significant increases in lysolipid, glycerolipid, monoacylglycerol and 
phospholipid observed in hexadecanedioic acid-treated rats compared with 
control rats. Nevertheless, reductions in sphingolipid, sterol and phospholipid (i.e. 
1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) and 1-oleoyl-2-linoleoyl-GPE 
(18:1/18:2)*), were observed in the kidney tissues of hexadecanedioic acid-
treated rats compared with control rats (Figure 4-29), (Appendix Table A2).  
A significant reduction in malonylcarnitine level (P=0.04) and plasmalogen (i.e. 1-
(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)*) (P=0.007) was also 
observed in hexadecanedioic acid-treated rats compared with controls, as shown 
in (Figure 4-29), (Appendix Table A2).  
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Carbohydrate metabolism 
Significant increases in the levels of glycogen breakdown products (i.e. 
maltotetraose (P=0.024), maltotriose (P=0.026) and maltose (P=0.039)) with 
significant reduction in glucose 6-phosphate level (P=0.028) were observed in 
kidney tissues of hexadecanedioic acid-treated rats compared with controls. In 
addition, a significant reduction in arabitol/xylitol level (P=0.018) in pentose 
phosphate, a parallel pathway to glycolysis, was observed in hexadecanedioic 
acid-treated rats compared with controls. Correspondingly, galactose 1-phosphate 
(fructose, mannose and galactose metabolism) and glucuronate (aminosugar 
metabolism) levels significantly decreased in the kidney samples from 
hexadecanedioic acid-treated rats compared with control rats (P=0.05), 
(P=0.017); respectively. (Figure 4-30) (Appendix, Table A2). 
Bile acid metabolism 
The levels of glycine-conjugated primary bile acids (i.e. glycocholate and 
glycochenodeoxycholate) and unconjugated bile acid (i.e. chenodeoxycholate) 
markedly decreased in the kidneys of hexadecanedioic acid-treated rats compared 
with control rats. Also, a significant increase in muricholic bile acid (tauro-alpha-
muricholate (P=0.028) and tauro-beta-muricholate (P=0.024) was observed in 
hexadecanedioic acid-treated rats compared with control rats. In addition, 
reduction in the levels of secondary bile acids (i.e. glycodeoxycholate (P=0.007), 
glycolithocholate (P=0.08) and glycohyodeoxycholate (P=0.04)) was observed in 
hexadecanedioic acid-treated rats compared with control rats. While, 
tauroursodeoxycholate (secondary bile acid) levels significantly increased in 
hexadecanedioic acid-treated rats compared with control rats (P=0.015) (Figure 
4-31) (Appendix, Table A2).  
Chapter 4 193 
Amino acid metabolism 
All amino acids are derived from intermediates in glycolysis, pentose phosphate 
pathway or the citric acid cycle. The metabolomics data shows changes in amino 
acid metabolism such as glycine, serine, threonine, histidine, lysine, tryptophan, 
leucine, isoleucine, valine, methionine, cysteine, and taurine metabolism. In the 
kidney samples, the levels of 3-phosphoserine (P=0.022), N2-acetyllysine (P=0.03) 
and N-acetylvaline (P=0.006) significantly downregulated in hexadecanedioic acid-
treated rats compared with controls (Figure 4-32).  
The levels of N-acetylglutamine, 1-methylhistidine, and N-acetyl-3-
methylhistidine reduced in hexadecanedioic acid-treated rats compared with 
controls. Furthermore, the levels of imidazole lactate (P=0.043), 1-
methylimidazoleacetate (P=0.001), alpha-hydroxyisovalerate (P=0.006), 
hypotaurine (P=0.002) and putrescine (P=0.017) significantly upregulated in 
hexadecanedioic acid-treated rats compared with controls (Figure 4-32).  
The levels of kynurenine, taurine, N-acetylputrescine and guanidinosuccinate 
increased in hexadecanedioic acid-treated rats compared with controls (Appendix 
Table A2). 
Differences between the groups (hexa vs control) were observed in some 
metabolites of urea and the citric acid cycle, for example arginine, N-delta-
acetylornithine, and creatine, which showed a trend towards increase in 
hexadecanedioic acid-treated rats compared with controls. Also, proline (P=0.02), 
N-methylproline (P=0.037) and guanidinoacetate (P=0.01) showed a significant 
increase in the kidney tissues of hexadecanedioic acid-treated rats compared with 
controls (Figure 4-33) (Appendix Table A2). 
Co-factors  
A reduction in some of the co-factors related to many pathways such as 1-
methylnicotinamide, flavin adenine dinucleotide (FAD), flavin mononucleotide 
(FMN), pterin, thiamin monophosphate, thiamin diphosphate and pyridoxamine 
phosphate were observed in the kidney tissues of hexadecanedioic acid-treated 
rats compared with control rats (Appendix, Table A2).  
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Figure 4-27: Fold enrichment pathway of significantly associated metabolites in kidney 
tissues. 
(A) Volcano plot shows up to 88 metabolites identified in kidney tissues, which are the top 10 by p-
value with fold change. Colours indicate metabolite membership in the most significant pathways 
according to hypergeometric enrichment test p-value. (B) Fold enrichment pathway of significantly 
associated metabolites in kidney tissues. Enrichment values are based on the significant compounds 
relative to all detected compounds in the pathway. Enrichment = (number of significant metabolites 
in pathway/ total number of detected metabolites in pathway)/ (total number of significant 
metabolites/ total number of detected metabolites). Fold change is red labelled. Welch T- test p-value 
marked as blue and Fisher p-value is marked as green. 
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Figure 4-28: Alteration in fatty acid metabolic pathways detected in kidney tissues of 
hexadecanedioic acid- treated WKY rats compared to control WKY rats. 
In kidney tissues, fatty acid metabolic pathways are affected by hexadecanedioate treatment. 
Hexadecanedioate induced increases in (A) Long chain fatty acid (B) branched fatty acid (15-
methylpalmitate), and (D) lysolipid (1-palmitoleoyl-GPC (16:1)* ). However, significant reduction in 
(C) dicarboxylate (i.e. sebacate) and (E) inositol (i.e. myo-inositol) was observed in hexadecanedioic 
acid-treated rats compared to control rats. Also, Ketone bodies levels significantly increased in the 
hexadecanedioic acid group compared to control rats (F). (P*<0.05), (P**<0.01), (P***<0.001). 
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Figure 4-29: The levels of fatty acids in kidney tissues of hexadecanedioic acid-treated WKY 
rats compared to control WKY rats. 
The levels of fatty acids (A) phospholipid, (B) acyl carnitine significantly increased, while (C) 
plasmalogen significantly decreased in hexadecanedioic acid-treated rats compared with control 
rats. (D) Glycerollipid level significantly increased in kidney tissue of hexadecanedioic acid-treated 
rats compared with control rats. Also, the level of (E) monoacylglycerol increased, though (F) 
sphingolipid and (G) sterol levels decreased in kidney tissues from the hexadecanedioic acid group 
compared to control rats. (P*<0.05), (P**<0.01), (P***<0.001). 
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Figure 4-30: Alteration in carbohydrate metabolism in kidney tissues of hexadecanedioic 
acid-treated WKY rats compared with control WKY rats. 
Hexadecanedioate induced significant changes in carbohydrate metabolism in kidney tissues. The 
levels of (A) glucose 6-phosphate, (B) arabotol/ xylitol and (C) glucuronate significantly decreased in 
kidney tissue of hexadecanedioic acid-treated rats compared with control rats. Also, the level of (D) 
galactose 1-phosphate decreased in the hexadecanedioic acid group compared to control rats. (E) 
Metabolites in glycogen metabolism (i.e. maltose and maltotetraose) showed a significant increase 
in hexadecanedioic acid-treated rats compared with control rats (P*<0.05). 
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Figure 4-31: Bile acid metabolism in kidney tissues of hexadecanedioic acid-treated WKY rats 
compared with control WKY rats. 
Hexadecanedioate induced significant changes in bile acid metabolism in kidney tissues. The levels 
of (A) primary bile acids (i.e. glycocholate and glycochenodeoxycholate) decreased, while tauro-
alpha-muricholate and tauro-beta-muricholate showed a significant increase in kidney tissues from 
hexadecanedioic acid-treated rats compared with control rats. Also, the level of (B) secondary bile 
acids (i.e. glycodeoxycholate) showed a significant decrease, while tauroursodeoxycholate level 
significantly increased in the hexadecanedioic acid group compared to control rats. (P*<0.05) 
(P**<0.01). 
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Figure 4-32: Amino acid metabolism in kidney tissues of hexadecanedioic acid-treated WKY 
rats compared with control WKY rats. 
Hexadecanedioate induced significant changes in amino acid metabolism in kidney tissues. The 
levels of (A) histidine (i.e. imidazole lactate and 1-methylimidazoleacetate) significantly increased in 
kidney tissue of hexadecanedioic acid-treated rats compared with control rats. Also, the level of (B) 
leucine, isoleucine and valine Metabolism (i.e. alpha-hydroxyisovalerate and N-acetylvaline) 
significantly changes in hexadecanedioic acid-treated rats compared with control rats. (C) 
Methionine, Cysteine, SAM and Taurine Metabolism level (i.e. hypotaurine) significantly increased, 
though taurocyamine decreased in hexadecanedioic acid-treated rats compared with control rats. 
(P*<0.05), (P**<0.01). 
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Figure 4-33: The citric acid cycle metabolism in kidney tissues of hexadecanedioic acid-
treated WKY rats compared with control WKY rats. 
Hexadecanedioate also induced significant changes in the urea cycle (A) related to the citric acid 
cycle metabolism in kidney tissues. The levels of arginine and N-delta-acetylornithine increased and 
the levels of N-methylproline and proline significantly increased in hexadecanedioic acid-treated rats 
compared with control rats. Also, the level of (B) creatine metabolism showed a significant increase 
in guanidinoacetate and a trend towards increase in creatine levels (P*<0.05). 
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4.5.6.3 Brain 
In the brain tissues, 12 metabolites achieved statistical significance (p≤0.05) and 
19 approached significance (0.05<p<0.10), as shown in the volcano plot (Figure 4-
34 A). These perturbed metabolites are correlated to super pathways, including 
lipid and amino acid metabolism (Appendix, Table A3). Pathway enrichment 
(Figure 4-34 B) demonstrated the highly altered metabolites in brain of 
hexadecanedioic acid-treated rats compared with control rats; including long 
chain fatty acids, polyunsaturated fatty acids, and dihydrobiopterin cofactors in 
tetrahydrobiopterin metabolism. 
Lipid metabolism 
In the brain, long chain fatty acids such as myristate (P=0.018), palmitate 
(P=0.014), oleate (P= 0.006), stearate (P=0.024) and palmitoleate (P=0.045) 
significantly increased, while nonadecanoate (P=0.08) and arachidate (P=0.074) 
showed a trend towards increase in hexadecanedioic acid-treated rats compared 
with control rats. Moreover, polysaturated fatty acids showed a significant 
increase, such as docosahexaenoate (DHA; 22:6n3) (P=0.0036), adrenate (22:4n6) 
(P=0.0043), dihomo-linolenate (20:3n3 or n6) (P=0.0103), arachidonate (20:4n6) 
(P=0.018), and docosapentaenoate (n6 DPA; 22:5n6) (P=0.004) in hexadecanedioic 
acid-treated rats compared with control rats. Also, linoleate (18:2n6), 
eicosapentaenoate (EPA; 20:5n3) and dihomo-linoleate (20:2n6) levels increased 
in hexadecanedioic acid-treated rats compared with control rats. The levels of 
lysolipid (P=0.04), phospholipid, sphingolipid and corticosterone increased in 
hexadecanedioic acid-treated rats compared with control rats, as shown in Figure 
(4-35) (Appendix Table A3). 
Amino acid metabolism 
Small changes were observed in the levels of amino acids in brain tissues of 
hexadecanedioic acid-treated rats compared with control rats. An elevation in 
alpha and beta hydroxyisovalerate levels. An increase in urea level within the urea 
cycle with a decrease in levels of N-acetyl-3-methylhistidine and anserine, a 
dipeptide metabolite of histidine with anti-oxidant function could suggest 
increasing anti-oxidant use (Figure 4-36) (Appendix, Table A3). 
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Co-factors 
An elevation in a number of co-factors such as flavin adenine dinucleotide (FAD), 
dihydrobiopterin (P=0.04) and pyridoxamine phosphate were observed in 
hexadecanedioic acid-treated rats compared with control rats (Appendix, Table 
A3). 
Chapter 4 203 
 
Figure 4-34: Fold enrichment pathway of significantly associated metabolites in brain tissues. 
(A) Volcano plot shows up to 31 metabolites are achieved in brain tissues, which are the top 10 by 
p-value with fold change. Colours indicate metabolite membership in the most significant pathways 
according to hypergeometric enrichment test p-value. (B) Fold enrichment pathway of significantly 
associated metabolites in brain tissues. Enrichment values are based on the significant compounds 
relative to all detected compounds in the pathway. Enrichment = (number of significant metabolites 
in pathway/ total number of detected metabolites in pathway)/ (total number of significant 
metabolites/ total number of detected metabolites). Fold change is red labelled. Welch T- test p-value 
marked as blue and Fisher p-value is marked as green. 
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Figure 4-35: Fatty acids metabolism in brain tissues of hexadecanedioic acid-treated WKY 
rats compared with control WKY rats. 
Hexadecanedioate also induced significant increases in (A) long chain fatty acid metabolism (i.e. 
oleate/ vaccinate), (B) polyunsaturated fatty acid (i.e. docosahexaenoate (DHA; 22: 6n3)), and (C) 
lysolipid (i.e. 1-stearoyl-GPI (18:0)). The levels of (D) phospholipid (1-stearoyl-2-oleoyl-GPE (18:0/ 
18:1), (E) sphingolipid (i.e. sphingosine) and (F) steroid (I.e. corticosterone) increased in brain 
tissues of hexadecanedioic acid-treated rats compared with control rats (P*<0.05) (P**<0.01). 
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Figure 4-36: Amino acid metabolism in brain tissues of hexadecanedioic acid-treated WKY 
rats compared with control WKY rats. 
Hexadecanedioate induced changes in amino acid metabolism in brain tissues of WKY rats. The 
level of (A) beta-hydroxyisovalerate and alpha-hydroxyisovalerate increased, while (B) N-acetyl-3-
methylhistidine level decreased in hexadecanedioic acid-treated rats compared with control rats. (C) 
Urea metabolite in the urea cycle increased in brain tissues of in hexadecanedioic acid-treated rats 
compared with control rats. Also, (D) dipeptide derivative (anserine) decreased in hexadecanedioic 
acid-treated rats compared with control rats. 
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4.5.6.4 Liver 
In the liver tissues, 30 metabolites achieved statistical significance (p≤0.05) and 
54 approached significance (0.05<p<0.10), as shown in the volcano plot (Figure 4-
37 A). These perturbed metabolites are correlated to super pathways, including 
lipid, carbohydrate, and amino acid metabolisms (Appendix, Table A4). A pathway 
enrichment overview of altered metabolites highlights branched fatty acid, acyl 
glycine fatty acid, sterol, eicosanoid, glutathione and oxidative phosphorylation 
metabolisms as being significantly enriched in the quantitative metabolomics of 
liver tissues of hexadecanedioic acid- treated rats compared with control rats 
(Figure 4-37 B). 
Lipid metabolism 
There were alterations in the lipid profiles in liver tissues. Long chain fatty acid 
products (i.e. margarate (17:0), 10-heptadecenoate (17:1n7) and 10-
nonadecenoate (19:1n9)), branched fatty acids (i.e. 15-methylpalmitate and 17-
methylstearate) and polyunsaturated fatty acid (i.e. dihomo-linoleate (20:2n6)) 
increased, with decreases in stearidonate (18:4n3) in hexadecanedioic acid-
treated rats compared with control rats. Furthermore, an increase in phospholipid 
metabolism was observed in the liver tissue of hexadecanedioic acid-treated rats 
compared with control rats (Figure 4-38). 
There was a significant elevation in sphingolipid metabolism as well as cholesterol 
(P=0.0106) and campesterol (P=0.024) levels of sterol metabolism in 
hexadecanedioic acid-treated rats compared with control rats. 1-(1-enyl-
stearoyl)-2-linoleoyl-GPE (P-18:0/18:2)* level significantly increased with an 
elevation of other plasmalogen metabolites in hexadecanedioic acid-treated rats 
compared with control rats, as shown in Table A4 (Appendix)). Also, an increase 
in monoacylglycerol (i.e. 1-myristoylglycerol (14:0)) was shown in 
hexadecanedioic acid-treated rats compared with control rats (Figure 4-38). 
Metabolomics data also shows that hexadecanedioate administration induced 
significantly decreased levels of monohydroxy fatty acid products (i.e.2-
hydroxypalmitate), while 4-hydroxybutyrate significantly increased in 
hexadecanedioic acid-treated rats compared with control rats. Additionally, 
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lysolipid (i.e. 1-lignoceroyl-GPC (24:0)) and acyl carnitine (i.e. linoleoylcarnitine*) 
levels significantly increased in hexadecanedioic acid-treated rats compared with 
control rats. However, acyl glycine fatty acid (i.e. hexanoylglycine) and 
prostaglandin F2 alpha levels significantly decreased in liver tissues of 
hexadecanedioic acid-treated rats compared with control rats (Figure 4-38) 
(Appendix Table A4). 
Bile acid metabolism 
A marked increase in muricholic bile acid (i.e tauro-alpha-muricholate (P=0.054) 
and tauro-beta-muricholate (P=0.047) (Figure 4-39 A) in addition to significant 
reduction in secondary (i.e glycodeoxycholate) bile acid was observed in the liver 
samples from hexadecanedioic acid-treated rats compared with control rats 
(P=0.018), as shown in (Figure 4-39 B) (Appendix, Table A4). 
Carbohydrate metabolism 
Changes were found in carbohydrate metabolism in the liver tissues of 
hexadecanedioic acid-treated rats compared with control rats. Arabonate levels 
in pentose phosphate metabolism and glucuronate level in aminosuger metabolism 
reduced in hexadecanedioic acid-treated rats compared with control rats. The 
levels of N-acetyl-glucosamine 1-phosphate and nucleotide sugar (i.e. UDP-N-
acetylgalactosamine and UDP-glucuronate) increased in hexadecanedioic acid-
treated rats compared with control rats, as shown in (Appendix Table A4). 
Amino acid metabolism 
Our metabolomics data exhibited reductions in amino acids such as gamma 
glutamyl amino acids metabolites, as well as N-acetyltyrosine and o-tyrosine of 
phenylalanine and tyrosine metabolism in hexadecanedioic acid-treated rats 
compared with control rats (Appendix, Table A4) (Figure 4-40 C). Furthermore, N-
acetylleucine, 4-methyl-2-oxopentanoate, N-acetylisoleucine, valine, and N-
acetyltryptophan decreased in hexadecanedioic acid-treated rats compared with 
control rats (Appendix, Table A4). Glycine, betaine, betaine aldehyde and 4-
hydroxyglutamate levels decreased, while N-acetylglutamate (P=0.026), S-
methylcysteine (P=0.012) and taurocyamine (P=0.005) significantly reduced in 
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hexadecanedioic acid-treated rats compared with controls (Figure 4-40 A) 
(Appendix, Table A4).  
Histidine levels decreased, with slightly increased 4-imidazoleacetate level in the 
histidine metabolism in hexadecanedioic acid-treated rats compared with controls 
(Appendix, Table A4). However, imidazole lactate (P=0.04) and 1-
methylimidazoleacetate (P=0.0052) significantly increased in hexadecanedioic 
acid-treated rats compared with control rats (Figure 4-40 D). In liver, increases in 
cysteine-glutathione disulphide levels with significant decreases in 5-oxoproline 
level (P=0.0078) in hexadecanedioic acid-treated rats compared with controls 
(Figure 4-40 B). This could suggest an increase in oxidizing environment.  
There was a reduction in ornithine metabolite in the urea cycle, with an increase 
in N-delta-acetylornithine level (P=0.068) in hexadecanedioic acid-treated rats 
compared with control rats (Appendix, Table A4). 
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Figure 4-37: Fold enrichment pathway of significantly associated metabolites in liver tissues. 
(A) Volcano plot shows up to 84 metabolites identified in liver tissues, which are the top 10 by p-
value with fold change. Colours indicate metabolite membership in the most significant pathways 
according to hypergeometric enrichment test p-value. (B) Fold enrichment pathway of significantly 
associated metabolites in liver tissues. Enrichment values are based on the significant compounds 
relative to all detected compounds in the pathway. Enrichment = (number of significant metabolites 
in pathway/ total number of detected metabolites in pathway)/ (total number of significant 
metabolites/ total number of detected metabolites). Fold change is red labelled. Welch T- test p-value 
marked as blue and Fisher p-value is marked as green. 
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Figure 4-38: Fatty acids metabolism in liver tissues of hexadecanedioic acid-treated WKY rats 
compared to control WKY rats. 
Hexadecanedioate induced marked elevation in (A) long chain fatty acids (i.e. margarate (17:0), (B) 
branched fatty acid (i.e. 15-methylpalmitate), (C) phospholipid (i.e. 1-oleoyl-2-linoleoyl-GPE 
(18:1/18:2)*, (D) sphingolipid (i.e. N-palmitoyl-sphinganine (d18:0/ 16:0), (E) plasmalogen (1-(1-enyl-
stearoyl)-2-linoleoyl-GPE (P-18:0/18:2)*), (F) cholesterol, (G) lysolipid ( 1-lignoceroyl-GPC (24:0) in 
liver tissues of hexadecanedioic acid-treated rats compared with control rats. However, significant 
reductions were found in monohydroxy fatty acid (i.e. 2-hydroxypalmitate) in liver tissues of 
hexadecanedioic acid-treated rats compared to control rats (P*<0.05). 
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Figure 4-39: Bile acid metabolism in liver tissues of hexadecanedioic acid-treated WKY rats 
compared to control WKY rats. 
Hexadecanedioate induced a marked increase in (A) primary bile acid and a significant decrease in 
(B) secondary bile acid metabolism in liver tissues of hexadecanedioic acid-treated rats compared 
to control rats (P*<0.05). 
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Figure 4-40: Alteration in metabolites within methionine, cysteine, and taurine metabolism, 
glutathione metabolism, and histidine metabolism detected in hexadecanedioic acid-treated 
WKY rats compared with control WKY rats. 
Hexadecanedioate induced a significant reduction in (A) methionine, cysteine, SAM and taurine 
metabolism (i.e.s-methylcysteine and taurocyamine) and (B) 5-oxoproline metabolite in glutathione 
metabolism, while the levels of cysteine-glutathione disulphide increased. (C) Gamma-glutamyl 
amino acid (gamma-glutamylglycine) level significantly reduced and a trend towards decrease was 
shown in gamma-glutamylmethionine. Also, (D) a significant increase was observed in histidine 
metabolism metabolites in liver tissues in hexadecanedioic acid-treated rats compared with control 
rats. (P*<0.05) (P**<0.01). 
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4.5.6.5 Heart 
In the heart tissues, 59 metabolites achieved statistical significance (p≤0.05) and 
62 approached significance (0.05<p<0.10), as shown in the volcano plot (Figure 4-
41 A). Heart samples from hexadecanedioic acid–treated rats displayed broad 
changes in lipids, carbohydrates, amino acid and nucleotide metabolisms 
(Appendix, Table A6). A pathway enrichment overview of altered metabolites 
highlights mevalonate, acyl carnitine fatty acid, oxidative phosphorylation, 
lysoplasmalogen, glycogen, leucine, lsoleucine and valine; and phospholipid 
metabolism as being significantly enriched in the quantitative metabolomics of 
heart tissues of hexadecanedioic acid-treated rats compared with control rats 
(Figure 4-41 B). 
Amino acids metabolism 
Heart samples from hexadecanedioic acid-treated rats exhibited a distinct amino 
acid metabolite signature in comparison to the control heart tissues. Significant 
elevations in most amino acid metabolites were shown such as threonine 
(P=0.0053), 1-methylimidazoleacetate (P=0.031), asparagine (P=0.038), 
isoleucine (P=0.026), beta-hydroxyisovaleroylcarnitine (P=0.04), tiglylcarnitine 
(P=0.01), phenyllactate (P=0.048), tryptophan (P=0.043), c-glycosyltryptophan 
(P=0.01), S-adenosylmethionine (SAM) (P=0.03) and methionine (0.026) (Appendix, 
Table A6). 
The levels of leucine, alphahydroxyisovaleroylcarnitine*, N6,N6,N6-
trimethyllysine, tyrosine, S-adenosylhomocysteine (SAH) and 3-(4-hydroxyphenyl) 
lactate increased in hexadecanedioic acid-treated rats compared to controls. 
Significantly lower levels of N-acetylaspartate (NAA) (P=0.002) and 
methysuccinate (P=0.014) were observed in hexadecanedioic acid-treated rats 
compared to control rats. However, a reduction in level of N-acetylglutamine was 
observed in hexadecanedioic acid-treated rats compared to control rats. 
Moreover, the urea cycle; arginine and proline metabolism metabolites were 
upregulated, such as argininosuccinate (P=0.04), dimethylarginine (SDMA+ ADMA) 
and N-delta-acetylornithine in hexadecanedioic acid-treated rats compared to 
control rats (Appendix, Table A6).  
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Carbohydrate metabolism 
In the heart tissues, elevations in the levels of glucose and glucose 6-phosphat, 
with a decrease in the 3-carbon glycolytic intermediate 3-phosphoglycerate in 
hexadecanedioic acid-treated rats compared to control rats, are suggestive of 
changing glycolytic use (Figure 4-42 A). An increase in glycogen breakdown 
products (e.g. maltotetraose, maltotriose (P=0.043), and maltose (P=0.013)) could 
suggest increased glucose demand (Figure 4-42 B). 
Increases in fructose could be consistent with increased glucose availability 
(Figure 4-43 B). However, the glycolytic end-products pyruvate and lactate were 
not changed between groups. Furthermore, pentose metabolite (i.e. 
ribulose/xylulose) and aminosugar (i.e. N-acetylneuraminate (P=0.042) and 
glucosamine-6-phosphate) increased in hexadecanedioic acid-treated rats 
compared to control rats (Figure 4-43 A, C). Also, a significant increase in the level 
of fumarate (P=0.014) along with a significant decrease in oxidative 
phosphorylation (i.e. phosphate) (P=0.04) in hexadecanedioic acid-treated rats 
compared to control rats, could suggest increasing demand for use in the TCA 
cycle though citrate levels did not change (Figure 4-43 D, E) (Appendix, Table A6). 
Lipid metabolism  
In the heart, fatty acids (i.e. malonyl carnitine and butyryl carnitine) levels 
increased, with significant increases in acylcarnitines (i.e. oleoylcarnitine 
(P=0.008), linoleoylcarnitine (P=0.002), 3-hydroxybutyrylcarnitine(1) (P=0.04), 3-
hydroxybutyrylcarnitine(2) (P=0.02), palmitoylcarnitine (P=0.04) and 
stearoylcarnitine (P=0.02)) in hexadecanedioic acid-treated rats compared to 
control rats (Appendix, Table A6). 
Significant increases were observed in the levels of phospholipids (i.e. 
trimethylamine N-oxide (P=0.026), 1,2-dioleoyl-GPC (18:1/18:1)* (P=0.043), 1-
palmitoyl-2-oleoyl-GPE (16:0/18:1) (P=0.043), 1-stearoyl-2-oleoyl-GPE 
(18:0/18:1) (P=0.035), 1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) (P=0.045), 1-
stearoyl-2-linoleoyl-GPE (18:0/18:2)* (P=0.04), 1,2-dioleoyl-GPE (18:1/18:1) 
(P=0.03), 1,2-dilinoleoyl-GPC (18:2/18:2) (P=0.044) and 1-oleoyl-2-linoleoyl-GPE 
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(18:1/18:2)* (P=0.038) in hexadecanedioic acid-treated rats compared with 
controls (Appendix, Table A6). 
There were also significant increases in the levels of lysolipids (i.e. 1-oleoyl-GPE 
(18:1) (P=0.045) and plasmalogen (i.e. 1-(1-enyl-palmitoyl)-2-oleoyl-GPE(P-
16:0/18:1)* (P=0.039), 1-(1-enyl-palmitoyl)-2-oleoyl-GPC(P-16:0/18:1)* 
(P=0.048), 1-(1-enyl-stearoyl)-2-oleoyl-GPE(P-18:0/18:1) (p=0.014) as well as 
lysoplasmalogen (i.e. 1-(1-enyl-palmitoyl)-GPE(P-16:0)* (P=0.046) and 1-(1-enyl-
oleoyl)-GPE (P-18:1)* (P=0.044) were observed as in hexadecanedioic acid-treated 
rats compared with controls (Appendix, Table A6). 
An elevation in the levels of polyunsaturated fatty acid (i.e. linoleate), 
monoacylglycerol (i.e. 1-oleoylglycerol (18:1) (P=0.04) and 2-oleoylglycerol 
(18:1)), diacylglycerol (i.e. 1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2)*) were 
observed in hexadecanedioic acid-treated rats compared with controls (Appendix, 
Table A6).  
The levels of sphingolipids and sterol (i.e. cholesterol and beta-sitosterol 
(P=0.032)) increased in hexadecanedioic acid-treated rats compared with 
controls. However, myo-inositol (P=0.008) and melvalonate (i.e. 3-hydroxy-3-
methylglutarate) (P=0.0024) levels significantly reduced in hexadecanedioic acid-
treated rats compared with controls (Figure 4-44) (Appendix, Table A6). 
Nucleotides metabolism 
Elevations in several nucleotides were observed in the heart tissues of 
hexadecanedioic acid-treated rats compared with controls. For example purine 
metabolism, adenine containing metabolites (i.e. xanthinosine (P=0.04), 
adenosine 5'-diphosphate (ADP). Also, elevation in the levels of adenosine 3'-
monophosphate (3'-AMP) (P=0.022), adenosine 2'-monophosphate (2'-AMP), 
adenosine, N1-methyladenosine (P=0.015), N6-succinyladenosine (0.034), 
pyrimidine metabolism, uracil, guanine and cytidine containing metabolites, and 
pyrimidine metabolism was observed in hexadecanedioic acid-treated rats 
compared with controls (Appendix Table A6).   
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Figure 4-41: Fold enrichment pathway of significantly associated metabolites in heart tissues. 
(A) Volcano plot shows up to 121 metabolites identified in heart tissues, which are the top 10 by p-
value with fold change. Colours indicate metabolite membership in the most significant pathways 
according to hypergeometric enrichment test p-value. (B) Fold enrichment pathway of significantly 
associated metabolites in heart tissues. Enrichment values are based on the significant compounds 
relative to all detected compounds in the pathway. Enrichment = (number of significant metabolites 
in pathway/ total number of detected metabolites in pathway)/ (total number of significant 
metabolites/ total number of detected metabolites). Fold change is red labelled. Welch T- test p-value 
marked as blue and Fisher p-value is marked as green. 
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Figure 4-42: Glycolysis and glycogen metabolism in heart tissues of hexadecanedioic acid-treated WKY rats compared to control WKY rats. 
In the heart, elevations in glucose and glucose 6-phosphate levels, with a decrease in the 3-carbon glycolytic intermediate 3-phosphoglycerate. Also, a marked increase 
in glycogen breakdown products (e.g. maltotetraose, maltotriose, and maltose) in hexadecanedioic acid-treated rats compared with control rats (P*0.05). 
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Figure 4-43: Carbohydrate metabolism in heart tissues of hexadecanedioic acid-treated WKY 
rats compared to control WKY rats. 
The levels of (A) ribulose/xylulose and (B) fructose increased in heart tissues of hexadecanedioic 
acid-treated rats compared with control rats. Also, there was a marked increase in aminosugar 
metabolism products (i.e. N-acetylneuraminate and glucosamine-6-phosphate). The fumarate level 
in the TCA cycle significantly increased, as well as reduction in phosphate level within oxidative 
phosphorylation metabolism in hexadecanedioic acid-treated rats compared with control rats 
(P*0.05). 
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Figure 4-44: Fatty acids metabolism in heart tissues of hexadecanedioic acid-treated WKY 
rats compared to control WKY rats. 
Hexadecanedioate causes notable changes in lipid profiles in heart tissues. The level of (A) 
oleoylcarnitine, (B) lysoplasmalogen (i.e. 1-(1-enyl-oleoyl)-GPE (P-18:1)*), (C) monoacylglycerol (i.e. 
1-oleoylglycerol (18:1)), (D) phospholipid metabolites (i.e. trimethylamine N-oxide, (E) lysolipid (i.e. 
1-oleoyl GPE (18:1)) and (F) plasmalogen fatty acids, significantly increased along with significant 
decreased in the level of (G) myo-inositol and mevalonate metabolite (i.e. 3-hydroxy-3-
methylglutarate) (P*0.05) (P**<0.01). 
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4.5.6.6 Aorta 
In aorta tissues, 23 metabolites achieved statistical significance (p≤0.05) and 23 
approached significance (0.05<p<0.10), as shown in the volcano plot (Figure 4-45 
A). These altered metabolites are correlated to super pathways, including lipid, 
carbohydrate, and amino acid metabolism (Appendix, Table A5). A pathway 
enrichment overview of altered metabolites highlights lysoplasmalogen, lysolipid 
and nicotinate and nicotinamide metabolisms as being significantly enriched in 
the quantitative metabolomics of aorta tissues from hexadecanedioic acid-treated 
rats compared with control rats (Figure 4-45 B). 
Amino acids metabolism 
Significant reductions were observed in some amino acid metabolites such as 
glycine (P=0.012), glutamate (i.e. pyroglutamine (P=0.047)) and taurocyamine 
(P=0.014) in hexadecanedioic acid-treated rats compared to control rats. Also, the 
levels of serine, asparagine, histidine, creatinine, 3-methoxytyrosine, valine and 
gamma-glutamylglycine decreased in hexadecanedioic acid-treated rats compared 
to control rats. Nevertheless, imidazole lactate, phenyllactate (PLA), 
indolelactate (P=0.049) and gamma-glutamylvaline levels increased in 
hexadecanedioic acid-treated rats compared to control rats, as shown in 
(Appendix, Table A5). 
Carbohydrate metabolism  
A significant reduction in the glycolysis metabolite (i.e. 1,5-anhydroglucitol) 
(P=0.045), with a significant increase in mannitol/sorbitol levels (P=0.037) in 
fructose metabolism was observed in hexadecanedioic acid-treated WKY rats 
compared to control rats. In addition, succinylcarnitine in the TCA cycle 
significantly increased (P=0.047), with an increase in citrate level in 
hexadecanedioic acid-treated rats compared to control rats that could suggest 
increased glucose and TCA demands (Appendix, Table A5). 
Lipid metabolism 
Downregulation was observed in the levels of lipid metabolites. There was a 
reduction in levels of polyunsaturated fatty acids (i.e. arachidonate (20:4n6)), 12-
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HETE, sphingolipid (i.e. N-palmitoyl-sphingosine (d18:1/16:0)), phospholipids (i.e. 
1-oleoyl-2-linoleoyl-GPC (18:1/18:2)*) and plasmalogen (i.e.1-(1-enyl-stearoyl)-2-
arachidonoyl-GPE (P-18:0/20:4)*) in hexadecanedioic acid-treated WKY rats 
compared to controls rats. Also, significant reductions were observed in levels of 
phospholipids, lysolipid, plasmalogen and lysoplasmalogen in hexadecanedioic 
acid-treated WKY rats compared to controls rats. However, phospholipid (i.e. 1-
stearoyl-2-oleoyl-GPG (18:0/18:1) increased in hexadecanedioic acid-treated 
aorta tissues compared to control rats (Figure 4-46) (Appendix Table A5). 
Bile acids metabolism  
Alteration in the bile acid profile was observed in hexadecanedioic acid-treated 
rats compared to control rats. Primary bile acids (i.e. tauro-beta-muricholate) 
level showed a significant increase in hexadecanedioic acid-treated rats compared 
to control rats (P=0.003). Also, secondary bile acid (i.e. glycodeoxycholate) 
(P=0.034) significantly decreased, with an increase in the level of deoxycholate in 
hexadecanedioic acid-treated rats compared to controls, as shown in (Appendix, 
Table A5). 
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Figure 4-45: Fold enrichment pathway of significantly associated metabolites in aorta tissues. 
(A) Volcano plot shows up to 46 metabolites identified in aorta tissues, which are the top 10 by p-
value with fold change. Colours indicate metabolite membership in the most significant pathways 
according to hypergeometric enrichment test p-value. (B) Fold enrichment pathway of significantly 
associated metabolites in aorta tissues. Enrichment values are based on the significant compounds 
relative to all detected compounds in the pathway. Enrichment = (number of significant metabolites 
in pathway/ total number of detected metabolites in pathway)/ (total number of significant 
metabolites/ total number of detected metabolites). Fold change is red labelled. Welch T- test p-value 
marked as blue and Fisher p-value is marked as green. 
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Figure 4-46: Fatty acids metabolism in aorta tissue of hexadecanedioic acid-treated WKY rats 
compared to control WKY rats. 
Significant reductions were observed in the lipid metabolites of aorta tissues of hexadecanedioic 
acid-treated rats compared with control rats. (A) Phospholipids, (B) lysolipid, (C) plasmalogen and 
(D) lysoplasmalogen (P*<0.05). 
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4.6 Discussion 
To understand the previously identified association between hexadecanedioate 
levels and elevation of blood pressure (Menni et al., 2015), it is important to 
examine the metabolic pathways to identify hexadecanedioate-induced changes 
in production or consumption of important biochemicals such as fatty acids, amino 
acids and glucose. This chapter determined the impact of hexadecanedioate 
treatment in WKY rats by conducting a metabolomics profiling study. Most 
notably, there were disruptions in fatty acid metabolism through the ω-oxidation 
pathway, which is located within the smooth endoplasmic reticulum (ER), as well 
as β oxidation in the mitochondria, and changes in glycolysis and glycogen 
metabolism, bile acid metabolism, the uric acid cycle, in addition to alteration in 
redox homeostasis.  
4.6.1 Alterations in fatty acid metabolism  
Analysis of the metabolomics dataset showed a significant increase in the DFA, 
hexadecanedioate, in all tested tissues except for the brain, where this 
metabolite was below the threshold of detection, as shown in Figure 4-19. This 
lack of detection in the brain may reflect poor diffusion through the blood-brain 
barrier. Also, the altered levels of DFAs, tetradecanedioate and 
octadecanedioate, in adipose tissues and decanedioate in the kidneys of 
hexadecanedioic acid-treated rats could suggest hexadecanedioate-induced 
changes in β-oxidation and a shift towards the ω-oxidation pathway. The ω-
oxidation pathway is a minor pathway for fatty acid oxidation, which is used when 
β-oxidation is deficient. ω-oxidation is increased in conditions that are 
characterized by increased levels of mono-carboxylic free fatty acid (i.e. obesity, 
starvation, diabetes, or chronic alcohol consumption) as well as disturbances in β-
oxidation (Wanders et al., 2011). ω-oxidation is considered to be a rescue pathway 
for many diseases, where an impairment occurs in mitochondrial fatty acid 
oxidation leading to an accumulation of fatty acids. ω-oxidation serves to break 
down accumulated fatty acids (Wanders et al., 2011). In addition to significant 
increases in peroxisomal ω-oxidation metabolites, marked changes in 
mitochondrial fatty acid β-oxidation metabolites were detected in tested tissues 
such as; phospholipids, lysolipid, sphingolipid, monoacylglycerol and acyl 
carnitine. Free fatty acids come from numerous biological molecules such as 
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triglycerides and phospholipids and are important sources of energy for 
mitochondrial oxidation and cellular ATP generation (Santos and Schulze, 2012). 
The β-oxidation of long chain fatty acids is considered to be a main source of 
energy for organs, particularly heart and skeletal muscles. Conversely, other 
tissues, mainly liver, kidney, and adipose tissue use the products of β-oxidation 
for the formation of ketone bodies in order to produce energy that can be utilized 
by other organs (Bartlett and Eaton, 2004). In our study, the levels of long-chain 
fatty acids significantly increased in kidney and liver tissues of hexadecanedioic 
acid-treated rats compared to control rats. A previous metabolomics study, which 
examine the effects of antihypertensive drugs on plasma metabolomic profiles of 
patients with essential hypertension, identified a reduction in plasma levels of 
long-chain fatty acids in bisoprolol-treated patients (Hiltunen et al., 2017).  
β-oxidation pathways involve dehydrogenation catalysed by acyl-CoA 
dehydrogenase, followed by hydration catalysed by enoyl-CoA hydratase via 
addition of water to the double bond. Dehydrogenation takes place after that via 
β-hydroxyacyl-CoA dehydrogenase to generate NADH. Acyl-CoA is formed and re-
enters the β-oxidation after being catalysed by β-ketoacyl-CoA via thiolytic 
cleavage (Poirier et al., 2006), as shown in Figure 4-47. 
Elevation in acylcarnitine levels were also detected in heart and kidney tissues of 
hexadecanedioic acid-treated rats compared to control rats, which could suggest 
a subtle shift toward fatty acid biosynthesis and impairment of mitochondrial β-
oxidative function. It has been found that increased levels of acylcarnitine is 
associated with high risk of cardiovascular dieases (Rizza et al., 2014). Adams et 
al., (2009) showed that increase of fatty acylcarnitines is related to defects in the 
fatty acid β-oxidation pathway. Fatty acids can enter the mitochondria by 
conjugating to carnitine, which forms a high-energy ester bond with long chain 
carboxylic acid through carnitine palmitoyl transferase 1 (CPT-1). Acylcarnitine is 
then produced and translocated transversely to the inner mitochondrial 
membrane via carnitine acylcarnitine translocase (CACT) and is cleaved by 
carnitine palmitoyl transferase 2 (CPT-2). Carnitine is then released in the 
mitochondrial matrix, whereas the fatty acid is conjugated back to coenzyme A 
and transferred to the β-oxidation pathway with production of acetyl-CoA for 
oxidative phosphorylation (Longo et al., 2006) (Figure 4-48). Alterations in 
acylcarnitine levels represents a defect in fatty acid oxidation, consequently 
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causing impairment in the utilization and production of glucose (Longo et al., 
2006; Longo, 2016). Hiltunen et al.(2017) provided evidence of an association 
between fatty acid metabolism and hypertension. The study identified a reduction 
in the plasma levels of acyl carnitine from hypertensive patients on 
antihypertensive medication (i.e. amlodipine, bisoprolol and losartan). In the 
same study amlodipine treatment also showed a significant reduction in the levels 
of circulating hexadecanedioate (Hiltunen et al., 2017).  
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Figure 4-47: β-oxidation pathway. 
β-oxidation pathways involve dehydrogenation and hydration to generate Acyl-CoA, which can then 
enter another β-fatty acid oxidation cycle or enter the citric acid cycle. Markedly changes in 
mitochondrial fatty acid β-oxidation metabolites were identified in tested tissues (e.g. heart, kidney, 
liver, adipose, aorta and brain) of hexadecanedioic acid-treated rats compared to control rats, which 
could suggest hexadecanedioate-induced changes in β-oxidation and a shift towards the ω-oxidation 
pathway. 
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Figure 4-48: Lipid synthesis and metabolism.  
Long-chain acyl-CoA esters are transported into mitochondria by a carnitine-dependent mechanism; these esters are then metabolised by β-oxidation within the 
mitochondria. Elevation in acylcarnitine levels was detected in heart and kidney tissues of hexadecanedioic acid-treated rats compared to control rats, which could 
suggest impairment of mitochondrial β-oxidative function. 
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4.6.2 Alterations in glucose utilization 
Our metabolomics results have shown that there is an increase in glycolysis and 
glycogen metabolism, in particular increases in the levels of glucose and fructose, 
in the heart tissues of hexadecanedioate-treated rats compared to controls. In 
addition, an elevation was observed in levels of glucose-6-phosphate in the heart 
tissues of hexadecanedioate-treated rats compared to control, while it was 
decreased in kidney tissues. Glucose-6-phosphate is a key step in glycogenolysis 
and gluconeogenesis pathways for glucose production, anaerobic glycolysis, and 
storing glucose (Figure 4-49). Several studies have identified a direct association 
between an alteration in glycolysis, and glucose oxidation along with changes in 
fatty acid oxidation and pulmonary hypertension (Assad and Hemnes, 2015; Fessel 
et al., 2012; Zhao et al., 2014). Impairment in fatty acid oxidation has been found 
to be associated with high glucose utilization in the spontaneously hypertensive 
rat (SHR) to provide energy from fatty acid oxidation (Hajri et al., 2001). 
Alterations in the glycolytic pathway are also reported to be associated with 
cardiac diseases, such as acute myocardial infarction (Carvajal and Moreno-
Sánchez, 2003; Bolk et al., 2001; Marsin et al., 2000). 
Glycolysis includes converting glucose into pyruvate, which is transformed into 
either acetyl CoA in the mitochondria, which enters the Krebs cycle (TCA cycle) 
or to lactate by fermentation (Feron, 2009; Jiang and Zhang, 2003; Zhao et al., 
2014). However, the glycolytic end-products pyruvate and lactate were not 
significantly changed in our samples, which could suggest increasing demand for 
use in the TCA cycle. Moreover, glucose-6 phosphate also convert to pentose 
phosphate by an oxidative, non-reversible pathway for generating ribose- 5-
phsophate (R5P) for nucleotide synthesis (Wamelink et al., 2008) (Figure 4-49). 
Our metabolomics results showed that a number of nucleotides were significantly 
increased in the heart tissues of hexadecanedioate-treated rats compared to 
controls, such as xanthine, adenosine 5'-diphosphate (ADP) and adenosine 3'-
monophosphate (3'-AMP). Also, the significant reduction in the pentose-phosphate 
metabolism in adipose and kidney tissues of hexadecanedioate-treated rats 
compared to controls could suggest defects in the regulation of glucose and 
changes in glycolytic use. This outcome signposts that there is a strong shift in 
metabolism, as the adipose tissues of hexadecanedioate-treated rats are less 
dependent on glycolysis and more dependent on fatty acid oxidation. Increasing 
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ω-oxidation is characterised by increased end products due to insufficient glucose 
metabolism. Fatty acid oxidation and glucose oxidation both produce 
mitochondrial acetyl-CoA. Thus, the rate of glucose oxidation has a direct effect 
on the rate of fatty acid oxidation. More energy can be produced by stimulating 
fatty acid oxidation instead of glucose oxidation (Zhao et al., 2014). In fact, fatty 
acid oxidation is considered to be more efficient mechanism for production of ATP 
and energy than glycolysis (Campbell et al., 2002; Zhao et al., 2014; Hajri et al., 
2001). Our metabolomics results identified increases in the levels of fatty acid 
metabolism in conjugation with altered glycolysis, which indicate alterations in 
the fatty acid oxidation pathway, which may be compensatory mechanisms to 
regulate elevations of blood pressure. 
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Figure 4-49: (A) Glycolysis metabolism and (B) glycogen metabolism.  
In heart (Hexa vs control), elevations in glucose and glucose 6-phosphate levels, with a decrease in 3-phosphoglycerate are suggestive of changing glycolytic use. An 
increase in glycogen breakdown products (e.g. maltotetraose, maltotriose, and maltose) could suggest increased glucose demand. Increases in fructose could be 
consistent with increased glucose availability. 
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4.6.3 Alteration in bile acids 
Our metabolomics results identified a significant elevation in taurine-conjugated 
primary bile acids in the adipose tissues of hexadecanedioic acid-treated rats 
compared with control rats. On the other hand, glycine-conjugated primary and 
unconjugated bile acids decreased in the kidney of hexadecanedioic acid-treated 
rats compared with control rats. In addition, several taurine-conjugated 
muricholic bile acids, as well as secondary bile acids, elevated in the kidney and 
adipose and liver tissues of hexadecanedioic acid-treated rats compared with 
control rats. Muricholic acid primary bile acids are formed only in the livers of 
rodents, and not formed in humans (Lefebvre et al., 2009; Takahashi et al., 2016) 
(Figure 4-52). The main primary bile acids produced in human livers are cholic 
acid and chenodeoxycholic acid, which are conjugated with taurine or glycine for 
secretion into bile (Chiang, 2013). In addition, both taurine and glycine 
conjugation are produced in rats, while taurine conjugated bile acids are mainly 
produced in mice (De Aguiar Vallim et al., 2013). Primary bile acids are converted 
to secondary bile acids (i.e. deoxycholic (3 ,12 -dihydroxy-5-cholanoic acid)) and 
lithocholic (3 -hydroxy-5-cholanoic acid) acids in humans and ω-muricholic acid in 
rodents in the distal ileum by intestinal microbial flora (Ajouz et al., 2014; 
Takahashi et al., 2016; De Aguiar Vallim et al., 2013) (Figure 4-50).  
Bile acids have many essential functions, such as eliminating molecules resulting 
from cholesterol in the liver, facilitating solubilisation of cholesterol in the 
gallbladder, and the intestinal absorption of cholesterol, lipids, and lipophilic 
vitamins. Furthermore, bile acids have also a regulatory function in molecule 
signalling that regulate some metabolic pathways, including glucose, lipid and 
energy metabolism by activate several nuclear receptors (i.e. farnesoid x receptor 
(FXR), pregnane X receptor (PXR) and Vitamin D), and G protein-coupled receptors 
(GPCRs) (i.e. Takeda G-protein-coupled receptor 5 (TGR5), sphingosine-1-
phosphate receptor 2 (S1PR2), and Muscarinic receptor) (Chiang, 2009, 2013; 
Hylemon et al., 2009; Shapiro et al., 2018; Zhou and Hylemon, 2014). Bile acids 
stimulate membrane G protein-coupled receptors (Gpbar-1, aka TGR5), which play 
a role in stimulating energy metabolism. TGR5 signalling activates cAMP, leading 
to stimulation of type 2 iodothyronine deiodinase (DIO2), which then converts 
thyroxine T4 to the biologically activate hormone T3. This results in increased 
levels of thyroid hormone and stimulation of mitochondrial oxygen consumption 
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and energy metabolism (Chiang, 2013, 2009; De Aguiar Vallim et al., 2013) (Figure 
4-51). Bile acids are also involved in the regulation of energy within certain tissues 
such as adipose tissues that are considered to be thermogenically competent 
(Fiorucci et al., 2009).  
Bile acids participate in the regulation of glucose, lipoprotein and lipid 
metabolism by activation of the Gαi GPCR, sphingosine-1-phosphate receptor 2 
(S1PR2). Bile acids only activate S1P2 in hepatocytes. S1PR2 activates the insulin 
receptor/AKT pathway through activation of a tyrosine kinase, Src, and epidermal 
growth factor receptor (EGFR). The S1P2/AKT pathway regulates hepatic glucose 
and lipid metabolism via the inhibition of glycogen synthase kinase 3β (GSK3β), 
leading to stimulation of glycogen synthase, glycogenesis and decreasing serum 
glucose (Chiang, 2013; De Aguiar Vallim et al., 2013) (Figure 4-52). 
It is currently unclear what the physiological role of bile acids may be on blood 
pressure regulation. Feasibly, an important future direction of bile acid signalling 
research would be important to determine the association between bile acid 
signalling and blood pressure elevation. 
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Figure 4-50: Primary and secondary bile acid metabolism pathways.  
Bile acids are hydroxylated steroids, which produced in the liver from cholesterol. Primary bile acids are conjugated to the amino acids glycrine or taurine, which converted 
to secondary bile acids, deoxycholate and lithocholate by bacterial 7α-dehydroxylation. In rodents, chenodeoxycholic acid is converted to α- and β-muricholic acids. 
Several taurine-conjugated muricholic bile acids and secondary bile acids elevated in the kidney and adipose and liver tissues of hexadecanedioic acid-treated rats 
compared with control rats. 
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Figure 4-51: TGR5-signaling pathway leading to downstream signalling via cAMP stimulation.  
Bile acids activate membrane G protein-coupled receptors (Gpbar-1, aka TGR5). TGR5 signalling 
activates cAMP, which leading to stimulation of type 2 iodothyronine deiodinase (DIO2), which then 
converts thyroxine T4 to the biologically activate hormone T3. This results in increased levels of 
thyroid hormone and stimulation of energy metabolism.  
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Figure 4-52: The role of bile acid in regulate hepatic downstream metabolism by activation of sphingosine 1-phosphate receptor 2 and the insulin signalling 
pathway (Zhou and Hylemon, 2014).  
Bile acids are signaling molecules and metabolic regulators that activate nuclear receptors (FXR), sphingosine-1-phosphate receptor 2 and G protein-coupled receptor 
signaling to regulate hepatic lipid, glucose, and energy homeostasis and maintain metabolic homeostasis. Abbreviations: S1PR2, sphingosine 1-phosphate receptor 2; 
Src, Src Kinase; EGFR, epidermal growth factor receptor; PPARα, peroxisome proliferator-activated receptor alpha; NTCP, Na+/taurocholate cotransporting polypeptide; 
BSEP, bile salt export pump; PC, phosphotidylcholine; PECK, phosphoenolpyruvate carboxykinase; G6Pase, glucose-6-phosphatase; PDK1, phosphoinositide-
dependent protein kinase 1; AKT, protein kinase B; SREBP, sterol regulatory element-binding protein; PKCf, protein kinase C zeta; FXR, farnesoid X receptor; SHP, 
small heterodimeric partner; GSK3b, glycogen synthase kinase 3 beta. 
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4.6.4 Alteration in Redox homeostasis 
In this metabolomics study, increases in cysteine-glutathione disulphide with 
decreases in S-adenosylhomocysteine (SAH) and S-methylcysteine (i.e. a product 
of cysteine oxidation) were observed in the liver tissues of hexadecanedioic acid–
treated rats. These metabolomic changes indicate alterations in cysteine 
availability, potentially reflecting use for the synthesis of glutathione, which was 
below the threshold of detection and could suggest an increasingly oxidizing 
environment. 
Glutathione (GSH) is the main intracellular antioxidant, which helps to eliminate 
peroxides and other oxidants. Lower levels of glutathione and/or higher levels of 
its oxidized form (i.e. glutathione disulfide (GSSH)) are indicators of elevated 
intracellular oxidative stress (Ashfaq et al., 2008). In addition, cysteine creates 
the main extracellular antioxidants that help to eliminate oxidants. Cysteine is 
more potent and reactive, so it is converted to its oxidized disulfide form. 
Released glutathione reacts with cysteine disulphide to generate glutathione-
cycteine disulfide, the levels of which can be used to assess overall body oxidative 
stress (Ashfaq et al., 2008). It has been found that cysteine has an 
antihypertensive function directly, or via its storage form (i.e. glutathione) 
through reduction of oxidative stress, increasing glucose metabolism and insulin 
resistance and controlling nitric oxide levels (Vasdev et al., 2009).  
Adequate levels of cysteine, glutamate and glycine are important to keep 
glutathione at appropriate levels. Therefore, many amino acids; such as 
glutamate, cysteine, and glycine are transported by gamma-glutamyl cycle into 
the cells (Vasdev et al., 2009; Kageyama et al., 2015). In our results, the reduction 
in gamma-glutamyl amino acids with decreased 5-oxoproline in the liver tissues of 
hexadecanedioic acid–treated rats compared to controls were detected, which 
may reflect decreased glutathione availability. Gamma-glutamyl peptide is 
catalysed to produce 5-oxoproline by gamma-glutamylcyclotransferase, which is 
one of the main enzymes in glutathione metabolism (Vasdev et al., 2009; 
Kageyama et al., 2015) (Figure 4-53). The association between the glutathione-
related redox system, redox biology, and hypertension is not fully understood and 
further studies are required to identify the glutathione-related parameters that 
are altered in hypertension (Vasdev et al., 2009). 
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In the brain tissues (hexadecanedioate vs control), decreases in anserine, a 
dipeptide metabolite of histidine with antioxidant function, could suggest 
increasing antioxidant use. Anserine has antioxidant functions, scavenging free 
radicals and metal chelation (Geissler et al., 2010). Also, anserine plays a major 
role in the regulation of matrix metalloproteinase protein which is responsible for 
cell proliferation, migration, differentiation, angiogenesis and apoptosis, in 
addition to its role in regulating glutathione levels (Geissler et al., 2010). These 
results indicate increased antioxidant activity in brain even though 
hexadecanedioate levels were not detected in brain tissues; may due to secondary 
mechanisms to prevent in disease progression. 
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Figure 4-53: Glutathione synthesis pathway.  
Glutathione is synthesised from glycine, glutamate and methionine-derived cysteine. Released 
glutathione reacts with cysteine disulphide to generate glutathione-cycteine disulphide. In liver 
tissues (Hexa vs control), an increase in cysteine-glutathione disulfide level, with a decrease in S-
adenosylhomocysteine and S-methylcysteine levels could suggest an increasingly oxidizing 
environment. Also, a reduction in gamma-glutamyl amino acids and 5-oxoproline levels could reflect 
decreased glutathione availability. Abbreviations: (GGT), Gamma-glutamyltransferase; (GCS), 
gamma-glutamylcysteine synthetase; (GS), glutathione synthetase; (GSH), Glutathione; (GSSG), 
Glutathione disulphide. 
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4.6.5 Alteration in uric acid cycle 
The metabolomics analysis also identified increases in arginine, N-delta-
acetylornithine, creatine, proline, N-methylproline and guanidinoacetate in the 
kidney tissues of hexadecanedioic acid-treated rats. Arginine is converted by 
arginase to ornithine, an essential precursor of urea and polyamines in the urea 
cycle (Tapiero et al., 2002). Arginine is also considered to be a precursor for 
creatine, which is important for energy metabolism. In addition, it has a role in 
the synthesis of nitric oxide and free radical molecules (Tapiero et al., 2002). 
Arginine and its metabolites may be considered markers for the progression of 
cardiovascular diseases such as hypertension and atherosclerosis (Popolo et al., 
2014). The kidney is a main site for generation of endogenous arginine (Popolo et 
al., 2014). In renal failure, the levels of arginine and nitric oxide are reduced. Any 
defect in arginine levels leads to a decrease in nitric oxide availability and a 
reduction in vascular relaxation, which results in hypertension and cardiovascular 
diseases (Gokce, 2004). 
In conclusion, we have shown that exogenous administration of hexadecanedioic 
acid, in addition to increasing blood pressure, impacts a number of metabolic 
readouts; including changes related to lipid and glucose metabolism and redox 
homeostasis. Therefore, downstream effects of hexadecanedioate administration 
are multifactorial, however from the data it is not possible to determine whether 
the metabolic changes are due to a direct effect of hexadecanedioate on the 
various tissues/ organs or are a secondary effect of the elevated blood pressure. 
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 Haemodynamic changes after 
modulating circulating hexadecanedioate levels 
by perturbing the endogenous ω-oxidation 
pathway 
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5.1 Introduction 
One of the major metabolic pathways impacted by hexadecanedioate 
administration is the ω-oxidation pathway (as identified in the previous chapter). 
Assessing the haemodynamic components of blood pressure regulation can give an 
insight into mechanisms that cause elevation in blood pressure (Ventura et al., 
2005). In this chapter, haemodynamic parameters are assessed to understand the 
mechanism by which hexadecanedioate-induced blood pressure elevation perturbs 
the endogenous ω-oxidation pathway. The ω-oxidation pathway consists of three 
steps involving three major enzymes. In the first step, the hydroxyl group is 
introduced onto the omega carbon by the CYP4A enzyme, followed by the 
oxidation of the hydroxyl group to an aldehyde by alcohol dehydrogenase to 
generate an oxo-fatty acid. In the last step, the oxidation of the aldehyde group 
to a carboxylic acid by aldehyde dehydrogenase produces a dicarboxylic fatty acid 
(Figure 4-24) (Sanders et al., 2008b; Menni et al., 2017; Kroetz et al., 1998). 
Hexadecanedioic acid is a long chain dicarboxylic acid which is generated during 
fatty acid ω-oxidation which is then metabolised by β-oxidation in peroxisomes 
(Reddy and Rao, 2006). As previously mentioned, ω-oxidation is a minor metabolic 
pathway that occurs in the smooth endoplasmic reticulum and also contributes to 
5-10% of total fatty acid metabolism in the liver (Wanders et al., 2011). In a 
previous association study, hexadecanedioate levels were found to be significantly 
correlated with gene expression of CYP4 and alcohol dehydrogenase in adipose 
tissues tested in 740 females from the TwinsUK cohort.(Menni et al., 2017; 
Moayyeri et al., 2013). This suggested that genetic variation may alter expression 
or activity of enzymes within the ω-oxidation pathway leading to altered levels of 
hexadecanedioate in hypertensive individuals  
In this chapter the activity of several different enzymes of the ω-oxidation 
pathway were individually modified by utilisation of specific agonist or antagonist 
together with characterization of hemodynamic parameters in the hypertensive 
SHRSP model and WKY rat strains.  
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5.2 Hypothesis 
Perturbing the endogenous ω-oxidation pathway via administration of specific 
enzyme inhibitors/activators will alter hexadecanedioate levels and lead to 
altered blood pressure. 
5.3 Aims 
The aims of this chapter were: 
1. To investigate the expression of the genes encoding the main enzymes of 
the ω-oxidation pathway in heart, aorta, kidney, adipose and liver tissues 
obtained from normotensive WKYGla and hypertensive SHRSPGla rats. 
2. To assess haemodynamic changes after modulation of endogenous 
hexadecanedioate levels by perturbing the first step of the ω-oxidation 
pathway (i.e. CYP4A) by utilising the specific agonist (Fenofibrate) in a 
normotensive rat (WKYGla) and the specific antagonist (HET0016) in a 
hypertensive rat model (SHRSPGla). 
3. To assess haemodynamic changes after modulation of endogenous 
hexadecanedioate levels by perturbing the last step of the ω-oxidation 
pathway (i.e. aldehyde dehydrogenase enzyme (ALDH)) by utilising a 
specific antagonist (disulfiram) in a hypertensive rat model (SHRSPGla). 
4. To investigate levels of protein expression of ALDH in liver tissue obtained 
from five-week-old, 16-week-old and 20-week-old male WKYGla and 
SHRSPGla rats. 
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5.4 Methods 
This study was conducted to determine differences in expression of ω-oxidation 
genes between two different rat strains, WKYGla and SHRSPGla. In addition to 
identifying whether antagonism or stimulation of enzymes within the ω-oxidation 
pathway lead to effective inhibition/stimulation of circulating hexadecandioate 
levels and blood pressure lowering in SHRSPGla or enhancing blood pressure in 
WKYGla. An overview of the study design is illustrated in Figure 5-1. 
5.4.1 Animals 
Adult male Wistar Kyoto (WKYGla) and the spontaneously hypertensive stroke prone 
rats (SHRSPGla) were obtained from breeding colonies maintained at the University 
Glasgow. The rats were housed in cages on a 12 hours light/dark circle at room 
temperature (21± 3°C). Food and water ad libidum were provided to the rats. The 
study protocols were approved by the home office and conducted in with complied 
the Animals’ Scientific Procedures Act1986 under the project license of Dr Delyth 
Graham (70/9021). 
5.4.2 Expression of main genes in ω oxidation pathways  
5.4.2.1 Experimental animals 
Gene expression study was carried out in tissues from adult male WKYGla (n=9) and 
SHRSPGla rats (n=4) aged 16-week old, which had been used as untreated controls 
in previous intervention studies.  
5.4.2.2 Samples 
Liver, heart, kidney, aorta and adipose tissues were harvested and snap-frozen in 
liquid nitrogen and stored at -80°C for RNA extraction and gene expression, as 
described in section 2.4.1. Gene expression was carried out using the following 
probes from Thermo Fisher, Paisley, UK: CYP4A (Rn00598510_m1), ADH1C 
(Rn01522111_g1), ALDH1L2 (Rn01503718_m1) and ALDH6A1 (Rn00579182_m1). 
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5.4.3 Experimental protocol for first step of ω-oxidation pathway 
(CYP4A)  
Twelve-week-old male WKYGla rats were treated orally with fenofibrate (Sigma 
Aldrich Co Ltd, Irvine, UK) mixed with baby food (egg custard with rice, Heinz 
Co.Ltd., Hayes, Middx.) (100 mg/kg per day; n=6) or vehicle (n=6) for 14 days 
(Figure 5-2). Male SHRSPGla rats were treated with daily subcutaneous injection 
with HET0016 (Cambridge Bioscience, Cambridge, UK) dissolved in sulfobutyl 
ether β-cycloodextrin (Sigma Aldrich Co Ltd, Irvine, UK) (4 mg/kg/day; n=3) or 
vehicle (n=2) for 14 days (Figure 5-3). Haemodynamic parameters were measured 
by radiotelemetry and kidney functions were assessed by 24 hrs metabolic cage 
collections. At sacrifice, blood samples were collected by cardiac puncture 
(Chapter 2, section 2.3.1). Main organs (i.e. heart, liver, kidney and vascular 
tissue) were snap frozen for molecular assessment and mesenteric arteries were 
taken to assess vascular function and morphology by wire myography. 
5.4.3.1 Radiotelemetry  
Telemetry probes (TA11PAC40, Dataquest IV Data Sciences International) were 
implanted at 10 weeks of age with 1 week of recovery before administration of 
the drugs and haemodynamic parameters (i.e. blood pressure, heart rate and 
locomotor activity) were monitored. More details are outlined in Section 2.2.2.2. 
5.4.4 Experimental protocol for last step of ω-oxidation pathway 
(ALDH) 
Twelve-week-old male SHRSPGla rats were treated daily with disulfiram (Sigma 
Aldrich Co Ltd, Irvine, UK) diluted in 100 µl of 100% w/v dimethyl sulfoxide (DMSO, 
Sigma Aldrich Co Ltd, Irvine, UK) or vehicle (n=10) via intraperitoneal injection 
(25 mg/kg/day, n=10) for 14 days. Blood pressure was measured by tail cuff 
plethysmography and cardiac functions were assessed by echocardiography. The 
main organs (i.e. heart, liver, kidney and vascular tissue) samples were snap 
frozen for mRNA expression analysis and mesenteric arteries were d to assess 
vascular function by wire myography. (Figure 5-4). 
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5.4.4.1 Tail Cuff Plethysmography 
Blood pressure was measured by tail cuff weekly for SHRSPGla rats starting from 
the age of 10 weeks. More details are outlined in Section 2.2.2.1. 
5.4.4.2 Echocardiography 
Echocardiography was performed at baseline and weekly over two weeks of 
disulfiram administration for SHRSPGla rats. Further details are mentioned in 
general methods Chapter 2, Section 2.2.3. 
5.4.5 Renal Function 
Renal function was assessed in WKYGla and SHRSPGla rats at the baseline and at the 
end of the two-week study by means of metabolic cage measurements. The rats 
were placed in metabolic cages for 24-hour measurement of fluid intake and urine 
output, and for urine collection. Urine was kept on ice and stored at -80°C until 
required for further biochemical analysis. See Section 2.2.4 for more details.  
5.4.6 Ex-vivo analysis 
At the end of the two weeks study, all rats were sacrificed and organ/tissue 
samples were removed and cleaned of any connective tissue (for more details see 
Section 2.3.1). Body and tissue weight and tibia length were recorded. Organ 
weights were normalised to tibia length and body weight (see Section 2.3.2 for 
further information). Ex-vivo investigations included wire myography (Section 
2.3.3) and mRNA expression (Section 2.4). 
5.4.7 Measurement of hexadecandioate levels in plasma samples 
Measurement of hexadecanedioate level in plasma samples of WKYGla and SHRSPGla 
rats were carried out by Dr Christian Reichel and Dr Anja Huber (Seibersdorf 
laboratories, Austria) using liquid chromatography–mass spectrometry (LC-
MS/MS). More details are given in Chapter 2, Section 2.5. 
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5.4.8 Measurement of Aldehyde dehydrogenase (ALDH) levels in 
liver samples 
5.4.8.1 Experimental animals 
Measurement of ALDH enzyme levels was carried out in liver tissues from 
untreated control male WKYGla (n=4/group) and SHRSPGla (n=4/group) rats aged 5-
week-old, 16-week-old and 20-week-old. These rats had been used as untreated 
controls in previous intervention studies. 
5.4.8.2 Samples 
Liver tissues were harvested into liquid nitrogen and stored at -80°C for ELISA 
assay to determine the level of aldehyde dehydrogenase. 
5.4.8.3 Enzyme-linked immunosorbent assay (ELISA) 
Aldehyde dehydrogenase (ALDH) levels were measured by using enzyme linked 
immunosorbent assay (ELISA), using a commercially available rat aldehyde 
dehydrogenase ELISA kit (MyBioSource, San Diego, USA), following the 
manufacturer’s instructions. The ALDH kit is based on ALDH antibody-ALDH 
antigen interactions (immunosorbency) and a Horseradish peroxidase (HRP) 
colorimetric detection system to detect ALDH antigen targets in samples. The liver 
tissues were weighed before homogenisation. Tissues were minced into small 
pieces and homogenised in a specified amount of PBS (usually 10 mg of tissue in 
100 μl of PBS). Homogenates were then centrifuged for 15 minutes at 1500 xg. The 
supernatants were then collected and stored at -80 ºC. On the day of the 
experiment, all the reagents and samples were left at room temperature for 30 
minutes before starting. Standards (50 μl) and samples (50 μl) were added in 
duplicate to 96-well flat bottom plates. HRP (100 μl) were then added to each 
well. The plate was covered and incubated for 60 minutes at 37ºC. The microtiter 
plate was then washed four times using Wellwash™ Microplate Washer (Thermo 
Scientific, Loughborough, UK). Chromogen solution A (50 μl) and chromogen 
solution B (50 μl) were added respectively to each well and the plates were 
covered from the light and incubated for 15 minutes at 37 ºC. After that, a stop 
solution (50 μl) was added to each well and the colour in the wells changed from 
blue to yellow. Absorbance readings were measured at 450 nm using SpectraMax 
190 Microplate Reader (Molecular Devices, USA).  
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5.4.9 Statistical analysis 
Telemetry data and echocardiography were analysed using a repeated measures 
ANOVA (general linear model). The mRNA analysis is described in more detail in 
Section 2.4.1.6 and 2.4.1.7. For the metabolic cage results, paired t-tests were 
used. Two sample t-tests were used in analysis the data, as appropriate. Statistical 
significance was assumed at P-value less than 0.05. All data are displayed as a 
mean with standard error of the mean. 
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Figure 5-1: Experimental strategy to perturb the endogenous ω-oxidation pathway utilising specific inhibitors and agonists of ω-oxidation pathway enzymes.  
Experimental strategy to assessing whether Inhibition/stimulation of a single or multiple enzymes in the ω-oxidation leads to effective inhibition/stimulation of circulating 
hexadecanedioate and blood pressure lowering in SHRSPGla or enhancing blood pressure in WKYGla. 
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Figure 5-2: Timeline of fenofibrate (CYP4A agonist) study. 
Twelve-week-old male WKYGla rats were treated orally with fenofibrate (100 mg/kg per day; n=6) or vehicle (n=6) for 14 days. Haemodynamic parameters were measured 
by radiotelemetry and kidney functions were assessed by 24 hrs metabolic cage collections. At sacrifice, blood samples were collected by cardiac puncture and main 
organs were harvested for molecular assessment. Mesenteric arteries were dissected to assess vascular function by wire myography.  
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Figure 5-3: Timeline of HET0016 (CYP4A antagonist) study. 
Twelve-week-old male SHRSPGla rats were treated with daily subcutaneous injection with HET0016 (4 mg/kg/day, n=3) or vehicle (n=2) for 14 days. Haemodynamic 
parameters were measured by radiotelemetry and kidney functions were assessed by 24 hrs metabolic cage collections. At sacrif ice, blood samples were collected by 
cardiac puncture and mesenteric arteries were dissected to assess vascular function by wire myography. 
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Figure 5-4: Timeline of disulfiram (aldehydehydrogenase antagonist) study. 
Twelve-week-old male SHRSPGla rats were treated with daily intraperitoneal injection with disulfiram (25 mg/kg/day, n=10) or or vehicle (n=10) for 14 days. Blood pressure 
was measured by tail cuff plethysmography and cardiac functions were assessed by echocardiography. The main organs were snap frozen for mRNA expression analysis 
and mesenteric arteries were dissected to assess vascular function by wire myography. 
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5.5 Results  
5.5.1 Expression of major genes in ω oxidation pathways  
In the heart, the expression of ALDH1L2 in SHRSPGla increased compared to WKYGla, 
although this did not reach significance (P=0.12), however the level of ALDH1L2 
expression for both strains was low (Table 5-1). There was no difference in 
ALDH6A1 expression in heart tissue between SHRSPGla and WKYGla (P=0.25). In the 
heart, the levels of CYP4A and ADH1C were below the threshold of detection 
(Figure 5-5). 
In the kidney, no significant differences were found in the expression of CYP4A 
(P=0.25) and ADH1C (P=0.53) in SHRSPGla compared to WKYGla rats. In addition, 
there were no differences in expression of ALDH1L2 (P=0.10) and ALDH6A1 
(P=0.24) between SHRSPGla and WKYGla rats (Figure 5-6). 
In liver, an increase in expression of CYP4A1 in SHRSPGla rats compated to WKYGla 
rats, although this did not reach significance (P=0.146). The expression of ADH1C 
in SHRSPGla decreased compared to WKYGla, although this did not reach significance 
(P=0.47). Interestingly, there was a significant reduction in expression of ALDH1L2 
(P=2X 10-3) in the liver tissues of SHRSPGla rats compared to WKYGla, although no 
differences were observed in ALDH6A1 expression in the liver tissues from the 
strains (Figure 5-7). 
In adipose tissue, CYP4A expression was below the threshold of detection. Also, 
no differences in expression of ADH1C (P=0.73) or in expression of ADH6A1 
(P=0.77) were found between SHRSPGla and WKYGla. In addition, there was no 
significant difference in expression of ALDH1L2 in adipose tissues of SHRSPGla and 
WKYGla rats (P=0.33) (Figure 5-8) (Table 5-1). The expression of the ω-oxidation 
genes was below the threshold of detection in aorta tissues. Cycle threshold values 
are listed in Table 5-1.  
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Figure 5-5: Expression of ALDH1L2 and ALDH6A1 in heart tissues of WKYGla and SHRSPGla rats. 
(A) An increase in expression of ALDH1L2 in heart tissue normalized to B2M of SHRSPGla (n=4) compared to WKYGla (n=9) (B) No difference in the expression of 
ALDH6A1 normalized to B2M between WKYGla and SHRSPGla rats. (Each point represents Mean ± Standard error of mean). 
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Figure 5-6: The expression of CYP4A1, ADH1C, ALDH1L2 and ALDH6A1 in kidney tissues of WKYGla and SHRSPGla rats. 
In Kidney, no difference in the expression of (A) CYP4A1, (B) ADH1C, (C) ALDH1L2 and (D) ALDH6A1 normalized to GAPDH between WKYGla (n=9) and SHRSPGla 
(n=4) rats. (Each point represents Mean ± Standard error of mean). 
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Figure 5-7: The expression of CYP4A1, ADH1C, ALDH1L2 and ALDH6A1 in liver tissues of WKYGla and SHRSPGla rats. 
An increase in expression of (A) CYP4A1 normalised to B2M in SHRSPGla rats (n=4) compated to WKYGla (n=9) rats. (B) A decrease in expression of ADH1C normalised 
to GAPDH in SHRSPGla rats compated to WKYGla rats. (C) The expression of ALDH1L2 normalised to GAPDH showed a significant reduction in SHRSPGla rats compated 
to WKYGla rats. However, no change were observed in the expression of (D) ALDH6A1 normalized to B2M between WKYGla and SHRSPGla rats. (Each point represents 
Mean ± Standard error of mean) (P***< 0.001). 
 
Chapter 5   257 
 
Figure 5-8: The expression of ADH1C, ALDH1L2 and ALDH6A1 in adipose tissues of control WKYGla and SHRSPGla rats. 
No differences in the expression of (A) ADH1C, (B) ALDH1L2 and (C) ALDH6A1 normalized to GAPDH in adipose tissues of WKYGla (n=9) and SHRSPGla (n=4) rats. 
(Each point represents Mean ± Standard error of mean). 
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 Table 5-1: Average Ct value of main genes in ω oxidation pathways and reference genes in heart, kidney, adipose and liver tissues. 
Tissue Group Gene of interest Mean Ct value Reference gene Mean Ct value 
Heart WKYGla ALDH1L2 39 B2M 19 
Heart SHRSPGla ALDH1L2 37 B2M 19 
Heart WKYGla ALDH6A1 20.4 B2M 19 
Heart SHRSPGla ALDH6A1 20.3 B2M 19 
Kidney WKYGla CYP4A 27.9 GAPDH 20.4 
Kidney SHRSPGla CYP4A 28.2 GAPDH 20.4 
Kidney WKYGla ADH1C 24 GAPDH 20 
Kidney SHRSPGla ADH1C 24.4 GAPDH 20.2 
Kidney WKYGla ALDH2L1 34.9 GAPDH 20 
Kidney SHRSPGla ALDH2L1 34.8 GAPDH 20 
Kidney WKYGla ALDH6A1 22.4 GAPDH 21.5 
Kidney SHRSPGla ALDH6A1 22.7 GAPDH 21.5 
Liver WKYGla CYP4A 27.4 B2M 18.5 
Liver SHRSPGla CYP4A 26.7 B2M 18.8 
Liver WKYGla ADH1C 19.7 GAPDH 22.3 
Liver SHRSPGla ADH1C 20.7 GAPDH 22.5 
Liver WKYGla ALDH2L1 25.1 GAPDH 23 
Liver SHRSPGla ALDH2L1 27.4 GAPDH 23.4 
Liver WKYGla ALDH6A1 22 B2M 19.2 
Liver SHRSPGla ALDH6A1 22.4 B2M 19.5 
Adipose WKYGla ADH1C 31.4 GAPDH 26 
Adipose SHRSPGla ADH1C 31.3 GAPDH 26 
Adipose WKYGla ALDH2L1 33.5 GAPDH 26.2 
Adipose SHRSPGla ALDH2L1 34.7 GAPDH 26.2 
Adipose WKYGla ALDH6A1 28.1 GAPDH 26 
Adipose SHRSPGla ALDH6A1 28.3 GAPDH 26 
Ct= cycle threshold 
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5.5.2 Pharmacological Intervention: Fenofibrate (CYP4A agonist) 
5.5.2.1 The effect of fenofibrate on haemodynamic parameters 
Analysis of the data identified that fenofibrate significantly decreased blood 
pressure in WKYGla rats, as demonstrated by the significant separation of systolic 
blood pressure (SBP) between control and fenofibrate-treated animals (P=0.01); 
as shown in Figure 5-9A. There were no significant differences in diastolic blood 
pressure (DBP) between the fenofibrate-treated rats and control rats (P=0.087) 
(Figure 5-9B). In addition, no significant changes in the heart rate and activity 
were observed over the course of the study between control and fenofibrate 
groups (P=0.0513; P=0.098 respectively) (Figure 5-9C, D). 
5.5.2.2 Vascular responses to exogenous noradrenaline and carbachol 
The mesenteric resistance arteries of rats treated with fenofibrate showed a trend 
towards lower maximal response to noradrenaline compared with arteries 
obtained from control rats, but this did not achieve significance (fenofibrate area 
under the curve 56.98 ± 8.9 versus control area under the curve 68.9 ± 11.3; 
P=0.431, EC50 P=0.594), as shown in Figure 5-10 A. In addition, the mesenteric 
resistance arteries of fenofibrate-treated rats showed a significant reduction in 
relaxation response to carbachol (fenofibrate AUC 95.8 ± 15.4 verses control AUC 
119.4 ± 12.17 P= 0.55, EC50 P=0.043), as shown in Figure 5-10 B. 
5.5.2.3 CYP4A expression in cardiovascular tissues 
The expression of CYP4A was assessed by quantitative real time PCR (qRT-PCR) in 
male WKYGla rats treated with fenofibrate or vehicle for two weeks. CYP4A was 
significantly higher in fenofibrate-treated rats compared to control in kidney 
(P=0.0001) and liver tissues (P=3X10-4) (Figure 5-11). However, the expression of 
CYP4A was below the threshold of detection in heart and aorta tissues. 
5.5.2.4 Renal function 
There was a small reduction in water intake after treatment with fenofibrate, 
which did not reach significant levels (∆ water intake=5.3 ml, P=0.212). 
Furthermore, no change was observed in water intake between fenofibrate-
treated rats compared to control rats (fenofibrate water intake 36 ± 3 ml versus 
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control water intake 34 ± 3 ml, P=0.61), as shown in Figure (5-12 A). In addition, 
there was no change in urine output between fenofibrate-treated rats and control 
rats (fenofibrate urine output 14.12 ± 1.4 ml versus control urine output 14.15 ± 
2.4 ml, P=0.99). Moreover, no significant changes in urine output were found after 
fenofibrate administration (P=0.402) (Figure 5-12 B). 
5.5.2.5 Organ mass index  
Cardiac (whole heart) mass index and left ventricular (left ventricle+septum) mass 
index were measured to determine cardiac and left ventricular hypertrophy at 
sacrifice. There was no significant difference in left ventricular index of 
fenofibrate-treated rats (2.64 ± 0.26 mg/g; P=0.45) compared to the control rats 
(2.49 ± 0.09 mg/g). In addition, no significant difference was observed in whole 
heart normalised to body weight of fenofibrate-treated rats compared to the 
whole heart weight of control rats, normalised to body weight (Table 5-2). 
There was also no significant difference between the left kidneys normalised to 
body weight between fenofibrate-treated rats (3.24 ± 0.09 mg/g) and control rats 
(3.03 ± 0.13 mg/g) (P=0.19). Furthermore, no change was observed in the right 
kidney of fenofibrate-treated rats (3.16 ± 0.12 mg/g, P=0.18) compared to control 
(2.94 ± 0.11 mg/g). There was also no changes in adiposity index of fenofibrate-
treated rats compared to control rats (Table 5-2). Interestingly, there was a 
significant increase in hepatic index of fenofibrate-treated rats (58.18 ± 1.66 
mg/g, P=4.07x 10-8) compared to the control rats (36.46 ± 0.56 mg/g). Organs 
mass index adjusted to tibia length showed the same pattern for all, as shown in 
Table 5-2.  
5.5.2.6 Hexadecandioate levels in plasma samples  
Hexadecanedioate levels in plasma samples obtained from fenofibrate-treated 
WKYGla rats did not change after two weeks of treatment with fenofibrate 
compared to untreated control WKYGla rats (fenofibrate 1.20 ± 0.06 ng/ml versus 
control 1.24 ± 0.09; ng/ml, P=0.79), as shown in Figure 5-13. 
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Figure 5-9: Radiotelemetry measurement (24-h averages) of haemodynamic parameters of fenofibrate-treated WKYGla rats (100 mg/kg per day, n=6) compared 
to control WKYGla rats (n=6) for 14 days.  
(A) Systolic blood pressure (mmHg) significantly decreased in fenofibrate-treated rats compared to control rats. However, no changes were observed in (B) diastolic 
blood pressure (mmHg), (C) Heart rate (bpm) or (D) activity (counts) of WKYGla rats treated with fenofibrate compared to control rats. Each point represents (mean ± 
standard error of mean). (P*<0.05).  
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Figure 5-10: Mesenteric resistance artery contractile response to noradrenaline and 
carbachol in WKYGla rats treated with fenofibrate or vehicle. 
Mesenteric resistance artery contractile response to noradrenaline (A) and relaxation to carbachol 
(B) in control (n=5) and fenofibrate treated (n=6) WKYGla rats. The mesenteric resistance arteries of 
rats treated with fenofibrate showed decrease in response to noradrenaline, and significant decrease 
in relaxation response to carbachol compared with arteries of control rats. Each point represents 
Mean ± Standard error of mean. 
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Figure 5-11: Expression of CYP4A in kidney and liver of fenofibrate-treated WKYGla rats compared to control WKYGla rats. 
Expression of CYP4A was significantly increased in (A) whole kidney and (B) liver of fenofibrate-treated rats (n=6) compared to control rats (n=6). Values are represented 
as mean ± SEM (P***<0.001), (P****<0.0001). 
 
0
2
4
6
8
10
Control WKY (n=6)
Fenofibrate WKY (n=6)
***
R
Q
 o
f 
C
Y
P
4
A
1
 v
s
 G
A
P
D
H
0
5
10
15
20
Control WKY (n=6)
Fenofibrate WKY (n=6)
****
R
Q
 o
f 
C
Y
P
4
A
1
 v
s
 A
C
T
B
A. B.
Chapter 5   
 
264 
 
Figure 5-12: Renal function was assessed by 24 hours metabolic cage collections in 
fenofibrate or vehicle-treated WKYGla rats. 
(A) Water intake and (B) urine output were measured pre and post treatment, which showed no 
significant difference between fenofibrate-treated WKYGla rats (n=6) and vehicle-treated WKYGla rats 
(n=6). Values are presented as mean ± SEM. 
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Table 5-2: Organ weight normalised to body weight and tibia length of fenofibrate-treated 
WKYGla rats (n=6) or vehicle (n=6) at sacrifice. 
Parameters Control Fenofibrate Ttest  
H/Bwt (mg/g) 3.58 ± 1.45 3.92 ± 0.42 0.422 
H/tib (mg/mm) 29.69 ± 1.45 30.68 ± 2.74 0.719 
LV+S/Bwt (mg/g) 2.46 ± 0.09 2.64 ± 0.26 0.449 
LV+S/tib (mg/mm) 20.47 ± 0.67  20.72 ± 1.63  0.870 
RK/Bwt (mg/g) 2.94 ± 0.11  3.16 ± 0.12  0.178 
RK/tib (mg/mm) 24.58 ± 1.29  24.64 ± 1.53  0.973 
LK/Bwt (mg/g) 3.03 ± 0.13  3.24 ± 0.09  0.196 
LK/tib (mg/mm) 25.28 ± 1.32 25.60 ± 1.20  0.848 
liver/Bwt (mg/g) 36.46 ± 0.56  58.18 ± 1.66 0.000* 
Liver/tib (mg/mm) 303.79 ± 8.33  458.50 ± 15.52  0.000* 
EPI/Bwt (mg/g) 7.35 ± 0.35 7.27 ± 0.58  0.888 
Epi/tib (mg/mm) 61.46 ± 4.06 57.34 ± 4.97 0.489 
Retro/bwt (mg/g) 6.87 ± 0.73 6.19 ± 1.09  0.572 
Retro/tib (mg/mm) 57.53 ± 6.75  49.25 ± 9.42  0.437 
Bwt (g) 323.13 ± 4.83 302.33 ± 8.09  0.052 
Tibia length (mm) 38.83 ± 0.60  38.33 ± 0.56  0.556 
Abbreviations: H/Bwt, Heart normalised to body weight; H/tib, Heart normalised to 
tibia length; LV+S/Bwt, Left Ventricular plus Septal wall normalised to body weight; 
LV+S/tib, Left Ventricular plus Septal wall normalised to tibia length; RK/Bwt, Right 
Kidney normalised to body weight; RK/tib, Right Kidney normalised to tibia length; 
LK/Bwt, Left Kidney normalised to body weight; LK/tib, Left Kidney normalised to 
tibia length; Epi/Bwt, Epididymal fat normalised to body weight; Epi/tib, Epididymal 
fat normalised to tibia length; Retro/Bwt, Retroperitoneal fat normalised to body 
weight; Retro/tib, Retroperitoneal fat normalised to tibia length; Liver/Bwt, Liver 
normalised to body weigth; Liver/tib, Liver normalised to tibia length. Units: mg/g, 
milligram per gram; mg/mm, milligram/millimetre; g, gram; mm, millimetre. All 
data are mean± SEM. (P*<0.05; Student Ttest used to compare fenofibrate-treated 
WKY rats to their respective controls).  
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Figure 5-13: Plasma levels of hexadecanedioate in WKYGla rats after treatment with oral 
fenofibrate or vehicle for two weeks. 
Circulating levels of hexadecanedioate did not show any differences in WKYGla rats after treatment 
with oral fenofibrate for two weeks (n=3) compared with controls (n=5). Values are presented as 
mean ± SEM. 
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5.5.3 Pharmacological Intervention: HET0016 (CYP4A antagonist) 
Due to prohibitive cost of the HET0016 compound, a pilot study was conducted 
initially with n=3 HET0016-treated rats and n=2 control to determine any induction 
of drug induced changes in blood pressure before pursuing a full study with this 
compound. 
5.5.3.1 The effect of HET0016 on haemodynamic parameters 
The radiotelemetry data showed that the haemodynamic parameters (i.e. systolic 
blood pressure, diastolic blood pressure, heart rate and activity remained 
unchanged over the course of the study between control and HET0016 treated 
groups, as shown in Figure 5-14. 
5.5.3.2 Vascular responses to exogenous noradrenaline and carbachol 
The mesenteric resistance arteries of rats treated with HET0016 showed no change 
in contractile response to noradrenaline compared with mesenteric resistance 
arteries of control rats (HET0016 area under the curve 33.04 ± 15.2 versus control 
area under the curve 24 ± 8.8), as shown in Figure 5-15 A. In addition, there 
assumed to be no difference in vascular relaxation in response to carbachol 
(HET0016 area under the curve 65.9 ± 18.9 verses control AUC 48.2.4 ± 7.6), as 
shown in Figure 5-15 B, although n=2 values are currently too small to carry out 
statistical analysis. The quality of the curves are compromised by the low n values, 
however the major outcome parameter was blood pressure, which showed 
identical levels between HET0016-treated and control rats.  
5.5.3.3 Renal function 
No change was observed in water intake between HET0016-treated rats compared 
to control rats (HET0016 water intake 40 ± 9.9 ml versus control water intake 41.2 
± 1.7 ml), as shown in Figure (5-16 A). In addition, there was no change in urine 
output between HET0016-treated rats and control rats (HET0016 urine output 13 
± 2.9 ml versus control urine output 16.9 ± 3.2 ml (Figure 5-16 B). However, the 
small sample size is skewing the data. Urine output baseline for control SHRSP 
animals is normally around 8-10 ml.  
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5.5.3.4 Organ mass index 
There was no change in cardiac index of HET0016-treated rats (4.23 ± 0.12 mg/g) 
compared to the control rats (4.06 ± 0.04 mg/g). In addition, no change in left 
ventricular index was observed between HET0016-treated rats (3.28 ± 0.12 mg/g) 
and the control rats (3.08 ± 0.04 mg/g) (Table 5-3). 
There was no difference between left kidneys in the HET0016-treated rats 
normalised to body weight (3.79 ± 0.12 mg/g) and the control rats (3.63 ± 0.06 
mg/g). Furthermore, no change was observed in the right kidneys of HET0016-
treated rats (3.62 ± 0.09 mg/g) compared to control (3.83 ± 0.26 mg/g). There 
was also no difference in the hepatic and adiposity indexes of HET0016-treated 
rats compared to control rats, after they were normalised to body weight. Tibia 
length corrections showed identical level, as shown in Table 5-3. 
5.5.3.5 Hexadecandioate levels in plasma samples  
Hexadecanedioate levels in plasma samples obtained from HET0016-treated 
SHRSPGla rats did not change after two weeks of treatment with HET0016 
compared to untreated control SHRSPGla rats (HET0016 1.083 ± 0.054 ng/ml versus 
control 1.26 ± 0.05 ng/ml), as shown in Figure 5-17.  
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Figure 5-14: Radiotelemetry measurement (24-h averages) of haemodynamic parameters in SHRSPGla rats treated with HET0016 (4 mg/kg per day, n=3) or 
control (n=2) for 14 days. 
There was no changes in (A) systolic blood pressure (mmHg), (B) diastolic blood pressure (mmHg), (C) heart rats (bpm) and activity (counts) of SHRSPGla rats treated 
with HET0016 over the course of the study. Each point represents (mean ± standard error of mean). Statistical analysis was not performed due to small n values. 
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Figure 5-15: Mesenteric resistance artery contractile response to noradrenaline and 
carbachol in SHRSPGla rats treated with HET0016 or vehicle.  
Mesenteric resistance artery contractile response to noradrenaline (A) and relaxation to carbachol 
(B) showed no changes between control (n=2) and HET0016-treated SHRSPGla rats (n=2). Each 
point represents Mean ± Standard error of mean. Statistical analysis was not performed due to small 
n values. 
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Figure 5-16: Renal function was assessed by metabolic cage collections during 24 hours in 
SHRSPGla treated with HET0016 (n=3) or vehicle (n=2). 
There were no apparent changes in (A) water intake and (B) urine output of SHRSPGla rats pre or 
post treatment (n=3) when comparing vehicle or HET0016 treated rats. Values are presented as 
mean ± SEM. Statistical analysis was not performed due to small n values. 
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Table 5-3: Organ weight normalised to body weight and tibia length of HET0016-treated 
SHRSPGla rats or vehicle at sacrifice. 
 
Parameters Control HET0016 
H/Bwt (mg/g) 4.23 ± 0.12 4.06 ± 0.04 
H/tib (mg/mm) 29.48 ± 1.28 28.48 ± 0.19 
LV+S/Bwt (mg/g) 3.28 ± 0.12 3.08 ± 0.04 
LV+S/tib (mg/mm) 22.89 ± 1.19 21.66 ± 0.34 
RK/Bwt (mg/g) 3.62 ± 0.09 3.83 ± 0.26 
RK/tib (mg/mm) 25.21 ± 0.89 26.93 ± 1.93 
LK/Bwt (mg/g) 3.79 ± 0.12 3.63 ± 0.06 
LK/tib (mg/mm) 26.43 ± 0.37 25.50 ± 0.50 
liver/Bwt (mg/g) 39.79 ± 0.69 40.95 ± 1.14 
Liver/tib (mg/mm) 277.27 ± 8.38 287.51 ± 7.23 
EPI/Bwt (mg/g) 11.68 ± 0.22 11.11 ± 0.24 
Epi/tib (mg/mm) 81.38 ± 1.63 78.02 ± 1.45 
Retro/bwt (mg/g) 8.33 ± 0.62 8.99 ± 0.9 1 
Retro/tib (mg/mm) 57.92 ± 3.28 63.15 ± 6.57 
Bwt (g) 256.25 ± 9.85 243.37 ± 9.66 
Tibia length (mm) 36.50 ± 1.50 36.00 ± 2.00 
Abbreviations: H/Bwt, Heart normalised to body weight; H/tib, Heart 
normalised to tibia length; LV+S/Bwt, Left Ventricular plus Septal wall 
normalised to body weight; LV+S/tib, Left Ventricular plus Septal wall 
normalised to tibia length; RK/Bwt, Right Kidney normalised to body 
weight; RK/tib, Right Kidney normalised to tibia length; LK/Bwt, Left 
Kidney normalised to body weight; LK/tib, Left Kidney normalised to tibia 
length; Epi/Bwt, Epididymal fat normalised to body weight; Epi/tib, 
Epididymal fat normalised to tibia length; Retro/Bwt, Retroperitoneal fat 
normalised to body weight; Retro/tib, Retroperitoneal fat normalised to 
tibia length; Liver/Bwt, Liver normalised to body weigth; Liver/tib, Liver 
normalised to tibia length. Units: mg/g, milligram per gram; mg/mm, 
milligram/millimetre; g, gram; mm, millimetre. All data are mean± SEM. 
Statistical analysis was not performed due to low n values. 
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Figure 5-17: Plasma levels of hexadecanedioate in SHRSPGla rats after treatment with 
HET0016 or vehicle for two weeks. 
Circulating levels of hexadecanedioate did not show any differences in SHRSPGla rats after treatment 
with HET0016 for two weeks (n=3) compared with untreated controls (n=2). Values are presented 
as mean ± SEM. Small n values prevented statistical analysis. 
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5.5.4 Pharmacological Intervention: Disulfiram (aldehyde 
dehydrogenase inhibitor) 
5.5.4.1 The effect of disulfiram on blood pressure 
A significant reduction in systolic blood pressure was observed in SHRSPGla rats 
after treatment with the aldehyde dehydrogenase antagonist, disulfiram, for two 
weeks. The reduction was observed in the first week of treatment (∆SBP 25.8 ± 
6.9 mmHg; P=0.001) and was maintained in the second week of treatment (∆SBP 
24.9 ± 5.2 mmHg; P=4.3x10-6), as shown in Figure 5-18. 
5.5.4.2 Vascular responses to exogenous noradrenaline and carbachol 
Significant lowering of maximal response to high doses of noradrenaline of the 
mesenteric resistance arteries obtained from disulfiram-treated SHRSPGla rats, 
suggesting reduced vascular reactivity compared to control vessels (disulfiram 
area under the curve 68.05 ± 4.06 versus control area under the curve 86.08 ± 
4.86; P=0.0127, EC50 P=0.15), as shown in Figure 5-19 A. Relaxation to carbachol 
was not significantly different in mesenteric resistance arteries of disulfiram-
treated rats and control rats (disulfiram area under the curve 178.20± 22.53 versus 
control area under the curve 168.19± 23.35; P=0.76, EC50 P=0.65) as shown in 
Figure 5-19 B. 
5.5.4.3 Echocardiography 
Cardiac function and cardiac mass were assessed by echocardiography for SHRSPGla 
rats at baseline and weekly after treatment with disulfiram. There was no 
significant difference in the left ventricular mass between the disulfiram-treated 
rats and the control group (P=0.07). No difference was observed after 
normalisation of left ventricular mass with body weight (P=0.701) or with tibia 
length (P=0.165). In addition, relative wall thickness (RWT) showed no significant 
change between disulfiram-treated rats compared with control rats (P=0.52), as 
shown in Table 5-4. Both fractional shortening (FS) and ejection fraction (EF), 
showed that there was no significant change in SHRSPGla rats after treatment with 
disulfiram (P=0.152), (P=0.414). Stroke volume for disulfiram-treated rats showed 
no difference compared with the control rats (P=0.142) as well as cardiac output 
(P=0.128) (Table 5-4). 
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5.5.4.4 Renal function 
There was no change in water intake between disulfiram-treated rats compared 
to control rats (disulfiram water intake 27.78 ± 1.22 ml versus control water intake 
29.75 ± 2.25 ml, P=0.52), as shown in Figure 5-20 A. In addition, no change was 
shown in urine output between disulfiram-treated rats and control rats (disulfiram 
urine output 8.36 ± 0.95 ml versus control urine output 9.94 ± 1.12 ml, P=0.31). 
Furthermore, no differences in water intake (P=0.69) and urine output (P=0.82) 
were observed after treatment with disulfiram. (Figure 5-20 B). 
5.5.4.5 Organ mass index 
Disulfiram-treated rats demonstrated no cardiac (3.83 ± 0.11 mg/g; P=0.84) or 
left ventricular (2.69 ± 0.09 mg/g; P=0.74) hypertrophy when compared to the 
control rats (3.78 ± 0.18 mg/g), (2.74 ± 0.09 mg/g); respectively. There was no 
significant difference between the right kidneys of disulfiram-treated rats 
normalised to body weight (3.63 ± 0.10 mg/g) when compared to control rats (3.57 
± 0.09 mg/g) (P=0.70). Also, no change was observed in the left kidneys of 
disulfiram-treated rats (3.52 ± 0.09 mg/g, P=0.90) compared to the control rats 
(3.54 ± 0.12 mg/g). The disulfiram-treated rats also did not show any differences 
in liver weight compared to control rats after being normalised to body weight 
(disulfiram 39.65 ± 1.37 mg/g versus control 37.45 ± 1.22 mg/g; P=0.25). In 
addition, the result demonstrated that no changes were observed in either 
epididymal fat or retroperitoneal fat as a result of disulfiram treatment. 
Epididymal fat normalised to body weight was 8.89 ± 0.77 mg/g for disulfiram 
versus 9.99 ± 0.91 mg/g for control; P=0.37). Retroperitoneal fat normalised to 
body weight was 10.09 ± 0.74 mg/g for disulfiram versus 10.03 ± 0.79 mg/g for 
control; P=0.39). Organ mass index adjusted to tibia length showed the same 
pattern for all parameters and was not significantly different between treatment 
groups (Table 5-5). 
5.5.4.6 mRNA expression 
mRNA was extracted and prepared from kidney, heart, aorta and liver samples of 
control and disulfiram-treated rats to investigate the association between 
aldehyde dehydrogenase genes ALDH6A1 and ALDH1L2 and reduction of blood 
pressure in SHRSPGla-treated rats compared with control. There were no 
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differences detected in the expression of ALDH1L2 in heart (P=0.64), whole kidney 
(P=0.92) and liver (P=0.88), as shown in Figure 5-21 A, C, and E respectively. 
Moreover, no significant differences in the expression of ALDH6A1 between control 
and disulfiram-treated rats were observed in any of the tested tissues; heart 
(P=0.96), whole kidney (P= 0.91) and liver (P=0.87) between control and 
disulfiram-treated rats (Figure 5-21 B, D, F) (Table 5-6). However, both genes 
ALDH1L2 and ALDH6A1 were below the threshold of detection in aorta tissues. 
 
Chapter 5   
 
277 
 
Figure 5-18: Systolic blood pressure (mmHg) of SHRSPGla rats treated with disulfiram (25 
mg/kg per day, n=10) or control (n=10) for 14 days by tail-cuff plethysmography. 
Significant reduction was observed in SBP of disulfiram-treated SHRSPGla rats (n=10) compared to 
control SHRSP rats (n=10), P****< 0.0001. Each point represents (mean ± standard error of mean). 
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Figure 5-19: Mesenteric resistance artery contractile response to noradrenaline and 
carbachol in SHRSPGla rats treated with disulfiram or vehicle. 
Mesenteric resistance artery contractile response to noradrenaline (A) and relaxation to carbachol 
(B) in control (n=10) and disulfiram-treated (n=10) SHRSPGla rats. (Each point represents Mean ± 
Standard error of mean). The mesenteric resistance arteries of rats treated with disulfiram showed 
significant reduction in response to noradrenaline, and no difference in relaxation response to 
carbachol compared to arteries of control rats. Each point represents Mean ± Standard error of mean. 
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Table 5-4: Echocardiographic measurements for SHRSPGla rats treated with disulfiram (25 mg/kg per day, n=10) or vehicle (n=10) for 14 days. 
 
 
Parameters Pre-treatment 1st week of treatment 2nd week of treatment 
ANOVA 
(general 
linear 
model) 
 control Disulfiram control Disulfiram control Disulfiram P value 
LVM (mg) 0.64 ± 0.02 0.59 ± 0.02 0.66 ± 0.02 0.67 ± 0.02 0.70 ± 0.03 0.65 ± 0.02 0.070 
LVM/BWt (mg/g) 2.74 ± 0.09 2.67 ± 0.103 2.77 ± 0.09 2.97 ± 0.07 2.88 ± 0.10 2.82 ± 0.06 0.701 
LVM/tib (mg/mm) 17.10 ± 0.05 16.04 ± 0.07 17.30 ± 0.05 17.50 ± 0.05 18.10 ± 0.08 17.80 ± 0.05 0.165 
FS % 52.03 ± 3.01 55.64 ± 1.99 53.55 ± 2.02 47.87 ± 2.99 52.76 ± 1.74 50.59 ± 2.02 0.152 
RWT (mm) 0.59 ± 0.03 0.54 ± 0.02 0.59 ± 0.024 0.55 ± 0.02 0.56 ± 0.02 0.55 ± 0.01 0.520 
SV (mls) 0.24 ± 0.01 0.25 ± 0.01 0.25 ± 0.01 0.26 ± 0.01 0.28 ± 0.02 0.29 ± 0.01 0.142 
CO (mls/min) 95.09 ± 6.33 104.80 ± 4.84 95.02 ± 6.81 96.13 ± 5.64 112.12 ± 7.23 109.99 ± 5.49 0.200 
EF % 87.77 ± 2.18 90.79 ± 1.27 89.47 ± 1.33 84.60 ± 2.38 89.07 ± 1.26 84.19 ± 1.68 0.128 
Bwt kg 234.4 ± 5.83 220.5 ± 5.31 242.3 ± 6.20 226.9 ± 6.98 243.4 ± 7.64 230.7 ± 6.71 0.000 
Abbreviations: LVM, Left Ventricular Mass; LVM/BWt, Left Ventricular Mass normalised to body weight; LVM/tib, Left Ventricular Mass 
normalised to tibia length; FS, Fractional Shortening; RWT, Relative Wall Thickness; SV, Strock Volume; CO, Cardiac Output; EF%, % 
Ejection Fraction; BWt kg, Body Weight in Kilogram. Unites: mg, milligram; mg/g, milligram per gram; mm, millimetre; mg/mm, milligram 
per millimetre; mls, millilitres; mls/min, milliliters/ minute. All data are mean± SEM. 
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Figure 5-20: Renal function was assessed by 24 hours metabolic cage collections in SHRSPGla 
rats treated with disulfiram or vehicle. 
No change was observed in (A) water intake and (B) urine output, which were measured pre and 
post treatment with disulfiram (n=10) or vehicle (n=10). Values are presented as mean ± SEM 
 
0
10
20
30
40
Control (n=10)
Disulfiram (n=10)
Pre-treatment Post-treatment
D
ru
n
k
 /
 2
4
 h
o
u
rs
 (
m
l)
0
5
10
15
Control (n=10)
Disulfiram (n=10)
Pre-treatment Post-treatment
U
ri
n
e
 /
2
4
 h
o
u
rs
 (
m
l)
A.
B.
Chapter 5   
 
281 
Table 5-5: Organ weight normalised to body weight and tibia length of disulfiram-treated 
SHRSPGla rats (n=10) or vehicle (n= 
10) at sacrifice. 
Parameters Control Disulfiram Ttest  
H/Bwt (mg/g)  3.78 ± 0.18 3.83 ± 0.11 0.840 
H/tib (mg/mm) 24.02 ± 1.11 22.86 ± 1.05 0.457 
LV+S/Bwt (mg/g) 2.74 ± 0.09 2.69 ± 0.09 0.744 
LV+S/tib (mg/mm) 17.29 ± 0.29  16.03 ± 0.68  0.102 
RK/Bwt (mg/g) 3.57 ± 0.09  3.63 ± 0.10 0.700 
RK/tib (mg/mm) 22.66 ± 0.51  21.48 ± 0.32  0.064 
LK/Bwt (mg/g) 3.54 ± 0.12  3.52 ± 0.09  0.900 
LK/tib (mg/mm) 22.52 ± 0.85 20.94 ± 0.69 0.168 
liver/Bwt (mg/g) 37.45 ± 1.22 39.65 ± 1.37 0.246 
Liver/tib (mg/mm) 236.92 ± 5.38  234.66 ± 5.69  0.776 
EPI/Bwt (mg/g) 9.99 ± 0.91 8.89 ± 0.77 0.371 
Epi/tib (mg/mm) 62.82 ± 5.03 53.29 ± 5.04 0.197 
Retro/bwt (mg/g) 10.03 ± 0.79 10.09 ± 0.74 0.399 
Retro/tib (mg/mm) 69.63 ± 4.60  59.93 ± 4.55  0.151 
Bwt (g) 255.19 ± 9.99 236.14 ± 6.95  0.135 
Tibia length (mm) 39.95 ± 0.30  39.65 ± 0.33  0.514 
Abbreviations: H/Bwt, Heart normalised to body weight; H/tib, Heart normalised to 
tibia length; LV+S/Bwt, Left Ventricular plus Septal wall normalised to body weight; 
LV+S/tib, Left Ventricular plus Septal wall normalised to tibia length; RK/Bwt, Right 
Kidney normalised to body weight; RK/tib, Right Kidney normalised to tibia length; 
LK/Bwt, Left Kidney normalised to body weight; LK/tib, Left Kidney normalised to 
tibia length; Epi/Bwt, Epididymal fat normalised to body weight; Epi/tib, 
Epididymal fat normalised to tibia length; Retro/Bwt, Retroperitoneal fat 
normalised to body weight; Retro/tib, Retroperitoneal fat normalised to tibia 
length; Liver/Bwt, Liver normalised to body weigth; Liver/tib, Liver normalised to 
tibia length. Units: mg/g, milligram per gram; mg/mm, milligram/millimetre; g, 
gram; mm, millimetre. All data are mean± SEM. 
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Figure 5-21: Expression of ALDH1L2 and ALDH6A1 in heart, kidney and liver of disulfiram-
treated SHRSPGla rats compared to control SHRSPGla rats. 
There was no change in expression of ALDH1L2 and ALDH6A1 in (A, B) heart (normalized to B2M), 
(C, D) kidney (normalized to GAPDH), and (E, F) liver (normalized to ACTB) between control (n=5) 
and disulfiram-treated rats (n=5). Each point represents Mean ± Standard error of mean. 
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Table 5-6: Average Ct value of ALDH1L2 and ALDH6A1 and deference genes in heart, kidney and liver tissues. 
Tissue Group Gene of interest Mean Ct value Reference gene Mean Ct value 
Heart Disulfiram ALDH1L2 34.1 B2M 18.2 
Heart Control ALDH1L2 34.4 B2M 18.2 
Heart Disulfiram ALDH6A1 20.7 B2M 18 
Heart Control ALDH6A1 20.7 B2M 18 
Kidney Disulfiram ALDH1L2 34 GAPDH 22 
Kidney Control ALDH1L2 34 GAPDH 22 
Kidney Disulfiram ALDH6A1 23.1 GAPDH 22.5 
Kidney Control ALDH6A1 23.2 GAPDH 22.7 
Liver Disulfiram ALDH1L2 30.5 ACTB 25.5 
Liver Control ALDH1L2 30 ACTB 25 
Liver Disulfiram ALDH6A1 27.5 ACTB 25.5 
Liver Control ALDH6A1 27 ACTB 25 
Ct= cycle threshold 
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5.5.5 Aldehyde dehydrogenase levels in liver samples. 
The levels of aldehyde dehydrogenase enzyme were measured in liver tissues from 
male SHRSPGla and WKYGla rats at different ages (i.e. five-week-old, 16-week-old 
and 20-week-old) (n=4/group). Levels of aldehyde dehydrogenase showed an 
increase in five-week-old rats (SHRSPGla 4.07 ± 0.20 ng/ml versus WKYGla 3.82 ± 
0.22 ng/ml; P=0.453) (Figure 5-22 A) and in sixteen-week-old rats (SHRSPGla 5.22 
± 0.25 ng/ml versus WKYGla 4.85 ± 0.103 ng/ml; P=0.242) (Figure 5-22 B) in 
SHRSPGla rats compared to WKYGla rats. Interestingly, the increase in ALDH levels 
at 20-week-old in SHRSPGla liver just failed to reach significance when compared 
to WKYGla rats (SHRSPGla 4.73 ± 0.22 ng/ml versus WKYGla 4.07 ± 0.06 ng/ml; P 
=0.062) (Figure 5-22 C). 
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Figure 5-22: Aldehyde dehydrogenase enzyme level in liver tissues of (A) five-week-old, (B) 16-week-old and (C) 20-week-old male WKYGla and SHRSPGla rats 
(n= 4/group). 
There was a trend in elevation of ALDH levels at 20-week-old in SHRSPGla liver compared to WKYGla rats. However, no difference was observed in ALDH levels at 5-
week and 16 week in liver tissues of SHRSPGla and WKYGla rats. Each point represents Mean ± Standard error of mean. 
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5.6 Discussion 
There are multiple potential mechanisms by which hexadecanedioate may act to 
elevate blood pressure. In this chapter, the role of ω-oxidation pathway was 
addressed in the link between hexadecanedioate levels and development of 
hypertension. By individually manipulating enzyme activity of CYP4A and ALDH I 
was able to demonstrate alterations in blood pressure levels and vascular 
reactivity. 
5.6.1 CYP4A 
The hypothesis was stimulation of the ω-oxidation pathway, CYP4A with specific 
agonists (fenofibrate) raises the circulating levels of hexadecanedioate causing 
blood pressure elevation in adult male WKYGla rats. In this study, we found that 
fenofibrate treatment caused a significant reduction in systolic blood pressure in 
WKYGla rats. In addition, a reduction in vascular function of mesenteric resistance 
arteries in response to noradrenaline and relaxation in response to carbachol 
compared to control rats. It has been found that treatment with fenofibrate 
increased systolic blood pressure by 3 mmHg in healthy people (Subramanian et 
al., 2006). Gilbert et al. (2013) found that fenofibrate decreased blood pressure 
in salt-sensitive hypertensive subjects but not in salt-resistant hypertensives; also 
it reduced heart rate and renal vasoconstriction. The study by Lee et al. 
demonstrated that fenofibrate causes a reduction in blood pressure in a model of 
DOCA-salt hypertension, thus decreasing renal cyclooxygenase-2 (COX-2) and 
increasing CYP4A expression (Lee et al., 2011). Similarly, this study showed that 
the expression of CYP4A was significantly increased in fenofibrate-treated WKYGla 
rats compared to control rats. 
Fenofibrate is used in the treatment of dyslipidaemia mainly associated with type 
2 diabetes mellitus (Rakhshandehroo et al., 2010). Fibrates and steroids are CYP4A 
inducers, which stimulate peroxisomal-proliferative responses through improving 
endothelial function and increasing the renal expression of cytochrome P450 
enzymes responsible for the formation of epoxyeicosatrienoic acids (EETs) and 20-
hydroxyeicosatetraenoicacid (20-HETE) (Gilbert et al., 2013). Cytochrome P450 
4A (Cyp4A) enzymes are members of the cytochrome P450 monoxygenase 
superfamily and catalyse microsomal-hydroxylation of fatty acids 
Chapter 5   
 
287 
(Rakhshandehroo et al., 2010). Members of CYP4A enzyme family that catalyse ω-
oxidation are dependent on PPARα (Hardwick et al., 2009). Activation of PPAR-α 
has also been found to increase the generation of nitric oxide, promoting renal 
excretion of Na+ via reduced Na+-K+ ATPase in the proximal tubule (Lee et al., 
2011). PPAR-α increases renal tubular CYP4A expression, thus elevating 20-HETE 
production which reduces sodium retention and blood pressure (Lee et al., 2011). 
It has been shown that 20-HETE, the major metabolite of CYP4A, has a different 
action on blood pressure regulation. It has a potent vasoconstriction action leading 
to increasing blood pressure (Williams et al., 2011b, 2011a). 20-HETE depolarises 
vascular smooth muscles by blocking the open-state probability of Ca2+-activated 
K+-channels (Williams et al., 2011b, 2011a). EETs also play a role in regulation of 
vascular tone by stimulation of smooth muscle large-conductance Ca2+-activated 
K+ channels, producing hyperpolarization and vasorelaxation (Williams et al., 
2011b, 2011a). Many studies have reported that sequence variants in the CYP4A 
gene that produce 20-HETE are linked with the development of hypertension in 
human population studies (Singh et al., 2007; Gainer et al., 2008; Williams et al., 
2011a). Previous experiments in mice suggested that PPAR-α might affect blood 
pressure. PPAR-α deficient mice are protected from hypertension induced by 
feeding a high-fat diet or by chronic treatment with glucocorticoids (Tordjman et 
al., 2001; Bernal-Mizrachi et al., 2003). The PPARa agonist fenofibrate has been 
reported to both decrease and increase blood pressure. These varying findings 
need further investigation. 
In the second study of this chapter, the hypothesis was inhibition of CYP4A with 
the potent, selective antagonist HET0016 (N-hydroxy-N′-(4-butyl-2-methylphenyl)-
formamidine) would result in a reduction in circulating hexadecandioate levels 
and blood pressure lowering in the hypertensive SHRSPGla rat model. Our results 
showed that no significant changes were observed in blood pressure or vascular 
function of SHRSPGla rats treated with CYP4A antagonist (HET0016) compared to 
vehicle treated rats. Due to prohibitive costs, the study was conducted as a pilot 
study with a small number of rats to determine if there any effect of HET0016 in 
blood pressure before pursuing a full study. Previous research performed by Toth 
et al showed that systolic blood pressure of spontaneously hypertensive rats (SHR) 
decreased after treatment with HET0016 (10 mg/kg·per day, in 10% lecithin 
solution; intraperitoneally for 5 days) (Toth et al., 2013). In addition, Singh et al 
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showed that dihydrotestosterone (DHT)-induced hypertension was reduced in 
male Sprague–Dawley rats after treatment with HET0016 (Singh et al., 2007). 
However, HET0016 had no effect on blood pressure in rats fed a low salt diet, 
while blood pressure increased by 18 mm/Hg after the rats were fed a high salt 
diet (Hoagland et al., 2003). Further studies have shown that HET0016 prevents 
the development of hypertension induced by adrenocorticotrophic hormone in 
male Sprague-Dawley rats (Zhang et al., 2009). 
HET0016 has anti-oxidative and anti-inflammatory effects in the cerebral arteries 
of spontaneously hypertensive rats (SHR), and disturbing the 20-HETE-mediated 
autocrine/paracrine signalling pathways in the vascular wall causes a decrease in 
blood pressure (Toth et al., 2013). Previous studies have indicated that the 
formation of 20-hydroxyeicosatetraenoic acid (20-HETE) is greater in hypertensive 
rat models than in normotensive rat, which may contribute to oxidative stress and 
endothelial dysfunction of hypertensive rats (Dunn et al., 2008). These results 
suggest that the chronic blockade of 20-HETE formation prevents the development 
of hypertension, since HET0016 is a selective cytochrome P450 4A inhibitor, which 
has a potent inhibitory effect on epoxyeicosatrienoic acid (EETs) and 20-HETE 
(Miyata et al., 2001). 
The current study has limitations regarding the dose, route of administration, the 
solubility of the drug, and the study was not sufficiently powered (i.e. small 
sample size). The function of the cytochrome P450 metabolites of arachidonic acid 
in the regulation and maintenance of hypertension is complex and remains to be 
fully determined, considering that the pathway has both pro-hypertensive and 
antihypertensive actions (Tordjman et al., 2001). Therefore, additional studies 
are required. 
5.6.2 ALDH 
The hypothesis was inhibition of aldehyde dehydrogenase (ALDH) with specific 
antagonists (disulfiram) leads to decrease the circulating levels of 
hexadecanedioate causing lowering of blood pressure in hypertensive SHRSPGla 
rats. Our results agreed with the hypothesis demonstrating that inhibition of the 
ω-oxidation pathway enzyme, aldehyde dehydrogenase, results in a significant 
lowering of blood pressure in hypertensive SHRSPGla rats after treatment with 
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disulfiram (aldehyde dehydrogenase inhibitor) for two weeks. A previous animal 
study found a reduction of blood pressure in spontaneously hypertensive rats 
treated with disulfiram by intraperitoneal injection 200 mg/kg for 4 consecutive 
days (Nikodijević et al., 1971). In addition to decreasing systemic blood pressure, 
disulfiram reduced intraocular pressure in rabbit models (Nagai et al., 2015). 
Conversely, one of the earlier systematic review studies identified no changes in 
blood pressure within six weeks of treatment with disulfiram (Peachey et al., 
1981). 
Disulfiram (tetraethylthioperoxydicarbonic diamide) is an irreversible aldehyde 
dehydrogenase antagonist which is used for the treatment of alcoholism (Soyka 
and Müller, 2017). It has also been found that disulfiram is associated with stage-
I and stage II hypertension, as an adverse reaction in patients with alcohol 
dependence (Kulkarni and Bairy, 2013; Grossman and Messerli, 2008; Kulkarni et 
al., 2014). However, many studies have suggested that severe hypotension occurs 
after the disulfiram-ethanol reaction (Moreels et al., 2012; Ho et al., 2007; 
Prancheva et al., 2010; Tummers-de Lind van Wijngaarden et al., 2013). 
Reduction in peripheral vascular resistance was also observed in albino rabbits 
treated with disulfiram, which could be a main underlying cause of the 
hypotension during the disulfiram-alcohol reaction (Bygdeman et al., 1962). In this 
study, the mesenteric resistance arteries of disulfiram-treated SHRSPGla rats 
showed a significant reduction in response to noradrenaline compared to control 
vessels (Figure 5-19 A). In addition to the antialcoholism effects of disulfiram, it 
also has shown recent promise as a pharmacotherapy for treating cocaine 
dependence by inhibition of dopamine beta-hydroxylase, the enzyme that 
catalyses the conversion of dopamine to noradrenaline (Gaval-Cruz and 
Weinshenker, 2009). In our study, disulfiram was selected based on its selective 
inhibition of ALDH. However, disulfiram may have further underlying pleiotropic 
mechanisms of action, which target several regulatory proteins/signaling 
pathways. 
The levels of ALDH enzyme were measured in our study in the liver tissues, which 
showed a trend to increase in 20-week-old SHRSPGla rats compared to WKYGla rats 
(Figure 5-22 C). This increase occurred despite a significant reduction in mRNA 
expression of ALDH1L2 (Figure 5-7 C) indicating that ALDH1L2 mRNA and ALDH 
proteins are differentially expressed. From these observations, the ALDH ELISA 
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assay measures total ALDH protein levels, whereas ALDH1L2 is only one of a large 
superfamily. It is possible that we have just not assessed the particular gene(s) 
responsible for the elevated ALDH level. Also, mRNA expression is regulated by 
many factors, such as miRNA, which may inhibit or stimulate the translation of 
target mRNAs (Fabian et al., 2010). 
The aldehyde dehydrogenase (ALDH) gene superfamily encodes important 
enzymes for the detoxification of endogenous and exogenous aldehyde substrates 
and maintaining redox balance (Vasiliou and Nebert, 2005). Analysis of the ALDH 
gene superfamily in the Human Gene Nomenclature Committee (HGNC) database 
suggested that the human genome includes 19 functional genes and three 
pseudogenes (Vasiliou and Nebert, 2005; Jackson et al., 2011). ALDH gene 
mutations cause defects in aldehyde metabolism, which are the basis of several 
diseases. For example, mutation in ALDH2 E504K raises the risk of Alzheimer's 
disease amongst the East Asian population (Jackson et al., 2011). Systolic and 
diastolic blood pressure were lower in a Japanese population who harboured the 
ALDH2 genetic polymorphism (i.e. heterozygous (*1/*2) and homozygous (*2/*2)) 
when compared to the *1/*1 group (Ota et al., 2016). The ALDH2*1/*1 genotype 
correlated with alcohol intake, and was found to be positively associated with 
hypertension (Yokoyama et al., 2013). GWAS on Asian populations has identified 
a genetic locus within the ALDH2 gene with a functional variant (rs671), which is 
highly associated with systolic blood pressure and diastolic blood pressure (Kalra 
et al., 2014). Also, the ALDH2 Glu504Lys polymorphism was associated with 
vascular endothelium-dependent dilation disorder in a Han Chinese population 
with hypertension (Ma et al., 2016). The ALDH2 rs671 L-genotypes have been 
found to have a protective effect on hypertension in the Han Chinese population, 
independent of alcohol consumption (Yokoyama et al., 2013). ALDH2 plays a 
protective role against oxidative stress through acetaldehyde oxidation. A 
deficiency in ALDH2 leads to increases in oxidative stress, which is a contributing 
factor for hypertension (Ohsawa et al., 2003). Mutations of the ALDH2 gene occur 
differentially amongst races; it is common in the Asian population, but it occurs 
rarely in Caucasian, European or American populations (Ma et al., 2016; Ota et 
al., 2016). Accordingly, ALDH2 genetic polymorphism is mostly associated with 
alcohol intake which may affect systolic blood pressure and cardiovascular 
diseases (Ma et al., 2016; Ota et al., 2016). 
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It would be beneficial to measure hexadecanedioate levels in our disulfiram 
treated rats compared to controls to understand the actual role of ALDH in 
hypertension. However, time constraints and cost prevented a full investigation.  
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5.6.3 ADH 
Alcohol dehydrogenase (ADH) is the second enzyme in the omega oxidation 
pathway. It has been found that expression of alcohol dehydrogenase 1B (class I), 
beta polypeptide (ADH1B) and alcohol dehydrogenase 1A (class I), Alpha 
polypeptide (ADH1A) are strongly associated with hexadecanedioate levels (Menni 
et al., 2017). A mutation in alcohol dehydrogenase-1B was previously found to be 
associated with an increased risk of alcoholism (Yokoyama et al., 2013; Borràs et 
al., 2000). Since moderate-to-heavy alcohol intake is known to increase blood 
pressure (Mori et al., 2015), the relationship between alcohol, hypertension and 
hexadecanedioate should be further investigated. Again, unfortunately time 
constraints meant that I was unable to carry out investigations to examine the 
effect of modulating ADH enzyme activity on blood pressure, but this would be 
beneficial for future studies.  
Future pharmacological intervention studies could employ the ADH anatagonist, 
formepizole, or the ADH activator GW4064 (an agonist of the farnesoid x receptor 
(FXR)). Fomepizole interacts with ADH zinc element and coenzyme nicotinamide-
adenine dinucleotide, which prevents its binding to the toxic alcohol and the 
formation of acidic ethylene glycol metabolites (Mégarbane, 2010). Fomepizole 
inhibits the formation of toxic metabolites by prolonging the elimination half-life 
of ethylene glycol and methanol, improving metabolic imbalance, and prevention 
of end-organ damage such as renal failure (Chu et al., 2002). FXR activation via 
administration of GW4064 leads to an increase in endothelial nitric oxide synthase 
(eNOS) as well as a decrease an endothelin–1 (ET–1) expression in cultured human 
vascular endothelial cells. The regulatory effects of FXR on eNOS and ET–1 in 
endothelial cells suggests that FXR may have a potential role in blood pressure 
regulation (Li et al., 2015). This is further supported by studies demonstrating 
GW4064 was able to reduced systolic blood pressure in SHR rats (Li et al., 2015). 
In conclusion, inhibition of the ω-oxidation pathway enzyme, aldehyde 
dehydrogenase, results in a significant lowering of blood pressure in hypertensive 
SHRSPGla rats. We were unable to determine whether levels of hexadecanedioate 
were also modified by disulfiram treament, and this will be a necessary next step 
for subsequent investigations. Taken together, our findings suggest that the ω-
oxidation pathway is a putative target for further research to elucidate the 
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mechanism by which hexadecanedioate affects blood pressure. However, 
increased endogenous levels of circulating hexadecanedioate may occur not only 
because of increased production through the ω-oxidation pathway but also 
because of decreased removal from the blood stream. In the next chapter I 
examine a potential mechanism that is linked to hexadecanedioate excretion from 
the body. 
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 Investigating the link between Slco1b2 
anion transporter genetic variants and 
hexadecanedioate levels 
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6.1 Introduction  
Results from previous chapters in this thesis have identified that elevation of 
circulating levels of hexadecanedioate is associated with increased blood 
pressure. To examine this relationship, we initially investigated the pathway 
responsible for hexadecandioate generation, the ω-oxidation pathway, which our 
results suggest is linked to increased production of the dicarboxylic acid during 
hypertension (chapter 5). An alternative mechanism that may lead to elevated 
circulating levels of hexadecanedioate is via altered activity of the solute carrier 
organic anion transporter (SLCO), which expresses the protein OATP (organic anion 
transporting polypeptide). This protein plays an important role in the clearance 
of a range of endogenous compounds from the blood stream, one of which has 
recently been identified as hexadecanedioate (Lai, 2013; Menni et al., 2017). The 
current chapter focuses on preliminary investigation of SHRSPGla and WKYGla 
genome sequence to identify variants in the rat Slco1b2 gene. The analysis 
identified variants within the 3’UTR of Slco1b2, which are located within 
predicted miRNAs binding sites and may therefore impact on post-transcriptional 
regulation of Slco1b2 gene expression.  
Eleven functional human OATP isoforms encoded by SLCO genes have been 
discovered and are designated by numbering and letters according to the amino 
acid sequence identities (Lai, 2013). The proteins within the subfamily are: 
OATP2A1, OATP3A1, OATP4A1, OATP5A1, OATP6A1, OATP1B1, OATP1B3, 
OATP2B1, OATP1C1 and OATP4C1 (Roth et al., 2012). OATPs are expressed in 
several organs; including the liver, muscle, intestine and the blood-brain barrier 
(BBB), where they control the absorption, distribution and excretion of a range of 
substrates (Lai, 2013).  
In a recent human GWAS study conducted by Menni et al. on 6447 participants 
from the TwinsUK and KORA cohorts, an association was identified between SNP 
(rs11045656), encoding an Val174Ala amino acid change within the human 
SLCO1B1 gene, which encodes the OATP1B1 protein, and hexadecanedioate levels 
in adipose tissue. However, this SNP did not demonstrate an association with 
hypertension (Menni et al., 2017). A genome-wide study discovered a functional 
variant of OATP1B1, OATP1B1-Val174Ala (rs4149056), which was significantly 
associated with 20 endogenous blood sample metabolites, including bile acids, 
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steroids and dicarboxylic fatty acids (Yee et al., 2016). The dicarboxylic fatty 
acids, tetradecanedioate and hexadecanedioate were identified as novel 
substrates of OATP1B1 (Yee et al., 2016). OATP1B1 is a protein that is selectively 
expressed and localized on the basolateral (sinusoidal) membrane of human 
hepatocytes (Lai, 2013; Roth et al., 2012). It is encoded by the SLCO1B1 gene and 
it plays an important role as a specific carrier for removal of endogenous 
compounds such as organic anions, bile acids, bilirubin, leukotriene C4, estradiol, 
thyroxine and prostaglandins (Roth et al., 2012; Lai, 2013). OATP1B1 also 
transports therapeutic drugs from the blood into the liver, for elimination from 
the body, such as statins, saquinavir, rifampicin, and valsartan (Lai, 2013; Roth et 
al., 2012) (Figure 6-1). OATP1B1 is also referred to as liver specific transporter 1 
(LST–1), OATP2 or OATP-C, and is involved in Na+- and ATP-independent transport 
of amphiphilic organic compounds (Hagenbuch, 2007).  
Homologous protein of human OATPs are found in various species, for instance, 
humans have two OATP1B transporters (OATP1B1 and OATP1B3), while rodent 
have a single homolog of this human protein, Oatp1b2 (also known as Oatp4 and 
Lst-1) (Zaher et al., 2008; Thakkar et al., 2015; Clarke et al., 2014). 
In order to examine the potential impact of the anion transporter Slco1b2 in the 
circulating levels of hexadecanedioate and blood pressure regulation, the genome 
sequence was compared between normotensive WKYGla and hypertensive SHRSPGla 
rats to identify putative genetics variants (SNPs) in the Slco1b2 gene. Atanur et 
al.(2013) previously carried out whole genome sequencing in 27 rat strains 
including the University of Glasgow maintained SHRSP and WKY rat strains. This 
dataset was used in this thesis to identify sequence differences in and near to the 
Slco1b2 gene. 
In this chapter, preliminary investigation of the Slco1b2 gene variants and their 
putative role in regulating hexadecanedioate levels were examined in the Glasgow 
SHRSP and WKY rat models. 
.
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Figure 6-1: The role of OATP1B1 (SLCO1B1) in uptake and elimination of bilirubin, statins and 
other drugs by the liver. 
The solute carrier organic anion transporter (SLCO), which encodes the protein organic anion 
transporting polypeptide (OATP). SLCO1B1 may have a role in hexadecanedioate elimination from 
the body. Any alteration in this liver transporter may cause increases in circulating hexadecanedioate 
levels leading to blood pressure elevation. 
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6.2 Hypothesis 
Genetic variants in the Slco1b2 anion transporter contribute to elevated 
circulating levels of hexadecanedioate in SHRSP rats.  
6.3 Aims  
The aims of this chapter are: 
1. To investigate the role of anion transporter Slco1b2 as a potential regulator 
of circulating hexadecanedioate levels by identifying genetic variants 
(SNPs) between the SHRSPGla and WKYGla rat strains 
2. To identify putative miRNA binding sites in the 3’UTR sequence of Slco1b2 
in SHRSPGla and WKYGla rats.  
3. To investigate differences in mRNA expression of Slco1b2 in liver tissues of 
SHRSPGla and WKYGla rats. 
4. To investigate differences in protein expression of Oatp1b2 in liver tissues 
of SHRSPGla and WKYGla rats. 
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6.4 Methods 
6.4.1 The genome sequence of SHRSPGla and WKYGla 
The genome sequences for SHRSPGla and WKYGla rats have been previously 
generated and published along with another 25 laboratory rat strains by Atanur et 
al. (2013). The annotated sequence variants in Slco1b2 between SHRSPGla and 
WKYGla were identified using variant visualiser and Ensembl genome browser (Rat 
Rnor_5.0). 
6.4.1.1 Variant visualiser on Rat Genome Database (RGD) 
Variants (SNPs) and indels between SHRSPGla and WKYGla rat strains were identified 
using variant visualiser on Rat Genome Database (RGD) using the the Rat Rnor_5.0 
Genome assembly version 79. The Rat Genome Database (RGD); 
http://rgd.mcw.edu/offers tools for gene prediction, identification of variants 
(SNPs) and hosts a ‘traits and phenotypes’ database for several rat strains.  
6.4.1.2 Rat Rnor_5.0 Genome assembly 
Examination of the rat genome RNA was performed using assembly 79 to identify 
the annotated sequence variants in Slco1b2. Ensembl; http://www.Ensembl.org/ 
is a joint project between the European Bioinformatics Institute (EMBL – EBI) and 
the Wellcome Trust Sanger Institute which aims to maintain and update annotation 
of a wide range of species genomes. Genomic variants are annotated to highlight 
sequence variants based on their predicted effect and to identify genes affected 
by large structural variants that are unique to each rat strain.  
6.4.1.3 Sequencing analysis 
Sequencing was analysed using CLC genomics workbench 7.5. Experimental 
sequences were aligned with known sequences derived from the bioinformatics 
database Ensembl genome browser. 
6.4.2 Computationally predicted target databases 
All this information was cross referenced with known miRNA precursor sequences 
that are mapped and stored in the target prediction database. Information for 
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miRNA sequences, annotation and biological function interpretations for genes of 
interest are housed in number of databases such as miRTarBase and miRBase 
databases. 
6.4.2.1 miRTarBase database 
miRTarBase 7.0 database; http://miRTarBase.mbc.nctu.edu.tw/ is a 
comprehensively annotated, experimentally validated miRNA-target interactions 
database. miRNA-target interactions have been validated experimentally by 
western blot, microarray and next-generation sequencing experiments and by 
reporter assay that are available in the literature.  
6.4.2.2 miRBase database 
miRBase database; http://www.mirbase.org/ is a searchable database of 
published miRNA sequences and annotation. The miRBase Sequence database lists 
predicted mature miRNA sequence (termed miR) and stem loop miRNA (hairpin) 
(termed mir in the database). Also, this database provides information about the 
location and sequence of both stem loop and mature sequences. 
6.4.3 Animals 
Wistar Kyoto (WKY) and spontaneously hypertensive stroke prone rats (SHRSP) 
were obtained from breeding colonies in Glasgow University. The rats were housed 
in cages on a 12 hours light/dark circle at room temperature (21± 3°C). Food and 
water ad libidum were provided to the rats. The study protocols were approved 
by the home office and conducted in accordance with the Animals’ Scientific 
Procedures Act1986 under the project license of Dr Delyth Graham (70/9021). 
6.4.4 Samples 
Liver tissues from male untreated WKYGla and SHRSPGla rats were obtained at five, 
sixteen and twenty-weeks of age. At sacrifice, liver tissues were harvested and 
snap-frozen in liquid nitrogen and stored at -80°C for western blot assay to 
determine the level of Oatp1b2 protein expression and Taqman assay for mRNA 
expression. 
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6.4.5  mRNA expression 
6.4.5.1 qRT-PCR  
RNA was extracted, quantified, DNAse treated and reverse transcribed as 
described in section 2.4.1 in liver tissues of 16-week-old male WKYGla and SHRSPGla 
rats. Total mRNA expression of Slco1b2 (Rn01492635_m1) was assessed by 
Taqman® assay systems. All samples were amplified in triplicate. Fluorescence of 
FAM and VIC dyes was measured for all reactions during temperature cycling as 
detailed in section 2.4.1.6. GAPDH was used as the housekeeping gene. Data was 
analysed as detailed in section 2.4.1.7. 
6.4.6 Western Blot 
6.4.6.1 Protein Extraction 
Protein from liver tissues was extracted using a 1X RIPA buffer (20 mM Tris HCl, 
pH 8, 150 mM NaCl, 0.5% nonidet P-40 (NP-40), 0.5% sodium deoxycholate, 0.1% 
sodium dodecyl sulphate (SDS), and 5 Mm ethylenediaminetetraacetic acid 
(EDTA), final pH 7.4. On the day of use, one tablet of Roche EDTA-free protease 
inhibitor cocktail table (Roche, Hertfordshire, UK) and one tablet of PhosSTOP 
Easy pack phosphatase inhibitor (Sigma Aldrich Co Ltd, Irvine, UK) were added for 
every 10 ml of RIPA lysis buffer used. The samples were homogenized using a bead 
homogeniser running at 30 Hz for 30 seconds and then centrifuged at 10,000 xg 
for 10 mins at 4°C. The supernatant containing the protein was transferred to a 
new tube and kept on ice. 5 μL of supernatant was removed to determine protein 
concentration, while the rest of the protein was stored at -80°C until needed. 
6.4.6.2 Protein Quantification 
The protein concentrations were determined using Pierce BCA (bicinchoninic acid) 
protein assay kit (Thermo fisher Scientific, Loughborough, UK), according to the 
manufacturer’s instructions. The bovine serum albumin (BSA) standards were 
provided in dilution range 25 ng/μl – 2 μg/μl. The samples were diluted 10x before 
quantification. Assay was performed in flat bottom 96 well plate and 25 μl of each 
sample and standards are add to the plate. Working reagent (WR) contains 
reagents A and B included in the kit, which were mixed at a ratio of 50:1; 
respectively. WR is then added to the plate by using a multichannel pipette and 
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then the plate was protected from light and incubated at 37 oC for 30 minutes. 
Absorbance at 562 nm was determined for all wells using a Wallac Victor2 plate 
reader (Wallac, Turku, Finland). Both standards and samples were measured in 
duplicate and the average calculated. Results were then calculated according to 
the linear equation based on the standard curve generated.  
6.4.6.3 Sample preparation 
Protein samples were prepared in a total volume of 20 μl at a concentration of 30 
μg/well μl with 4x loading buffer (NuPAGE LDS Sample buffer) as follows: 
Reagent  Volume (μl) 
Nuclease-free water  (15-X) μl 
Protein  X μl 
NuPAGE LDS Sample buffer (4X)  5 μl 
Total volume  20 μl 
Samples were denatured for 10 minutes at 99oC to ensure proteins were denatured 
and cooled on ice immediately for at 5 minutes before adding to gels. 
6.4.6.4 Sodium dodecyl sulphate-polyacrylamide electrophoresis  
Protein were resolved using sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). 12% polyacrylamide gel contains 40% (v/v) of N, N’-
methylene-bis-acrylamide (polyacrylamide 30%), 25% (v/v) of Tris pH 8.8 (11.25 
mM), 0.1% (v/v) SDS, 300 μl ammonium persulphate (APS) and 30 μl of 
N,N,N’,N’Tetramethylethylenediamine (TEMED) were used. A 5% stacking gel 
containing 13.3% (v/v) polyacrylamide 30%, 25% (v/v) Tris pH 6.8 (3.75 mM), 0.1% 
(v/v) SDS, 1% (v/v) APS and 0.1% (v/v) TEMED. 
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Resolving gel  
Reagent  Volume 
30% acrylamide   12 ml 
1.5 M Tris (pH8.8)   7.5 ml 
10% SDS   300 μl 
H2O   10.2 ml 
TEMED   30 μl 
10% APS   300 μl 
Stacking gel  
Reagent  Volume 
30% acrylamide   2 ml 
0.5 M Tris (pH6.8)   3.75 ml 
10% SDS    159 μl 
H2O   9.1 ml 
TEMED   15 μl 
10% APS   150 μl 
Subsequently, gels were loaded with samples and 15 μl of Precision Plus Protein™ 
(10–250 kD) ladder (Bio-Rad Laboratories, Watford, UK). Gels were 
electrophoresed at 150 V in running buffer (50 ml 20x NuPAGE bolt running buffer 
to 950 ml deionized water) for 1 hour. 
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6.4.6.5  Protein blotting 
Following electrophoresis, the stacking gel was removed and lanes not including 
protein were cut from the resolving gel. Four pieces of Whatman 3 mm 
chromatography blotting paper and a piece of Amersham Hybond-P polyvinylidene 
difluoride membrane (Amersham Bioscience UK Limited, Buckingham, UK). Filter 
paper and transfer sponges were equilibrated in transfer buffer and membranes 
were activated with methanol. Transfer buffer consists of 0.025 M Tris pH10.5; 
0.2 M Glycine; 20% methanol. Transfer apparatus was prepared as follows (cathode 
to anode): 1X transfer sponge, 2x Whatman sheets, gel, membrane, 2x Whatman 
sheets, and 1x transfer sponge. Blots were transferred at 100V for 90 minutes. 
Transfer Buffer 
Reagent  Volume (2L) 
Tris (Base)   6.06 g 
Glycine  28.8 g 
Methanol  400 ml 
Deionized water 1600 ml 
6.4.6.6  Antibody probing and washing 
Once the membranes had been transferred, membranes were blocked with SEA 
BLOCK solution (Thermo Scientific, Loughborough, UK) (1:1 dilution with Tris-
buffered saline Tween buffer (1xTBS-T)) for 1 hour. Blocking was carried out on a 
lab shaker (Luckham R100) at 50 oscillations per minute.  
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SEA BLOCK solution consisted of: 
Steelhead salmon serum 
Phosphate-buffered saline  
0.1% sodium azide 
TBS-T (Tris-buffered saline Tween buffer) 0.5% tween (10x Stock) 
Reagent  Volume 
Tris base  24.2 g 
NaCl  87.7 g 
Tween 20  5 ml 
Distilled water   1000 ml 
PH to 7.5 with HCl 
Following blocking, the membranes were washed with 1x TBS-T three times for 10 
minutes each and then incubated with primary antibody Oatp4 (Oatp1b2)/ IgG1κ 
light chain (Figure 6-2) (Santa Cruz Biotechnology, INC) diluted in blocking buffer 
at the 1:1000 dilution overnight at 4ºC with shaking. Following overnight 
incubation, the membrane was washed three times for 10 minutes with 1x TBST-
T at room temperature, followed by incubation with 1:15000 dilution of the 
appropriate secondary antibody, goat anti-mouse IgG (H+L) (Thermo Scientific, 
Loughborough, UK) for 1 hour at room temperature with shaking. The membrane 
was then washed with 1x TBS-T three times for 10 minutes followed by washing 
with phosphate-buffered saline (PBS) (Sigma Aldrich Co Ltd, Irvine, UK) for 1 
minute at room temperature with shaking. Proteins were developed using Li-COR 
(Li-COR, Nebraska, USA). The images were visualized and analysed using Image 
StudioTM Software. Membranes were then incubated with housekeeping protein 
GAPDH Rabbit / IgG Polyclonal antibody (Thermo Scientific, Loughborough, UK) 
diluted in blocking buffer at the 1:5000 dilution overnight at 4ºC with shaking. 
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Following overnight incubation, the membrane was washed three times for 10 
minutes with 1x TBST-T at room temperature, followed by incubation with 1:15000 
dilution of the appropriate secondary antibody, rabbit anti-mouse IgG (H+L) 
(Thermo Scientific, Loughborough, UK) for 1 hour at room temperature with 
shaking. The membrane was then washed with 1x TBS-T three times for 10 minutes 
followed by washing with phosphate-buffered saline (PBS), for 1 minute at room 
temperature with shaking. Proteins were developed using Li-COR exactly as 
described above. 
6.4.6.7 Membrane stripping and re-probing 
The level of a protein in a sample was measured relative to the level of a 
housekeeping protein. Membranes were stripped to remove conjugated antibodies 
and re-probed with antibodies specific to the housekeeper. The membranes were 
stripped in 10 ml of a mild stripping buffer (0.2 M Glycine, 1% SDS, and 1% 
Tween20R, pH 2.2) for 10 minutes at room temperature on a shaker at 50 
oscillations per minute, then washed with 1x TBS-T 3 times for 10 minutes each. 
Membranes were then re-incubated overnight at 4 oC, washed and analysed for 
the housekeeping protein exactly as described above. 
Stripping buffer 
Reagent   Volume 
Glycine  15 g 
SDS  1 g 
Tween 20  10 mL 
Distilled water  800 mL 
Adjust pH to 2.2 
Bring volume up to 1 L with distilled water 
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Figure 6-2: Representative image of the Oatp4 (Oatp1b2) expression in liver tissues shows 
the range and band size provided by the manufacturer (Santa Cruz Biotechnology). 
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6.4.7 Statistical analysis 
All results are displayed as mean ± SEM using Graphpad Prism. Western blot and 
Taqman gene expression data were analysed using student’s T-test. Statistical 
significance was assumed at P-value less than 0.05. 
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6.5 Results 
6.5.1 Homologue of human SLCO1B1 in rat (Rattus Norvegicus) 
The Ensembl genome browser was used to confirm the rat homologue of the human 
SLCO1B1 gene and the rat Slco1b2 is located on rat chromosome 4 (Figure 6-3).  
6.5.2 Comparison of rat Slco1b2 genome sequence between 
SHRSPGla and WKYGla 
We have examined 15,000 bp upstream from the transcriptional start site of 
Slco1b2. We identified two genetic variants within the target Slco1b2 gene when 
comparing SHRSPGla and WKYGla genome sequence using Ensembl genome browser 
(Rat Rnor_5.0). 
(1) An insertion of 9 nucleotides (GTCTATCTA) within an intronic region (intron 3 
of 14) on chromosome 4 at position 240,062,637 bp, band 4q44 forward strand in 
the WKYGla strain rather than G nucleotide in the SHRSPGla strain.  
(2) Deletion of 4 nucleotides (TATC) within the 3’untranslated region (UTR), on 
chromosome 4 at position 240,102,755 bp of the WKYGla genome sequence (Figure 
6-4). 
6.5.3 miRNA / transcription factors binding sites within Slco1b2 
gene and potential impact of the deletion 
Here, we used miRTarBase database to identify predicted miRNA binding sites 
within the target gene Slco1b2 gene. The analysis was carried out in sequences of 
3 different species; human, rat and mouse, which showed 3 miRNAs were 
identified within target human SLCO1B1 (i.e. miR_335_5p, miR_26b_5p and 
miR_511_5p). One miRNA was also identified within target mouse Slco1b2 
(miR_698_3p) using Next-Generation Sequencing (NGS). However, no miRNA has 
yet been identified in rat Slco1b2 (Figure 6-6).  
The analysis was then carried out in sequences of rat and mouse using CLC 
genomics workbench to rely on the conservation in the target region (i.e. deleted 
4 nucleotides TATC) within 3’UTRs between the two species. The Sequence 
alignment that involved the deleted 4 nucleotides (TATC) (blue highlighted) in rat 
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showed lack of sequence of conservation when compared to mouse sequence 
(Figure 6-7). 
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Figure 6-3: Ensembl genome browser (Rat Rnor_5.0) identified human SLCO1B1 and its rat homolog Slcolb2. 
Slco1b2, located on rat chromosome 4, is a single rodent homolog of the human SLCO1B1 gene on chromosome 12 (green highlight). 
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Figure 6-4: Genotype Analysis of Slco1b2 sequence identified an insertion of 9 nucleotides and a deletion of 4 nucleotides in WKYGla strain compared to 
SHRSPGla strain. 
Screenshot taken from RGD browser identifying an insertion of 9 nucleotides in WKYGla at position 240,062,637 bp and a deletion of 4 nucleotides in the WKYGla strain 
at position 240,102,755 bp on rat chromosome 4. 
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Figure 6-5: 3’ untranslated downstream sequence of the Slco1b2 (NM_031650) gene in SHRSPGla. 
Green highlighted nucleotides represent the stop codon (TAA) and red highlighted nucleotides indicate the position of deletions within 3’UTR of the WKYGla. 
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Figure 6-6: MiRTarBase analysis showed the identified miRNA within a target (A) human 
SLCO1B1, (B) mouse Slco1b2 and (C) rat Slco1b2. 
MiRTarBase analysis showed (A) three miRNAs within target human SLCO1B1 was identified in 
several validation methods. In addition, (B) one miRNA was identified within target mouse Slco1b2 
using Next-Generation Sequencing (NGS). However, no miRNA was identified in rat Slco1b2 (C). 
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Figure 6-7: Rat and mouse Slco1b2 3’ UTR region sequences. 
The rat’s sequence alignment that involved the deleted 4 nucleotides (TATC) (blue highlighted, red arrow) showed the absence of conservation when compared to mouse 
sequence alignment.  
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6.5.4 Slco1b2 expression in liver tissues of SHRSPGla and WKYGla 
Slco1b2 mRNA levels were assessed by quantitative real time PCR (qRT-PCR) in 
liver samples from male WKYGla and SHRSPGla aged 16-week old . Slco1b2 mRNA 
expression was significantly decreased in SHRSPGla compared to WKYGla (P=0.008) 
(Figure 6-8). 
6.5.5 Oatp1b2 protein expression in liver tissues of SHRSPGla and 
WKYGla 
To further investigate the extent of the changes in Slco1b2 expression, total 
protein Oatp1b2 levels in the liver tissues from WKYGla and SHRSPGla were 
measured by Western blot. Representative immunoblots are shown in Figure 6-9 
A, B. 
Smeared bands are detected, which limited the analysis and prevented confident 
interpretation of the data. However, the analysis was preformed according to the 
predicted and observed molecular weights of Oatp1b2 provided by Santa Cruz 
Biotechnology (Figure 6-2). Oatp1b2 protein in SHRSPGla rat at 5 weeks of age 
significantly decreased when compared to WKYGla levels. While protein levels in 
liver sample from SHRSPGla rats at 16 weeks and 20 weeks showed no difference 
to that of WKYGla rats (Table 6-1), (Table 6-2). 
 
Chapter 6  317 
 
 
Figure 6-8: The expression level of Slco1b2 in liver tissues of SHRSPGla and WKYGla rats. 
The expression level of Slco1b2 was significantly decreased in liver tissues of 16-week-old SHRSPGla 
(n=4) compared to WKYGla rats (n=8) (P**<0.01). Values are presented as mean ± SEM. 
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Figure 6-9: Western blot analysis of Oatp1b2 in WKYGla and SHRSPGla rats from liver tissue. 
Protein lysates from snap frozen liver tissue from SHRSPGla and WKYGla rats were prepared, 
quantified, electrophoresed, blotted, and probed for Oatp1b2. (A) Representative immunoblots of 
SHRSPGla at 20 weeks, WKYGla at 20 weeks and SHRSPGla at 5 weeks (n=4/group). (B) 
Representative immunoblots of WKYGla at 5 weeks, SHRSPGla at 16 weeks and WKYGla at 16 weeks 
(n=4/group). GAPDH bands demonstrates equivalent sample loading, while smearing was observed 
in Oatp1b2 bands, which limited the analysis. 
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Table 6-1: Intensity levels of Oatp1b2 in liver tissue of SHRSPGla compared to WKYGla 
(n=4/group). 
Age 5 weeks  16 weeks  20 weeks  
Strain WKY SHRSP WKY SHRSP WKY SHRSP 
Oatp1b2 intensity 
1090 878 1400 1470 1400 1030 
1130 910 1080 1150 1280 1090 
1440 1020 1280 989 1040 1340 
1510 913 1170 1100 1000 1330 
TTEST (P value) 0.02 0.67 0.89 
 
Table 6-2: Protein expression of Oatp1b2 normalized to GAPDH in liver tissue of SHRSPGla 
compared to WKYGla (n=4/group). 
Age 5 weeks  16 weeks  20 weeks  
Strain WKY SHRSP WKY SHRSP WKY SHRSP 
Oatp1b2/GAPDH 
0.06 0.03 0.08 0.11 0.07 0.04 
0.06 0.03 0.07 0.08 0.06 0.04 
0.10 0.03 0.09 0.06 0.04 0.05 
0.12 0.04 0.06 0.07 0.04 0.05 
TTEST (P value) 0.01 0.77 0.27 
 
Due to the presence of smearing, we were unable to detect the exact bands with confidence. 
Therefore, we relied on the molecular weights of Oatp1b2 provided by the manufacturer for our 
analysis. Reduction in protein expression levels of Oatp1b2 in liver tissue of 5 weeks old SHRSPGla 
compared to WKYGla.There were no differences in expression levels of Oatp1b2 in liver tissue of 
SHRSPGla at 16 weeks and 20 weeks compared to WKYGla. GAPDH demonstrates equivalent sample 
loading, and expression levels of Oatp1b2 are displayed as ratio intensity normalised to GAPDH. 
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6.6 Discussion 
The recent studies by Yu et al.(2016) and Menni et al (2017) have indicated an 
association between human SLCO1B1 mutations and hexadecanedioate serum 
levels. These associations would suggest that human SLCO1B1 has a putative role 
in hexadecanedioate removal from the body and any alteration in this transporter 
may cause increases in circulating hexadecanedioate levels potentially leading to 
blood pressure elevation. In this chapter, the rat Slco1b2 homolog was 
investigated by comparing the genome sequence of the normotensive WKYGla and 
hypertensive SHRSPGla rats and identifying genetic variants (SNPs) between these 
rat strains. We examined 15,000 bp upstream of the transcriptitonal start site to 
explore how far SNPs and indels may exist from the affected gene. The analysis 
demonstrated an insertion of 9 nucleotides (GTCTATCTA) within an intronic region 
of the WKYGla strain rather than G nucleotide in the SHRSPGla strain. Also, there 
was a deletion of 4 nucleotides (TATC) in the 3’UTR of WKYGla genome sequence 
(Figure 6-3).  
Intronic variants may affect structure and function of proteins by affecting 
alternative splicing of mRNA. Alternative splicing is a regulatory process of gene 
expression, resulting in multiple protein isoforms being encoded by a single gene. 
Cis- and trans-acting regulatory elements regulate the alternative splicing. During 
this process, cis-acting regulatory elements in the precursor mRNA sequence 
determine which particular exons are included and excluded from the final 
produced mRNA. Accordingly, proteins are translated from spliced mRNAs. The 
mechanisms affecting alternative splicing include alteration of either cis-acting 
elements by a direct impact on the expression of one gene or trans-acting factors 
which may affect the expression of many genes (Wang and Cooper, 2007). Time 
constraints prevented further investigation of the impact of the 9 nucleotides 
insertion within the intronic region of Slco1b2, however future studies could 
examine the proximity of the variant to the nearest canonical splice site together 
with investigation of any potential splice variants.  
The 3’UTR plays a role in post-transcriptional regulation of gene expression 
through mRNA stability and translational efficiency. Mutations affecting the 3’UTR 
region may interfere with mRNA stability and translation through affecting the 
termination codon and polyadenylation signal leading to overexpression or 
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downregulation of proteins (Mignone et al., 2002; Chatterjee and Pal, 2009). 
MicroRNA (miRNA) binding sites are located within the 3’UTR, and therefore SNPs 
and indels identified within these regions may affect the binding sequences of 
miRNAs on their target mRNA and subsequently alter the gene expression levels 
(Gu et al., 2016). miRNAs are small non-coding RNAs (trans-acting elements), 
which regulate protein-coding gene expression at the post-transcriptional phase 
either by promoting destabilization/degradation of mRNA or inhibition of 
translation leading to RNA silencing or regulation of mRNA abundance (Matoulkova 
et al., 2012). Due to their ubiquitous role in gene regulation, miRNAs are involved 
in a wide range of physiological processes such as cell proliferation and apoptosis, 
also their dysregulation has been related to many pathological disorders; such as 
diabetes and cancer (Vimalraj and Selvamurugan, 2011). The main feature of 
miRNA function is that a specific miRNA can control multiple mRNA targets that 
are involved in the same biological pathway which makes them good candidates 
for novel therapeutics (Wahid et al., 2010; Vimalraj and Selvamurugan, 2011) 
(Figure 6-11). Bioinformatics approaches using computational methods, are 
extensively used for identification of predicted miRNA binding sites and their 
functional annotation (Liu et al., 2014). 
The rat genome database incorporated with miRTarBase database have been used 
in this study to determine whether the identified genetic variants disrupt 
predicted miRNA binding sites. The analysis carried out by using miRTarBase 
database showed that no miRNAs within the target gene (Slco1b2) were identified 
in the rat genome sequence. However, when the analysis was carried on the 
human SLCO1B1 and mouse Slco1b2, 3 miRNAs were identified in human SLCO1B2 
gene by different validation methods (i.e. literature, western blot and qPCR), one 
miRNA was identified in mouse Slco1b2 gene using next-generation sequencing. 
The lack of sufficient rat Slco1b2 genome information may have limited further 
identification of target miRNAs. As mature miRNA and their target sequences can 
be well conserved across species, the sequence conservation in the 3' UTR was 
examined between rat and mouse using the CLC genomics workbench. Our analysis 
showed that a lack of conservation near to the identified deletion region was 
observed in the sequence of 3’UTR region between rat and mouse making the 
analysis challenging to predict potential target miRNA. 
Chapter 6 
 
322 
Several clinical studies have been conducted to investigate genetic variants in the 
human SLCO1B1 gene and their association with cardiovascular and metabolic 
diseases. For example, loss of function mutations have been identified in the 
SLCO1B1 gene among African-American individuals from the Atherosclerosis Risk 
in Communities (ARIC) study (Yu et al., 2016). This study not only showed an 
association between SLCO1B1 and hexadecanedioate serum levels, but also 
demonstrated that one copy of the mutated T allele in SLCO1B1 was associated 
with increased risk of incident heart failure (Yu et al., 2016).  
A single nucleotide polymorphism rs4149056 (known as Val174Ala) that introduced 
amino acids changes within the transmembrane domains of OATP1B1 (i.e. 
alteration of the amino acid at position 174 from valine to alanine) has been found 
to be associated with a decrease OATP1B1 activity and increased plasma levels of 
statins and subsequent muscle toxicities (Clarke et al., 2014; Pasanen et al., 2007; 
Hartkoorn et al., 2010; Huang et al., 2012). Furthermore, this SNP rs4149056 was 
found to be correlated with high levels of tetradecanedioate and 
hexadecanedioate in plasma samples from individuals on pravastatin/cyclosporine 
treatment, which indicates the potential utility of tetradecanedioate and 
hexadecanedioate as quantitative biomarkers of OATP1B1 activity (Yee et al., 
2016). Downregulation of OATP activity was found to be associated with 
impairment in bile acid removal from the blood to hepatocytes leading to 
increased excretion of sulphated and glucuronic acid conjugated bile acids into 
the urine (Kullak-Ublick et al., 2000; Gartung and Matern, 1997; Takikawa, 2002). 
In the current study, the expression of Slco1b2 was significantly decreased in 
hypertensive SHRSPGla rats compared to normotensive WKYGla rats (Figure 6-8). 
This could be associated with elevated circulating hexadecanedioate levels as well 
as increases in bile acid metabolite levels in liver, kidney and adipose tissues of 
hexadecanedioate-treated rats compared to untreated control WKY rats, as shown 
in Chapter 4. To confirm this result, protein expression of Oatp1b2 was measured 
in liver tissue of SHRSPGla rats compared to WKYGla rats, which suggested a 
reduction in Oatp1b2 expression at 5 weeks of age in SHRSPGla rats compared to 
WKYGla rats, whereas no differences were observed in adult rats (Figure 6-10). 
Previous studies have shown that the expression of Oatp1b2 is low at neonatal 
stage, significantly rising after weaning age and reaching a peak, which is 
maintained at high levels during adulthood. However, the expression of Oatp1b2 
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is shown to decrease in liver tissues of aged rats (Hou et al., 2014; Cheng et al., 
2005). RNA and protein represent different molecular stages of the genetic 
information flow process within a cell, in which these molecules are dynamically 
produced and degraded. Indeed, proteins may have different half lives as the 
result of different protein synthesis and degradation that may account for the 
mRNA and protein discrepancies (Greenbaum et al., 2003). This may explain why 
expression of the Slco1b2 gene and expression of the Oatp1b2 protein are different 
in SHRSP rats at 16 weeks of age. Moreover, a potential limitation to this study is 
the presence of smeared bands of Oatp1b2, which prevent the detection of 
specific bands of the protein. This may be due to technical reasons e.g. errors or 
limitations resulting from poor quality Oatp1b2 antibodies for western blotting, 
which may contribute to the poor quality blots. Further studies would be required 
to determine whether the differences are due to biological or technical reasons. 
This could also cause discrepant results between mRNA and protein levels in this 
study. 
In conclusion, this study has identified genetic variants within the Slco1b2 gene 
that may contribute to altered expression/function of the Oatp1b2 transporter, 
which may in turn contribute to elevated levels of circulating hexadecanedioate 
in the SHRSP rat model of hypertension. Further investigation will be required to 
confirm these findings and determine the underlying mechanisms. 
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 General Discussion 
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7.1  Overview Summary 
It is well established that hypertension is the major indicator of early 
cardiovascular risk in populations. The clinical management of hypertension is one 
of the most common interventions in UK primary care, accounting for 
approximately £1 billion in drug costs alone (NICE, 2018a). The annual healthcare 
cost of cardiovascular disease; including hypertension in the UK is estimated at 
around £16.3 billion (Luengo-Fernández et al., 2006). A substantial reduction in 
healthcare costs will be achieved if all the hypertensive patients had their blood 
pressure controlled to target (Elliott, 2003). However, effective blood pressure 
control to meet the clinical targets in hypertensive patients has been unsuccessful 
(Kotchen, 2003; Egan et al., 2011), with an increase in an incidence of resistant 
hypertension (Naseem et al., 2017; Barochiner et al., 2013; Cifkova et al., 2016). 
Suboptimal therapy is the most common reason for failure to reach the blood 
pressure target. In addition, the complexity of medical regimens failed to control 
hypertension due to the challenge of patient adherence (Calhoun et al., 2008; 
Carey and Whelton, 2018; Krieger et al., 2018). Development of antihypertensive 
drugs has essentially stalled over the last decade, and there is still much 
uncertainty and no clear single identifiable cause underlying the pathophysiology 
of hypertension. There is an urgent need to discover novel pathways that will 
identify novel drug targets or enable effective targeting of therapy. For those 
reasons, this study sought to investigate a novel pathway for hypertension, 
involving hexadecanedioate, since previous work identified a direct association 
between hexadecanedioate and both blood pressure elevation and mortality 
(Menni et al., 2015). To allow clinical translation, we require a deeper 
understanding of the mechanisms by which hexadecanedioate influences blood 
pressure and it’s potential as a therapeutic target. Therefore, this study was 
designed to examine the functional role of hexadecanedioate on blood pressure 
and end-organ damage, and identify a putative novel pathway for hypertension. 
Here we provide evidence to confirm that administration of exogenous 
hexadecanedioic acid elevated circulating hexadecanedioate levels in parallel 
with a rise in systolic blood pressure in normotensive WKY rats. Vascular function 
was also examined, which identified significant increases in vascular reactivity to 
noradrenaline in mesenteric resistance arteries of WKY rats treated orally with 
hexadecanedioic acid (Chapter 3).  
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In support of these findings a metabolomics study was conducted to identify the 
metabolic effects of hexadecanedioate-induced blood pressure elevation. A 
previous metabolomic study was carried out in the pulmonary vascular system, 
which identified increased dicarboxylic fatty acids, including hexadecanedioate in 
conjunction with disrupted glycolysis in lung tissues from human pulmonary 
arterial hypertension (Zhao et al., 2014). Similarly, our study exhibited multiple 
dicarboxylic acids, including hexadecanedioate to be significantly accumulated in 
cardiovascular tissues obtained from hexadecanedioic acid treated WKY rats. In 
addition, subtle changes in fatty acid metabolism and energetics-related 
metabolites were identified, indicating a disruption of β-oxidation and an increase 
of -oxidation in this condition and pointing to a putative role in elevating blood 
pressure in both the systemic and pulmonary circulations (Chapter 4). Indeed, 
impairment of mitochondrial β-oxidative function is associated with increased 
dicarboxylate fatty acids, reflecting a shift toward increased use of peroxisomal 
ω-oxidation. Animals studies have identified that the downregulation of fatty acid 
β-oxidation enzymes is also associated with increased use by mitochondria of 
oxygen-sparing glycolytic pathways for adenosine triphosphate (ATP) production 
(de las Fuentes et al., 2006). Fatty acid oxidation is a more efficient process for 
ATP production in comparison with glycolysis (Zhao et al., 2014). Any abnormality 
in glycolytic and fatty acid metabolism causes metabolic dysfunctions and both 
are now recognised as a potential biological mechanism leading to pulmonary 
vascular remodelling, ventricular hypertrophy and systolic heart failure (de las 
Fuentes et al., 2006; Assad and Hemnes, 2015; Rubattu et al , 2016). 
Our analysis also identified marked increases in hepatic, renal and adipose levels 
of bile acid profiles as well as significant increases in hepatic and renal levels of 
cholesterol in hexadecanedioic acid treated WKY rats (Chapter 4). A previous 
study were performed by Wu et al.(1999) found that serum total bile acids levels 
were higher in essential hypertensive patients and in spontaneously hypertensive 
rats. Wu et al suggested that bile acids are able to induce hypertension by 
inhibiting the transcription of both 11β-hydroxysteroid dehydrogenase (11b-HSD) 
and CYP11B2 in vasculature, leading to a decrease in aldosterone and an increase 
in corticosterone production in vessels and increased vasoconstrictor responses to 
noradrenaline. In fact, aldosterone and bile acids are both produced from 
cholesterol in a series of reactions. Cholesterol, aldosterone, and bile acids are 
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involved in development of hypertension. However, the associations between bile 
acids, cholesterol and hexadecandioate in hypertension remain to be identified 
and further investigations are required to determine the underlying mechanisms. 
For a better understanding of the role of hexadecandioate in blood pressure 
regulation, molecular levels of ω-oxidation pathway were examined. Our gene 
expression analysis identified a significant reduction in the final enzyme of the ω-
oxidation pathway, aldehydehydrogenase (ALDH1L2 isoform), in liver tissues 
obtained from hypertensive SHRSP rats compared to normotensive WKY (Chapter 
5). Our results corroborate findings by Menni et al (2017), which verified 
significant correlations between high circulating levels of hexadecanedioate and 
the levels of encoding enzymes involved in the ω-oxidation pathway. For further 
investigation, pharmacological intervention studies were carried out to examine 
the enzymes involved in the ω-oxidation pathway by perturbing the endogenous 
ω-oxidation pathway utilising specific inhibitors and agonists for several enzymes 
in the pathway. Here we identified a significant reduction in blood pressure of the 
hypertensive SHRSP rat model after inhibition of aldehyde dehydrogenase enzyme 
by administration of the specific antagonist (disulfiram). It would be important to 
measure the level of hexadecandioate in plasma samples and the protein 
expression of ALDH in these treated rats. Also, it would be beneficial to activate 
the ALDH enzyme by specific agonist (Alda-1) in normotensive WKY rats to fully 
confirm the effect of altering endogenous hexadecandioate levels and gain a 
better understanding of the role of ALDH in hypertension. Unfortunately, time and 
budget limitations in the present study prevented a more in-depth investigation. 
Although a number of GWAS on blood pressure and hypertension have been 
published, two GWAS studies have determined an association between 
hypertension and ω-oxidation pathway genes, including ALDH and ADH. Firstly, a 
GWAS study carried out by Adeyemo et al (2009) identified an association between 
rs991316 SNPs in ADH7 and rs1550576 SNPs in ALDH1A2 and hypertension in African 
Americans populations. Secondly, ALDH2 gene was found to be associated with 
blood pressure and hypertension in Asian ancestry (Yang et al., 2012). Therefore, 
further investigation is needed to verify the role of ω-oxidation enzymes, ALDH 
and ADH in elevation of hexadecanedioate levels. 
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Interestingly, administration of the CYP4A enzyme in the ω-oxidation pathway by 
the agonist (fenofibrate), which showed a significant reduction in blood pressure 
with significant increase in the hepatic and renal expression of CYP4A in 
fenofibrate-treated WKY rats compared to vehicle-treated WKY rats (Chapter 5). 
The unexpected reduction in blood pressure may point to the role of peroxisome 
proliferator-activated receptor-alpha (PPAR-α), which may also be activated by 
fenofibrate administration leading to reductions in blood pressure and sodium 
retention (Lee et al., 2011). Activation of PPAR-α increases the expression of renal 
tubular CYP4A expression, thus increasing the production of 20-
hydroxyeicosatetraenoic acid (20-HETE) which leads to reduces sodium retention 
and blood pressure (Lee et al., 2011). It would be important to conduct future 
studies in fenofibrate-treated SHRSP rats, since blood pressure reductions have 
also been identified with fenofibrate treatment in DOCA-salt hypertension rats as 
well as in salt-sensitive hypertensive patients (Lee et al., 2011; Gilbert et al., 
2013). Nevertheless, the mechanisms underlying the reduction of blood pressure 
are still unknown. 
The dicarboxylic fatty acid, hexadecanedioate is mainly metabolised in liver, and 
transported across the hepatocyte sinusoidal membrane by organic-anion-
transporting polypeptide (OATP) encoded by solute carrier organic anion (SLCO) 
gene. We hypothesized that mutations in this transporter may lead to elevated 
circulating levels of hexadecanedioate and subsequently may cause elevation of 
blood pressure. Several studies have been successful in identifying the association 
between elevated circulating hexadecanedioate levels and SNPs (rs414056) in 
human SLCO1B1 gene (Yu et al., 2016; Yee et al., 2016; Menni et al., 2017). These 
SNPs have been previously identified as being association with risk of statin related 
myopathy (Ramsey et al., 2014; Bakar et al., 2017). In this thesis, we have 
extended these studies by preliminary investigation of the genome sequences of 
the rat homolog, the Slco1b2 gene in two rat models, the spontaneously 
hypertensive stroke-prone (SHRSP) and normotensive Wistar–Kyoto (WKY) rats and 
identified SNPs within their genome sequences. Our results have identified two 
genetic variants within WKY sequence; which are a deletion of 4 nucleotides 
within 3’untranslated region (UTR) and an insertion of 9 nucleotides within the 
intronic region on chromosome 4 (Chapter 6). These mutations may interfere with 
the Slco1b2 gene expression resulting in dysregulation of protein function. Hepatic 
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mRNA expression of Slco1b2 was also examined to verify this result, which showed 
a significant downregulation of Slco1b2 mRNA levels in hypertensive SHRSP rats 
compared to normotensive WKY (Chapter 6). This suggests that the genetic 
polymorphism in this gene may affect SLCO function, leading to reduced hepatic 
uptake of hexadecanedioate and other metabolites. Xiang et al. (2009) found that 
OATP1B1 mutation also altered the uptake of certain bile acid profiles. This may 
explain the results of elevated bile acid metabolomic profiles in many of the 
examined tissues (i.e. adipose, kidney and liver) of hexadecanedioic acid-treated 
WKY rats (Chapter 4). Therefore, these findings indicate that under condition of 
decreased hepatic OATP1B1 levels, these changes can reduce hepatic clearance 
of circulating hexadecanedioate in hypertensive SHRSP rats. This may explain why 
baseline circulating hexadecanedioate levels were significantly higher in SHRSP 
rats compared with WKY rats (Menni et al., 2015). 
7.2  Future perspectives 
In this thesis, we have confirmed the role of hexadecanedioate on vascular 
function assessed by wire myography. However, we still not entirely sure about 
the molecular mechanisms, which influence vascular tone and contractile 
response observed during blood pressure elevation. As we know, perturbing 
vascular smooth muscle cell signalling influences vascular reactivity and tone 
leading to vascular resistance and hypertension (Touyz et al., 2018). Therefore, 
further investigation is needed to prove the mechanism of hexadecanedioate in 
vascular tissues. One way to do that is by in vitro analysis of vascular cells to 
understand how elevated circulating levels of hexadecanedioate contribute to 
increased vascular reactivity and blood pressure elevation. Vascular smooth 
muscle cells and endothelial cells of aorta and mesenteric resistant arteries are 
obtained from SHRSP and WKY rats could be isolated and cultured. Vascular cells 
could be treated with a range of hexadecanedioate concentrations (1x10-8 to 3x10-
5 mol/l) or vehicle. The expression of critical ion transporters, channels, and 
signalling molecules involved in calcium homeostasis could be examined by qRT-
PCR and western analysis. This would include, voltage dependent Ca2+ channels, 
transient receptor potential channel (TRPC), plasma membrane calcium ATPase 
(PMCA), sarco/endoplasmic reticulum calcium pump (SERCA), and Na+/Ca2+ 
exchangers.  
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The previous unpublished SILAC studies mentioned in Chapter 1, Section 1.14, 
have demonstrated significantly increased aldehyde dehydrogenase protein levels 
in vascular smooth muscle cells from SHRSP rats, suggesting potential ω-oxidation 
pathway dysregulation. It is essential to examine the impact of disulfiram 
treatment on these cellular mechanisms. Similarly to the proposed in vitro studies 
with hexadecanedioate, vascular smooth muscle cells and endothelial cells 
isolated from aorta and mesenteric resistant arteries of SHRSP could be treated 
with disulfiram (5 µmol/l) or vehicle and the expression of critical Ca2+ ion 
signalling molecules examined by measuring the expressions of relevant proteins 
and mRNAs. In fact, intracellular calcium [Ca2+]i of vascular smooth muscle cell 
not only regulates the contractile response but also impacts on the activity of 
several calcium dependent transcription factors and proteins (Touyz et al., 2018). 
Therefore, intracellular calcium concentration [Ca2+]i should be measured using 
direct fluorescence methods to determine the short-term hexadecanedioate 
treatment on Ca2+ in vascular smooth muscle cells (VSMCs) of WKY and SHRSP rats.  
In our study, the mutation within the Slco1b2 genome sequence encoding the 
Oatp1b2 protein was confirmand between the two rat strains, SHRSP and WKY. 
However, the physiologic and pharmacologic roles of OATPs of the 1B subfamily 
and hepatic reuptake of hexadecanedioate are still not clearly understood. To 
investigate the roles of Oatp1b2 in hexadecanedioate clearance and its association 
to blood pressure elevation, knockout mice (Slco1a/1b–/–) could be utilized, which 
have been previously generated by Van de Steeg et al., (2010). It would be 
important to measure blood pressure together with hexadecanedioate, bilirubin 
and bile acids levels in plasma and liver samples in these knockout mice compared 
to wild type. Confirmation of a functional role for Slco1b2 on hexadecanedioate 
levels in a different species would provide important corroborative evidence for 
our findings in the rat. 
In this thesis, we proposed that examining in parallel alterations at both the whole 
animal, metabolomics and molecular levels, would not only help to identify novel 
therapeutic targets but also help to provide a better understanding of 
pathophysiology of hypertension. However, the current study has limitations due 
to the enormous complexity of biological systems, which makes the reliable 
predictions about the biological role of novel targets difficult. It is suggested that 
these difficulties impact our ability to determine the main organ(s) affected by 
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elevation of the hexadecanedioate levels. Limitations also arise from the short 
duration of the animal studies and pathophysiologic processes compared to a 
lifetime of development of hypertension in humans. In addition, it was difficult to 
determine the direct ortholog of ω-oxidation enzymes shared between rat and 
human. Some of our studies were stastically under powered. Although, it would 
be benifical to increase the animals number, that was impossible within the time 
frame of this thesis. 
This project was conducted to provide better understanding of the effect of 
hexadecanedioate in elevation of blood pressure and involved initial studies to 
determine the underling pathways and mechanisms. From our findings, we can 
suggest a number of targets, which are associated with altered hexadecanedioate 
levels and consequently development of hypertension; including 
aldehydehydrogenase (ALDH) and solute carrier organic anion (SLCO). 
Identification of these putative targets will be important for the scientific and 
medical researcher community in the cardiovascular field to advance 
understanding of hypertension and intermediate phenotypes. It is anticipated that 
a clearer understanding of hypertension pathogenesis will lead to better targeted 
treatments and thereby reduce the burden of hypertension-related cardiovascular 
morbidity and mortality. In this case, we can suggest that hexadecanedioate will 
be shown as “low-hanging fruit” gathered at beginning of an effort that is 
eventually expected to not only alter our view of pathophysiology of hypertension, 
but also a promising focal point for novel treatment targets and clinical 
management.  
In conclusion, multiple in vivo, ex vivo and molecular techniques have been 
applied in identification of the role of hexadecanedioate in modulating of blood 
pressure. The data from this multilayered study supports our hypothesis and 
provides strong corroborative evidence of a causal role for hexadecandioate in 
blood pressure regulation and identifies novel targets; including ω- oxidation 
pathway and solute carrier organic anion mechanism in regulation of blood 
pressure. Further work needs to be prioritised to elucidate the underpinning 
mechanisms, to allow these findings to be translated ultimately into novel drugs 
for treatment of hypertension. 
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Appendices 
Table A 1: Biochemical compounds profiled in adipose tissues. 
Biochemical metabolites 
Super 
Pathway 
Sub Pathway 
Mean ±SEM Fold of change 
Welch's Two-
ample t-Test 
HEXA/Control 
Statistical Values 
Control HEXA p-value q-value 
tetradecanedioate Lipid Fatty Acid, Dicarboxylate 0.92 ± 0.04 1.10 ± 0.07 1.19 0.0451 0.9911 
hexadecanedioate Lipid Fatty Acid, Dicarboxylate 0.67 ± 0.07 1.36 ± 0.11 2.04 0.0008 0.3253 
octadecanedioate Lipid Fatty Acid, Dicarboxylate 0.86 ± 0.08 1.51 ± 0.28 1.76 0.0416 0.9911 
myristoylcarnitine Lipid 
Fatty Acid Metabolism (Acyl 
Carnitine) 
1.73 ± 0.46 0.78 ± 0.34 0.45 0.0592 0.9911 
oleoylcarnitine Lipid 
Fatty Acid Metabolism (Acyl 
Carnitine) 
1.86 ± 0.53 0.81 ± 0.14 0.44 0.0738 0.9911 
16-hydroxypalmitate Lipid Fatty Acid, Monohydroxy 0.91 ± 0.05 1.26 ± 0.15 1.39 0.082 0.9911 
1,2-dipalmitoleoyl-GPC 
(16:1/16:1)* 
Lipid Phospholipid Metabolism 0.76 ± 0.12 1.20 ± 0.09 1.58 0.0385 0.9911 
1-oleoyl-GPI (18:1)* Lipid Lysolipid 1.08 ± 0.25 0.59 ± 0.09 0.55 0.0826 0.9911 
1-palmitoleoylglycerol (16:1)* Lipid Monoacylglycerol 0.85 ± 0.16 1.35 ± 0.17 1.59 0.0574 0.9911 
sphingomyelin(d18:1/20:1, 
d18:2/20:0)* 
Lipid Sphingolipid Metabolism 0.85 ± 0.16 1.42 ± 0.31 1.67 0.096 0.9911 
taurocholate Lipid Primary Bile Acid Metabolism 0.33 ± 0.10 3.12 ± 1.38 9.55 0.0035 0.5904 
taurochenodeoxycholate Lipid Primary Bile Acid Metabolism 0.45 ± 0.20 3.07 ± 1.60 6.82 0.0151 0.9911 
tauro-alpha-muricholate Lipid Primary Bile Acid Metabolism 0.41 ± 0.16 1.92 ± 0.77 4.74 0.0706 0.9911 
tauro-beta-muricholate Lipid Primary Bile Acid Metabolism 0.25 ± 0.09 2.85 ± 1.09 11.24 0.0013 0.3253 
Taurodeoxycholate Lipid Secondary Bile Acid metabolism 0.33 ± 0.14 4.55 ± 2.67 13.98 0.0061 0.7659 
Sedoheptulose-7-hosphate Carbohydrate Pentose Phosphate Pathway 1.10 ± 0.0 0.96 ± 0.0 0.87 0.0416 0.9911 
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Table A 2: Biochemical compounds profiled in kidney tissues. 
Biochemical metabolites Super Pathway Sub Pathway 
Mean ±SEM 
Fold of change 
Welch's Two-
ample t-Test 
HEXA/Control 
Statistical Values 
Control HEXA p-value q-value 
3-phosphoserine Amino Acid 
Glycine, Serine and Threonine 
Metabolism 
1.25 ± 0.11 0.82 ± 0.09 0.66 0.0222 0.3176 
N-acetylasparagine Amino Acid Alanine and Aspartate Metabolism 1.12 ± 0.06 0.89 ± 0.04 0.79 0.0095 0.3176 
N-acetylglutamine Amino Acid Glutamate Metabolism 1.03 ± 0.04 0.91 ± 0.06 0.88 0.0989 0.4515 
1-methylhistidine Amino Acid Histidine Metabolism 1.034 ± 0.02 0.95 ± 0.03 0.92 0.0715 0.4515 
N-acetyl-3-methylhistidine* Amino Acid Histidine Metabolism 1.19 ± 0.14 0.84 ± 0.12 0.71 0.0998 0.4515 
imidazole lactate Amino Acid Histidine Metabolism 0.90 ± 0.04 1.09 ± 0.07 1.22 0.0433 0.3819 
1-methylimidazoleacetate Amino Acid Histidine Metabolism 0.77 ± 0.05 1.51 ± 0.16 1.96 0.0014 0.2872 
N2-acetyllysine Amino Acid Lysine Metabolism 1.16 ± 0.07 0.93 ± 0.03 0.80 0.0306 0.3176 
kynurenine Amino Acid Tryptophan Metabolism 0.91 ± 0.43 2.95 ± 1.14 3.25 0.0667 0.4515 
alpha-hydroxyisovalerate Amino Acid 
Leucine, Isoleucine and Valine 
Metabolism 
0.89 ± 0.04 1.29 ± 0.10 1.45 0.0062 0.3176 
N-acetylvaline Amino Acid 
Leucine, Isoleucine and Valine 
Metabolism 
1.10 ± 0.04 0.90 ± 0.042 0.82 0.0122 0.3176 
hypotaurine Amino Acid 
Methionine, Cysteine, SAM and 
Taurine Metabolism 
0.71 ± 0.08 1.37 ± 0.14 1.92 0.0027 0.2995 
taurine Amino Acid 
Methionine, Cysteine, SAM and 
Taurine Metabolism 
0.83 ± 0.08 1.52 ± 0.31 1.83 0.0815 0.4515 
taurocyamine Amino Acid 
Methionine, Cysteine, SAM and 
Taurine Metabolism 
1.18 ± 0.13 0.86 ± 0.10 0.73 0.0761 0.4515 
arginine Amino Acid 
Urea cycle; Arginine and Proline 
Metabolism 
0.91 ± 0.06 1.14 ± 0.10 1.26 0.0886 0.4515 
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proline Amino Acid 
Urea cycle; Arginine and Proline 
Metabolism 
0.96 ± 0.03 1.06 ± 0.02 1.11 0.0204 0.3176 
N-delta-acetylornithine Amino Acid 
Urea cycle; Arginine and Proline 
Metabolism 
0.88 ± 0.06 1.01 ± 0.03 1.15 0.0955 0.4515 
N-methylproline Amino Acid 
Urea cycle; Arginine and Proline 
Metabolism 
0.89 ± 0.06 1.04 ± 0.03 1.16 0.0374 0.3602 
creatine Amino Acid Creatine Metabolism 0.94 ± 0.02 1.07 ± 0.06 1.13 0.0985 0.4515 
guanidinoacetate Amino Acid Creatine Metabolism 0.89 ± 0.05 1.14 ± 0.04 1.28 0.0103 0.3176 
putrescine Amino Acid Polyamine Metabolism 0.76 ± 0.13 1.56 ± 0.20 2.05 0.0176 0.3176 
N-acetylputrescine Amino Acid Polyamine Metabolism 0.62 ± 0.01 1.15 ± 0.23 1.85 0.0738 0.4515 
guanidinosuccinate Amino Acid 
Guanidino and Acetamido 
Metabolism 
0.86 ± 0.09 1.16 ± 0.12 1.35 0.0866 0.4515 
glucose 6-phosphate Carbohydrate 
Glycolysis, Gluconeogenesis, and 
Pyruvate Metabolism 
1.16 ± 0.08 0.91 ± 0.05 0.79 0.0276 0.3176 
arabitol/xylitol Carbohydrate Pentose Metabolism 1.19 ± 0.09 0.91 ± 0.03 0.76 0.0182 0.3176 
maltotetraose Carbohydrate Glycogen Metabolism 0.79 ± 0.09 1.22 ± 0.09 1.53 0.0247 0.3176 
maltotriose Carbohydrate Glycogen Metabolism 0.86 ± 0.07 1.15 ± 0.06 1.34 0.0266 0.3176 
maltose Carbohydrate Glycogen Metabolism 0.92 ± 0.04 1.04 ± 0.02 1.13 0.0397 0.3653 
galactose 1-phosphate Carbohydrate 
Fructose, Mannose and Galactose 
Metabolism 
1.13 ± 0.08 0.94 ± 0.04 0.83 0.0526 0.4195 
glucuronate Carbohydrate Aminosugar Metabolism 1.13 ± 0.06 0.82 ±0.07 0.72 0.0173 0.3176 
tricarballylate Energy TCA Cycle 0.85 ± 0.08 1.28 ± 0.18 1.50 0.0523 0.4195 
myristate (14:0) Lipid Long Chain Fatty Acid 0.81 ± 0.06 1.88 ± 0.70 2.33 0.0853 0.4515 
myristoleate (14:1n5) Lipid Long Chain Fatty Acid 0.74 ± 0.09 1.73 ± 0.44 2.33 0.0195 0.3176 
palmitoleate (16:1n7) Lipid Long Chain Fatty Acid 0.76 ± 0.06 2.59 ± 0.03 3.42 0.08 0.4515 
10-heptadecenoate (17:1n7) Lipid Long Chain Fatty Acid 0.77 ± 0.09 2.57 ± 1.20 3.32 0.0636 0.4474 
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10-nonadecenoate (19:1n9) Lipid Long Chain Fatty Acid 0.80 ± 0.08 2.72 ± 1.40 3.39 0.0831 0.4515 
15-methylpalmitate Lipid Fatty Acid, Branched 0.81 ± 0.05 2.35 ± 1.12 2.90 0.0912 0.4515 
sebacate (decanedioate) Lipid Fatty Acid, Dicarboxylate 1.31 ± 0.15 0.89 ± 0.03 0.68 0.0245 0.3176 
hexadecanedioate Lipid Fatty Acid, Dicarboxylate 0.89 ± 0.01 1.31 ± 0.08 1.46 0.0029 0.2995 
malonylcarnitine Lipid Fatty Acid Synthesis 1.10 ± 0.05 0.87 ± 0.08 0.79 0.0405 0.3653 
butyrylcarnitine Lipid 
Fatty Acid Metabolism (Acyl 
Carnitine) 
0.67 ± 0.14 1.33 ± 0.16 1.99 0.0345 0.3492 
propionylcarnitine Lipid 
Fatty Acid Metabolism (Acyl 
Carnitine) 
0.91 ± 0.11 1.20 ± 1.04 1.32 0.0895 0.4515 
3-hydroxybutyrylcarnitine (2) Lipid 
Fatty Acid Metabolism (Acyl 
Carnitine) 
0.88 ± 0.05 1.06 ± 0.03 1.21 0.0304 0.3176 
3-hydroxybutyrate (BHBA) Lipid Ketone Bodies 0.88 ± 0.05 1.05 ± 0.03 1.20 0.0153 0.3176 
myo-inositol Lipid Inositol Metabolism 1.05 ± 0.02 0.97 ± 0.01 0.93 0.0105 0.3176 
trimethylamine N-oxide Lipid Phospholipid Metabolism 0.84 ± 0.09 1.47 ± 0.16 1.74 0.0181 0.3176 
1-palmitoyl-2-palmitoleoyl-GPC 
(16:0/16:1)* 
Lipid Phospholipid Metabolism 0.89 ± 0.05 1.24 ± 0.10 1.38 0.0166 0.3176 
1-stearoyl-2-arachidonoyl-GPI 
(18:0/20:4) 
Lipid Phospholipid Metabolism 1.05 ± 0.03 0.96 ± 0.03 0.91 0.0637 0.4474 
1-palmitoyl-2-oleoyl-GPG 
(16:0/18:1) 
Lipid Phospholipid Metabolism 0.88 ± 0.04 1.11 ± 0.04 1.26 0.0038 0.3161 
1-palmitoyl-2-oleoyl-GPE 
(16:0/18:1) 
Lipid Phospholipid Metabolism 0.89 ± 0.05 1.17 ± 0.08 1.31 0.0228 0.3176 
1-oleoyl-2-linoleoyl-GPE 
(18:1/18:2)*  
Lipid Phospholipid Metabolism 1.07 ± 0.05 0.94 ± 0.16 0.88 0.0954 0.4515 
1-palmitoleoyl-GPC (16:1)*  Lipid Lysolipid 0.79 ± 0.08 1.38 ± 0.05 1.73 0.0008 0.2872 
1-(1-enyl-palmitoyl)-2-
arachidonoyl-GPC (P-16:0/20:4)* 
Lipid Plasmalogen 1.09 ± 0.03 0.90 ± 0.04 0.83 0.0069 0.3176 
glycerol Lipid Glycerolipid Metabolism 0.81 ± 0.07 1.13 ± 0.09 1.40 0.0196 0.3176 
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1-palmitoleoylglycerol (16:1)* Lipid Monoacylglycerol 0.69 ± 0.13 3.07 ± 1.30 4.43 0.0226 0.3176 
sphingomyelin (d18:1/20:0, 
d16:1/22:0)* 
Lipid Sphingolipid Metabolism 1.06 ± 0.05 0.92 ± 0.04 0.87 0.0797 0.4515 
palmitoyl dihydrosphingomyelin 
(d18:0/16:0)*  
Lipid Sphingolipid Metabolism 1.06 ± 0.05 0.92 ± 0.05 0.87 0.0959 0.4515 
7-hydroxycholesterol (alpha or 
beta) 
Lipid Sterol 1.49 ± 0.31 0.79 ± 0.11 0.53 0.0634 0.4474 
glycocholate Lipid Primary Bile Acid Metabolism 1.35 ± 0.18 0.63 ±0.17 0.46 0.0565 0.4255 
chenodeoxycholate Lipid Primary Bile Acid Metabolism 1.49 ± 0.43 0.77 ± 0.23 0.51 0.0973 0.4515 
glycochenodeoxycholate Lipid Primary Bile Acid Metabolism 1.51 ± 0.29 0.65 ± 0.29 0.43 0.0548 0.4203 
tauro-alpha-muricholate Lipid Primary Bile Acid Metabolism 0.68 ± 0.13 1.17 ± 0.05 1.73 0.0285 0.3176 
tauro-beta-muricholate Lipid Primary Bile Acid Metabolism 0.60 ± 0.19 1.50 ± 0.26 2.50 0.0241 0.3176 
glycodeoxycholate Lipid Secondary Bile Acid Metabolism 1.75 ± 0.31 0.45 ± 0.16 0.26 0.0073 0.3176 
glycolithocholate Lipid Secondary Bile Acid Metabolism 1.56 ± 0.7 0.49 ± 0.19 0.31 0.0799 0.4515 
tauroursodeoxycholate Lipid Secondary Bile Acid Metabolism 0.68 ± 0.14 1.39 ± 0.18 2.06 0.0158 0.3176 
glycohyodeoxycholate Lipid Secondary Bile Acid Metabolism 1.26 ± 0.12 0.48 ± 0.214 0.38 0.0472 0.3994 
orotate Nucleotide 
Pyrimidine Metabolism, Orotate 
containing 
0.92 ± 0.05 1.39 ± 0.14 1.52 0.0176 0.3176 
pseudouridine Nucleotide 
Pyrimidine Metabolism, Uracil 
containing 
1.09 ± 0.06 0.96 ± 0.04 0.88 0.0917 0.4515 
1-methylnicotinamide 
Cofactors and 
Vitamins 
Nicotinate and Nicotinamide 
Metabolism 
1.40 ± 0.19 0.95 ± 0.05 0.68 0.0545 0.4203 
riboflavin (Vitamin B2) 
Cofactors and 
Vitamins 
Riboflavin Metabolism 1.09 ± 0.06 0.94 ± 0.03 0.86 0.0694 0.4515 
flavin adenine dinucleotide (FAD) 
Cofactors and 
Vitamins 
Riboflavin Metabolism 1.06 ± 0.03 0.97 ± 0.03 0.91 0.0405 0.3653 
flavin mononucleotide (FMN) 
Cofactors and 
Vitamins 
Riboflavin Metabolism 1.05 ± 0.03 0.93 ± 0.04 0.89 0.0273 0.3176 
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alpha-tocopherol 
Cofactors and 
Vitamins 
Tocopherol Metabolism 0.78 ± 0.15 1.12 ± 0.08 1.43 0.0843 0.4515 
5-methyltetrahydrofolate 
(5MeTHF) 
Cofactors and 
Vitamins 
Folate Metabolism 0.84 ± 0.07 1.19 ± 0.09 1.42 0.0184 0.3176 
pterin 
Cofactors and 
Vitamins 
Pterin Metabolism 1.30 ± 0.11 0.85 ± 0.10 0.65 0.0354 0.3497 
thiamin monophosphat 
Cofactors and 
Vitamins 
Thiamine Metabolism 1.07 ± 0.03 0.96 ± 0.03 0.90 0.0459 0.396 
thiamin diphosphate  
Cofactors and 
Vitamins 
Thiamine Metabolism 1.04 ± 0.03 0.89 ± 0.05 0.85 0.0587 0.4342 
retinol (Vitamin A) 
Cofactors and 
Vitamins 
Vitamin A Metabolism 0.63 ± 0.18 1.24 ± 0.12 1.96 0.0702 0.4515 
pyridoxamine phosphate 
Cofactors and 
Vitamins 
Vitamin A Metabolism 1.07 ± 0.03 0.95 ± 0.05 0.89 0.0829 0.4515 
hippurate Xenobiotics Benzoate Metabolism 0.88 ± 0.08 1.17 ± 0.09 1.32 0.0526 0.4195 
catechol sulfate Xenobiotics Benzoate Metabolism 0.66 ± 0.15 1.49 ± 0.40 2.25 0.0293 0.3176 
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Table A 3: Biochemical compounds profiled in brain tissues. 
Biochemical metabolites Super Pathway Sub Pathway 
Mean ±SEM 
Fold of Change 
Welch's Two-
Sample t-Test 
(HEXA/Control) 
Statistical Values 
Control HEXA p-value q-value 
N-acetyl-3-
methylhistidine* 
Amino acid Histidine Metabolism 1.24 ± 0.13 0.78 ± 0.18 0.63 0.0893 0.9868 
beta-hydroxyisovalerate Amino acid 
Leucine, Isoleucine and Valine 
Metabolism 
0.96 ± 0.06 1.21 ± 0.11 1.26 0.0854 0.9868 
alpha-hydroxyisovalerate Amino acid 
Leucine, Isoleucine and Valine 
Metabolism 
0.85 ± 0.08 1.11 ± 0.06 1.30 0.054 0.9868 
urea Amino acid 
Urea cycle; Arginine and Proline 
Metabolism 
0.94 ± 0.04 1.09 ± 0.05 1.17 0.0611 0.9868 
anserine Peptide Dipeptide Derivative 1.13 ± 0.07 0.77 ± 0.22 0.68 0.0917 0.9868 
myristate (14:0) Lipid Long Chain Fatty Acid 0.90 ± 0.05 1.11 ± 0.05 1.23 0.0184 0.9868 
palmitate (16:0) Lipid Long Chain Fatty Acid 0.89 ± 0.04 1.22 ± 0.09 1.36 0.0143 0.9868 
palmitoleate (16:1n7) Lipid Long Chain Fatty Acid 0.79 ± 0.09 1.11 ± 0.08 1.39 0.045 0.9868 
stearate (18:0) Lipid Long Chain Fatty Acid 0.87 ± 0.07 1.16 ± 0.07 1.33 0.0239 0.9868 
nonadecanoate (19:0) Lipid Long Chain Fatty Acid 0.91 ± 0.05 1.07 ± 0.07 1.18 0.0878 0.9868 
arachidate (20:0) Lipid Long Chain Fatty Acid 0.94 ± 0.04 1.09 ± 0.07 1.16 0.0742 0.9868 
oleate/vaccenate (18:1) Lipid Long Chain Fatty Acid 0.90 ± 0.02 1.31 ± 0.09 1.45 0.0061 0.9175 
eicosapentaenoate (EPA; 
20:5n3) 
Lipid 
Polyunsaturated Fatty Acid (n3 and 
n6) 
0.87 ± 0.09 1.23 ± 0.14 1.42 0.0593 0.9868 
docosahexaenoate (DHA; 
22:6n3) 
Lipid 
Polyunsaturated Fatty Acid (n3 and 
n6) 
0.88 ± 0.02 1.33 ± 0.10 1.52 0.0036 0.9175 
linoleate (18:2n6) Lipid 
Polyunsaturated Fatty Acid (n3 and 
n6) 
0.79 ± 0.09 1.06 ± 0.07 1.33 0.0651 0.9868 
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dihomo-linolenate (20:3n3 
or n6) 
Lipid 
Polyunsaturated Fatty Acid (n3 and 
n6) 
0.87 ± 0.09 1.29 ± 0.07 1.49 0.0103 0.9868 
arachidonate (20:4n6) Lipid 
Polyunsaturated Fatty Acid (n3 and 
n6) 
0.88 ± 0.06 1.27 ± 0.12 1.44 0.0178 0.9868 
adrenate (22:4n6) Lipid 
Polyunsaturated Fatty Acid (n3 and 
n6) 
0.88 ± 0.05 1.34 ± 0.10 1.52 0.0043 0.9175 
docosapentaenoate (n6 
DPA; 22:5n6) 
Lipid 
Polyunsaturated Fatty Acid (n3 and 
n6) 
0.84 ± 0.09 1.32 ± 0.17 1.58 0.0352 0.9868 
dihomo-linoleate (20:2n6) Lipid 
Polyunsaturated Fatty Acid (n3 and 
n6) 
0.89 ± 0.06 1.23 ± 0.14 1.37 0.0784 0.9868 
1-stearoyl-2-oleoyl-GPE 
(18:0/18:1) 
Lipid Phospholipid Metabolism 0.92 ± 0.06 1.15 ± 0.09 1.24 0.0781 0.9868 
1-stearoyl-GPI (18:0) Lipid Lysolipid 0.77 ± 0.11 1.23 ± 0.15 1.60 0.0402 0.9868 
sphingosine Lipid Sphingolipid Metabolism 0.94 ± 0.03 1.11 ± 0.08 1.19 0.0887 0.9868 
4-cholesten-3-one Lipid Sterol 0.92 ± 0.21 0.49 ± 0.0 0.54 0.0895 0.9868 
corticosterone Lipid Steroid 0.78 ± 0.21 1.20 ± 0.13 1.54 0.0773 0.9868 
adenosine 3'-
monophosphate (3'-AMP) 
Nucleotide 
Purine Metabolism, Adenine 
containing 
1.19 ± 0.10 0.80 ± 0.12 0.68 0.0599 0.9868 
flavin adenine dinucleotide 
(FAD) 
Cofactors and 
Vitamins 
Riboflavin Metabolism 0.99 ± 0.01 1.09 ± 0.05 1.11 0.0877 0.9868 
coenzyme A 
Cofactors and 
Vitamins 
Pantothenate and CoA Metabolism 1.17 ± 0.10 0.91 ± 0.10 0.77 0.0985 0.9868 
dihydrobiopterin 
Cofactors and 
Vitamins 
Tetrahydrobiopterin Metabolism 0.83 ± 0.08 1.20 ± 0.12 1.45 0.037 0.9868 
pyridoxamine phosphate 
Cofactors and 
Vitamins 
Vitamin B6 Metabolism 0.97 ± 0.03 1.06 ± 0.04 1.09 0.0984 0.9868 
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Table A 4: Biochemical compounds profiled in liver tissues. 
Biochemical metabolites 
Super 
Pathway 
Sub Pathway 
Mean ±SEM 
Fold of Change 
Welch's Two-
Sample t-Test 
(HEXA/Control) 
Statistical Values 
Control HEXA p-value q-value 
glycine Amino Acid  
Glycine, Serine and Threonine 
Metabolism 
1.06 ± 0.03 0.97 ± 0.03 0.91 0.074 0.4467 
betaine Amino Acid  
Glycine, Serine and Threonine 
Metabolism 
1.05 ± 0.05 0.90 ± 0.05 0.86 0.0543 0.4467 
betaine aldehyde Amino Acid  
Glycine, Serine and Threonine 
Metabolism 
1.04 ± 0.05 0.91 ± 0.05 0.88 0.0831 0.4467 
N-acetylglutamate Amino Acid  Glutamate Metabolism 1.08 ± 0.04 0.87 ± 0.06 0.80 0.0261 0.4467 
4-hydroxyglutamate Amino Acid  Glutamate Metabolism 1.19 ± 0.09 0.97 ± 0.03 0.81 0.0724 0.4467 
histidine Amino Acid  Histidine Metabolism 1.03 ± 0.01 0.96 ±0.03 0.93 0.0998 0.4467 
imidazole lactate Amino Acid  Histidine Metabolism 0.87 ± 0.06 1.09 ± 0.07 1.25 0.04 0.4467 
1-methylimidazoleacetate Amino Acid  Histidine Metabolism 0.79 ± 0.08 1.52 ± 0.20 1.91 0.0052 0.4467 
4-imidazoleacetate Amino Acid  Histidine Metabolism 0.79 ± 0.11 1.12 ± 0.09 1.41 0.0598 0.4467 
N-acetyltyrosine Amino Acid  
Phenylalanine and Tyrosine 
Metabolism 
1.26 ± 0.01 0.90 ± 0.07 0.72 0.0559 0.4467 
o-Tyrosine Amino Acid  
Phenylalanine and Tyrosine 
Metabolism 
1.12 ± 0.04 0.93 ± 0.032 0.82 0.0051 0.4467 
N-acetyltryptophan Amino Acid  Tryptophan Metabolism 1.15 ± 0.12 0.85 ± 0.09 0.74 0.0976 0.4467 
N-acetylleucine Amino Acid  
Leucine, Isoleucine and Valine 
Metabolism 
1.22 ± 0.11 0.93 ± 0.07 0.76 0.0574 0.4467 
4-methyl-2-oxopentanoate Amino Acid  
Leucine, Isoleucine and Valine 
Metabolism 
1.12 ± 0.09 0.92 ± 0.55 0.82 0.0984 0.4467 
N-acetylisoleucine Amino Acid  
Leucine, Isoleucine and Valine 
Metabolism 
1.11 ± 0.08 0.89 ± 0.06 0.80 0.0653 0.4467 
valine Amino Acid  
Leucine, Isoleucine and Valine 
Metabolism 
1.05 ± 0.03 0.96 ± 0.04 0.91 0.0967 0.4467 
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S-adenosylhomocysteine 
(SAH) 
Amino Acid  
Methionine, Cysteine, SAM and 
Taurine Metabolism 
1.09 ± 0.05 0.96 ± 0.03 0.88 0.0372 0.4467 
S-methylcysteine Amino Acid  
Methionine, Cysteine, SAM and 
Taurine Metabolism 
1.07 ± 0.03 0.91 ± 0.04 0.85 0.0123 0.4467 
taurocyamine Amino Acid  
Methionine, Cysteine, SAM and 
Taurine Metabolism 
1.16 ± 0.04 0.92 ± 0.04 0.80 0.0052 0.4467 
ornithine Amino Acid  
Urea cycle; Arginine and Proline 
Metabolism 
1.12 ± 0.09 0.92 ± 0.06 0.82 0.0982 0.4467 
N-delta-acetylornithine Amino Acid  
Urea cycle; Arginine and Proline 
Metabolism 
0.95 ± 0.06 1.16 ± 0.08 1.22 0.0684 0.4467 
cysteine-glutathione 
disulfide 
Amino Acid  Glutathione Metabolism 0.67 ± 0.08 1.09 ± 0.17 1.61 0.0591 0.4467 
5-oxoproline Amino Acid  Glutathione Metabolism 1.09 ±0.05 0.88 ± 0.04 0.81 0.0078 0.4467 
gamma-glutamylglycine Peptide Gamma-glutamyl Amino Acid 1.15 ± 0.05 0.96 ± 0.02 0.83 0.0106 0.4467 
gamma-
glutamylmethionine 
Peptide Gamma-glutamyl Amino Acid 1.08 ± 0.04 0.93 ± 0.06 0.86 0.0596 0.4467 
gamma-glutamyltyrosine Peptide Gamma-glutamyl Amino Acid 1.08 ± 0.06 0.91 ±0.06 0.85 0.0821 0.4467 
gamma-glutamylvaline Peptide Gamma-glutamyl Amino Acid 1.18 ± 0.08 0.92 ± 0.12 0.78 0.0925 0.4467 
arabonate/xylonate Carbohydrate Pentose Metabolism 1.23 ± 0.15 0.88 ± 0.13 0.71 0.0815 0.4467 
UDP-glucuronate Carbohydrate Nucleotide Sugar 0.79 ± 0.05 1.22 ± 0.17 1.55 0.0502 0.4467 
UDP-N-
acetylgalactosamine 
Carbohydrate Nucleotide Sugar 0.82 ± 0.09 1.17 ± 0.08 1.42 0.0295 0.4467 
glucuronate Carbohydrate Aminosugar Metabolism 1.09 ± 0.06 0.85 ± 0.08 0.78 0.0505 0.4467 
N-acetyl-glucosamine 1-
phosphate 
Carbohydrate Aminosugar Metabolism 0.83 ± 0.02 1.35 ± 0.02 1.62 0.0889 0.4467 
alpha-ketoglutarate Energy TCA Cycle 1.23 ± 0.0 0.93 ± 0.0 0.76 0.0905 0.4467 
phosphate Energy Oxidative Phosphorylation 1.04 ± 0.0 0.96 ± 0.0 0.92 0.0264 0.4467 
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margarate (17:0) Lipid Long Chain Fatty Acid 0.94 ± 0.06 1.13 ± 0.07 1.20 0.0687 0.4467 
10-heptadecenoate 
(17:1n7) 
Lipid Long Chain Fatty Acid 0.92 ± 0.10 1.18 ± 0.08 1.27 0.0804 0.4467 
10-nonadecenoate 
(19:1n9) 
Lipid Long Chain Fatty Acid 0.87 ± 0.18 1.35 ± 0.18 1.56 0.0765 0.4467 
stearidonate (18:4n3) Lipid 
Polyunsaturated Fatty Acid (n3 and 
n6) 
1.08 ± 0.07 0.91 ± 0.04 0.84 0.0814 0.4467 
dihomo-linoleate (20:2n6) Lipid 
Polyunsaturated Fatty Acid (n3 and 
n6) 
0.90 ± 0.09 1.19 ± 0.10 1.33 0.0571 0.4467 
15-methylpalmitate Lipid Fatty Acid, Branched 0.93 ± 0.04 1.60 ± 0.26 1.72 0.0469 0.4467 
17-methylstearate Lipid Fatty Acid, Branched 0.98 ± 0.08 1.42 ± 0.22 1.44 0.0999 0.4467 
hexadecanedioate Lipid Fatty Acid, Dicarboxylate 0.90 ± 0.05 1.23 ± 0.13 1.37 0.0421 0.4467 
hexanoylglycine Lipid Fatty Acid Metabolism (Acyl Glycine) 1.08 ± 0.04 0.80 ± 0.07 0.74 0.016 0.4467 
linoleoylcarnitine* Lipid 
Fatty Acid Metabolism (Acyl 
Carnitine) 
0.93 ± 0.05 1.07 ± 0.04 1.15 0.054 0.4467 
4-hydroxybutyrate (GHB) Lipid Fatty Acid, Monohydroxy 0.96 ± 0.04 1.12 ± 0.05 1.17 0.0442 0.4467 
2-hydroxypalmitate Lipid Fatty Acid, Monohydroxy 1.07 ± 0.04 0.92 ± 0.04 0.86 0.0224 0.4467 
prostaglandin F2alpha Lipid Eicosanoid 1.28 ± 0.15 0.81 ± 0.09 0.63 0.0238 0.4467 
1-stearoyl-2-linoleoyl-GPC 
(18:0/18:2)* 
Lipid Phospholipid Metabolism 0.91 ± 0.05 1.05 ± 0.05 1.15 0.0942 0.4467 
1-oleoyl-2-linolenoyl-GPC 
(18:1/18:3) 
Lipid Phospholipid Metabolism 0.65 ± 0.14 1.18 ± 0.19 1.81 0.0991 0.4467 
1-stearoyl-2-linoleoyl-GPE 
(18:0/18:2)* 
Lipid Phospholipid Metabolism 0.96 ± 0.03 1.09 ± 0.05 1.15 0.0579 0.4467 
1,2-dioleoyl-GPE 
(18:1/18:1) 
Lipid Phospholipid Metabolism 0.97 ± 0.01 1.09 ± 0.05 1.12 0.0951 0.4467 
1,2-dilinoleoyl-GPC 
(18:2/18:2) 
Lipid Phospholipid Metabolism 0.85 ± 0.08 1.06 ± 0.06 1.24 0.0707 0.4467 
1-oleoyl-2-linoleoyl-GPE 
(18:1/18:2)* 
Lipid Phospholipid Metabolism 0.98 ± 0.02 1.08 ± 0.03 1.10 0.0449 0.4467 
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1,2-distearoyl-GPC 
(18:0/18:0) 
Lipid Phospholipid Metabolism 0.89 ± 0.06 1.06 ± 0.04 1.18 0.0631 0.4467 
1-linoleoyl-2-
arachidonoyl-GPC 
(18:2/20:4)* 
Lipid Phospholipid Metabolism 0.95 ± 0.03 1.11 ± 0.08 1.18 0.0888 0.4467 
1-lignoceroyl-GPC (24:0) Lipid Lysolipid 0.90 ± 0.05 1.07 ± 0.05 1.18 0.0364 0.4467 
1-(1-enyl-stearoyl)-2-
oleoyl-GPE (P-18:0/18:1) 
Lipid Plasmalogen 0.91 ± 0.04 1.07 ± 0.06 1.17 0.0681 0.4467 
1-(1-enyl-stearoyl)-2-
linoleoyl-GPE (P-
18:0/18:2)* 
Lipid Plasmalogen 0.89 ± 0.06 1.12 ± 0.06 1.26 0.0227 0.4467 
1-(1-enyl-stearoyl)-2-
arachidonoyl-GPE (P-
18:0/20:4)* 
Lipid Plasmalogen 0.97 ± 0.02 1.07 ± 0.04 1.11 0.0539 0.4467 
1-myristoylglycerol (14:0) Lipid Monoacylglycerol 0.82 ± 0.08 1.66 ± 0.51 2.04 0.0935 0.4467 
N-palmitoyl-sphinganine 
(d18:0/16:0) 
Lipid Sphingolipid Metabolism 0.92 ± 0.04 1.12 ± 0.07 1.22 0.0483 0.4467 
behenoyl sphingomyelin 
(d18:1/22:0)* 
Lipid Sphingolipid Metabolism 0.94 ± 0.04 1.08 ± 0.04 1.14 0.0426 0.4467 
sphingomyelin 
(d18:1/21:0, d17:1/22:0, 
d16:1/23:0)* 
Lipid Sphingolipid Metabolism 0.94 ± 0.05 1.14 ± 0.08 1.21 0.0749 0.4467 
tricosanoyl sphingomyelin 
(d18:1/23:0)* 
Lipid Sphingolipid Metabolism 0.84 ± 0.05 1.14 ± 0.11 1.35 0.0338 0.4467 
cholesterol Lipid Sterol 0.92 ± 0.03 1.03 ± 0.01 1.12 0.0106 0.4467 
campesterol Lipid Sterol 0.89 ± 0.05 1.07 ± 0.04 1.20 0.0241 0.4467 
tauro-alpha-muricholate Lipid Primary Bile Acid Metabolism 0.66 ± 0.18 1.48 ± 0.33 2.23 0.0542 0.4467 
tauro-beta-muricholate Lipid Primary Bile Acid Metabolism 0.71 ± 0.14 2.25 ± 0.67 3.16 0.0472 0.4467 
glycodeoxycholate Lipid Secondary Bile Acid Metabolism 1.67 ± 0.44 0.45 ± 0.16 0.27 0.0179 0.4467 
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3-methylcytidine Nucleotide 
Purine Metabolism, Adenine 
containing 
1.09 ± 0.05 0.86 ± 0.08 0.78 0.0751 0.4467 
5-methylcytidine Nucleotide 
Purine Metabolism, Adenine 
containing 
1.07 ± 0.03 0.95 ± 0.02 0.88 0.0159 0.4467 
quinolinate 
Cofactors and 
Vitamins 
Purine Metabolism, Adenine 
containing 
0.88 ± 0.11 1.24 ± 0.14 1.41 0.0561 0.4467 
N1-Methyl-2-pyridone-5-
carboxamide 
Cofactors and 
Vitamins e 
Nicotinate and Nicotinamide 
Metabolism 
1.09 ± 0.12 0.78 ± 0.10 0.71 0.0552 0.4467 
pyridoxal 
Cofactors and 
Vitamins 
Vitamin B6 Metabolism 1.06 ± 0.05 0.94 ± 0.05 0.88 0.0693 0.4467 
pyridoxate 
Cofactors and 
Vitamins 
Vitamin B6 Metabolism 1.44 ± 0.19 0.86 ± 0.08 0.60 0.0568 0.4467 
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Table A 5: Biochemical compounds profiled in aorta tissues. 
Biochemical metabolites 
Super 
Pathway 
Sub Pathway 
Mean ±SEM 
Fold of Change 
Welch's Two-
Sample t-Test 
(HEXA/Control) 
Statistical Values 
Control HEXA p-value q-value 
glycine Amino acids 
Glycine, Serine and Threonine 
Metabolism 
1.41 ± 0.72 1.13 ± 0.054 0.80 0.0122 0.6182 
serine Amino acids 
Glycine, Serine and Threonine 
Metabolism 
1.34 ± 0.05 1.12 ± 0.96 0.84 0.0953 0.6182 
asparagine Amino acids 
Alanine and Aspartate 
Metabolism 
0.89 ± 0.02 0.79 ± 0.04 0.89 0.0606 0.6182 
pyroglutamine* Amino acids Glutamate Metabolism 1.56 ± 0.06 1.23 ± 0.11 0.79 0.0471 0.6182 
histidine Amino acids Histidine Metabolism 1.47 ± 0.10 1.18 ± 0.09 0.8 0.0652 0.6182 
imidazole lactate Amino acids Histidine Metabolism 0.73 ± 0.05 1.00 ± 0.11 1.38 0.0769 0.6182 
phenyllactate (PLA) Amino acids 
Phenylalanine and Tyrosine 
Metabolism 
0.82 ± 0.07 0.99 ± 0.05 1.21 0.0723 0.6182 
3-methoxytyrosine Amino acids 
Phenylalanine and Tyrosine 
Metabolism 
1.08 ± 0.12 0.73 ± 0.15 0.68 0.0953 0.6182 
indolelactate Amino acids Tryptophan Metabolism 1.13 ± 0.07 1.43 ± 0.11 1.27 0.0497 0.6182 
valine Amino acids Leucine, Isoleucine and Valine 1.84 ± 0.08 1.56 ± 0.11 0.84 0.0805 0.6182 
taurocyamine Amino acids 
Methionine, Cysteine, SAM 
and Taurine Metabolism 
0.63 ± 0.03 0.49 ± 0.03 0.78 0.0141 0.6182 
creatinine Amino acids Creatine Metabolism 0.55 ± 0.03 0.47 ± 0.02 0.85 0.0561 0.6182 
gamma-glutamylglycine Amino acids Gamma-glutamyl Amino Acid 1.75 ± 0.47 0.95 ± 0.12 0.54 0.0787 0.6182 
gamma-glutamylvaline Amino acids Gamma-glutamyl Amino Acid 0.86 ± 0.09 1.17 ± 0.11 1.35 0.0756 0.6182 
1,5-anhydroglucitol (1,5-AG) Carbohydrate 
Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
1.06 ± 0.09 0.81 ± 0.05 0.77 0.0457 0.6182 
mannitol/sorbitol Carbohydrate 
Fructose, Mannose and 
Galactose Metabolism 
0.56 ± 0.04 0.72 ± 0.06 1.29 0.0371 0.6182 
citrate Energy TCA Cycle 1.14 ± 0.10 1.62 ± 0.27 1.43 0.0992 0.6182 
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succinylcarnitine Energy TCA Cycle 0.43 ± 0.07 0.77 ± 0.13 1.79 0.0473 0.6182 
arachidonate (20:4n6) Lipid 
Polyunsaturated Fatty Acid 
(n3 and n6) 
1.77 ± 0.14 1.29 ± 0.15 0.72 0.0525 0.6182 
12-HETE Lipid Eicosanoid 2.10 ± 0.19 1.51 ± 0.24 0.74 0.0908 0.6182 
1,2-dipalmitoyl-GPC 
(16:0/16:0) 
Lipid Phospholipid Metabolism 1.12 ± 0.03 0.99 ± 0.03 0.89 0.0186 0.6182 
1-oleoyl-2-linoleoyl-GPC 
(18:1/18:2)* 
Lipid Phospholipid Metabolism 1.17 ± 0.08 0.97 ± 0.03 0.82 0.0528 0.6182 
1-palmitoyl-2-stearoyl-GPC 
(16:0/18:0) 
Lipid Phospholipid Metabolism 1.19 ± 0.02 1.02 ± 0.04 0.86 0.0112 0.6182 
1-stearoyl-2-oleoyl-GPG 
(18:0/18:1) 
Lipid Phospholipid Metabolism 0.69 ± 0.09 0.93 ± 0.04 1.33 0.0718 0.6182 
1-linoleoyl-2-arachidonoyl-
GPC (18:2/20:4n6)* 
Lipid Phospholipid Metabolism 1.19 ± 0.10 0.86 ± 0.08 0.72 0.0398 0.6182 
1-palmitoyl-GPE (16:0) Lipid Lysolipid 2.19 ± 0.14 1.62 ± 0.11 0.74 0.008 0.6182 
1-stearoyl-GPE (18:0) Lipid Lysolipid 2.08 ± 0.16 1.50 ± 0.14 0.72 0.0264 0.6182 
1-oleoyl-GPE (18:1) Lipid Lysolipid 2.70 ± 0.24 1.9 ± 0.09 0.71 0.0219 0.6182 
1-(1-enyl-palmitoyl)-2-
arachidonoyl-GPE (P-
16:0/20:4)* 
Lipid Plasmalogen 1.00 ± 0.03 0.89 ± 0.03 0.88 0.0197 0.6182 
1-(1-enyl-stearoyl)-2-
arachidonoyl-GPE (P-
18:0/20:4)* 
Lipid Plasmalogen 1.00 ± 0.03 0.88 ± 0.04 0.88 0.0584 0.6182 
1-(1-enyl-palmitoyl)-GPE (P-
16:0)* 
Lipid Lysoplasmalogen 1.38 ± 0.16 0.94 ± 0.05 0.68 0.0309 0.6182 
1-(1-enyl-oleoyl)-GPE (P-
18:1)* 
Lipid Lysoplasmalogen 1.43 ± 0.19 0.96 ± 0.06 0.67 0.0478 0.6182 
N-palmitoyl-sphingosine 
(d18:1/16:0) 
Lipid Sphingolipid Metabolism 2.4 ± 0.21 1.85 ± 0.12 0.77 0.0638 0.6182 
tauro-beta-muricholate Lipid Primary Bile Acid Metabolism 0.32 ± 0.13 2.12 ± 0.88 6.55 0.0029 0.6182 
deoxycholate Lipid 
Secondary Bile Acid 
Metabolism 
0.42 ± 0.00 0.79 ± 0.19 1.91 0.0917 0.6182 
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glycodeoxycholate Lipid 
Secondary Bile Acid 
Metabolism 
1.12 ± 0.23 0.45 ± 0.05 0.40 0.0337 0.6182 
N1-methyladenosine Nucleotide 
Purine Metabolism, Adenine 
containing 
0.80 ± 0.06 0.62 ± 0.06 0.72 0.0134 0.6182 
N6-succinyladenosine Nucleotide 
Purine Metabolism, Adenine 
containing 
0.20 ± 0.05 0.35 ± 0.05 1.70 0.061 0.6182 
2'-deoxyuridine Nucleotide 
Pyrimidine Metabolism, Uracil 
containing 
1.28 ± 0.06 0.72 ± 0.09 0.57 0.0079 0.6182 
cytosine Nucleotide 
Pyrimidine Metabolism, 
Cytidine containing 
0.97 ± 0.14 1.40 ± 0.17 1.45 0.0919 0.6182 
nicotinate ribonucleoside 
Cofactors 
and Vitamins 
Nicotinate and Nicotinamide 
Metabolism 
0.92 ± 0.06 0.75 ± 0.02 0.82 0.0432 0.6182 
nicotinamide adenine 
dinucleotide (NAD+) 
Cofactors 
and Vitamins 
Nicotinate and Nicotinamide 
Metabolism 
0.91 ± 0.07 1.42 ± 0.16 1.55 0.0187 0.6182 
pyridoxate 
Cofactors 
and Vitamins 
Vitamin B6 Metabolism 2.34 ± 0.32 1.53 ± 0.22 0.65 0.0614 0.6182 
catechol sulfate Xenobiotics Benzoate Metabolism 0.84 ± 0.22 1.37 ± 0.15 1.63 0.0955 0.6182 
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Table A 6: Biochemical compounds profiled in heart tissues. 
Biochemical metabolites 
Super 
Pathway 
Sub Pathway 
Mean ±SEM 
Fold of Change 
Welch's Two-
Sample t-Test 
(HEXA/Control) 
Statistical Values 
Control HEXA p-value q-value 
threonine Amino acids 
Glycine, Serine and 
Threonine Metabolism 
0.61 ± 0.02 0.72 ± 0.02 1.18 0.0053 0.2036 
asparagine Amino acids 
Alanine and Aspartate 
Metabolism 
1.17 ± 0.04 1.29 ± 0.03 1.11 0.038 0.2036 
N-acetylaspartate (NAA) Amino acids 
Alanine and Aspartate 
Metabolism 
1.67 ± 0.04 1.33 ± 0.05 0.8 0.0018 0.2036 
N-acetylglutamine Amino acids Glutamate Metabolism 1.32 ± 0.11 1.09 ± 0.04 0.82 0.0903 0.2036 
1-methylimidazoleacetate Amino acids Histidine Metabolism 0.53 ± 0.06 0.79 ± 0.07 1.47 0.0313 0.2036 
N6,N6,N6-trimethyllysine Amino acids Lysine Metabolism 0.89 ± 0.05 1.02 ± 0.04 1.15 0.0948 0.2036 
phenyllactate (PLA) Amino acids 
Phenylalanine and Tyrosine 
Metabolism 
0.82 ± 0.05 1.33 ± 0.21 1.63 0.0482 0.2036 
tyrosine Amino acids 
Phenylalanine and Tyrosine 
Metabolism 
0.57 ± 0.04 0.67 ± 0.03 1.18 0.0584 0.2036 
3-(4-hydroxyphenyl)lactate Amino acids 
Phenylalanine and Tyrosine 
Metabolism 
1.49 ± 0.05 1.82 ± 0.08 1.22 0.0529 0.2036 
tryptophan Amino acids Tryptophan Metabolism 0.63 ± 0.04 0.74 ± 0.01 1.19 0.0427 0.2036 
C-glycosyltryptophan Amino acids Tryptophan Metabolism 0.99 ± 0.05 1.304 ± 0.06 1.32 0.01 0.2036 
leucine Amino acids 
Leucine, Isoleucine and 
Valine Metabolism 
0.57 ± 0.05 0.67 ± 0.02 1.18 0.0837 0.2036 
beta-
hydroxyisovaleroylcarnitine 
Amino acids 
Leucine, Isoleucine and 
Valine Metabolism 
1.65 ± 0.12 2.07 ± 0.14 1.26 0.0444 0.2036 
alpha-hydroxyisovaleroyl 
carnitine* 
Amino acids 
Leucine, Isoleucine and 
Valine Metabolism 
0.86 ± 0.11 1.15 ± 0.07 1.34 0.0907 0.2036 
methylsuccinate Amino acids 
Leucine, Isoleucine and 
Valine Metabolism 
1.71 ± 0.17 1.17 ± 0.07 0.68 0.0141 0.2036 
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isoleucine Amino acids 
Leucine, Isoleucine and 
Valine Metabolism 
0.71 ± 0.03 0.82 ± 0.02 1.16 0.0266 0.2036 
tiglylcarnitine Amino acids 
Leucine, Isoleucine and 
Valine Metabolism 
1.47 ± 0.12 2.02 ± 0.10 1.37 0.0108 0.2036 
methionine Amino acids 
Methionine, Cysteine, SAM 
and Taurine Metabolism 
0.67 ± 0.04 0.80 ± 0.02 1.20 0.0266 0.2036 
S-adenosylmethionine 
(SAM) 
Amino acids 
Methionine, Cysteine, SAM 
and Taurine 
1.39 ± 0.07 1.66 ± 0.07 1.19 0.0254 0.2036 
S-adenosylhomocysteine 
(SAH) 
Amino acids 
Methionine, Cysteine, SAM 
and Taurine Metabolism 
0.81 ± 0.07 0.97 ± 0.05 1.20 0.0782 0.2036 
argininosuccinate Amino acids 
Urea cycle; Arginine and 
Proline Metabolism 
1.10 ± 0.06 1.43 ± 0.12 1.29 0.0438 0.2036 
dimethylarginine (SDMA + 
ADMA) 
Amino acids 
Urea cycle; Arginine and 
Proline Metabolism 
0.89 ± 0.05 1.06 ± 0.06 1.18 0.0541 0.2036 
N-delta-acetylornithine Amino acids 
Urea cycle; Arginine and 
Proline Metabolism 
1.15 ± 0.05 1.36 ± 0.08 1.18 0.079 0.2036 
glucose Carbohydrate 
Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
0.74 ± 0.06 0.96 ± 0.09 1.30 0.0822 0.2036 
glucose 6-phosphate Carbohydrate 
Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
0.77 ± 0.15 1.42 ± 0.28 1.85 0.0692 0.2036 
3-phosphoglycerate Carbohydrate 
Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
2.87 ± 0.59 1.67 ± 0.12 0.58 0.0929 0.2036 
ribulose/xylulose Carbohydrate Pentose Metabolism 2.03 ± 0.23 2.70 ± 0.16 1.33 0.0649 0.2036 
maltotetraose Carbohydrate Glycogen Metabolism 0.46 ± 0.11 1.40 ± 0.60 3.02 0.0925 0.2036 
maltotriose Carbohydrate Glycogen Metabolism 0.47 ± 0.08 1.07 ± 0.27 2.27 0.0431 0.2036 
maltose Carbohydrate Glycogen Metabolism 0.473 ± 0.05 0.86 ± 0.11 1.82 0.0132 0.2036 
fructose Carbohydrate 
Fructose, Mannose and 
Galactose Metabolism 
1.31 ± 0.22 2.12 ± 0.19 1.61 0.055 0.2036 
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glucosamine-6-phosphate Carbohydrate Aminosugar Metabolism 0.82 ± 0.16 1.52 ± 0.25 1.85 0.0619 0.2036 
N-acetylneuraminate Carbohydrate Aminosugar Metabolism 1.59 ± 0.10 1.96 ± 0.10 1.23 0.042 0.2036 
fumarate Energy TCA Cycle 1.14 ± 0.03 1.28 ± 0.03 1.12 0.0144 0.2036 
phosphate Energy Oxidative Phosphorylation 1.55 ± 0.05 1.38 ± 0.05 0.89 0.0382 0.2036 
linoleate (18:2n6) Lipid 
Polyunsaturated Fatty Acid 
(n3 and n6) 
0.22 ± 0.13 0.52 ± 0.16 2.39 0.0955 0.2036 
hexadecanedioate Lipid Fatty Acid, Dicarboxylate 0.63 ± 0.06 0.98 ± 0.08 1.57 0.0091 0.2036 
malonylcarnitine Lipid Fatty Acid Synthesis 1.69 ± 0.05 1.91 ± 0.09 1.13 0.0546 0.2036 
butyrylcarnitine Lipid 
Fatty Acid Metabolism (also 
BCAA Metabolism) 
0.59 ± 0.27 1.19 ± 0.10 1.99 0.0801 0.2036 
3-hydroxybutyrylcarnitine 
(1) 
Lipid 
Fatty Acid Metabolism(Acyl 
Carnitine) 
2.26 ± 0.24 3.03 ± 0.21 1.34 0.0377 0.2036 
3-hydroxybutyrylcarnitine 
(2) 
Lipid 
Fatty Acid Metabolism(Acyl 
Carnitine) 
2.24 ± 0.31 3.64 ± 0.31 1.62 0.0188 0.2036 
palmitoylcarnitine Lipid 
Fatty Acid Metabolism(Acyl 
Carnitine) 
0.76 ± 0.19 1.72 ± 0.36 2.28 0.0409 0.2036 
stearoylcarnitine Lipid 
Fatty Acid Metabolism(Acyl 
Carnitine) 
0.45 ± 0.14 1.65 ± 0.48 3.65 0.0241 0.2036 
linoleoylcarnitine* Lipid 
Fatty Acid Metabolism (Acyl 
Carnitine) 
0.49 ± 0.08 2.83 ± 0.71 5.72 0.0022 0.2036 
oleoylcarnitine Lipid 
Fatty Acid Metabolism (Acyl 
Carnitine) 
0.51 ± 0.02 3.81 ± 1.14 7.48 0.0076 0.2036 
myo-inositol Lipid Inositol Metabolism 0.29 ± 0.005 0.27 ± 0.002 0.93 0.0078 0.2036 
phosphoethanolamine Lipid Phospholipid Metabolism 0.78 ± 0.03 0.68 ± 0.023 0.87 0.0324 0.2036 
trimethylamine N-oxide Lipid Phospholipid Metabolism 0.79 ± 0.14 1.37 ± 0.07 1.74 0.026 0.2036 
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1-palmitoyl-2-linoleoyl-
GPC (16:0/18:2) 
Lipid Phospholipid Metabolism 0.48 ± 0.14 0.92 ± 0.07 1.91 0.071 0.2036 
1,2-dioleoyl-GPC 
(18:1/18:1)* 
Lipid Phospholipid Metabolism 0.33 ± 0.11 0.76 ± 0.13 2.30 0.0432 0.2036 
1-stearoyl-2-linoleoyl-GPC 
(18:0/18:2)* 
Lipid Phospholipid Metabolism 0.61 ± 0.18 1.20 ± 0.12 1.97 0.0711 0.2036 
1-palmitoyl-2-palmitoleoyl-
GPC (16:0/16:1)* 
Lipid Phospholipid Metabolism 0.21 ± 0.06 0.41 ± 0.05 1.95 0.0678 0.2036 
1-oleoyl-2-linoleoyl-GPC 
(18:1/18:2)* 
Lipid Phospholipid Metabolism 0.53 ± 0.17 1.09 ± 0.15 2.06 0.0712 0.2036 
1-palmitoyl-2-linoleoyl-GPI 
(16:0/18:2) 
Lipid Phospholipid Metabolism 0.66 ± 0.16 1.06 ± 0.02 1.6 0.0914 0.2036 
1-palmitoyl-2-oleoyl-GPE 
(16:0/18:1) 
Lipid Phospholipid Metabolism 0.28 ± 0.07 0.62 ± 0.08 2.22 0.043 0.2036 
1-stearoyl-2-oleoyl-GPE 
(18:0/18:1) 
Lipid Phospholipid Metabolism 0.19 ± 0.05 0.41 ± 0.06 2.11 0.0349 0.2036 
1-palmitoyl-2-
arachidonoyl-GPE 
(16:0/20:4)* 
Lipid Phospholipid Metabolism 0.37 ± 0.09 0.68 ± 0.07 1.84 0.0757 0.2036 
1-palmitoyl-2-linoleoyl-GPE 
(16:0/18:2) 
Lipid Phospholipid Metabolism 0.56 ± 0.14 1.18 ± 0.14 2.10 0.0459 0.2036 
1-stearoyl-2-linoleoyl-GPE 
(18:0/18:2)* 
Lipid Phospholipid Metabolism 0.69 ± 0.17 1.49 ± 0.21 2.15 0.0402 0.2036 
1,2-dioleoyl-GPE 
(18:1/18:1) 
Lipid Phospholipid Metabolism 0.22 ± 0.06 0.56 ± 0.10 2.59 0.0275 0.2036 
1-palmitoyl-2-linolenoyl-
GPC (16:0/18:3)* 
Lipid Phospholipid Metabolism 0.23 ± 0.09 0.49 ± 0.08 2.14 0.0715 0.2036 
1-palmitoleoyl-2-linoleoyl-
GPC (16:1/18:2)* 
Lipid Phospholipid Metabolism 0.35 ± 0.14 0.86 ± 0.13 2.49 0.0536 0.2036 
1,2-dilinoleoyl-GPC 
(18:2/18:2) 
Lipid Phospholipid Metabolism 0.59 ± 0.23 1.56 ± 0.27 2.60 0.0442 0.2036 
1-oleoyl-2-linoleoyl-GPE 
(18:1/18:2)* 
Lipid Phospholipid Metabolism 0.49 ± 0.60 1.14 ± 0.27 2.30 0.0388 0.2036 
1-palmitoleoyl-GPC (16:1)* Lipid Lysolipid 0.19 ± 0.082 0.48 ± 0.11 2.47 0.0592 0.2036 
1-stearoyl-GPC (18:0) Lipid Lysolipid 0.40 ± 0.15 0.77 ± 0.14 1.91 0.093 0.2036 
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1-palmitoyl-GPE (16:0) Lipid Lysolipid 0.16 ± 0.06 0.36 ± 0.08 2.29 0.0637 0.2036 
1-stearoyl-GPE (18:0) Lipid Lysolipid 0.25 ± 0.09 0.60 ± 0.13 2.41 0.0554 0.2036 
1-oleoyl-GPE (18:1) Lipid Lysolipid 0.09 ± 0.04 0.25 ± 0.07 2.91 0.0458 0.2036 
1-stearoyl-GPI (18:0) Lipid Lysolipid 0.18 ± 0.05 0.84 ± 0.49 4.62 0.0946 0.2036 
1-oleoyl-GPI (18:1)* Lipid Lysolipid 0.19 ± 0.07 0.57 ± 0.19 3.07 0.0682 0.2036 
1-linoleoyl-GPI (18:2)* Lipid Lysolipid 0.41 ± 0.16 0.88 ± 0.20 2.13 0.0688 0.2036 
1-(1-enyl-palmitoyl)-2-
oleoyl-GPE (P-16:0/18:1)* 
Lipid Plasmalogen 0.45 ± 0.12 0.96 ± 0.13 2.11 0.0385 0.2036 
1-(1-enyl-palmitoyl)-2-
linoleoyl-GPE (P-
16:0/18:2)* 
Lipid Plasmalogen 1.04 ± 0.26 2.11 ± 0.29 2.04 0.05 0.2036 
1-(1-enyl-palmitoyl)-2-
palmitoyl-GPC (P-
16:0/16:0)* 
Lipid Plasmalogen 0.40 ± 0.16 0.72 ± 0.082 1.80 0.0777 0.2036 
1-(1-enyl-palmitoyl)-2-
oleoyl-GPC (P-16:0/18:1)* 
Lipid Plasmalogen 0.24 ± 0.08 0.44 ± 0.07 1.84 0.0482 0.2036 
1-(1-enyl-stearoyl)-2-
oleoyl-GPE (P-18:0/18:1) 
Lipid Plasmalogen 0.29 ± 0.06 0.64 ± 0.11 2.23 0.0143 0.2036 
1-(1-enyl-stearoyl)-2-
linoleoyl-GPE (P-
18:0/18:2)* 
Lipid Plasmalogen 1.09 ± 0.27 2.29 ± 0.32 2.09 0.0503 0.2036 
1-(1-enyl-palmitoyl)-2-
linoleoyl-GPC (P-
16:0/18:2)* 
Lipid Plasmalogen 0.49 ± 0.23 1.16 ± 0.24 2.31 0.0629 0.2036 
1-(1-enyl-palmitoyl)-GPC 
(P-16:0)* 
Lipid Lysoplasmalogen 0.77 ± 0.33 1.78 ± 0.33 2.31 0.0532 0.2036 
1-(1-enyl-palmitoyl)-GPE 
(P-16:0)* 
Lipid Lysoplasmalogen 0.48 ± 0.17 1.19 ± 0.24 2.47 0.0468 0.2036 
1-(1-enyl-oleoyl)-GPE (P-
18:1)* 
Lipid Lysoplasmalogen 0.56 ± 0.21 1.55 ± 0.35 2.77 0.0438 0.2036 
Appendices 
 
353 
1-(1-enyl-stearoyl)-GPE (P-
18:0)* 
Lipid Lysoplasmalogen 0.45 ± 0.15 1.09 ± 0.29 2.41 0.0617 0.2036 
1-oleoylglycerol (18:1) Lipid Monoacylglycerol 0.22 ± 0.09 0.48 ± 0.09 2.16 0.0406 0.2036 
2-oleoylglycerol (18:1) Lipid Monoacylglycerol 0.28 ± 0.21 0.75 ± 0.20 2.69 0.0592 0.2036 
1-palmitoyl-3-linoleoyl-
glycerol (16:0/18:2)* 
Lipid Diacylglycerol 0.29 ± 0.19 0.56 ±0.11 1.90 0.0845 0.2036 
N-palmitoyl-sphingosine 
(d18:1/16:0) 
Lipid Sphingolipid Metabolism 0.21 ± 0.07 0.42 ± 0.07 1.97 0.0647 0.2036 
sphingomyelin 
(d18:1/24:1, d18:2/24:0)* 
Lipid Sphingolipid Metabolism 0.38 ± 0.13 0.64 ± 0.07 1.70 0.0975 0.2036 
sphingomyelin 
(d18:1/20:0, d16:1/22:0)* 
Lipid Sphingolipid Metabolism 1.24 ± 0.46 2.32 ± 0.37 1.88 0.097 0.2036 
palmitoyl 
dihydrosphingomyelin 
(d18:0/16:0)* 
Lipid Sphingolipid Metabolism 0.31 ± 0.06 0.47 ± 0.05 1.53 0.0543 0.2036 
sphingomyelin 
(d18:2/24:1, d18:1/24:2)* 
Lipid Sphingolipid Metabolism 0.45 ± 0.15 0.79 ± 0.09 1.79 0.0766 0.2036 
3-hydroxy-3-
methylglutarate 
Lipid Mevalonate Metabolism 0.67 ± 0.01 0.59 ± 0.01 0.89 0.0024 0.2036 
cholesterol Lipid Sterol 0.49 ± 0.21 0.97 ± 0.14 1.94 0.0907 0.2036 
beta-sitosterol Lipid Sterol 0.51 ± 0.19 1.18 ± 0.18 2.31 0.0324 0.2036 
xanthosine Nucleotide 
Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
0.62 ± 0.08 0.89 ± 0.07 1.43 0.0401 0.2036 
2'-deoxyinosine Nucleotide 
Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
0.72 ± 0.06 1.10 ± 0.16 1.53 0.0651 0.2036 
adenosine 5'-diphosphate 
(ADP) 
Nucleotide 
Purine Metabolism, Adenine 
containing 
2.39 ± 0.99 4.31 ± 0.54 1.81 0.0987 0.2036 
adenosine 3'-
monophosphate (3'-AMP) 
Nucleotide 
Purine Metabolism, Adenine 
containing 
0.47 ± 0.08 0.82 ± 0.09 1.74 0.0215 0.2036 
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adenosine 2'-
monophosphate (2'-AMP) 
Nucleotide 
Purine Metabolism, Adenine 
containing 
0.61 ± 0.17 0.94 ± 0.09 1.54 0.0757 0.2036 
adenosine Nucleotide 
Purine Metabolism, Adenine 
containing 
0.53 ± 0.14 0.95 ± 0.18 1.78 0.0829 0.2036 
N1-methyladenosine Nucleotide 
Purine Metabolism, Adenine 
containing 
1.01 ± 0.05 1.40 ± 0.11 1.39 0.0147 0.2036 
N6-succinyladenosine Nucleotide 
Purine Metabolism, Adenine 
containing 
1.99 ± 0.19 2.72 ± 0.19 1.37 0.0335 0.2036 
guanine Nucleotide 
Purine Metabolism, Guanine 
containing 
0.58 ± 0.11 1.18 ± 0.17 2.05 0.0181 0.2036 
2'-deoxyguanosine Nucleotide 
Purine Metabolism, Guanine 
containing 
0.89 ± 0.07 1.72 ± 0.37 1.94 0.0809 0.2036 
pseudouridine Nucleotide 
Pyrimidine Metabolism, 
Uracil containing 
0.99 ± 0.06 1.13 ± 0.04 1.13 0.0907 0.2036 
5-methyluridine 
(ribothymidine) 
Nucleotide 
Pyrimidine Metabolism, 
Uracil containing 
0.93 ± 0.04 1.19 ± 0.08 1.29 0.0129 0.2036 
cytidine Nucleotide 
Pyrimidine Metabolism, 
Cytidine containing 
1.04 ± 0.03 1.20 ± 0.05 1.16 0.0168 0.2036 
5-methyl-2'-deoxycytidine Nucleotide 
Pyrimidine Metabolism, 
Cytidine containing 
0.62 ± 0.04 0.75 ± 0.04 1.20 0.0838 0.2036 
nicotinate ribonucleoside 
Cofactors 
and Vitamins 
Nicotinate and Nicotinamide 
Metabolism 
1.45 ± 0.24 2.35 ± 0.41 1.62 0.0869 0.2036 
nicotinamide riboside 
Cofactors 
and Vitamins 
Nicotinate and Nicotinamide 
Metabolism 
1.39 ± 0.07 1.70 ± 0.14 1.22 0.0915 0.2036 
nicotinamide adenine 
dinucleotide (NAD+) 
Cofactors 
and Vitamins 
Nicotinate and Nicotinamide 
Metabolism 
0.74 ± 0.09 1.09 ± 0.09 1.48 0.0297 0.2036 
riboflavin (Vitamin B2) 
Cofactors 
and Vitamins 
Riboflavin Metabolism 0.52 ± 0.06 0.81 ± 0.12 1.57 0.0702 0.2036 
flavin mononucleotide 
(FMN) 
Cofactors 
and Vitamins 
Riboflavin Metabolism 0.55 ± 0.12 0.94 ± 0.15 1.72 0.0952 0.2036 
pantothenate 
Cofactors 
and Vitamins 
Pantothenate and CoA 
Metabolism 
0.83 ± 0.05 0.94 ± 0.04 1.13 0.0997 0.2036 
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coenzyme A 
Cofactors 
and Vitamins 
Pantothenate and CoA 
Metabolism 
1.62 ± 0.22 0.86 ± 0.24 0.53 0.0305 0.2036 
biliverdin 
Cofactors 
and Vitamins 
Hemoglobin and Porphyrin 
Metabolism 
1.06 ± 0.12 1.53 ± 0.12 1.44 0.029 0.2036 
thiamin (Vitamin B1) 
Cofactors 
and Vitamins 
Thiamine Metabolism 0.47 ± 0.04 0.66 ± 0.06 1.42 0.0201 0.2036 
retinol (Vitamin A) 
Cofactors 
and Vitamins 
retinol (Vitamin A) 0.27 ± 0.06 0.54 ± 0.10 2.02 0.0652 0.2036 
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